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Summary 
 
GATA-1 is a key haematopoietic transcription factor which plays a pivotal role in 
differentiation of the erythroid, megakaryocytic, eosinophilic, mast cell and dendritic cell 
lineages. Since its initial cloning and characterisation in 1989 a huge amount of 
information has been gathered on the molecular mechanisms of action of GATA-1. This 
knowledge has helped understanding of the processes by which cells enact differentiation 
programmes and suppress alternative lineage choices. GATA-1 produces at least two 
protein isoforms – the well characterised GATA-1 full-length (GATA-1FL) isoform and a 
truncated isoform – GATA-1 short (GATA-1s). GATA-1FL comprises two conserved Zinc 
fingers (which interact with DNA and essential co-factors), a C-terminal tail (of mostly 
unknown function) and an N-terminal domain (thought to confer activation properties to 
the molecule, but which may also be involved in transcriptional repression). GATA-1s 
lacks the N-terminal domain but is otherwise identical. The biological role of GATA-1s is 
unknown and this isoform received scant attention until the discovery that GATA-1FL 
mutations were linked to a rare, but highly informative, acute megakaryoblastic leukaemia 
seen in children with Down syndrome (constitutional trisomy 21). This discovery was 
particularly interesting, not only because the association between trisomy 21 and the X-
linked GATA-1 mutation was extremely tight (being seen in 100% of the cases examined), 
but also because the GATA-1FL mutations were not randomly located, but rather clustered 
within the N-terminus, allowing unhindered production of the GATA-1s isoform. This 
finding led to interest in the pathological and physiological role of GATA-1s in 
haematopoiesis.  
Some insight has been gained into the pathological role of GATA-1s by creation of a 
GATA-1s knock-in transgenic mouse and by experiments looking at the ability of GATA-
1s to rescue GATA-1 deficient embryonic stem (ES) cell lines. GATA-1s produces hyper-
proliferation of fetal liver meg-erythroid progenitors but allows at least partial 
differentiation of these cells. However, a number of key questions remain. In particular 
what is the physiological role of GATA-1s and the reason for the tight association between 
trisomy 21 and GATA-1s mutations? 
Given this background, this thesis describes experiments designed to address the 
physiological role of GATA-1s, to establish whether additional GATA-1 isoforms exist, 
and to investigate the association between GATA-1 isoform expression and trisomy 21.  Summary   3 
Firstly a comprehensive expression analysis was performed in murine and human primary 
tissues and cell lines. This aimed to identify whether GATA-1s had a unique expression 
profile, either in particular lineages, or at distinct stages of haematological ontogeny. 
Reverse-transcriptase polymerase chain reaction (RT-PCR) and western blot analyses 
showed that the expression patterns of GATA-1s and GATA-1FL were virtually identical, 
with the possible exception of one human primary monocytic cell preparation which 
appeared to preferentially express GATA-1s.  
Before proceeding to further analysis of GATA-1s a search was made for additional 
GATA-1 isoforms using in silico analysis, RT-PCR and western blotting. This led to 
identification of a clone carrying a GATA-1 mutation involving the C-terminal tail, 
derived from a patient with chronic myeloid leukaemia. An analysis of the properties of 
this clone was performed, confirming its altered C-terminus and demonstrating that this 
conferred increased transactivation properties on the molecule as measured by luciferase 
assays. This observation suggests that the C-terminal tail may be an important, and 
previously under-recognised, functional region of the GATA-1 molecule. The discovery of 
this potentially hyper-functioning GATA-1 mutation led to investigation of whether 
GATA-1 mutations could be a widespread phenomenon in CML. However, GATA-1 
mutational analysis in 21 patient samples from CML blast crisis did not reveal any 
additional coding mutations. 
To address the physiological role of GATA-1s, attempts were made to perform gene 
targeting in murine embryonic stem cells to produce isoform specific knock-out cells i.e. 
ES cells engineered so that they exclusively express the GATA-1FL isoform (a GATA-1s 
knock-out) or the GATA-1s isoform (a GATA-1FL knockout). These cells could then be 
used in in vitro haematopoietic differentiation assays and for transcriptional profiling. In 
this way it was hoped to establish whether GATA-1s fulfilled any unique roles in primitive 
or definitive haematopoiesis that could not be compensated for by the presence of the 
GATA-1FL isoform. Unfortunately, despite evidence of apparently successful targeting 
from PCR screening of ES cell clones, it was impossible to confirm the existence of 
endogenously targeted alleles on Southern blotting. Following exhaustive attempts at 
screening further clones and subclones (more than 1000 clones in total), this approach was 
abandoned in favour of transgenic expression of GATA-1 isoforms in cell lines. 
Transgenic expression studies in murine ES cells showed that whilst GATA-1FL 
expression led to an expansion in numbers and maturity of erythroid and non-erythroid 
haematopoietic colonies in vitro, GATA-1s was incapable of supporting colony formation Summary   4 
in this assay. Studies then moved on to human cell lines. Two cell lines were identified, 
both capable of in vitro haematopoietic differentiation into megakaryocytic and erythroid 
cells, but one carrying trisomy 21 (Meg-01) and the other disomic for chromosome 21 
(K562). GATA-1FL expression in these cells generally drove differentiation along the 
megakaryocytic or erythroid lineage as measured by DNA ploidy analysis, 
haemoglobinisation, upregulation of erythroid or megakaryocytic gene expression (by 
quantitative PCR) and suppression of alternative lineage genes (PU.1 and Ikaros) and 
genes associated with progenitor proliferation (cyclin D2 and c-myb). GATA-1s, in 
contrast, produced less evidence of differentiation with lower DNA ploidy, less up-
regulation of erythroid genes and failure to repress other lineage and haematopoietic 
progenitor associated genes. Examination of the link with trisomy 21 confirmed that that 
the chromosome 21 candidate gene Erg3 was upregulated in trisomic cells and that 
expression of GATA-1s appeared to confer a selective advantage in the presence of 
trisomy 21. However, no clear mechanistic reasons for the selective advantage could be 
identified. 
Overall, these studies show widespread GATA-1s expression in haematopoietic cells, 
confirm the association with inadequate repression of genes associated with primitive 
progenitors, and suggest that the C-terminal tail of GATA-1 may be an important 
functional part of the molecule. Finally, these observations have generated a number of 
testable hypotheses which could form the basis for future work.    5 
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1  Introduction 
All cells in the body contain essentially identical genetic information and yet they can 
differentiate into a wide variety of cell types each with a unique function. The mechanisms 
underlying these choices to become one cell type or another are only partially understood 
and have many layers of complexity. In general, differentiation involves expression of a set 
of genes needed for specialised cellular functions and repression of genes not needed in 
that cell type. Transcription factors play a key role in this process, these are proteins that 
bind DNA upstream of genes and help determine whether the gene is expressed or not. In 
addition, tissues capable of self-renewal must possess a subset of cells known as stem cells. 
Understanding the mechanisms by which cells self-renew and differentiate is vital to both 
basic biology and many aspects of health and disease including the formation of cancers, 
ageing and developmental anomalies.   
Haematopoiesis describes the generation of large numbers of mature blood cells from 
small numbers of haematopoietic stem cells. In this introduction the cellular and molecular 
basis of mammalian haematopoietic cell differentiation will be discussed, with particular 
reference to the critical role of transcription factors. A key haematopoietic transcription 
factor – GATA-1- forms the basis of this thesis and will be discussed in depth. The 
introduction will end by addressing the relevance of this basic science to understanding the 
molecular pathogenesis of certain leukaemias by focussing on a rare but highly informative 
leukaemia – acute megakaryoblastic leukaemia associated with trisomy 21 (Down 
syndrome). 
 
1.1 Haematopoiesis 
Blood cells comprise at least eight mature cell types with different functions and lifespan. 
Most only survive a few hours (granulocytes) to a few weeks (erythrocytes). Every day 
approximately 10
13 new myeloid cells are required to replace these losses (Hoffbrand, et al 
2005). In addition, certain subsets are capable of rapid change in response to external 
stresses such as hypoxia, infection and inflammation. Within the adult bone marrow, blood 
cells are found in various stages of development. It has long been known that bone marrow 
cells can regenerate the blood compartment, but the idea of multipotent progenitors 
capable of producing a number of different blood cell types emerged in the 1960s and 70s 
following seminal work by Metcalf and Moore and by Till and McCullough. These groups Introduction   22 
documented the existence of colony forming units (CFUs), derived from mouse bone 
marrow, capable of producing cells of different lineages when transferred to irradiated 
recipients and then subdivided them on the basis of their response to various colony 
stimulating factors (Metcalf 1970a, Metcalf 1999, Till and McCulloch 1961).  At the top of 
the haematopoietic progenitor tree sit haematopoietic stem cells (HSCs). These stem cells 
comprise about 0.01-0.05% of the total marrow population, hence the production of mature 
cells from these relatively rare stem cells involves both expansion and differentiation. The 
stages of cellular differentiation are shown in Fig 1.1. 
 
Fig 1.1 Hematopoietic differentiation.  
Adapted from Hitzler and Zipursky, Nature Reviews Cancer (Hitzler and Zipursky 2005) 
  
The sites of haematopoiesis and the exact nature of the cells produced vary during 
development. This reflects the changing needs of the embryo, fetus and adult organism. 
After birth the majority of haematopoiesis in the resting state occurs in the bone marrow. 
However before birth the fetal liver is the main haematopoietic organ. In order to 
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understand the molecular and cellular events underlying haematopoiesis it is important to 
be aware of changes in the system during ontogeny.   
1.1.1 Haematopoiesis during development 
Since blood cells are essential for carriage of oxygen to the developing cells in the early 
embryo, haematopoiesis and accompanying vasculogenesis (formation of blood vessels) 
are very early events in embryogenesis and major defects in the genes critical for blood 
formation are usually lethal at an early stage. Haematopoietic cells arise from primitive 
embryonic mesoderm. The process by which mesoderm is induced to become 
haematopoietic tissue is largely unknown, although the gene Bone Morphogenetic Protein 
4 (BMP-4) appears to play a particularly important role (Johansson and Wiles 1995). 
Blood cell development occurs in at least two phases. The first occurs within the blood 
islands of the yolk-sac – known as primitive (embryonic) haematopoiesis and the second 
arises within the embryo itself and produces mature haematopoietic stem cells capable of 
multi-lineage blood cell production - known as definitive (adult) haematopoiesis. The 
relationship between the development of the vascular and haematopoietic systems remains 
controversial although evidence is now accumulating in favour of a shared progenitor cell 
known as the haemangioblast (Huber, et al 2004). It is important to be aware of the 
differences between embryonic and adult blood production when considering the effects of 
mutations in haematopoietic genes as these may vary depending on the developmental 
stage at which the mutation was acquired and/or the stage at which the gene is normally 
active. 
1.1.1.1   Extra-embryonic and intra-embryonic haematopoiesis 
The first recognisable blood cells are seen in the extra-embryonic yolk sac at 7-7.5 days 
post coitus / E7-7.5 (days post coitus is referred to as the prefix E) in the mouse embryo 
(Cumano and Godin 2007). Mesodermal cells initially form homogenous aggregates 
known as haemangioblastic chords. They then form discrete structures known as blood 
islands comprising a central cluster of blood cells surrounded by cells with endothelial 
characteristics. The blood cells appear to be mainly erythrocytes which are large and 
nucleated and resemble both the early proerythroblasts seen in adult bone marrow and 
erythrocytes from lower vertebrates such as fish and birds. For these reasons they are 
known as primitive erythrocytes. Later in embryogenesis blood cell formation shifts to the 
fetal liver and then the thymus, spleen and bone marrow. Initially it was thought this 
represented sequential migration to, and colonisation of, these organs by the HSCs that had Introduction   24 
initially formed in the yolk-sac. Early experiments using transplantation assays and 
formation of interspecies chimeras (such as quail-chick grafts) established that, although 
the yolk-sac was capable of a partial contribution to haematopoiesis after birth, there 
appeared to be separate areas capable of generation of haematopoietic stem cells within the 
embryo itself (Dieterlen-Livre 1975).  
The intra-embryonic site of haematopoiesis was narrowed down by a combination of 
grafting experiments (Godin, et al 1993) and  in vitro culture and cytological analysis 
(Tavian, et al 1999). Haematopoietic capability appeared to be located in the dorsal aorta 
and its underlying mesenchyme. This aortic region is also referred to as the Aorta-Gonads-
Mesonephros region (AGM), describing its developmental fate. Generation of HSCs in this 
region occurs at E10.5 (Medvinsky and Dzierzak 1996), establishment of a circulation 
between the yolk-sac and embryo itself occurs at E8. This left open the question as to 
whether these areas were capable of independent HSC generation or whether they merely 
provided a permissive environment for colonisation and expansion of yolk-sac derived 
HSCs. Elegant organ explant cultures of intact para-aortic splanchnopleura (the 
mesodermal-endodermal association created by subdivision of the lateral plate mesoderm 
by the formation of the coelomic cavity early in development) isolated from the day 8 
embryo, before establishment of a yolk-sac derived circulation, have proved that this 
region is indeed capable of independent generation of HSCs (Cumano, et al 1996). Further 
work has identified the precise locations within the AGM important for generation of 
intraembyronic HSCs. Firstly, the existence of haematopoietic intra-aortic clusters 
(HIACs) has been demonstrated; comprising immature haematopoietic cells as well as 
some more differentiated cells. These are located in the ventral wall of the dorsal aorta 
intimately associated with endothelial cells. Secondly, a region below the aortic floor 
known as the subaortic patches (SAPs) was identified due to its strong expression of genes 
and proteins important in haematopoietic development. Its appearance precedes that of 
HIACS leading to the hypothesis that HSCs may arise there and migrate to the HIAC 
region (Cumano and Godin 2007). Fig 1.2 summarises the important features of intra and 
extra-embryonic haematopoiesis discussed above. Besides differences in location, intra-
embryonic HSCs appear functionally different from yolk-sac HSCs. They have much more 
extended differentiation capacity being capable of formation of lymphoid and myeloid 
cells whilst yolk sac HSCs are unable to contribute to lymphopoiesis in transplant 
experiments (Yokota, et al 2006). Although the majority of experiments described above 
have been carried out using avian and murine models, most of these observations have 
been confirmed in humans (Tavian, et al 2001).  Introduction   25 
The debates as to the origin of HSCs in yolk sac versus dorsal aorta have recently acquired 
new relevance with the unexpected observation that the placenta, another extra-embryonic 
site, may provide an additional source of HSCs in  the mouse (Corbel, et al 2007, Zeigler, 
et al 2006). At E11 (at the same time as fetal liver colonisation from dorsal aorta derived 
HSCs), cells recovered from the placenta show long-term repopulating (LTR) activity in 
transplantation assays (a classic assay for HSC activity) (Gekas, et al 2005, Ottersbach and 
Dzierzak 2005). Three possibilities exist to explain their presence – firstly they may 
represent circulating HSCs generated in the dorsal aorta and preferentially isolated from 
the placenta due to its large blood supply. Secondly the placenta may provide an 
appropriate niche for the expansion and survival of HSCs generated elsewhere. Finally the 
placenta may be a site of de novo generation of HSCs. Overall the weight of experimental 
evidence probably favours the second option but definitive proof is awaited (Gekas, et al 
2005, Ottersbach and Dzierzak 2005). 
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Fig 1.2:  Sites and types of haematopoiesis during murine fetal life 
The first recognisable blood cells are seen at 7.5 days post-coitus (days post-coitus = E) 
emerging in the extra-embryonic yolk sac and forming blood islands with production of 
primitive erythroblasts (top of figure). By E9.5 the first definitive haematopoiesis is 
emerging (middle of figure). By E10.5 the major site of haematopoiesis has switched to the 
Aorta-Gonad-Mesonephros (AGM) region of the dorsal aorta with evidence of 
haematopoietic intra-aortic clusters (HIACS) of cells and expression of haematopoietic 
genes in sub-aortic patches (SAPs). By E12 production has switched to the fetal liver 
(bottom of figure). This remains the major haematopoietic organ until after birth when a shift 
occurs to bone-marrow derived haematopoiesis. Introduction   26 
1.1.1.2   Primitive and definitive haematopoiesis 
In addition to changes in the site of haematopoiesis, the nature of the cells produced also 
varies during ontogeny. These cells are produced in two overlapping waves termed 
primitive and definitive haematopoiesis. 
Primitive haematopoiesis: As discussed above the first wave of blood formation in the yolk 
sac produces a transient population of primitive erythrocytes that are large and nucleated. 
The progenitors of these cells are detected between E7.25 and E9 in mouse embryos (day 
15-18 in humans). Primitive pro-erythroblasts enter the newly formed embryonic 
circulation at E8.25 and undergo maturation resulting in an increase in haemoglobin, 
reduction in size and nuclear condensation. In the mouse they display active globin 
switching from early βH-1 expression to later εγ expression and an α-globin cluster change 
from ζ to α-1 and α-2 expression. In fact all of the globin genes from the alpha (ζ, α-1 and 
α-2) and beta (εγ,βH-1, β-1 and β-2) globin clusters are expressed in primitive erythrocytes 
(Leder, et al 1992, Trimborn, et al 1999). This maturation is accompanied by enucleation 
and these circulating primitive erythrocytes can persist until a few days after birth 
(Kingsley, et al 2006).  
It has long been assumed that primitive haematopoiesis is unilineage but evidence is now 
emerging for other primitive lineages.  Primitive macrophage production has been 
observed to accompany the first wave of primitive haematopoiesis with cells positive for 
the mouse pan-macrophage marker F4/80 being detectable in early blood islands (Naito, et 
al 1996). Evidence has also emerged for the existence of primitive megakaryopoiesis 
(Tober, et al 2007, Xu, et al 2001). This would make developmental sense as the ability to 
transport nutrients and oxygen to tissues in the very early embryo must depend on red 
cells, the formation of a vascular system, and a method to maintain its integrity and prevent 
bleeding. Indeed knock-out mice generated to look at genetic control of very early stages 
of haematopoiesis usually die in early embryonic life, and death is often accompanied by 
anaemia and haemorrhage. The latter could be a function of inadequate vasculogenesis or 
inadequate haemostasis or a combination of the two. Megakaryocytes are first detectable at 
the same time, and in the same location, as primitive erythroid precursors. Single colonies 
contain both primitive erythroid and megakaryocytic cells suggesting a common primitive 
meg-erythroid progenitor (MEP). This has been confirmed using serial dilution 
experiments to show that a single progenitor cell can give rise to both lineages. Platelets 
are first detected at E10.5 and early platelets appear larger than those from later stage 
embryos and adults and are reticulated (Tober, et al 2007). These observations are Introduction   27 
particularly important when considering the potential target cell for mutations in childhood 
acute megakaryocytic leukaemia as discussed in section 1.3.2.  
Definitive haematopoiesis: The second wave of blood production leads to HSCs capable of 
long-term repopulating ability in adult recipients and has therefore been termed definitive 
haematopoiesis. These HSC proliferate extensively in fetal life and then sustain blood 
production throughout life. Definitive haematopoietic activity is first detected at about 
E10.5-12.5 in mice (day 35-42 in humans) and arises in a number of regions. Definitive 
erythrocytes differ phenotypically from primitive erythrocytes- they are smaller and 
usually enucleate before entry into the bloodstream. In  mice only the adult globin genes 
(α-1, α-2, β-1 and β-2) are expressed in definitive cells (Leder, et al 1992, Trimborn, et al 
1999).  Humans undergo an additional embryonic to fetal (γ-globin) switch before 
switching to adult β chain around the time of birth and may express fetal haemoglobins 
even in adult life (Stamatoyannopoulos 2005). 
Although often equated with intraembryonic HSCs (i.e. those generated in the AGM 
region/dorsal aorta discussed in 1.1.1.1), the yolk-sac also contributes to definitive 
haematopoiesis. Yolk-sac derived HSCs are capable of some haematopoietic reconstitution 
of adult recipients as shown by recent cell tracking experiments in mice where yolk-sac 
HSCs pulse-labelled using inducible Cre-recombinase activity (see chapter 4.2.2.2) at E 
7.5 were found to comprise 1-10% of all the major peripheral blood cells and erythroid 
precursors in the bone marrow (BM) in 9-12 month old mice (Samokhvalov, et al 2007). 
Whether yolk-sac derived precursors can contribute to lymphoid reconstitution remains 
controversial (Matsuoka, et al 2001, Yoder, et al 1997). Some of this may be explained by 
the methods used to assess developmental potential of yolk-sac derived precursors –
plasticity is a recognised feature of stem cell populations and therefore experimental 
manipulation such as transgene expression and transplantation may take cells out of their 
normal context and allow them to display properties not pertinent to their normal role in 
vivo (Herzog, et al 2003). Overall it seems likely that yolk-sac progenitors are capable of 
producing mature blood cells of at least the erythroid and myeloid lineage in the fetus but 
have only a limited capacity to contribute to adult haematopoiesis in normal development. 
In fact, it has recently been postulated that yolk-sac (and possibly the more mature 
haematopoietic cells associated with HIACs in the AGM region- see 1.1.1.1 above) 
precursors may be responsible for the majority of fetal blood production. This would allow 
AGM derived definitive HSCs to devote themselves to self replication- necessary to create 
a large stem cell pool to sustain haematopoiesis throughout adult life- rather than diverting 
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model is given weight by emerging evidence for distinct properties of LTR-HSCs isolated 
before or after birth. Fetal HSCs are highly proliferative cells undergoing mainly 
symmetrical self renewal on division. These cells appear to undergo an intrinsically 
regulated switch at around 3-4 weeks postnatally that changes them into largely quiescent 
cells which undergo asymmetric division producing differentiated progeny, in addition to 
self renewal (Bowie, et al 2007).  
1.1.1.3   Haematopoietic niches 
The evidence reviewed in 1.1.1.1 describes the various sites for generation of HSCs. Once 
generated these HSCs need to settle in permissive sites that allow them to survive, expand 
and differentiate to form mature blood cells. Although the yolk-sac can support erythroid 
and megakaryocytic differentiation, there is little evidence for differentiation of mature 
haematopoietic cells in the AGM region. Instead these cells appear to home to successive 
organs which act as sites of expansion and differentiation – initially the fetal liver at E10, 
then the thymus (T cell development) and spleen (predominantly B cell and macrophage 
development), and finally to the bone marrow. Bone marrow haematopoiesis is first 
detected at E17.5 in the mouse (week 20 in the human) and by the time of birth is the 
major site of haematopoiesis. As discussed above the placenta may also represent a site for 
expansion (and/or generation) of HSCs and again these cells appear to home to fetal liver 
before differentiating. The molecular basis for homing of stem cells is not fully understood 
although there is evidence that the chemokine receptor CXCR4, expressed on HSCs, and 
its ligand CXCL12 (also known as stromal cell derived factor 1 / SDF-1) play important 
roles in directing homing to BM and localisation of HSCs within supportive 
microenvironments (Sugiyama, et al 2006). The molecular basis for fetal liver homing is 
presently unknown and SDF-1 knockout mice have normal fetal liver myelopoiesis making 
the CXCR4-SDF-1 system unlikely to play a role here (Nagasawa, et al 1996). Expression 
of the adhesion molecule integrin α-4 is essential for entry into the fetal liver but is 
unlikely to direct homing per se (Qian, et al 2007). 
The decision of HSCs to enter cell cycle, self renew or differentiate is not merely a cell 
autonomous event, additional regulation is achieved by surrounding cells that interact 
directly via cell to cell contact and indirectly by secretion of various growth factors and 
signalling molecules. These surrounding cells and signalling molecules are collectively 
known as the haematopoietic niche. Most observations about the properties of this niche 
come from studies of bone marrow haematopoiesis. Evidence for a crucial role of 
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has been obtained using knockout mice. These studies have concentrated on bone marrow 
haematopoiesis and have shown crucial roles for genes such as angiopoietin-1 (expressed 
by osteoblasts and HSCs and responsible for keeping HSCs in a resting multipotent state), 
as well as Notch and Wnt signalling pathways (Calvi, et al 2003, Cumano and Godin 
2007). Overall they have shown that the number of HSCs is limited and tightly linked to 
the number of osteoblasts. In addition, localisation of HSCs in association with the 
endosteal surface of bone seems to be mediated via a calcium sensing receptor; indeed 
endochondrial ossification has been shown to be an essential prerequisite for establishment 
of normal BM haematopoiesis (Adams, et al 2006). Other studies have also shown that 
cells with an HSC phenotype are also in direct contact with the endothelium of sinusoids 
although the nature of the interaction between these cell types is unknown (Kiel, et al 
2005). This is an exciting and rapidly growing field. Identification of signals that allow 
HSC expansion and survival are particularly important for the transplant field which would 
be revolutionised by the ability to efficiently culture and expand HSCs in vitro.   
Unfortunately, very little is known about the properties of the fetal liver haematopoietic 
niche. HSCs are known to undergo massive expansion in the fetal liver between E12 and 
E15 so dissection of the signals that govern this would be particularly interesting. Fetal 
liver does not contain differentiated osteoblasts although it does contain mesenchymal 
stromal cells capable of differentiation into osteoblasts, chondrocytes and adipocytes in 
vitro (Mendes, et al 2005). It appears likely that these mesenchymal elements will play 
important roles in controlling HSC activity along with liver endothelial cells and /or 
currently un-identified cell types. 
Even less is known about the fetal spleen. This organ is capable of supporting 
haematopoietic differentiation from E13-14. It does not support expansion of HSC 
numbers but provides a supportive micro-environment for the differentiation of 
haematopoietic precursors. There is some evidence that fetal spleen stroma may 
preferentially induce certain mature cell types such as macrophages (Bertrand, et al 2006). 
Homing of HSCs to the bone marrow occurs from E17.5 onwards in the mouse. After birth 
the bone marrow rapidly takes over as the major site of haematopoiesis although it should 
be noted that the liver and spleen are also capable of haematopoiesis in adults at times of 
haematopoietic stress (e.g. severe haemolytic anaemias such as thalassaemia) or bone 
marrow stromal dysfunction (e.g. primary myelofibrosis). In addition some paediatric 
haematological disorders such as Juvenile Myelomonocytic Leukaemia are associated with 
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1.1.2 The haematopoietic hierarchy 
The discussion above has concentrated on where HSCs are generated during development 
and how their ability to produce mature progeny may vary during ontogeny. This next 
section will focus on the nature of the haematopoietic stem cell and the process of 
differentiation into mature blood cells.    
1.1.2.1   The haematopoietic stem cell 
Haematopoietic stem cells sit at the top of the haematopoietic hierarchy and are able to 
both self-renew and produce all mature blood cell types. They are defined by their ability 
to stably reconstitute the entire haematopoietic system upon transplantation to 
appropriately conditioned adult recipients – the classic assay for HSC being long-term 
reconstituting activity (LTR activity). HSCs have a number of possible developmental 
options including apoptosis, self renewal, proliferation, quiescence or differentiation. The 
molecular processes that underlie these developmental fate decisions are discussed below. 
At a cellular level haematopoiesis is often depicted in a hierarchical fashion with HSCs 
giving rise to progenitors which then go on to mature along single or multiple pathways 
(Reya, et al 2001) as shown in figure 1.1. Although useful, this model is undoubtedly an 
oversimplification and may not reflect the true situation in vivo.  
1.1.2.2    Progenitor cells 
The progenitor cell compartment consists of all the intermediate progeny between 
multipotent stem cells and mature differentiated cell types. Progenitor cells are classically 
described on the basis of their ability to form colonies in vitro. The earliest progenitor cells 
retain some stem cell characteristics in that they are capable of repopulating an adult 
organism producing all the different mature blood cell types but cannot maintain long term 
activity. These cells are called short-term HSCs (ST-HSCs). Next, multipotent progenitors 
(MPPs) emerge- these are capable of in vitro multi-lineage output but cannot repopulate 
mice in vivo, probably reflecting their limited proliferative capacity. Classically the earliest 
true lineage division was thought to occur between the lymphoid and myeloid 
compartments. In vitro assays identified committed progenitors capable of forming large 
colonies containing multiple maturing myeloid cell types (mixed colony forming cells – 
CFC, also known as the common myeloid progenitor - CMP) but which do not contain any 
lymphoid cells (Akashi, et al 2000, Kondo, et al 1997). Lymphoid cells are thought to arise 
from their own common lymphoid progenitor (CLP) (Kondo, et al 1997). The CMP goes 
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macrophage CFC and eosinophil CFCs. Progenitors also become less proliferative, 
producing progressively smaller colonies, although the overall number of progenitors in 
each compartment increases due to successive amplification steps.  
More recently, progenitor cells and the various HSC populations have been further 
classified by their expression of cell surface antigens (usually detected by flow cytometry) 
and at the level of gene expression. This has allowed much more sophisticated dissection 
of the various intermediate progenitor populations. The model of a complete and 
irreversible split between myeloid and lymphoid compartments as the first step in lineage 
commitment has recently been challenged (Adolfsson, et al 2005). A population of 
immunophenotypically defined ST-HSCs (LSK+CD34+Flt3+ cells) possess, at the single 
cell level, a combined myeloid and lymphoid differentiation potential. However some 
experimental evidence suggests they have lost the capacity to produce megakaryocytic and 
erythroid cells (Adolfsson, et al 2005). This suggests that the first lineage split is into a 
meg-erythroid precursor versus a common myeloid-lymphoid precursor. This model has 
been challenged by other groups (Forsberg, et al 2006). However, cell populations which 
are myeloid-lymphoid primed with multilineage potential, but with little or no meg-
erythroid potential, do appear to be detectable by analysis of the expression of key lineage 
specific transcriptional regulators at the single cell level in both fetal liver and adult bone 
marrow (Månsson, et al 2007). Overall the balance of evidence seems to favour the early 
emergence of meg-erythroid precursors during the transition from HSC to committed 
progenitors. In fact, this debate probably illustrates some of the difficulties in using a 
cellular hierarchy model to explain haematopoiesis. Intermediate populations may not exist 
as distinct entities with irreversible branch points marking splitting between different 
lineages. There may instead be a progressive change in the balance of transcription factors 
within the cell that preferentially encourages it along certain pathways (Hu, et al 1997). 
1.1.3 Lineage specification at the molecular level 
The differentiation of mature lineage-specific cells from multipotent progenitors involves 
the institution of a specific programme of gene expression. At the molecular level this 
involves both production of proteins vital for cell function and repression of irrelevant 
protein production. For example, red blood cells must express haemoglobin to carry 
oxygen but have no need to express immunoglobulin genes whilst B lymphocytes require 
high levels of immunoglobulin gene expression but do not need any haemoglobin. Thus 
two processes are involved in the molecular control of differentiation; gene expression and 
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(mRNA) by RNA polymerase II (pol II) and translation of this messenger RNA into 
protein which may then undergo a number of post-translational modifications. The cell has 
a number of ways of specifying which proteins it wants to express and those it does not. 
These include control at the epigenetic level with modifications of chromatin preventing or 
encouraging entry of the transcriptional machinery. The decision about which individual 
genes to transcribe into mRNA is generally controlled by transcription factors which bind 
deoxyribonucleic acid (DNA) upstream of their target genes and direct mRNA synthesis by 
pol II. Transcription factors often work in combination in the form of a transcription factor 
complex. Post-transcriptional control also exists, so not every mRNA is destined to be 
transcribed into protein. In particular, an emerging field is the post-transcriptional control 
of mRNA stability and translation by a number of regulatory small RNA molecules known 
as microRNAs (He and Hannon 2004). The discovery of these highly conserved RNA 
duplexes has had massive implications for the understanding of developmental regulation 
of gene expression as well as producing powerful tools for the manipulation of gene 
expression in the laboratory. Downstream of mRNA translation a number of control points 
exist with post-translational modification of proteins and the ability of the cell to target 
these proteins to certain areas of the cell or target them for degradation. From this brief 
overview it can be seen that unravelling the complexities of cellular differentiation is likely 
to require many different approaches.  
1.1.3.1   The role of cytokines in differentiation 
Early studies established that cellular differentiation also requires the presence of 
exogenous cytokines (Metcalf 1970b). Some of these cytokines appear to be lineage 
specific such as erythropoietin (EPO) for red blood cells and thrombopoietin for platelet 
production, whilst others appear to act on more primitive progenitors such as 
granulocyte/macrophage colony stimulating factor (GM-CSF) which acts on earlier 
myeloid precursors. Two potential models exist for the role of cytokines in cellular 
differentiation: they could play a permissive role, or an instructive role (Socolovsky, et al 
1998). In the permissive model the commitment of a progenitor to a particular lineage is a 
stochastic (random) event, after which differentiation proceeds along a predetermined 
programme and the role of cytokines is to ensure survival or proliferation of these lineage 
committed cells. Alternatively, in instructive models activation of cytokine receptors 
would lead to the institution of a particular programme of differentiation for example EPO 
signalling would turn on erythroid genes to produce erythroid differentiation. The weight 
of experimental evidence now favours the permissive model. It has been shown that 
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identical culture conditions with the same exogenous growth factors leads to very different 
lineage outputs in the “twin” colonies (Suda, et al 1984). This implies that the cellular fates 
of the daughter cells were not determined by their exogenous culture conditions. Addition 
of cytokines to culture media does not alter the differentiation potential of stem cells 
(Metcalf 1991). Also, experiments altering cytokine receptors either by ectopic expression 
of growth factors in multipotent progenitors or experiments switching the intracellular 
domain of one growth factor for that of another are unable to redirect lineage choice. 
Instead the result seems to be to increase proliferation and/or ensure the survival of 
progenitors and committed cells (Socolovsky, et al 1998). Therefore, it appears that 
cytokine receptor expression is the result rather than the cause of lineage commitment. The 
production of cytokines would then serve to expand and/or ensure the survival of cells 
bearing the appropriate receptor allowing the organism to match production of individual 
lineages to need. Overall, evidence points to transcription factors being the key molecules 
that determine cellular differentiation – these are discussed below. 
1.1.3.2   The role of transcription factors in differentiation 
Transcription factors are defined by their ability to bind DNA upstream of their target gene 
at promoters, enhancers or other regulatory sequences. They are classified into a number of 
groups depending on the nature of their DNA binding domains (Stegmaier, et al 2004). 
The main groups, with representative examples, are listed in Table 1.1.  
Class (DNA binding domain)  Examples 
Helix-turn-Helix motif: 
Homeodomain  
Paired box 
 
HoxA9 
Pax-3 
Zinc-co-ordinating DNA binding domains: 
4 Cysteine zinc finger of nuclear type 
2 Cysteine 2 Histidine Zinc Finger 
Diverse Cysteine 4 Zinc Finger 
 
Retinoid X receptors 
Sp1, Ikaros 
GATA-1.2.3 
Basic domains: 
Leucine Zipper  
Helix-loop-helix  
 
c-Jun 
E2A, MyoD 
Beta Scaffold factors with minor groove 
contacts: 
NFkappaB, Runx-1 
 
Miscellaneous  
Pocket domain 
 
P107 
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The transcriptional control of haematopoiesis is a huge area of research, this system is 
regarded as a paradigm for molecular regulation of cellular differentiation. Identification of 
key transcription factors has come from a number of sources: naturally occurring 
mutations, the study of induced mutations in invertebrates and lower vertebrates 
(especially Drosophila, zebrafish and Caenorhabditis elegans) and the characterisation of 
chromosomal translocations found in human leukaemias. In fact more than 50% of known 
transcriptional regulators were discovered as genes involved in leukaemogenesis – 
haematopoietic cell fate and leukaemia development are closely related (Orkin 2000). 
Elucidation of the functions of these transcription factors has been heavily dependent on 
the development of experimental techniques allowing control of gene expression in the 
mouse (transgenic technology). Two major methods exist for assessing transcription factor 
function. Firstly the gene can be introduced as a transgene and the effects of ectopic 
expression assessed in vitro or in vivo. Alternatively a gene knockout can be created where 
the endogenous copy of the gene is replaced by an inactivated form. These techniques have 
recently been supplemented by the ability to knock down gene expression using RNA 
interference (RNAi) technology. Large numbers of transcription factors have been 
identified and elaboration of the experimental evidence for each factor is beyond the scope 
of this introduction. Instead examples will be discussed to illustrate key features of the 
process. The role of GATA-1 in differentiation will be reviewed in section 1.2. 
1.1.3.2.1 Master regulators 
The identification of a number of transcription factors whose expression was limited to 
particular cell lineages, along with the observation that ectopic expression of some 
transcription factors could lead to reprogramming of cells from one lineage to another, led 
to the concept of “master regulators”. These master regulators are proposed to act at 
cellular hierarchy branch points (nodal points) and determine the decision to proceed along 
one path or another. This general principle is best illustrated by the key muscle master 
regulator - myogenic determining factor Myo-D. Ectopic expression of Myo-D is able to 
induce a complete phenotypic conversion of fibroblasts into myoblasts including 
expression of key muscle genes and a muscle specific redistribution of organelles (Blau 
and Baltimore 1991, Davis, et al 1987). However Myo-D requires cofactors for this switch 
as shown by cell fusion experiments. In these experiments ectopic Myo-D is able to 
stimulate expression of muscle specific genes in fibroblasts but not hepatocytes. Fusion of 
Myo-D expressing human hepatocytes with native (non-MyoD expressing) mouse 
fibroblasts results in expression of both human and mouse muscle specific genes. This 
implies that fibroblasts supply the necessary co-factors needed to institute a muscle pattern 
of gene expression in hepatocytes (Schafer, et al 1990).  Introduction   35 
In the haematopoietic lineage a number of master regulators have been identified. These 
genes appear to be capable of lineage specification when ectopically expressed in 
progenitors or more committed cell types. For example, expression of Maf B in 
transformed chicken haematopoietic precursors produces monocytic differentiation (Kelly, 
et al 2000). Other master regulators identified in haematopoiesis are listed in table 1.2.  
1.1.3.2.2 Concentration dependent effects 
A number of transcription factors have been shown to have concentration dependent 
effects. For example, using purified fetal liver haematopoietic progenitors from PU.1 
knockout mice it was shown that transfection of these cells with a green fluorescent protein 
(GFP) tagged PU.1 expressing retroviral vector led to production of macrophage and B cell 
colonies. A low level of PU.1 expression was associated with a B cell fate and a high level 
with formation of macrophage colonies (DeKoter and Singh 2000).  The mechanisms by 
which concentration of a transcription factor influences its output are currently unknown 
but are consistent with the hypothesis that transcription factors form networks with other 
regulatory proteins and that the overall balance of positive and negative factors may be 
important in determining a cells fate. 
Transcription 
factor 
Expression pattern  Effects of Over-
expression 
Mouse Knockout 
Phenotype  
GATA-1  Prog, E, Meg, Eos, Mast, 
Dendritic cells 
Increased E, Meg, Eo, 
Decreased myeloid 
Blocked meg and E 
GATA-2  Prog, Meg, Mast  Reduced mature E  Decreased Prog 
GATA-3  Prog, T cells, Th2  Increased Th2, reduced 
Th1 
No T cells 
PU.1  Prog, myeloid, B cells  Increased myeloid  No Myeloid T or B 
FOG-1  Prog, E, Meg, Mast  Reduced Eos  Blocked E, no Meg 
C/EBPα  Myeloid, eos  Increased Eos  No neutrophils &Eos 
MafB Monocyte  Increased  monocytes  NK 
Runx-1  Haematopoietic cells    No definitive 
haematopoiesis 
Pax-5  B cells  Reduced other lineages  No B cells 
Ikaros  Prog, T cells    No lymphoid cells 
Table 1.2: Master Haematopoietic Transcription Factors. Abbreviations: Prog, 
progenitors; E, erythroid; Meg, megakaryocyte; Eos, eosinophil; blocked, arrested 
development; NK, not known - adapted from (Orkin 2000) 
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There is evidence that master regulators not only switch on a programme of gene 
expression but also suppress alternative choices. This is consistent with their proposed role 
at branch points in the cellular hierarchy – essentially providing a binary switch between 
two cell fates. As mentioned previously this is undoubtedly an oversimplification, but 
experimental evidence does exist for concurrent activation and repression of genes as 
discussed for GATA-1 below in section 1.2.4 (Rodriguez, et al 2005).  
1.1.3.2.4 The importance of cellular context and timing of expression 
As shown by the cell fusion experiments with Myo-D described in 1.1.3.2.1 (Schafer, et al 
1990) a cell must express appropriate co-regulators and/or lack repressors in order to be 
able to respond to a transcription factor. The timing and site of expression of transcription 
factors is also crucial. This is particularly pertinent to haematopoiesis which varies in site 
and nature during ontogeny. Some transcription factors appear to be absolutely required for 
both primitive and definitive haematopoiesis such as GATA-2 and Scl, whilst others can 
selectively affect one or the other; Runx-1/AML-1 and c-myb produce severe defects in 
definitive haematopoiesis whilst leaving primitive haematopoiesis unaffected (Shivdasani 
and Orkin 1996). In addition, the effect of a transcription factor can differ between adult 
bone marrow haematopoiesis and fetal liver definitive haematopoiesis. It is important to be 
aware of these differences when interpreting the results of murine knock-out models as the 
early effects on blood formation, even in the fetal liver, could arise from a crucial role in 
yolk-sac derived haematopoiesis or intra-embryonic derived haematopoiesis, failure to 
dissect out which system is involved could lead to erroneous conclusions about the cause 
of the phenotype (Pina and Enver 2007).  
1.1.3.2.5 Altering specificity by use of isoforms 
Many key regulators exist as a number of different isoforms. The production of different 
isoforms is usually achieved by alternative splicing of mRNA incorporating different 
exons into the final protein product. Transcription factors may utilise different isoforms at 
different stages of differentiation within a cell type, at different stages of development, or 
in completely different cell types. This use provides some economy of effort – allowing a 
constant DNA binding motif to interact with the same set of genes, whilst varying the 
association domains with other proteins to produce varied outcomes. For example, studies 
looking at transcriptional regulation of the granulocytic gene myeloperoxidase (MPO) have 
shown that the transcription factor C-EBP binds to the MPO enhancer in both multipotent 
progenitors (MPPs) and more committed myeloid cells. However, different isoforms are 
used in these two populations with predominance of the C-EBPα isoform in MPPs and C-
EBPβ in myeloid cells (Ford, et al 1996). It is often impossible to selectively knockout Introduction   37 
isoforms using transgenic technology, making analysis of their contributions to cellular 
differentiation particularly challenging. 
1.1.3.3    Other methods of control of gene expression 
Transcription factors are not the only means by which a cell can regulate gene expression. 
Detailed discussion of epigenetic, post-transcriptional and post-translational factors is 
beyond the scope of this thesis but an appreciation of their potential roles is essential when 
interpreting studies looking at cellular differentiation. They are briefly reviewed below: 
1.1.3.3.1 Epigenetic regulation of gene expression 
The term epigenetic refers to changes in the gene expression profile that arise during 
development, are heritable, but do not involve alteration of the DNA sequence. The two 
principal mechanisms of epigenetic control are DNA methylation and histone 
modifications. 
DNA methylation: Mammalian DNA can be covalently modified by methylation of 
cytosine at CpG dinucleotides. This methylation is vital for aspects of developmental 
biology such as genomic imprinting and X-inactivation (Jaenisch and Bird 2003). More 
recently reversible DNA methylation has been shown to be important during cellular 
differentiation; regulation of this methylation appears to be intimately related to chromatin 
remodelling. Histone methylation, discussed below, is linked to DNA methylation, and 
may be a mechanism to promote cellular memory of the differentiated state (Bird 2002). 
Histone Modifications: Chromatin can exist in two opposing states; open or closed. Open 
active chromatin is accessible for entry of transcriptional machinery and subsequent 
mRNA synthesis. Closed chromatin is associated with transcriptionally inactive sites. The 
transition between these two states is governed by modifications of histones, the proteins 
around which DNA is wound to make up chromatin, as shown in fig 1.3. Methylation of 
lysine residues by histone methyltransferases (HMTs) also alters transcriptional 
accessibility (Jaenisch and Bird 2003, Wu and Sun 2006). HATs, HDACs and HMTs can 
form multi-protein complexes involving transcription factors. For example, Pu.1 and 
GATA-1 are known to interact and anatagonise one another’s lineage specific programme 
of gene expression. This physical interaction leads to recruitment of a repression complex 
which includes a histone methyltransferase leading to transcriptional silencing of erythroid 
genes (Stopka, et al 2005). 
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Fig 1.3. The epigenetic control of gene expression.  
Acetylation of lysine residues by histone acetyltransferases (HATs), marks transcriptionally 
competent regions and equates with gene activation (left-hand side of figure). Histone 
deacetylases (HDACs) reverse this activated phenotype, causing gene repression (right-
hand side). Methylation of lysine residues by histone methyltransferases (HMTs) also alters 
transcriptional accessibility. Transcription factors can also interact with HATs, HDACs and 
HMTs modulating their activity.  
1.1.3.3.2 Small non-coding RNAs 
Regulation of gene expression by non-coding regulatory small RNA molecules is a 
recently discovered but fundamental mechanism by which cells can regulate patterns of 
gene expression. A number of different classes of small RNAs have been described. The 
two main classes are small-interfering (si)-RNAs and micro-RNAs. siRNAs take part in an 
evolutionarily conserved pathway known as RNA interference. This pathway acts as a 
sequence specific gene silencing process induced by exposure to double stranded RNA, 
and may have arisen initially as an endogenous defence mechanism against viral infection. 
Micro-RNAs are related to siRNAs but appear to be encoded in gene-like elements 
organised in a characteristic inverted repeat in the genome. When transcribed these micro-
RNAs give rise to a characteristic stem-looped precursor which is cleaved by an enzyme 
called dicer into short 21-25bp RNA duplexes (He and Hannon 2004). The proposed 
mechanisms of gene silencing by micro-RNAs are illustrated in figure 1.4.   
Although incompletely understood, miRNAs have been shown to play key roles in 
haematopoiesis. This is probably best illustrated by the discovery of miR-181 (Chen, et al 
2004). This micro-RNA was found to be expressed in murine haematopoietic cells and 
levels of expression were dynamically regulated during lineage commitment. Higher levels 
were seen in B cells and ectopic expression of miR181 in HSCs led to increased B cell 
numbers in vitro and in vivo (Chen, et al 2004). Later studies have shown crucial roles for 
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miR-223 in granulopoiesis (Johnnidis, et al 2008). The authors also showed that one of the 
targets of miR-223 is Mef-2c a transcription factor that normally promotes myeloid 
progenitor proliferation. This underscores the recurrent theme that transcription factors are 
just one part of a network of gene regulatory factors whose net effect is to repress or 
activate functional protein production by the cell. Deregulated micro-RNA expression has 
also been associated with haematopoietic malignancy (Garzon and Croce 2008). 
 
Fig 1.4 Mechanisms of gene regulation by micro-RNAs 
Transcription of micro-RNAs gives rise to a characteristic stem-looped precursor which is 
cleaved by an enzyme (dicer) into short 20-25bp RNA duplexes. These duplexes interact 
with a mulitiprotein complex; RISC (RNA-induced silencing complex). The duplex provides 
sequence specificity and the associated proteins exert gene silencing via one of 3 
mechanisms 1) cleavage of mRNA 2) blockade of translation 3) transcriptional silencing via 
histone assembly.  
1.1.3.3.3 Post-transcriptional control of gene expression 
The detection of mRNA in a cell does not necessarily equate to the production of 
functional protein. Micro-RNAs are only one of many mechanisms that a cell possesses to 
regulate the degradation of mRNA or facilitate its translation into protein. Other control 
mechanisms include processes that regulate turnover of RNA and processes that provide 
quality control by the degradation of faulty transcripts. Although the basic mechanisms of 
RNA processing are well described, the degree to which they are dynamically regulated 
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and gene specific are not well understood (Mata, et al 2005). Another level of control is at 
the level of translation into protein. Precise mechanisms that control gene specific 
translation rather than global effects on cellular protein production are largely unknown, 
with the exception of microRNAs discussed above (Gebauer and Hentze 2004). Finally, a 
cell can control protein activity by a number of post-translational modifications such as 
phosphorylation, acetylation and sumoylation. These may modify interactions with other 
proteins or DNA or target the protein for degradation via the ubiquitin-proteasome 
pathway (Hernandez-Hernandez, et al 2006). These are discussed with reference to 
GATA-1 below. A better understanding of gene-specific post-transcriptional control is 
likely to provide more insights into mechanisms of cellular differentiation in the future.  
 
1.2 GATA-1: a key haematopoietic transcription factor 
The general themes outlined above are well illustrated by a more in depth analysis of the 
function of a master regulator in haematopoiesis – GATA-1.   
1.2.1  The GATA family of transcription factors 
The GATA family comprises 6 known transcription factors GATA 1-6. They all share a 
common mechanism of DNA binding, namely the use of two characteristic C4 zinc-finger 
motifs (unique to the family), to bind to a DNA consensus sequence (A/T)GATA(A/G). 
The DNA binding regions are highly homologous between the members but the rest of the 
molecule is divergent. The GATA factors fall into two broad subgroups – those involved 
with haematopoiesis: GATA1, 2 and 3, and those not expressed in haematopoietic tissues: 
GATA 4, 5, 6. The latter are expressed in several tissues including intestine, heart and lung 
(Ferreira, et al 2005). GATA-1 (also known as NF-E1, ERYF-1 and GF-1) was the 
founding member of this family and was first identified as a protein binding to the β-globin 
3’enhancer- reflecting its fundamental role in erythropoiesis (Wall, et al 1988).  
1.2.2  Cloning and initial characterisation of GATA-1 
GATA-1 was cloned in 1989 using a cDNA expression library constructed from mouse 
erythroleukaemia (MEL) cells (Tsai, et al 1989). Further characterisation showed GATA-1 
to be expressed in both the primitive and definitive erythroid lineages, megakaryocytic, 
eosinophil and mast cell lineages (Ferreira, et al 2005). More recently a role in the 
dendritic cell lineage has been described (Gutierrez, et al 2007). It was also shown to be Introduction   41 
abundantly transcribed in the Sertoli cells of the testis although this utilised a different 
promoter associated with a testes-specific non-transcribed first exon (known as IT to 
contrast with the haematopoietic first exon IE) (Ito, et al 1993). GATA-1 is highly 
conserved between mammalian and avian species including humans, mice and chickens 
and a GATA-1 equivalent has also been cloned in Zebrafish (Lyons, et al 2002). Both 
murine and human GATA-1 genes are located on the X chromosome (Zon, et al 1990). 
Structure: GATA-1 has at least two isoforms – the common full length isoform known as 
GATA-1FL and a shortened version of the protein GATA-1s. GATA-1FL encodes a 413 
amino acid protein with at least 3 functional domains: an N terminal activation (or 
repression) domain, an N-terminal zinc finger and a C-terminal zinc finger. GATA-1s 
lacks the N terminal activation domain. The intron-exon structure and protein domains are 
illustrated in Fig 1.5. The N-terminal activation domain is important for interaction with 
other proteins and is discussed in detail in section 1.2.8 below. The C-terminal Zinc finger 
is responsible for recognition of, and binding to, the GATA-1 consensus sequence on 
DNA. The N-terminal zinc finger does not bind DNA directly but contributes to the 
stability and specificity of this binding. In addition the N-terminal zinc finger is 
responsible for interaction with important GATA-1 cofactors including Friend of GATA-1 
(FOG-1). Some of these factors associate exclusively with the N-finger whilst others, such 
as erythroid krüppel-like factor (EKLF), bind both the N- and C-fingers. There is also 
evidence that GATA-1 can homodimerise (Crossley, et al 1995), which may be important 
in the regulation of promoters with multiple GATA binding sites.  
Transcriptional Control: GATA-1 activity is highly regulated and is controlled at the 
transcriptional level by different mechanisms in different cell types. DNase I 
hypersensitivity analysis of the GATA-1 locus in erythroid cells reveals 3 main 
hypersensitive sites termed HS1, 2 and 3. HS1 lies between 3.9 and 2.6 kilobases (kb) 
upstream of the erythroid first exon (IE). HS2 corresponds to the putative GATA1 
haematopoietic promoter in the region of IE. HS3 is located in the first intron. These are 
also shown in Fig 1.5.  
The various GATA regulatory elements contain duplicated GATA binding sites and 
cotransfection experiments have shown that GATA-1 or other family members are able to 
regulate GATA-1 transcription (Hannon, et al 1991, Nicolis, et al 1991, Tsai, et al 1991) 
suggesting auto-regulation as at least part of the mechanism of transcriptional control. 
Studies looking at the individual function of these regulatory regions were carried out by 
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these in transgenic mice. The proximal HS1 element was sufficient for faithful 
recapitulation of GATA-1 expression patterns in primitive haematopoiesis and revealed 
very early GATA-1 transcription in E7.0 embryos. However this element was insufficient 
for expression in definitive haematopoietic cells. Expression of the reporter gene in these 
cells required both the HS3 intronic element and the HS1 region (Onodera, et al 1997). 
Interestingly the HS3 intronic region does not behave like a classical enhancer or promoter 
and is unable to transactivate reporter genes when used alone. The mechanism by which 
this element activates transcription is still unknown (Shimizu and Yamamoto 2005). 
 
Fig 1.5 GATA-1 Structure  
a) genomic DNA locus showing location of DNase hypersensitive sites (not to scale) b) 
primary mRNA transcript showing location of two alternative start codons. Coloured blocks 
represent exons and black lines represent introns c) alternative splicing or translation 
produces two polypeptide chains corresponding to the two isoforms GATA-1FL and GATA-
1s d) protein structure showing the two zinc fingers and the N-terminal domain. 
Further studies have shown that lineage specific GATA-1 expression requires different 
regions of  HS1, with megakaryocytic expression requiring the whole 317bp sequence 
whilst erythroid expression can be recapitulated using only the 5’ 62bp (Nishimura, et al 
2000, Vyas, et al 1999b). Eosinophil expression requirements vary yet again being 
independent of the HS1 region (Guyot, et al 2004) but requiring a double GATA motif in 
HS2 (Yu, et al 2002a). There are likely to be several other cis-regulatory elements not yet 
fully characterised and it appears that, despite significant areas of homology between 
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murine and human GATA-1 in terms of function and regulation, the chromatin structures 
between the mouse and human loci vary significantly (Valverde-Garduno, et al 2004).   
Post-transcriptional and post-translational control: A number of post-translational 
modifications to the GATA-1 protein have been reported. These include acetylation, 
phosphorylation and Sumoylation.  GATA-1 acetylation has been described in a wide 
variety of species with variable effects on function although overall it appears that 
acetylation mutants are associated with a reduced ability of GATA-1 to rescue GATA-1 
deficient phenotypes in model systems (Boyes, et al 1998, Ferreira, et al 2005). It has been 
proposed that the combination of acetylation and phosphorylation of GATA-1 targets the 
protein for degradation via the ubiquitin-proteasome pathway (Hernandez-Hernandez, et al 
2006). GATA-1 phosphorylation patterns seem to vary during induction of haematopoietic 
differentiation in cell lines (Crossley and Orkin 1994). In addition, phosphorylation of 
GATA-1 seems to be dynamically regulated in response to cytokine-induced signalling in 
haematopoietic progenitors (Kadri, et al 2005, Towatari, et al 2004). However, the 
generation of transgenic mice with serine to alanine mutations at sites of phosphorylation 
revealed that prevention of phosphorylation is still compatible with normal haematopoietic 
development as measured by peripheral blood counts. More in depth analysis of these mice 
revealed mild defects in erythroid progenitor cell numbers in adult bone marrow but no 
functional impairment even in response to acute erythropoietic stress (Rooke and Orkin 
2006). Finally, Sumoylation involves the ligation of a small ubiquitin-like peptide (SUMO) 
to a lysine residue on a target protein. Unlike ubiqutination this does not target a protein 
for degradation but rather seems to affect localisation, stability and interactions with other 
proteins. Sumoylation has been shown to be important in regulating the activity of several 
key cellular proteins including p53 and c-Jun. GATA-1 is sumoylated in vivo but non-
sumoylatable mutants have no detectable loss of activity in reporter gene assays. This 
suggests this modification does not play a major part in affecting transcriptional function, 
although a more subtle role in regulation is possible (Collavin, et al 2004).   
Initial insights into GATA-1 function relied heavily on assessing the effects of mutation or 
ablation of GATA-1 in knockout mice and ES cells as described below. The crucial role of 
GATA-1 in megakaryocytic and erythroid development has been further reinforced by 
descriptions of human diseases due to inherited or acquired mutations in GATA-1 
including thrombocytopenia, anaemia and acute megakaryoblastic leukaemia.  Introduction   44 
1.2.3  GATA-1 plays a key role in erythropoiesis  
GATA-1 DNA binding sites are found upstream of virtually all erythroid expressed genes 
leading to early predictions that it may play a key role in erythropoiesis (Evans, et al 
1988). Binding of GATA-1 to these sites led to strong transcriptional activation using in 
vitro reporter assays (Martin and Orkin 1990). To further investigate the role of GATA-1 
in haematopoiesis, GATA-1 knock out embryonic stem (ES) cells were generated and 
tested for their ability to contribute to different tissues in a chimaeric mouse (Pevny, et al 
1991). The mutant ES cells contributed to all non-haematopoietic tissues tested and 
produced some white blood cells but were completely unable to contribute to mature 
erythroid cells. This study established that GATA-1 had a direct role in haematopoiesis and 
that other proteins were unable to compensate for GATA-1 deficiency. It did not, however, 
establish the stage at which erythropoiesis was blocked or the effect of GATA-1 ablation 
on presumptive target genes.  
1.2.3.1   Effects of GATA-1 deficiency in vitro  
To address this, the knockout cells were utilised in in vitro ES cell differentiation studies. 
These showed that GATA-1 null ES cells fail to generate primitive erythroid precursors in 
cultures of embryoid bodies (Simon, et al 1992) or secondary replating experiments 
looking for emergence of typical tight haemoglobinised primitive colonies in the presence 
of erythropoietin (Keller, et al 1993, Weiss, et al 1994). Generation of definitive cells 
appeared initially normal but these cells were unable to mature, becoming blocked at the 
pro-erythroblast stage of differentiation followed by cell death (Weiss, et al 1994). 
Surprisingly the arrested GATA-1 null definitive pre-erythroblasts actually expressed 
putative GATA-1 target genes at normal levels despite their complete lack of GATA-1 
expression. In particular, they expressed all the embryonic and adult globin transcripts. 
Although not interpreted as such at the time, this may actually have reflected the presence 
of primitive erythroid precursors rather than definitive as the latter are not thought to 
express embryonic globins (Trimborn, et al 1999). Alternatively it could reflect more 
promiscuous globin gene expression in definitive cells in the absence of GATA-1. The 
related family member GATA-2 was massively up-regulated in these cells suggesting that 
GATA-2 is able to compensate partially for GATA-1 in early, but not late, erythroid 
progenitors (Weiss, et al 1994). In the absence of GATA-1, proerythroblasts die by 
apoptosis (Weiss and Orkin 1995). The mechanism behind this is not fully understood but 
phosphorylated GATA-1 can upregulate expression of the cellular survival gene E4bp4 Introduction   45 
and result in increased levels of the anti-apoptotic gene Bcl-XL (Yu, et al 2005). This 
suggests GATA-1 plays roles in cellular survival pathways as well as maturation.  
1.2.3.2   GATA-1 knockout embryos die due to severe anaemia  
5 years after the first description of generation of GATA-1 knockout ES cells, and their use 
in chimaeric embryos, the results of germline transmission were reported (Fujiwara, et al 
1996). Male GATA-1 null embryos die between E10.5-E11.5 due to severe anaemia. Prior 
to this (E9.5) they showed extreme pallor but had detectable erythroid cells, arrested at an 
early pro-erythroblastic-like stage. Female heterozygotes are anaemic at birth but recover 
during the neonatal period, presumably because of selection for erythroid progenitors 
expressing the normal GATA-1 allele. These studies confirmed the essential role of 
GATA-1 in erythropoiesis but suggested that, in contrast to the in vitro experiments, both 
primitive and definitive erythropoiesis were similarly affected by a cellular maturation 
block.  
1.2.3.3   Knockdown variants allow survival of embryos 
The existence of knockout ES cells facilitated a number of subsequent experiments looking 
at the ability of various mutants to rescue erythropoiesis in vitro and in vivo. Survival of 
GATA-1 deficient embryos long enough to assess phenotypes has been achieved by 
generation of two knockdown variants. “GATA-1 low” mice express about 20% of wild-
type GATA-1 levels. Although the majority of these mice die at E13.5-14.5 due to 
anaemia, a small number survive to adulthood. These mice, although anaemic at birth, 
recover and have a normal lifespan (McDevitt, et al 1997b). “GATA1.05” mice express 
lower levels – about 5% of wild-type- and, as expected, show a more severe phenotype 
dying between E11.5 and E12.5 with a huge accumulation of undifferentiated erythroid 
precursors in the yolk sac (Takahashi, et al 1997). Interestingly, longer follow up of these 
mice reveals that they have an increased risk of two types of leukaemia – an early onset 
erythroblastic leukaemia and a later onset B cell leukaemia. These leukaemias can be 
prevented by transgenic restoration of GATA-1 expression (Shimizu, et al 2004).  
One key study using these knockdown mice established the in vivo requirements for the 
different domains of GATA-1 during primitive and definitive haematopoiesis (Shimizu, et 
al 2001). Transgenic mice carrying mutations in the C-terminal zinc finger (ΔCF), the N-
terminal finger (ΔNF) or the N-terminal trans-activation domain (ΔNT) were crossed with 
GATA1.05 mice. The N and C zinc finger mutants failed to rescue the male hemizygous 
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corresponds to a naturally occurring isoform of GATA-1; GATA-1s discussed in more 
detail below) was able to rescue both primitive and definitive erythropoiesis but its ability 
to do this was strongly dependent on level of expression. Levels equivalent to endogenous 
GATA-1 production were able to prevent early embryonic lethality up to E15.5 but high 
levels of expression were needed to allow survival beyond this. This suggests that GATA-
1s can support early primitive erythropoiesis in the yolk sac but not definitive 
erythropoiesis. There appeared to be some functional redundancy between the N-terminal 
zinc finger and the N-terminal activation domain in that either was able to compensate for 
the other in primitive erythropoiesis but a compound mutant (ΔNTNF) was unable to do 
so. In addition, the expression of haem biosynthesis genes was normal in primitive 
erythrocytes from the ΔNF mutant but severely impaired in definitive erythrocytes from 
these same mice (Shimizu, et al 2001). Overall these results suggest that primitive 
erythropoiesis can proceed despite lack of some, but not all, co-factor binding sites (which 
are known to be present in the N-terminal finger and the N-trans-activation domain) but 
that definitive erythropoiesis requires more complex interactions. 
1.2.4  Mechanisms of GATA-1 activity 
These early descriptions of the phenotypic effects of GATA-1 deficiency were followed by 
investigation of the underlying mechanisms by which GATA promotes erythroid 
development. An overview of the effects of GATA-1 on gene expression was achieved 
using GATA-1 rescue of a GATA-1 null ES cell line (G1E) (Weiss, et al 1997), followed 
by RNA extraction at various time points and analysis using microarray technology 
(Welch, et al 2004). This revealed that GATA-1 expression affected transcript levels of a 
very large number of genes (far more than the previously known targets of GATA-1) some 
of which showed rapid change after GATA-1 rescue whilst others showed a lag period 
presumably reflecting the need for synthesis and assembly of cofactors, or involvement of 
intermediate genes. In addition, GATA-1 does not merely activate gene expression - many 
transcripts were down-regulated by GATA-1 expression. Later, a biotinylation-tagging 
proteomic approach identified protein partners of GATA-1 in erythroid cells using mass 
spectrometry. Experiments looking at co-purification of proteins in this system showed that 
GATA-1 was able to form at least 5 distinct activating and repressing complexes in the cell 
(Rodriguez, et al 2005). One of the key repressive complexes consisted of GATA-1, its 
cofactor FOG-1 and the MeCP1 complex. The latter complex is a methyl-DNA binding 
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1.2.4.1   GATA-1 Cofactors 
Discussion of all the known partners of GATA-1 is beyond the scope of this introduction. 
Instead a few key interactions will be discussed that illustrate important points 
FOG-1: FOG-1 is a nine zinc finger protein which binds to the N-terminal Zinc finger of 
GATA-1. Although it has no direct DNA binding activity it seems to be a key member of 
complexes involved both activation and repression of target genes (Rodriguez, et al 2005, 
Tsang, et al 1997). The phenotype of FOG-1 knockout mice closely resembles that of 
GATA-1 knockout mice (Tsang, et al 1998). In contrast to GATA-1 however, FOG-1 
deficiency results in complete ablation of the megakaryocytic lineage suggesting additional 
roles for this factor in this lineage. Proof that FOG-1/GATA-1 association was essential for 
erythroid differentiation came from the analysis of GATA-1 mutants unable to bind FOG-1 
(Crispino, et al 1999). Naturally occurring human mutations that disrupt GATA-1 FOG-1 
interactions produce a congenital dyserythropoietic anaemia associated with severe 
thrombocytopenia (Nichols, et al 2000).  Since this first report, several mutations in the 
GATA-1 N-terminal zinc finger have been described (Freson, et al 2001, Freson, et al 
2002, Mehaffey, et al 2001, Yu, et al 2002b). All these affected families have 
thrombocytopenia but the degree of anaemia reflects the degree of disruption of FOG-1 
binding. 
PU.1: PU.1 is a member of the Ets family of transcription factors and is a master 
regulatory gene for the lymphoid and granulocytic lineage (Scott, et al 1994). Therefore 
GATA-1 and PU.1 should show reciprocal activation patterns in the two lineages and this 
indeed appears to be the case. Direct physical interaction between GATA-1 and PU.1 leads 
to functional antagonism (Nerlov, et al 2000, Rekhtman, et al 1999). There is evidence that 
the stoichiometry of these transcription factors determines cellular fate (Rekhtman, et al 
1999). This suggests that these factors could play a part in lineage specification as well as 
maturation with small fluctuations in the relative levels of these factors leading to 
reciprocal inhibition, which in combination with positive autoregulation could lead to an 
eventual dominance of one over the other (Bottardi, et al 2007). 
Krϋppel-like factors: GATA-1 forms a synergistic physical interaction with the related 
factors Sp1 and erythroid Krϋppel-like factor (EKLF). The former appears essential for 
early embryonic development, and the latter is essential for definitive erythropoiesis. These 
Krϋppel-like factors recognise CACC motifs that often exist in close proximity to GATA-1 
binding sites. It has been proposed that EKLF/GATA-1 co-operation is essential for Introduction   48 
bringing distant regulatory elements together – perhaps best studied in the case of the β-
globin locus which forms an active chromatin hub, comprising multiple regulatory regions, 
with extensive looping of intervening chromatin (Drissen, et al 2004, Letting, et al 2003). 
Again this example illustrates that the effects of transcription factor interaction can be 
mediated at levels other than direct interaction with RNA pol II. 
Runx-1 (AML-1): Runx-1 plays a key role in the emergence of HSCs from the dorsal aorta 
during early intraembryonic haematopoiesis (Cai, et al 2000) with a complete failure of 
definitive haematopoiesis seen in Runx-1 knockout mice (Okuda, et al 1996). In addition, 
conditional knockouts have shown an important role for this gene in adult haematopoiesis 
(Ichikawa, et al 2004) and megakaryocyte maturation (Song, et al 1999).  Runx-1 and 
GATA-1 show functional co-operation and physical interaction in mice and Drosophila 
during haematopoietic lineage commitment (Elagib, et al 2003, Waltzer, et al 2003). In 
primary human haematopoietic progenitor culture, Runx-1 is upregulated immediately 
prior to megakaryocyte differentiation and is downregulated prior to erythroid 
differentiation (Elagib, et al 2003). Using cell lines induced to undergo megakaryocyte 
differentiation, the same group showed physical interactions between Runx-1 and GATA-1 
by co-immunoprecipitation. These interactions were dependent on the N and C terminus of 
GATA-1 but not the zinc finger domains (Elagib, et al 2003). These physical interactions 
also had functional significance as measured by synergy in activating a megakaryocyte 
promoter driven reporter gene. Recent evidence suggests that GATA-1 may target Runx-1 
for phosphorylation and thereby change its activity from a repressor to an activator of 
transcription (Elagib and Goldfarb 2007). This illustrates yet another potential mechanism 
for cross–talk between opposing or synergistic transcription factors.  
Gfi-1b: Gfi-1b is a transcriptional repressor involved in megakaryocyte and erythroid 
differentiation. Analysis of GATA-1 interacting proteins in erythroid cells showed that 
Gfi-1b/GATA-1 complexes bind upstream of the myc and myb genes thought to be 
important in the proliferation arrest that is observed with terminal erythroid differentiation 
(Rodriguez, et al 2005). These GATA-1/GFi-1b complexes did not bind other known 
GATA-1 cofactors such as FOG-1. In addition Gfi-1b was not found binding to other 
putative GATA-1 targets. Hence, this may represent a distinct mechanism by which 
GATA-1 could negatively regulate cell cycle genes.  
miR 144 and miR 451: Reports of modulation of  microRNA levels during  haematopoietic 
development are beginning to emerge (Zhan, et al 2007). A recent microarray study 
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the G1E knockout cell line (Dore, et al 2008). The two most strongly upregulated were 
miR 144 and miR 451. GATA-1 binds to upstream regulatory units and directly controls 
the expression of these microRNAs. They also showed that zebrafish embryos depleted of 
miR 451 had abnormal erythroid maturation (Dore, et al 2008). The microRNAs had 
multiple targets but analysis of these showed significant enrichment for nuclear proteins. 
This lends support to a theory that terminal maturation may be promoted by microRNAs 
by clearing the cells of transcription factors needed for earlier lineage specification but no 
longer needed in mature daughter cells. This had previously been suggested by studies in 
plants where 34/49 identified targets of microRNAs were transcription factors despite 
these representing only 6% of the coding genes in these species (Rhoades, et al 2002). 
1.2.4.2   Regulators of GATA-1 expression 
GATA-2:  The second member of the GATA family also plays a pivotal role in 
haematopoiesis. In contrast to GATA-1, GATA-2 appears to act primarily at the level of 
the HSC and is important for production and expansion of HSCs in the AGM region and 
for proliferation of HSCs in adult bone marrow (Ling, et al 2004). GATA-2 
downregulation appears to be required for haematopoietic differentiation (Persons, et al 
1999). The observation of up to 50 fold up-regulation of GATA-2 in GATA-1 knockouts 
first pointed to a possible reciprocal relationship between the two factors (Weiss, et al 
1994). It appears that the combination of GATA-2 downregulation and GATA-1 
upregulation is important for normal erythroid differentiation. GATA-2 binds upstream of 
its own promoter, recruits a co-factor with histone modification activity (CBP) and induces 
an open chromatin configuration. GATA-1 has been shown to displace this GATA-2/CBP 
complex from the GATA-2 promoter, leading to formation of inactive chromatin and loss 
of GATA-2 expression (Grass, et al 2003). GATA-1 also displaces GATA-2 from the α-
globin complex, with the opposite effect of activation of gene expression (Anguita, et al 
2004).  
GATA-1 (autoregulation): GATA-1 expression is dynamically regulated and GATA-1 
appears to influence its own expression at transcriptional and post-transcriptional levels. 
Binding to its own upstream regulatory elements leads to a positive feedback loop whereby 
GATA-1 levels are rapidly upregulated once a critical level of expression has been 
achieved. The interaction with GATA-2 described above ensures that this upregulation is 
co-incident with GATA-2 downregulation. However, GATA-1 levels appear to decline 
with terminal differentiation (Suzuki, et al 2003). In fact, over-expression of GATA-1 in 
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2000). This has been shown to be due to an intrinsic red cell defect but it is not cell-
autonomous – in mouse chimaeras the presence of wild-type erythroid cells can rescue 
overexpressing cells and promote their terminal differentiation (Gutierrez, et al 2004, 
Whyatt, et al 2000). Furthermore, it has been shown that activation of death receptors is 
linked to GATA-1 degradation via caspase mediated cleavage (Ferreira, et al 2005). The 
Fas death receptor is expressed on all erythroid cells but the ligand (Fas-L) is only 
expressed on mature cells. One possible model is that expression of Fas-L on terminally 
mature cells feedsback to immature precursors, down regulates GATA-1 levels and 
encourages them to differentiate rather than proliferate and thereby matches blood cell 
production to demand.  Since this interaction involves homotypic signalling it would 
explain the rescue of overexpressing cells in the presence of normal mature erythroid 
precursors. This model has been further complicated, however, by a second observation 
that GATA-1 can be protected from cleavage by the presence of a nuclear chaperone; Heat 
Shock protein 70 (HSP70) (Ribeil, et al 2007). These authors showed that the presence of 
EPO caused nuclear co-localisation of HSP70 and GATA-1 and prevention of caspase 
mediated cleavage. This interaction appeared to be crucial for the prevention of apoptosis 
in proerythroblasts. A number of overlapping mechanisms appear to operate at different 
progenitor levels to ensure a matching of mature blood cell output with demand. An 
overview is shown in Fig 1.6. 
Fig 1.6 GATA-1 autoregulation and cross regulation with GATA-2 during 
commitment to the erythroid lineage.  
During early haematopoiesis GATA-2 predominates, GATA-2 down regulation and GATA-1 
up-regulation are required for erythropoiesis. GATA-1 inhibits GATA-2 and also upregulates 
its own expression leading to a gradual switch from GATA-2 to GATA-1 production. GATA-1 
production peaks in intermediate erythroid precursors before being down-regulated to allow 
terminal differentiation. This down-regulation is facilitated by caspase mediated cleavage of 
GATA-1 by activation of Fas death receptors (expressed on all haematopoietic precursors) 
by Fas ligand (Fas-L) which is only present on terminally differentiated cells. Early 
haematopoietic precursors are protected from this GATA-1 cleavage via an erythropoietin 
(EPO) mediated recruitment of nuclear chaperone proteins.  
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1.2.5  The role of GATA-1 in megakaryocyte development 
Megakaryocyte maturation involves a number of specialised processes. As megakaryocytes 
mature they undergo endoreduplication – the doubling of DNA content in S-phase without 
subsequent cell division - leading to sequential increases in ploidy with each cell cycle- 
accompanied by expansion of their cytoplasmic mass. This leads to large cells (up to 100 
microns in diameter) with high chromosome numbers (up to 128 N), hence their name –
mega-karyocyte. Maturation is accompanied by amplification of platelet organelles and 
demarcation membranes – the precursors of platelet membranes. The cells then form pro-
platelet projections which give rise to circulating platelets (Deutsch and Tomer 2006).  
1.2.5.1    Generation of transgenic mice with selective loss of 
GATA-1 expression in the megakaryocytic lineage 
As discussed above megakaryocytes and erythroid cells appear to originate from a 
common meg-erythroid progenitor (MEP) cell. Initial indications that GATA-1 has crucial 
roles in the differentiation of both of these lineages came from overexpression studies. 
Expression of GATA-1 in retrovirally transformed chicken myeloblasts induces 
differentiation into thromboblasts (the avian equivalent of megakaryocytes) as well as 
erythroid and eosinophil lineages (Kulessa, et al 1995). In murine systems, overexpression 
of GATA-1 in the transformed myeloid precursor line 416B leads to production of 
megakaryocytes (Visvader, et al 1992). In addition the GATA-1 knockout chimaeric mice 
have large numbers of immature megakaryocyte precursors in their fetal livers (Pevny, et 
al 1995). Since GATA-1 knockout mice die early from lethal anaemia, it is not possible to 
use this system to examine the requirement for GATA-1 in megakaryocytes. Instead two 
mutant lines of mice have been generated that exploit the known differences in 
requirements for upstream regulatory elements for GATA-1 expression in the two lineages 
(Shivdasani, et al 1997). This was achieved by replacement of an 8kb segment upstream of 
the erythroid first exon of GATA-1, encompassing the testes first exon and the HS1 region, 
with a neomycin resistance gene flanked by LoxP sites (see chapter 4.2.2.2 for a 
description of this technology). When transmitted through the germline this mutant strain - 
called neoΔHS - produced a moderate fetal anaemia and reduced platelet levels in 
hemizygous males. Removal of the neomycin selection cassette by Cre-recombinase 
expression - to produce a second strain - ΔNeoΔHS -led to restoration of nearly normal red 
blood cell production but left the platelet defect unchanged (Shivdasani, et al 1997). 
GATA-1 mRNA is undetectable in megakaryocytes from neoΔHS mice but easily 
detectable in erythroid cells. Low levels of  GATA-1 mRNA are detectable in ΔNeoΔHS Introduction   52 
megakaryocytes but the phenotype of the megakaryocytes are the same in both strains 
suggesting this level is too low to sustain normal megakaryopoiesis.  The platelet counts 
are reduced to about 15% of normal levels in these mice although megakaryocyte numbers 
are greatly elevated. This increase in numbers is independent of platelet count – 
heterozygous females also show this defect despite having normal peripheral platelet 
counts – this rules out a secondary response to thrombocytopenia as the cause of the 
megakaryocytic hyperplasia. Overall these findings suggest that GATA-1 is a negative 
regulator of cell proliferation in early megakaryocyte precursors. In addition, electron 
microscopy confirmed that megakaryocyte precursors are structurally immature with large 
segmented nuclei, lack of cytoplasmic granules, underdeveloped demarcation membranes 
and excess rough endoplasmic reticulum (rRER). Proplatelet formation appears blocked 
and reduced polyploidisation is seen (Vyas, et al 1999a).  Platelets are similarly abnormal 
being spherical rather than discoid, large, with few α-granules and an excess of rRER.  
These results suggest a second role in cellular maturation. This mirrors the role of GATA-1 
in erythroid cells with dual effects on cellular proliferation and terminal maturation.  
1.2.5.2   Gene expression mirrors that seen in the erythroid lineage 
Gene expression profiling of ΔNeoΔHS megakaryocytes versus wild type megakaryocytes 
confirmed down regulation of some GATA-1 target genes such as NF-E2 (p45 subunit) 
and GP1bα in GATA-1 deficient cells, but others such as GpIIb were only modestly 
affected (Muntean and Crispino 2005). This may have been because of an upregulation of 
GATA-2 (5.5 fold) and Ets-1 (6 fold) – the promoters of many megakaryocytic genes 
(including GpIIb) have multiple GATA and Ets binding sites. Therefore, like erythroid 
development, GATA-2 and other transcription factors may be able to partially compensate 
for GATA-1 loss especially in the early stages of differentiation but are incapable of 
producing fully mature cellular progeny.  
1.2.5.3   Rescue of proliferation and differentiation defects can be 
uncoupled and mapped to different domains of GATA-1 
Later experiments assessed the ability of various GATA-1 mutant proteins to rescue the 
megakaryocytic phenotype in ΔNeoΔHS primary fetal liver progenitor cells in vitro (Kuhl, 
et al 2005). These showed that reversal of the proliferation defect and differentiation defect 
can be uncoupled. Specifically the FOG-1 binding domain and amino-acid residues 84-110 
in the N-terminus are both needed to restore differentiation, whilst residues 54-110 are 
needed to prevent abnormal growth (Kuhl, et al 2005).  Of note the naturally occurring 
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This would imply that this variant should have retained differentiation capacity but may 
not be able to control megakaryocyte growth.  This prediction has been strengthened by 
another set of rescue experiments using ΔNeoΔHS fetal liver cells cultured in vitro 
(Muntean and Crispino 2005). ΔNeoΔHS fetal liver cells were retrovirally transfected with 
GFP tagged cDNAs encoding wild type GATA-1, GATA-1s (no N-terminal) or a GATA-1 
mutant unable to interact with FOG-1. Wild-type GATA-1 was able to restore normal 
proliferation and maturation of the cultured megakaryocytes. GATA-1s expression led to 
generation of proplatelets, suggesting effective maturation, but did not correct the 
hyperproliferative phenotype The FOG-1 mutant led to reduced proliferation well below 
that of wild type and a block in differentiation. This result is in contrast to those discussed 
above where the FOG-1 mutant appeared to have normal growth characteristics. Both these 
sets of experiments have to be interpreted with caution as substantial overexpression of the 
exogenous constructs may have influenced the observed phenotypes. 
1.2.6  Role in other lineages 
1.2.6.1   Eosinophils 
The role of GATA-1 in eosinophil development was first suggested by the GATA-1 
overexpression studies in avian haematopoietic progenitors, already discussed in relation to 
erythroid and megakaryocytic differentiation (Kulessa, et al 1995). Interestingly, in these 
experiments eosinophil development was seen to ensue when low levels of GATA-1 were 
expressed whilst higher levels were associated with erythroid and megakaryocytic 
differentiation. Eosinophil differentiation is prevented by deletion of a double GATA 
binding site in the GATA-1 promoter (Yu, et al 2002a).  
1.2.6.2   Mast Cells 
Mast cells, although originating from HSCs in the bone marrow, only undergo proliferation 
and terminal differentiation in connective or mucosal tissues. GATA-1 expression is 
virtually undetectable in bone marrow mast cell progenitors but is upregulated during 
maturation in the tissues (Harigae, et al 1998). Use of the transgenic “GATA-1 low” mice 
showed that GATA-1 deficiency caused proliferation of mast cell precursors countered by 
increased levels of apoptosis, which resulted in normal numbers of mature cells. These 
mature cells have abnormal morphology and functional defects (Migliaccio, et al 2003).  Introduction   54 
1.2.6.3   Dendritic cells 
Recently, a new role has been described for GATA-1 in the dendritic cell lineage 
(Gutierrez, et al 2007). Dendritic cells (DCs) can develop from myeloid and lymphoid 
progenitors. Myeloid derived DCs share precursors with macrophages until late stages of 
differentiation. GATA-1 is expressed in both myeloid and lymphoid derived DCs and 
circulating monocytes but not in macrophages. Experiments using a conditional floxed 
GATA-1 knockout allele (see chapter 4) which can be activated in adult mice, showed that 
loss of GATA-1 led to a significant reduction in circulating monocytes and dendritic cell 
numbers but had no effect on macrophages. GATA-1 also appears to be needed for DC 
activation/maturation in response to inflammatory stimuli (Gutierrez, et al 2007). Further 
investigation of the role of GATA-1 in this lineage is needed.  
1.2.6.4   Sertoli cells 
Finally, GATA-1 expression has been detected in Sertoli cells of the testis in a 
developmental stage specific pattern. Despite this, no phenotype arises from GATA-1 
deletion in this lineage (Lindeboom, et al 2003). Its function remains unknown. 
1.2.7  GATA-1 also plays roles in lineage commitment 
Although early overexpression studies suggested that different levels of GATA-1 
influenced lineage choice in multipotential progenitors (Kulessa, et al 1995, Visvader, et al 
1992), it was unclear whether GATA-1 was acting at the level of lineage commitment or 
favouring outgrowth of mature precursors.  GATA-1 knockout embryos seem capable of 
production of early pro-erythroblasts and megakaryocytes which then get blocked in their 
differentiation and display abnormalities in survival pathways (Weiss and Orkin 1995). 
This led to a general view that GATA-1 was important in maturation and survival but not 
initial lineage determination. This has recently been challenged (Stachura, et al 2006). The 
association of GATA-1 mutations with the myeloproliferative disorder transient abnormal 
myelopoiesis (TAM), which displays features of erythroid, megakaryocytic and basophil 
maturation, suggests activity at a relatively early stage of the haematopoietic hierarchy 
(Hitzler and Zipursky 2005). In addition GATA1.05 mice are seen to develop both B cell 
and myeloid leukaemias suggesting that reduced GATA-1 activity affects normal 
CMP/CLP commitment (Shimizu, et al 2004). Further examination of “GATA-1 low” 
mice reveals a unique progenitor population, not seen in normal mice, capable of trilineage 
commitment to mast cells, megakaryocytes and erythroid cells (Ghinassi, et al 2007). 
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expression of GATA-1. This suggests GATA-1 also plays a role at the level of MEP/Mast 
cell progenitor commitment and that levels of this transcription factor determine lineage 
choice. Finally, studies of thrombopoietin stimulated GATA-1 null ES cells show that 
these cells can form immature blasts capable of indefinite proliferation. On restoration of 
GATA-1 activity these cells differentiate into both megakaryocytic and erythroid cells 
suggesting that they represent a common meg-erythroid progenitor (Stachura, et al 2006).  
1.2.8  GATA-1 isoforms 
As discussed in section 1.2.2, and illustrated in Fig 1.5, GATA-1 appears to have at least 
two isoforms. The longer isoform GATA-1 full-length (GATA-1FL) represents the normal 
haematopoietic isoform produced by translation of the full length mRNA product.  The 
short isoform (GATA-1s) lacks the N terminus and has been the subject of intense interest 
recently due to its association with unique, highly informative, preleukaemic and 
leukaemic conditions associated with trisomy 21 – transient abnormal myelopoiesis (TAM) 
and acute megakaryoblastic leukaemia (AMKL). This association is discussed in detail in 
section 1.3.2. Possible roles of GATA-1s in normal haematopoiesis are discussed below.  
1.2.8.1   GATA-1s is produced by alternative translation in mice 
GATA-1s was first detected by western blotting. Antibodies raised against the N terminus 
of GATA-1 produced a single band with a molecular weight (MW) of 47kD corresponding 
to GATA1-FL. Use of a polyclonal antibody raised against the zinc-finger domains also 
produced this 47kD FL band but an additional 40kD band was also seen (Calligaris, et al 
1995). The GATA-1 gene in mice encodes a unique 1.8kb mRNA with no evidence to date 
of alternative splicing. Although most eukaryotic mRNAs have a single open reading 
frame and a single functional translation initiation site, usually the AUG codon that lies 
closest to their 5’ end, it is possible to produce more than one polypeptide from a single 
mRNA (Kozak 1986a). According to the scanning model of mRNA translation a 40S 
ribosomal subunit binds to the capped 5’ end of mRNA and migrates along the mRNA 
until it reaches the first AUG codon. At this point it stops, couples with a 60S subunit and 
initiates protein synthesis (Alberts 2008). Recognition and ribosomal arrest at the first 
AUG is aided by an optimal surrounding sequence namely CCACCAUGG (called a Kozak 
sequence (Kozak 1986b)), the A nucleotide at -3 and the G at +4 being the most critical. If 
this Kozak sequence is suboptimal some 40S subunits will stop and initiate but others will 
bypass this site and continue until they reach a second AUG triplet. This “leaky scanning” 
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GATA-1 translation seems entirely compatible with this model. The first AUG does not 
possess an optimal Kozak sequence and a second potential translation initiation site occurs 
in frame at codon 84. Hence leaky scanning would be capable of producing long and short 
forms of the protein. This was confirmed by in vitro transcription/translation experiments 
(Calligaris, et al 1995). Different methods of isoform production appear to operate in 
humans - alternative splicing of the mRNA producing an exon 1-2-3 splice for GATA-1FL 
and exon 1-3 splice variant for GATA-1s has been demonstrated, although it is still 
possible that alternative translation also operates in this system (Rainis, et al 2003).  
The original description of GATA-1s was accompanied by expression patterns in the 
developing embryo (Calligaris, et al 1995). The authors looked at lysates from day 8.5 
whole embryos and day 11.5 fetal liver. Interestingly, both isoforms were readily detected 
at day 11.5 but only GATA-1s was seen at day 8.5. This raises the possibility that GATA-
1s may play a role in yolk-sac derived haematopoiesis.  
1.2.8.2   GATA-1s shows reduced transactivation potential in vitro 
In order to test its functional ability, GATA-1s was co-transfected with a GATA-1 reporter 
gene into COS cells. These experiments showed an approximately 50% reduction in the 
ability of GATA-1s to transactivate the reporter gene compared to GATA-1FL, consistent 
with the notion that the N terminus acts as a transactivation domain binding co-factors to 
enhance GATA-1 activity (Calligaris, et al 1995, Martin and Orkin 1990). Despite this, the 
identification of interacting partners has remained elusive. Interestingly Runx-1 appears to 
bind the N and C terminals (Elagib, et al 2003).  A large phage peptide library screening 
project identified the HIV accessory protein Nef (Secco, et al 2003), although the 
relevance of this in vivo is unclear.  Overall, as discussed below, it has been difficult to 
demonstrate non-redundant activities for the N-terminus. It is possible that the requirement 
for this region in non-haematopoietic cell lines may reflect the fact that other essential 
GATA-1 cofactors are absent in these cells making low affinity interactions with the N 
terminus rate limiting for transactivation.  
1.2.8.3   Creation of a transgenic mouse expressing GATA-1s 
Early experiments looking at the domain function of GATA-1 (discussed in section 1.2.3.3 
above) had suggested that an N terminal mutant mimicking the structure of GATA-1s was 
able to rescue primitive erythropoiesis in GATA1.05 (knockdown) mice. The effect on 
definitive haematopoiesis was variable depending on expression levels of the mutant – 
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rescue in some mice (Shimizu, et al 2001). These experiments contrasted with earlier in 
vitro work which appeared to show that the N terminal domain was dispensable for 
erythroid and megakaryocytic differentiation. For example, GATA-1 lacking an N terminal 
domain was equally effective as N-terminal containing mutants at restoring haematopoiesis 
during embryoid body formation in GATA-1 deficient ES cells (Blobel, et al 1995). In 
addition, megakaryocytic differentiation can be induced in the absence of the N terminus in 
the early myeloid cell line 416D (Visvader, et al 1995). Finally, rescue of terminal 
erythroid differentiation in the GATA-1 knockout ES cell line G1E was shown not to 
depend on the presence of the N terminus (Weiss, et al 1997). None of these experiments 
were able to recapitulate normal patterns of GATA-1 isoform expression and they all only 
model certain aspects of the role of GATA-1 in developmental haematopoiesis, lineage 
choice, or terminal differentiation, making their interpretation difficult.   
In order to investigate the function of GATA-1s in vivo, a mouse model was created where 
GATA-1 at the endogenous locus was replaced by a construct capable of exclusive GATA-
1s expression (a GATA-1s knock-in model or effectively a GATA-1FL knockout) (Li, et al 
2005). Many of these mice survived to adulthood and showed essentially normal 
haematological indices with normal white and red blood cell counts, normal platelet 
numbers, morphology and function and normal megakaryocyte numbers in adult spleens. 
However, 10-15% of mice were lost in utero. More detailed examination of the in utero 
phenotype showed a perturbation of fetal haematopoiesis with hyperproliferation of a 
transient wave of yolk sac and fetal liver progenitors. At E12.5 affected embryos showed 
gross fetal liver pallor with reduced numbers of erythrocytes accompanied by a large 
increase in the number of cells expressing the megakaryocytic marker CD41. These 
CD41+ progenitors displayed marked hyperproliferation and reduced, but not blocked, 
maturation when cultured in vitro. These abnormalities were first detected at E9.5 in the 
yolk sac and the abnormal cell population appeared to have shifted to fetal liver by E11.5, 
however expression here was only transient with a falling off of progenitor numbers by 
E14.5 and essentially normal appearances by E16.5.  The effect of GATA-1s on gene 
expression during megakaryocytic differentiation was then assessed by microarray 
profiling of GATA-1s and wild type GATA-1 fetal liver-derived megakaryocytes. An 
additional comparison was also made with the same cells derived from mice carrying the 
megakaryocyte specific GATA-1 knockdown mutation ΔNeoΔHS discussed in section 
1.2.5.1 above.  Overall this analysis shows that megakaryocytic genes, normally 
upregulated on differentiation, are still upregulated in the presence of GATA-1s but to a 
lesser extent. This contrasts with ΔNeoΔHS where mature gene expression is blocked. In 
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GATA-1. These include myc, myb, GATA-2, PU.1 and Ikaros. The first three genes are 
important for proliferation of progenitors whilst the last two play essential roles in lineage 
choice (myeloid and lymphoid respectively). Overall this data suggests that GATA-1s is 
capable of uncoupling differentiation and proliferation and that, far from being an essential 
transactivation domain, the N terminus may actually function as a critical repressor of 
proliferative genes and those responsible for alternative lineage choice. One important 
limitation of this study is that, although knocked-in to the endogenous locus, GATA-1s 
expression does not mimic its physiologic expression pattern. GATA-1s will be produced 
in place of GATA-1FL as the first ATG is followed by the GATA-1s coding sequence. 
Interestingly a second mouse model has been created using N-ethyl-N-nitrosurea 
mutagenesis that carries a mutation in the initiation codon of GATA-1 thereby preventing 
translation of GATA-FL. In contrast to the GATA-1s knock-in this mutation is embryonic 
lethal in males at a time equivalent to GATA-1 null mice. Heterezygous females exhibit 
thrombocytopenia and a fetal blast population with mast cell like progenitor characteristics. 
The authors were unable to document GATA-1s production at the protein level despite the 
presence of mRNA transcripts (Majewski, et al 2006).  
1.2.8.4   Insights from a naturally occurring human mutation  
The discovery of a Brazilian family with an inherited mutation in GATA-1FL which 
preserves GATA-1s function has actually produced a far better knockout model than those 
described above! In this family a mutation in the splice site at the end of exon 2 means that 
no FL GATA-1 transcript is produced but that GATA-1s is still transcribed at a level 
equivalent to unaffected family members (Hollanda, et al 2006). Analysis of the family 
uncovered 7 affected males over 2 generations with full penetrance. Female heterozygotes 
had no detectable phenotype despite the prediction that they would express the mutant 
allele in 50% of their cells due to Lyonisation. All affected males had a moderate to severe 
macrocytic anaemia, accompanied by neutropenia but normal platelet counts. Bone 
marrow examination revealed trilineage dysplasia, reduced erythropoiesis and 
granulopoiesis but normal or increased numbers of megakaryocytes some of which were 
small and immature. Despite normal counts, peripheral blood platelets were 
morphologically and functionally abnormal. Overall these data suggest that GATA-1s is 
incapable of supporting normal adult erythropoiesis and megakaryopoiesis. Additionally, 
neutropenia has not previously been described in association with GATA-1 deficiency, the 
mechanism for this is unclear. Interestingly this kindred- and the mouse GATA-1s knock-
in described above- do not appear to have an increased incidence of leukaemia or transient 
abnormal myelopoiesis - discussed below.  The differences between the human and mouse Introduction   59 
data may be explained by differences in levels of expression of GATA-1s (high in the 
mouse, physiological in the human). It was previously shown that high levels of a GATA-1 
NT mutant were required to rescue definitive haematopoiesis (Shimizu, et al 2001). 
1.2.8.5   Summary of known GATA-1s function  
Overall these studies, although sometimes conflicting, suggest that GATA-1s may have a 
role in normal yolk-sac haematopoiesis but that the expression of GATA-1FL is required 
for normal levels of definitive haematopoiesis (Hollanda, et al 2006, Shimizu, et al 2001). 
Mutational analysis has shown a vital role for the N-terminus in regulation of fetal liver 
megakaryocyte proliferation (Kuhl, et al 2005, Muntean and Crispino 2005), and 
microarray studies have confirmed inadequate repression of genes involved in cellular 
proliferation and lineage choice in GATA-1FL knockouts (Li, et al 2005). A model could 
be proposed whereby GATA1s is responsible for a background level of megakaryopoiesis 
and erythropoiesis which may be particularly important in early embryogenesis when early 
reliable establishment of platelet and red blood cell production is an essential requirement 
for embryonic survival. The N-terminus (GATA-1FL) is then required to take part in 
sophisticated transcriptional networks associated with lineage choice and maintenance of a 
proper balance between gene repression and activation in definitive haematopoiesis. 
Whether GATA-1s has any unique role in haematopoiesis, or whether it is redundant in the 
presence of a fully functioning GATA-1FL allele, has not been tested to date. The role of 
GATA-1 mutations in the development of leukaemia will be discussed below. 
1.3 Leukaemia 
Leukaemia is the medical term given to malignancies of the haematopoietic system. Study 
of leukaemia has shed much light on the genetic basis for haematopoiesis and knowledge 
of key molecular events in haematopoiesis has allowed some major advances in the 
management of patients with leukaemia. This disease is a good example of the 
interdependence between basic biology and translational medicine. Leukaemia is classified 
according to the presumptive cell of origin and kinetics of disease (acute or chronic). The 
major broad classification of acute leukaemias is into acute myeloid leukaemia (AML) and 
acute lymphoblastic leukaemia (ALL). AML is further subdivided using a number of 
different systems. Traditionally sub-classification of AML was based on cell of origin 
using an agreed nomenclature known as the FAB (French-American-British) class i.e. 
undifferentiated myeloblast,  promyelocyte, myelomonocyte, monocyte, eosinophil, 
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by the World Health Organisation to reflect differences in disease biology and to 
incorporate key cytogenetic features that determine outcome (Jaffe 2001). ALL is 
subdivided into B cell ALL and T cell ALL, there is then further subdivision according to 
the apparent stage of developmental arrest e.g. pro-B, preB, mature B.  
The causes of leukaemia are generally unknown. There are few well-established risk 
factors with the exceptions being; exposure to ionising radiation, chemicals such as 
benzene or previous chemotherapy (Hoffbrand, et al 2005). The majority of cases are 
sporadic, although occasionally acute myeloid leukaemia can arise secondary to an 
inherited bone marrow failure syndrome (Alter 2002) or a germline mutation in a 
haematopoietic regulatory gene e.g.  Runx-1 (Owen, et al 2008). 
1.3.1 The genetic basis for leukaemia development 
Leukaemias are characterised by deregulation of proliferation, maturation and cell 
survival/apoptosis pathways with the balance shifted towards survival even in the face of 
cellular stress. Initial clues as to the molecular basis for leukaemia came from the study of 
recurring chromosomal translocations identified in subsets of leukaemic cells. Cloning and 
characterisation of these translocation breakpoints led to identification of key genes whose 
disruption could lead to a malignant phenotype. The number of identified translocations 
has rapidly increased with over 100 now described (Gilliland 2001). This far exceeds the 
number of identified subtypes of leukaemia. In addition it has become clear that many 
other genetic changes occur in leukaemia cells such as point mutations in genes or their 
regulatory regions, intrachromosomal amplification, loss of heterozygosity, epigenetic 
histone modifications, alterations in protein degradation and changes in microRNA 
profiles. Some of these abnormalities are primary transforming events whist others are 
secondary to genomic instability and disrupted regulatory processes in transformed cells, 
or may follow selective pressure such as chemotherapy treatment. Despite this apparent 
complexity a number of themes emerge that help us to understand the molecular basis for 
leukaemia development. These are discussed below: 
1.3.1.1   Class 1 and Class 2 mutations 
Very early observations on the nature of malignant transformation and the kinetics of 
disease acquisition, well before the era of molecular medicine, suggested that the 
development of cancer requires more than one genetic change (Ashley 1969). This 
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supressor genes (Knudson 2001). Study of the myriad of translocation partners and other 
genetic mutations in leukaemias has identified that genes often fall in to one of two groups 
which are now termed Class 1 and Class 2. Class 1 mutations confer a proliferative or 
survival advantage to cells but do not affect haematopoietic differentiation, these often 
involve signal transduction pathways or genes with roles in the cell cycle, examples 
include the bcr/abl translocation in CML or Flt-3 activating mutations in AML. Class 2 
mutations primarily affect differentiation and have only modest effects on 
proliferation/survival, these often involve transcription factors, for example the 
PML:RARα translocation in acute promyelocytic leukaemia (Gilliland 2001). It is 
noteworthy that transcription factor mutations are rarely null mutations instead they 
usually produce either quantitative or qualitative effects on function, basal levels of 
transcription factor activity are probably crucial for cell survival (Rosenbauer, et al 2005). 
It is hypothesised that, in order to undergo leukaemic transformation, a cell must acquire 
both a Class 1 and a Class 2 mutation (Gilliland 2001). This hypothesis was originally 
questioned by the observation that many acute myeloid leukaemias only appeared to carry 
a single dominant mutation in a class 2 gene such as the t(8:21) – AML-1-ETO or t(15:17) 
PML-RARα, but more recently it has emerged that these cells often carry additional 
mutations in class I genes that are not detectable by conventional cytogenetics such as a 
Flt-3 activating mutation (Nakao, et al 1996). In fact activation of multiple signal 
transduction pathways appears to be a feature of AML and clinical outcome is inversely 
related to the number of pathways activated (Kornblau, et al 2006). One conclusion from 
these observations is that a single “targeted therapy” is unlikely to be sufficient for the vast 
majority of leukaemias. Instead an approach targeting both Class 1 and Class 2 mutations 
is much more likely to be successful. Another prediction is that in some cases it should be 
possible to identify premalignant clones that have acquired one class of mutation but are 
yet to acquire a second. This is discussed below: 
1.3.1.2   In utero acquisition of mutations 
One observation that led to the two hit hypothesis of malignancy was that the incidence of 
malignancy generally rises with age, presumably reflecting the time needed to acquire the 
requisite number of mutations.  An exception to this general rule is seen in childhood 
malignancy. Tumours in childhood often show very distinct age profiles. This may reflect 
transformation of a developmentally restricted progenitor population. These fetal or 
neonatal progenitors often have periods of rapid proliferation or other cellular activity that 
puts them at increased risk of mutations. Any cell acquiring such a mutation has a limited 
window in which to acquire a second mutation before the population as a whole terminally Introduction   62 
differentiates or is extinguished. Examples of such tumours include retinoblastoma – 
involving fetal retinoblasts and neuroblastoma involving embryonic neural crest cells. 
In the haematopoietic system certain leukaemias show distinct peaks of incidence in 
childhood including most types of ALL and certain rare myeloid leukaemias. The first 
indication that a prenatal event may be involved came from observations of leukaemia in 
identical twins. The concordance rate for leukaemia in monozygotic twins varies greatly 
depending on the subtype e.g.  approximately 50% for infant leukaemias, 10% for common 
childhood ALL and <1% for adult ALL or AML (Greaves 2005). This was initially 
interpreted to reflect a common inherited susceptibility to infant leukaemia. However 
further investigation has shown that this high rate of concordance is due to blood cell 
chimaerism between twins that share a common placental circulation (mono-chorionic 
twins). Using molecular techniques it has been possible to show that the twins share 
identical breakpoints in leukaemic fusion genes. This implies that the fusion arose in a 
haematopoietic progenitor in one twin and progeny of this cell passed via the placental 
circulation to the other twin. The need for a second postnatal event means that concordance 
is not 100%. In fact a concordance of 50% makes a second postnatal (or independent pre-
natal) event extremely common. This may be because the majority of infant ALLs are 
associated with MLL gene abnormalities and it has recently been shown that this mutation 
renders the cell very vulnerable to DNA damage (Eguchi, et al 2006). For childhood 
common ALL concordance is still high. Identification of twins discordant for common 
ALL has allowed elegant studies looking at the kinetics of pre-malignant clones in an 
unaffected twin who carries a Class 2 mutation but is yet to develop acute leukaemia (and 
may never do so) (Hong, et al 2008). These findings have been shown to be of general 
relevance to childhood leukaemia. In particular the startling observation has been made 
that 1% of a randomly selected sample of newborn blood spots (taken as part of routine 
neonatal Guthrie screening for metabolic diseases) have a detectable Tel:AML-1 t(12:21) 
translocation (Mori, et al 2002). Fortunately, only about 1% of these children will go on to 
develop ALL providing further support for the need for more than one mutation. These 
observations have also helped develop hypotheses for the likely causes of the peak of 
leukaemia incidence in children aged 2-5 years old. In particular it hypothesised that 
prenatally the rapid proliferation of lymphoid precursors accompanied by physiological 
gene rearrangements needed to produce unique B and T cell antigen recognition receptors 
predisposes to chromosomal translocations. If these translocations lead to a proliferative or 
survival advantage then these cells will undergo clonal expansion of a usually rare 
intermediate population. Postnatally this small clone remains static in size and would 
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selective pressure is unknown but evidence is accumulating that a delayed exposure to 
certain infections may be responsible (Greaves 2006).  
Although the majority of evidence for the in utero origins of leukaemia has arisen from 
study of childhood ALL there is also evidence for a similar process in some forms of 
childhood AML. In one study Guthrie cards were retrieved from children presenting with 
AML and the t(8:21) translocation – AML1-ETO,  50% of these children had the same 
mutation detectable at birth with the oldest child being 12 years 2 months of age when they 
presented with overt AML (Wiemels, et al 2002). This data is supported by mouse models 
of AML-1-ETO which do not develop leukaemia unless exposed to low dose chemical 
carcinogens – presumably triggering a second mutation (Higuchi, et al 2002).  
1.3.1.3   The cellular origins of leukaemia 
As alluded to above, leukaemic cells often have normal cellular counterparts (Greaves 
1986). An emerging concept in cancer biology is that tumours may contain some cancer 
stem cells - rare cells with indefinite self-renewal properties, that drive the formation of 
tumours (Reya, et al 2001). The existence of leukaemia stem cells was first suggested by 
experiments in the 1960s and 70s that showed that only a small subset of leukaemic cells 
were capable of extensive proliferation in vitro. Also, in vivo transfer experiments were 
only able to demonstrate spleen colonies in 1-4% of mice (Bruce and Van Der Gaag 1963). 
When considering the cell of origin for the leukaemic transformation in AML two 
possibilities exist. Firstly, leukaemic transformation may occur in the normal HSC or 
secondly a more committed progenitor (or even a mature cell) could re-acquire self 
renewal properties secondary to transformation. HSCs are particularly good targets for 
leukaemic transformation as maintenance of self-renewal activity may be easier than 
turning it on de novo. In addition HSCs are long lived cells which undergo multiple rounds 
of cell division giving them ample time and opportunity to acquire multiple mutations. 
This does not mean that restricted progenitors cannot be the target cells for leukaemic 
transformation – they could inherit an original first hit from an HSC and the second hit 
could be acquired in a downstream progenitor. Alternatively, a committed progenitor could 
acquire a mutation that conferred stem cell like properties of self renewal.  Evidence for 
both pathways exists, although it is likely that HSC transformation is commoner. One 
elegant study showed that in most AML subtypes transfer of a primitive CD34+CD38- 
subpopulation (comprising only 0.2-1.0% of the patients leukaemic cells) was capable of 
transferring AML into NOD/SCID mice, whilst the CD34+CD38+ cells which comprised 
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CD34+CD38- cells did not only sustain stable leukaemic engraftment but also produced a 
leukaemia that was morphologically and immunophenotypically identical to the original 
patient’s leukaemia. This implies that this primitive population of leukaemic stem cells 
were capable of partially differentiating to produce more mature although still aberrant 
progeny – a leukaemic cellular hierarchy exists that parallels the normal haematopoietic 
cellular hierarchy. This leads to the important conclusion that the bulk cell population in 
the tumour does not necessarily equate to the cell of origin of the leukaemia. Evidence 
does exist for the alternative model of acquisition of stem cell properties in more mature 
cells. In particular transfection of a leukaemic fusion gene t(11:19) MLL-ENL transcript 
into either HSCs, common myeloid progenitors or granulocyte-macrophage progenitors 
produces exactly the same leukaemia, irrespective of progenitor stage, on transfer to mice 
(Cozzio, et al 2003). In the case of ALL the concept of a stem cell population is less well 
established. This probably reflects the unique properties of lymphocytes which allow 
clonal expansion at mature stages of differentiation, hence the ability to repopulate 
NOD/SCID mice has been demonstrated in many different fractions of the leukaemic cell 
population, including relatively mature CD19+ compartments (le Viseur, et al 2008). 
Overall, the concept of leukaemic stem cells, particularly in AML, is an important one. 
Therapies directed at the bulk cells in the tumour will produce rapid cytoreduction (and 
therefore an apparent response) but may leave the cancer stem cell population untouched. 
This will inevitably lead to relapse at a later date. Understanding the properties of the 
cancer stem cell will be crucial for effective targeted therapy. Unfortunately, akin to 
normal HSCs, despite being capable of expansion and self renewal these cells are often 
relatively quiescent, and may be relatively drug resistant due to expression of high levels 
of efflux pumps (Elrick, et al 2005). This makes devising effective therapy particularly 
challenging. 
1.3.1.4   Primary and secondary changes in leukaemic cells 
Despite the extensive acquisition of information on molecular events in leukaemic cells we 
are still far away from a comprehensive explanation of the stepwise acquisition of 
abnormalities that lead to a fully leukaemic phenotype. One of the major problems is that 
the vast majority of leukaemias only present when fully established and causing clinical 
symptoms. At this stage the cells have often acquired multiple genetic abnormalities some 
fundamental to leukaemogenesis and some secondary events. Dissecting out the primary 
initiating events can be very difficult at this stage. By analogy with the concept of 
leukaemic stem cells discussed above, directing therapies at secondary events will leave 
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are to be effective. In addition, using this information it may be possible to identify 
leukaemia at a premalignant stage. This raises the possibility of preventative treatment 
rather than waiting for a fully malignant, clinically aggressive phenotype, possibly 
associated with a reduced chance of cure. This is akin to screening for, and treating, 
premalignant lesions in other systems such as colonic polyps or cervical intraepithelial 
neoplasia. The existence of clinically rare leukaemias with a recognised pre-leukaemic 
phase has provided a unique opportunity to study the multiple genetic and cellular events 
needed to produce full-blown leukaemia in vivo. The paradigm for this is Down syndrome 
associated acute megakaryoblastic leukaemia discussed below. 
 
1.3.2 Down syndrome and leukaemia 
Down syndrome is caused by Trisomy 21 and has an incidence of 1 in 600-800 live births 
making it the commonest human chromosomal abnormality. It has long been known that 
children with Down Syndrome have an increased incidence of leukaemia approximately 
10-20 fold above that of the general population (Lange, et al 1998). This is not due to a 
general cancer predisposition syndrome, the incidence of other tumours is often reduced 
below background (Hasle, et al 2000). Both ALL and AML are commoner in these 
children but it is the existence of two rare, interrelated, and almost unique, phenomena that 
has been particularly informative- namely a transient abnormal myelopoiesis (TAM)  and 
acute megakaryoblastic leukaemia (AMKL).  
1.3.2.1   TAM and AMKL - natural history and clinical features 
Children with Down syndrome (DS) have a 500 fold increased incidence of acute 
megakaryoblastic leukaemia which nearly always manifests between the ages of 1 and 4 
years (Lange, et al 1998). In fact children presenting in this age range with AMKL almost 
always have evidence of trisomy 21 – if not already clinically apparent then genetic testing 
often reveals mosaicism or, more rarely, an acquired trisomy 21 in the leukaemic blast cell 
population. This AMKL is clinically and biologically distinct from an alternative infant 
AMKL which is associated with a (1:22) translocation. The infant form has no association 
with Down syndrome and is clinically aggressive with a poor treatment outcome (Ma, et al 
2001). In contrast DS associated AMKL has a good prognosis in children, with 10 year 
overall survival rates of 79% (Hama, et al 2008). This may reflect the presence of a 
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such as the cystathionine-β-synthetase which potentiates the effects of cytarabine – a drug 
known to be very effective in AML (Taub, et al 1999). 
Children with Down syndrome display another relatively unique haematological disorder 
known variously as transient abnormal myelopoiesis (TAM), transient myeloproliferative 
disorder (TMD) or transient leukaemia. As the name suggests this disorder is associated 
with increased numbers of immature myeloid cells in the circulation which are often 
present at or before birth and usually resolve within the first three months of life. The 
classification of this disorder has caused some controversy as these cells are phenotypically 
indistinguishable from leukaemia cells – they are morphologically and 
immunophenotypically identical to AMKL cells, monoclonal (Kurahashi, et al 1991) and 
may have acquired additional genetic mutations (Zipursky 2003). This would suggest that 
they are leukaemic blasts. Evidence against this comes from their biological behaviour– 
these cells often spontaneously disappear without any active treatment. Further elucidation 
of the molecular basis of TAM and full-blown AMKL, discussed below, has led to the 
conclusion that TAM represents a preleukaemic phase of AMKL. Like AMKL, TAM is 
also tightly linked to the presence of trisomy 21. Virtually no cases have been described in 
otherwise normal children. 
Clinically TAM is often asymptomatic and found incidentally on a routine full blood count 
performed for other indications such as cardiac surgery. However, it can present clinically 
with organomegaly or a skin rash. In some patients (reported to be up to 20% in one 
prospective study (Al-Kasim, et al 2002)) the disease may take a more severe course with 
hepatic failure or cardiopulmonary disease. The main pathology seems to be extensive 
blast cell proliferation in the liver with associated hepatic fibrosis. This can cause 
significant morbidity and mortality but may respond to low dose chemotherapy 
(cytarabine) if treatment is started early enough (Al-Kasim, et al 2002). The incidence of 
TAM is currently unknown. This is because children with Down syndrome do not all 
undergo full blood count analysis at birth. Since TAM is often clinically silent this means a 
large number of cases go undetected. A number of small cohort studies have put the 
incidence at about 10% of all babies with Down syndrome (Zipursky, et al 1997). A recent 
prospective study reported the outcome for 48 children with TAM, this confirmed the early 
mortality in severe cases but also that 89% of children spontaneously cleared their blast 
population. 19% of infants went on to develop AMKL. Risk factors for progression to 
AMKL were male sex and presence of additional cytogenetic abnormalities at diagnosis of 
TAM (Massey, et al 2006). It is worth noting that the various figures in the literature are 
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the risk of TAM 10% and the risk of progression from TAM to AMKL 20-30%. If this 
latter figure were correct then the risk of AMKL would be 2-3 in 100, not 1 in 500. This 
probably reflects the fact that there is a reporting bias – the incidence of AMKL in patients 
presenting to tertiary referral centres with Down syndrome complications may well be 
higher than in an unselected population. A number of cohort studies are currently assessing 
the true incidence and natural history of TAM (Vyas and Roberts 2006). 
From these basic clinical facts, a number of predictions can be made. Firstly the 
development of AMKL must require at least 3 genetic events; trisomy 21 is required for 
TAM but not sufficient, as 90% of Down syndrome children appear haematologically 
normal; a second event is needed to develop TAM but again this is not sufficient for 
AMKL as most children recover completely; and a third event is then needed in children 
who go on to develop AMKL, this stepwise progression is illustrated in Fig 1.7. A second 
prediction is that the age range of children with AMKL suggests leukaemic transformation 
occurs in a cell with developmentally restricted potential such as a yolk sac or fetal liver 
progenitor. Lastly, the nature of the blasts in TAM and AMKL suggest involvement of 
genes important in the specification of megakaryocytic and erythroid lineages. 
Over the last 6 years remarkable progress has been made in unravelling the molecular basis 
of TAM and AMKL. This will be reviewed below: 
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1.3.2.2   GATA-1 mutations and DS TAM/AMKL 
The tight association between trisomy 21 and TAM/AMKL led to the assumption that any 
unique genetic mutations in this disorder would be discovered in chromosome 21 genes. It 
was surprising therefore, that the real breakthrough came with the discovery in 2002 that 
all (6/6) cases of DS-AMKL studied had mutations in the X-linked gene GATA-1. This 
association between GATA-1 mutations and Down syndrome AMKL was tightly linked – 
other DS ALL and AML, other non-DS AMKL and various AML, MDS and healthy 
control samples (92 samples in total) were all negative for GATA-1 mutations (Wechsler, 
et al 2002). The detected GATA-1 mutations all resulted in premature termination of 
GATA-1 in the N terminal activation domain i.e. they prevented synthesis of GATA-1FL 
but should not interfere with production of the GATA-1s isoform. These predictions were 
confirmed by western blotting showing absence of the 47kDa GATA-1FL protein but 
presence of a 40kDa GATA-1s band. The mutations were not present in remission bone 
marrow samples from the same patients, confirming that they were somatically acquired. 
This report was confirmed by a number of groups all of whom reported the extremely high 
incidence of GATA-1 mutations in DS AMKL and the clustering of these mutations in the 
N-terminus. Overall 45 out of 53 reported cases have confirmed GATA-1 mutations 
(Ahmed, et al 2004, Groet, et al 2003, Hitzler, et al 2003, Magalhaes, et al 2006, 
Wechsler, et al 2002, Xu, et al 2003). To date only one case has been reported of a GATA-
1 mutation in an individual without trisomy 21- an adult with AMKL (Harigae, et al 2004). 
This represents a virtually unprecedented level of concordance between a genetic mutation, 
an underlying constitutional disorder and risk of leukaemia.  
An obvious question is at what stage GATA-1 mutations exert their effect – are they 
responsible for the eventual leukaemic transformation or do they produce the preleukaemic 
disorder TAM? A number of studies addressed this and confirmed that the latter was 
correct – GATA-1 mutations in the N-terminus are also seen in virtually all cases of TAM. 
73 out of 80 reported cases have detectable GATA-1 mutations (Ahmed, et al 2004, Groet, 
et al 2003, Hitzler, et al 2003, Magalhaes, et al 2006, Rainis, et al 2003, Shimada, et al 
2004, Xu, et al 2003). These studies also established a number of other important facts: 
The GATA-1 mutation is acquired prenatally:  A number of observations point to the 
prenatal acquisition of GATA-1 mutations. TAM is usually present at birth and Guthrie 
blood samples taken in the first 2 weeks of life have shown GATA-1 mutations (Ahmed, et 
al 2004). In addition two pairs of identical twins have been reported with TAM. In both 
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the mutation in one twin which was then passed on to the other twin via a shared 
circulation (Rainis, et al 2003, Shimada, et al 2004). There are many case reports of Down 
Syndrome fetuses presenting before birth with hydrops fetalis or massive hepatomegaly 
detected on ultrasound scanning – clinical features of TAM have been recorded on fetal 
blood sampling and, in one study, a GATA-1 mutation was confirmed in a stillborn infant 
with clinical signs of TAM (Heald, et al 2007). Fetuses with TAM like features have been 
reported from 25 weeks gestation onwards (Robertson, et al 2003).  Finally, a study using 
autopsy material from fetuses with Down syndrome found GATA-1 mutations in 2/9 fetal 
liver samples at 21 and 23 weeks gestation. These fetuses were not known to have features 
of TAM (Taub, et al 2004). Although a very small study, this level of detection suggests 
that the incidence of GATA-1 mutations may be larger than that of clinically detectable 
TAM.  
GATA-1 mutations in TAM and AMKL in the same patient are identical: In cases where 
samples from TAM and AMKL have been available in the same patient the mutation in 
GATA-1 has always been identical (Rainis, et al 2003). In addition in patients presenting 
with AMKL with no obvious antecedent history of TAM, examination of Guthrie spots has 
confirmed a GATA-1 mutation identical to the AMKL associated mutation in 3 out of 4 
cases studied (Ahmed, et al 2004). This provides molecular evidence for the long held 
assertion that AMKL arises due to evolution of a persisting TAM clone rather than as a 
completely independent event i.e. that TAM represents a preleukaemic phase of AMKL. 
This same study showed that the size of the GATA-1 mutation clone can vary considerably 
at birth. This leads to a hypothesis that the clinical presentation of TAM is determined by 
clone size, which may in turn be related to the gestational age at which the GATA-1 
mutation was first acquired (Vyas and Roberts 2006). This is illustrated in fig 1.8. 
In some patients multiple GATA-1 mutations are detectable: Using sensitive techniques it 
is possible to detect, in some cases of TAM, more than one mutant clone, each carrying a 
different GATA-1 mutation, (Ahmed, et al 2004). This implies that either trisomy 21 is 
associated with very high rates of somatic mutation (unlikely due to the specificity of 
GATA-1 mutations and the lack of mutations in other genes studied such as Runx-1 (Xu, et 
al 2003)) or, as is thought more likely, the GATA-1s mutation confers a selective 
advantage to progenitor cells. The clones may vary in size although the size of the clone 
does not seem to determine the risk of progression to AMKL (Xu, et al 2006). 
GATA-1 mutations and trisomy 21 are only required in the haematopoietic cells for 
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who do not appear clinically to have Down syndrome. These patients usually have either 
mosaicism for trisomy 21 or have an acquired trisomy 21 in their blast cell population. One 
report of identical twins with just such an acquired trisomy 21 has shown clinical presence 
of TAM in both twins and progression to AMKL in one twin. Trisomy 21 was not 
detectable in karyotypic analysis of non-TMD cells and disappeared with disease 
resolution (Carpenter, et al 2005). Since these patients displayed the full TAM/AMKL 
phenotype it appears that both trisomy 21 and GATA-1 mutations are only required in the 
haematopoietic cells. This suggests that these genetic abnormalities act in a cell 
autonomous manner rather than altering the microenvironment or extrinsic signalling 
pathways to cause excessive cellular proliferation. 
 
Fig 1.8 Proposed impact of clone size and acquisition of mutations on 
clinical presentation 
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clinical evidence of TAM showed GATA-1 mutations in 2/21 of their Guthrie spot 
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tests from children with trisomy 21 and identified GATA-1 mutations in 22 of them (3.8%) 
(Pine, et al 2007). This leads to questions about the clinical definition of TAM – should all 
children with GATA-1 mutations be considered to have TAM or only those with clinically 
evident disease? Interestingly, it appears that clinical evidence of TAM (presumably 
reflecting a large abnormal clone size) is not associated with an increased risk of 
transformation to AMKL and in fact these patients often respond better to treatment than 
patients with no antecedent history of TAM (Klusmann, et al 2008). These are important 
considerations as parents of children with TAM are obviously concerned about the risk of 
progression to AMKL – this risk is likely to vary depending on the definition of TAM 
used. Prospective studies looking at the natural history of TAM are required.  
Although alternative translational start points are identifiable, only GATA-1s protein is 
ever detectable in these cells:  Over 100 GATA-1 mutations have been described to date 
all of which fall in the N terminal domain. Some of these mutations lead to predictions of 
alternative, out of frame, start codon usage between the codon 1 and codon 84 – the start 
codon for GATA-1s (Hitzler, et al 2003). Many studies have not shown actual evidence of 
GATA-1s production by western blotting, but in those that have done so, only the 40kDa 
GATA-1s band has ever been detected, even if other start codons appear possible (Xu, et al 
2003). This implies that the GATA-1s protein is vital for the pathology of the disease 
rather than just loss of the full length isoform.  
1.3.2.3   Evidence for a fetal liver progenitor cell population as the 
target for GATA-1 mutations 
A number of pieces of evidence point to TAM/AMKL arising from transformation of a 
fetal haematopoietic progenitor rather than definitive adult haematopoietic cells. Firstly 
TAM and AMKL are characterised by blast accumulation in the liver and/or spleen with 
relative sparing of the bone marrow (Miyauchi, et al 1992, Zipursky 2003). Blasts from 
TAM show evidence of fetal and adult globin expression (Ito, et al 1995). As discussed in 
section 1.2.8.3 the GATA-1s knock-in mouse shows a specific developmentally restricted 
defect in yolk-sac and fetal liver haematopoiesis which is then followed by normal adult 
haematopoiesis (Li, et al 2005). Most compellingly however is the simple observation that 
TAM and AMKL are developmentally restricted to the first 3 months and 4 years of life 
respectively. AML in children with Down syndrome older than 4 usually lacks the GATA-
1 mutation and biologically is more akin to sporadic AML (Hasle, et al 2008). Adults with 
acquired trisomy 21 and AMKL do not have detectable GATA-1 mutations and their 
disease is biologically distinct from DS-AMKL (Vyas and Roberts 2006). The regression Introduction   72 
of TAM corresponds to the switch from fetal liver to bone marrow haematopoiesis 
(Crispino 2005). This age restriction would be compatible with the transformed cell having 
an intrinsically limited lifespan or with a failure of the postnatal haematopoietic 
environment to sustain embryonic precursors. Although it should be noted that an 
alternative explanation is that the GATA-1s containing clones have a proliferative 
advantage, but are not immortalised, and therefore eventually die out due to failure of self-
renewal. Of interest, in one study, telomerase activity (associated with malignancy and the 
ability of cells to undergo multiple rounds of division without senescence) was found in 
15/29 samples from AMKL patients but only 4/34 cases of TAM. In addition 3 out of the 4 
telomerase positive TAM cases were associated with particularly severe disease (Holt, et al 
2002). In terms of the lineage affiliation of the progenitor cell in AMKL, the blasts in 
TAM and AMKL express both erythroid and megakaryocytic genes at the mRNA level 
and display typical erythroid and megakaryocytic cell surface marker expression patterns 
(Ito, et al 1995, Miyauchi, et al 1992). This suggests the involvement of a cell capable of at 
least a bipotential meg-erythroid fate. Interestingly many cases of TAM are also associated 
with increased numbers of circulating basophils and more rarely eosinophils. In vitro 
culture of TAM blasts also sometimes produces basophils (Zipursky 2003). The origin and 
commitment of cells to the basophil/mast cell lineage remains one of the unresolved 
features of haematopoiesis, as does the developmental relationship between the two 
lineages (Arinobu, et al 2005, Gurish and Boyce 2006). The recent description of a 
tripotential meg-erythroid-mast cell progenitor population in “GATA-1 low” mice may be 
relevant here (Ghinassi, et al 2007). The discovery of yolk-sac derived primitive 
megakaryopoiesis discussed in section 1.1.1.2 (Tober, et al 2007) provides another 
possible target cell for GATA-1s mutations. 
Overall, the evidence above suggests that the GATA-1 mutation is acquired in fetal life 
and is responsible, in conjunction with trisomy 21, for development of the preleukaemic 
condition TAM. GATA-1s therefore acts as a second genetic hit in this condition (see Fig 
1.7). What have we learnt about the first and third hits? 
1.3.2.4   First genetic hit – Trisomy 21 
Perhaps least is known about the contribution of trisomy 21 to the development of AMKL. 
Trisomy 21 appears to be an essential pre-requisite for the oncogenic activity of GATA-1 
mutations, as shown by the absence of leukaemia in mouse models of GATA-1s and the 
human GATA-1s expressing kindred (Hollanda, et al 2006, Li, et al 2005). Trisomy 21 
itself seems to predispose to haematopoietic disorders independent of the increase in Introduction   73 
leukaemia. Children with Down syndrome often display polycythaemia, macrocytosis and 
thrombocytosis at birth (Kivivuori, et al 1996). In addition, study of trisomy 21 is of 
general relevance to leukaemia in the non-DS population –acquired tri or tetrasomy 21 is a 
frequent finding in ALL and internal amplification of chromosome 21 is a very poor 
prognostic feature in these disorders.  It seems possible that trisomy 21 may exert its effect 
due to a gene dosage with overexpression of an oncogenic gene located on chromosome 21 
co-operating with GATA-1 mutations to produce TAM/AMKL. Consistent with this, 
mouse models of Down syndrome show elevated expression of most triplicated genes, to 
about 1.5 times normal, across a wide range of tissues throughout development (Roper and 
Reeves 2006). However, it is now becoming clear that trisomy 21 may exert its effects in 
many ways other than a pure gene dosage effect. Paradoxically, the more that is discovered 
about the genes that are responsible for the Down syndrome phenotype (including recent 
description of a key role for the NFAT transcription factors that recapitulate many features 
of Down syndrome when over-expressed in mice (Arron, et al 2006, Gwack, et al 2006)) 
the more complex the picture becomes. Besides simple gene dosage, the effects of trisomy 
21 may be caused by altered balance between recessive and dominant alleles or many co-
incident small effects. In addition interaction between trisomic gene products and normal 
disomic genes in the cell will cause many secondary effects (Roper and Reeves 2006). 
Examination of the consequences of trisomy 21 has been complicated by the different 
chromosomal locations of mouse and human genes i.e. mouse equivalents of human 
chromosome 21 genes are scattered across 3 mouse chromosomes with 2/3 on chromosome 
16 and the rest on chromosomes 10 and 17. The best mouse model is probably the Ts65Dn 
mouse which contains an extra chromosome 16 segment making it trisomic for about half 
of the human chromosome 21 genes (Kirsammer, et al 2008). The recent description of a 
mouse carrying an extra copy of human chromosome 21 has prompted much excitement – 
this model recapitulates many of the features of Down syndrome including craniofacial 
abnormalities, learning difficulties and heart defects (O'Doherty, et al 2005). No 
haematopoietic phenotype has been described to date, although studies are ongoing.  
Unravelling the role of trisomy 21 has been attempted at cellular and molecular levels. 
Firstly, at a cellular level, two groups have looked at fetal liver haematopoiesis in autopsy 
material from Down syndrome fetuses (Chou, et al 2008, Tunstall-Pedoe, et al 2008). They 
both came to almost exactly the same conclusions by independent means. Namely that fetal 
liver multipotential progenitor cells (identified as CD34+CD38+ cells) show a striking 
increase in meg-erythroid potential with concomitant decrease in the CMP population. In 
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increased clonogenicity on serial replating and increased erythroid and megakaryocytic 
output on transplantation to adult NOD/SCID mice. These features were restricted to fetal 
liver and not seen in bone marrow progenitors from the same fetuses (Tunstall-Pedoe, et al 
2008). GATA-1 mutations were not seen in any of the samples (41 in total) – this contrasts 
with previous work showing GATA-1 mutations in 2/9 fetal liver samples (Taub, et al 
2004). This may reflect the earlier gestational age of fetal samples used in this study 
(median 15 weeks (Tunstall-Pedoe, et al 2008) and range 13-23 weeks (Chou, et al 2008)). 
The absence of GATA-1 mutations allows the conclusion to be made that trisomy 21 leads 
to abnormalities in the haematopoietic progenitor compartment independent of GATA-1 
mutations. This may provide an appropriate cellular substrate for GATA-1s expression to 
exert a phenotypic effect.  
Another autopsy study revealed that peripheral blood samples from aborted Down 
syndrome fetuses have reduced CD34+ haematopoietic progenitors compared to age 
matched controls. This was also associated with reduced telomere length (Holmes, et al 
2006). This contrasts with the above studies which showed normal CD34+ numbers in 
fetal liver and may reflect alteration in cellular localisation and transition between fetal 
liver and bone marrow in DS fetuses rather than an HSC deficiency per se.  
Several different approaches have been taken to dissect out the molecular consequences of 
trisomy 21, and the molecular basis for co-operation between trisomy 21 genes and 
GATA-1s mutations. Thanks to the human genome project the complete sequence of 
chromosome 21 is known (Hattori, et al 2000)  which encodes more than 350 genes. It is 
possible to look at these chromosome 21 genes and take a candidate gene approach for 
those that might play a key role in haematopoietic differentiation. Alternatively, since we 
are a long way from a complete description of the molecular basis for haematopoiesis, it is 
important not to discount genes that may have novel roles in this process – in order to 
identify such unknown genes expression profiling can be attempted. 
A candidate gene approach: Initial speculation pointed to a possible role for Runx-1 
(AML-1) as the chromosome 21 co-operating gene. Many lines of evidence point to this 
gene being a prime candidate. Runx-1 is the commonest gene to be mutated in AML, it lies 
in the DS critical region, it is already known to exhibit gene dosage effects (albeit at the 
level of haploinsufficiency) with a predisposition to AML seen in familial platelet disorder 
(FPD) (Song, et al 1999), and it plays critical roles in erythroid and megakaryocytic 
differentiation. In addition it is known to physically interact with GATA-1 at both the N 
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any association between Runx-1 perturbation and DS-AMKL. Importantly, Runx-1 
overexpressing mice do not have an increased incidence of AMKL (Shimizu, et al 2008). 
Mutational analysis of Runx-1 in children with DS-AMKL has failed to identify any 
abnormalities (Rainis, et al 2003, Wechsler, et al 2002). A number of microarray studies 
have looked for overexpressed genes in DS-AMKL and have not seen any evidence of 
Runx-1 upregulation (Bourquin, et al 2006). Finally, the Ts65Dn mouse shows a 
myeloproliferative disease characterised by megakaryocytic hyperplasia and macrocytosis- 
using elegant crossing experiments between Ts65DN mice and AML-1 haplo-insufficient 
mice it is possible to restore disomy at the Runx-1 locus in Ts65Dn mice. This had no 
effect on the megakaryocytic phenotype (Kirsammer, et al 2008). This is probably the 
most compelling evidence to date that Runx-1 overexpression is not the dominant 
determinant of the leukaemic phenotype in Down syndrome. This does not necessarily 
mean it does not play a role, as extensively discussed above, transcription factors are 
dynamically regulated and both spatial and temporal patterns of expression are important 
as well as stoichiometry with other proteins in the cell. Runx-I may well interact with other 
chromosome 21 genes to produce subtle changes in cellular potential.  
Another candidate gene is Erg3. A recent study showed that it is expressed in HSCs, 
megakaryoblastic cell lines and AMKL samples (Rainis, et al 2005). In vitro 
differentiation of cell lines along the megakaryocytic lineage led to Erg3 upregulation and 
forced expression of Erg3 leads to a switch from erythroid to megakaryocytic gene 
expression in MEP like cell lines. Erg3 binds directly to the SCL enhancer – a gene shown 
to be a key regulator of megakaryocytic development. Of interest another chromosome 21 
gene Ets-2 also binds to this region. This has led to a model of TAM/AMKL development, 
where combinatorial effects of Runx-1, Erg3 and possibly Ets2 lead to a skewing towards 
megakaryocytic fate and an expansion of megakaryocytic precursors in the fetal liver. This 
population is then vulnerable to effects of GATA-1 mutation leading to further 
proliferation and cellular transformation (Rainis, et al 2005).  This is shown in figure 1.9.  
Gene expression studies: A large study using samples from 24 DS-AMKL and 39 non-DS 
AMKL patients looked at gene expression differences between trisomy 21 associated 
TAM/AMKL and non-trisomy 21 cases. This showed that DS AMKL had a quite distinct 
gene expression profile (Bourquin, et al 2006). As expected a number of pro-proliferative 
genes initially identified in the mouse GATA-1s knock-in model (Li, et al 2005) were also 
overexpressed in DS-AMKL such as GATA-2, myc and kit. In addition increased 
expression of GATA-1 and two chromosome 21 genes Bach-1 and SON were seen in DS-
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with NF-E2 for essential cofactors needed to bind to megakaryocyte cis-regulatory 
elements (Toki, et al 2005). SON has homology with the myc family suggesting a possible 
role in cell cycle control. Bach-1 is added to the model proposed in fig 1.9 by providing a 
partial block to megakaryocytic differentiation in addition to the pro-proliferative effects of 
other chromosome 21 genes. 
 
Fig 1.9 Proposed model of combinatorial effects of chromosome 21 gene 
overexpression and additional mutations on development of AMKL. 
A second microarray pulled out 551 differentially expressed genes with 105 overexpressed 
in DS-AMKL and 446 in non DS-AMKL (Ge, et al 2006). This study confirmed the Bach-
1 and GATA-1 upregulation reported previously. It also identified a gene - Bone marrow 
stromal-cell antigen 2 (BST2) - which was significantly underexpressed in DS-AMKL. 
This gene encodes a protein important in interaction between HSCs and stroma. The 
authors hypothesise that lack of BST2 leads to altered stromal interactions and increased 
sensitivity of DS blasts to chemotherapy (Ge, et al 2006).  
Normal megakaryopoiesis is associated with micro-RNA down-regulation– presumably 
unblocking translation of genes responsible for megakaryocyte differentiation. In 
megakaryoblastic cell lines a number of miRNAs showed increased expression – which 
may reflect a differentiation block. Intriguingly, one of the upregulated miRNAs was 
encoded on chromosome 21 – miR 99a. Whether this contributes to the pathology of 
TAM/AMKL or the trisomy 21 MEP proliferation is unknown (Garzon, et al 2006).  
1.3.2.5   Third genetic hit - mutations in Jak 2 and 3? 
Since TAM often spontaneously resolves, the combination of trisomy 21 and GATA-1 
mutations are insufficient to cause full–blown AMKL. A third genetic hit is needed. 
Overall, it seems likely that the third molecular event leading to full-blown AMKL will 
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differ between patients – this is consistent with most leukaemias in that a limited number 
of critical genes (often transcription factors), disrupted in a variety of ways, are common to 
many different leukaemias (Rosenbauer, et al 2005), but subsequent genetic events are 
more heterogeneous.  Clinical evidence for this comes from a pair of identical twins 
sharing trisomy 21 and identical GATA-1 mutations. Both twins showed clonal evolution 
to AMKL but in one twin this was associated with a del(20q) and the other a trisomy 8 
(Stark, et al 2002). This does not exclude a common third event followed by genomic 
instability but does show that cytogenetic abnormalities diverge at this point.  
An initial attempt to identify the third hit used gene expression profiling to compare TAM 
and AMKL blasts from children with Down syndrome. These two groups showed 
remarkably similar gene expression profiles – consistent with their direct clonogenic 
relationship - but the investigators were able to pull out a few differentially expressed 
genes, most notably CDKN2C and N-myc as well as a tumour antigen PRAME 
(McElwaine, et al 2004). CDKN2C has already been identified as a mediator of GATA-1 
cell cycle arrest. N-myc is a neuroblastoma associated oncogene overexpressed in TAM 
compared to AMKL. A second smaller study comparing AMKL and TAM did not pull out 
the same genes (Lightfoot, et al 2004). Instead a number of genes such as myosin light 
chain and N-acetyltransferase, not known to play roles in malignant transformation, were 
identified presumably reflecting altered cellular homeostasis in these cells.  
In 2006 a group looking for aberrant tyrosine kinase activation in acute myeloid leukaemia 
identified a Jak3 activating mutation in an AMKL cell line – CMK (Walters, et al 2006). 
This approach involved a mass-spectroscopy based screen to identify tyrosine 
phosphorylated proteins which might be responsible for activation of key signal 
transduction pathways essential for the leukaemic phenotype. Further analysis showed the 
presence of an activating mutation in the pseudokinase domain of Jak-3 in these cells. 
Screening of Jak-3 in AMKL patients led to the identification of two further Jak-3 
mutations - 1 in a patient with DS-AMKL and another in a non-DS AMKL sample. The 
authors went on to show that mice transplanted with BM cells containing a Jak3 activating 
mutation, develop a florid megakaryoblastic leukaemia. However, this does not appear to 
be secondarily transplantable suggesting, unsurprisingly, that Jak-3 activation alone cannot 
fully transform cells. This initial report was followed by several others – a Jak2 mutation 
was described in AMKL associated with trisomy 21 (although with no detectable GATA-1 
mutation), again this was an activating mutation that produced megakaryocytic hyperplasia 
in a mouse model (Mercher, et al 2006). Further reports describe Jak-2 and Jak-3 
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Norton, et al 2007, Sato, et al 2008) and also some loss of function mutations (De Vita, et 
al 2007). The association does not appear to be as tight as with GATA-1 – in fact Jak 
mutations are seen in TMD as well as AMKL (De Vita, et al 2008) and are not necessarily 
associated with GATA-1 mutations (Mercher, et al 2006) – in addition only a limited 
subset of DS-AMKL/TAM patients have any Jak mutations identified (Norton, et al 2007). 
It therefore appears likely that Jak mutations may be important determinants of disease 
progression and outcome but may not be the primary event associated with development of 
AMKL in most cases. It is interesting to note that these alterations in Jak activity would 
never have been identified by microarray studies as they result from point mutations 
leading to activation rather than changes in gene expression levels. The identification of 
key cellular events in malignancy requires multiple approaches and new developments in 
proteomics such as those used by Walters et al above are likely to provide crucial insights 
(Walters, et al 2006).  
1.3.3 Chronic myeloid leukaemia 
In depth discussion of another haematological malignancy – chronic myeloid leukaemia is 
beyond the scope of this introduction. Study of this disease has provided many key insights 
into the molecular pathogenesis of malignancy (Melo and Barnes 2007). Its characteristic 
chromosomal translocation – t(9;22) bcr-abl, was the first consistent chromosomal 
abnormality to be associated with a specific human cancer and remains a paradigm for the 
role of chromosomal translocations in malignant transformation. It is mentioned here 
because of certain parallels with transient abnormal myelopoiesis, along with suggestive 
sequencing database information, which led to the hypothesis that GATA-1 could play a 
role in progression of CML from chronic phase to blast crisis.  
1.3.3.1   Molecular pathology 
CML is characterised by the presence of a reciprocal t(9:22)(q34:q11) translocation. This 
leads to the production of the bcr-abl oncoprotein with enhanced tyrosine kinase activity 
which leads to immortalisation of HSCs. CML is a bi- or tri-phasic disease. In the initial 
chronic phase patients display a massive expansion of the granulocytic lineage with 
increased circulating mature granulocytes and hepatosplenomegaly associated with 
expansion of granulocytic precursors in these organs. This chronic phase lasts for a median 
of 3-4 years before progressing to an acute (blast crisis) phase associated with a block to 
cellular differentiation and the appearance of blast cells. At this stage the disease behaves 
like an acute leukaemia and can have myeloid or lymphoid characteristics compatible with Introduction   79 
transformation of a multipotent precursor/HSC. An intermediate phase, between chronic 
phase and blast crisis, associated with a progressive accumulation of immature precursors 
and blasts is also seen in some patients – known as accelerated phase.  It is presumed that 
development of these acute phases is associated with acquisition of further mutations. 
According to the 2 hit theory of leukaemogenesis bcr-abl would provide a type I mutation 
affecting cellular proliferation and an additional type II mutation in a transcription factor 
should be necessary to provide the differentiation block. Despite a massive accumulation 
of knowledge as to the molecular consequences of the bcr-abl translocation, much less is 
known about this second event (Melo and Barnes 2007).  
1.3.3.2   Similarities with transient abnormal myelopoiesis 
The blood film in chronic myeloid leukaemia typically shows a high white cell count, 
presence of variable numbers of immature precursors, often a marked basophilia and 
eosinophilia and thrombocytosis (Jaffe 2001). The erythrocyte lineage is usually 
unaffected. These appearances, especially the basophilia, share a resemblance to the blood 
film in TAM. In addition, in one study, 60% of patients progressing to myeloid blast crisis 
expressed megakaryocyte markers on their blast cells (Murakami, et al 1994). The reason 
for such a skewed granulocytic/platelet output with relative sparing of the erythroid 
lineage, despite bcr-abl being detectable in the stem cell compartment, has not been 
elucidated. Although GATA-1 mutations are said to be exclusive to DS-AMKL and TAM, 
the studies showing this specificity did not look at patients with CML (Wechsler, et al 
2002). Therefore the mutational status of GATA-1 in CML is currently unknown. 
1.3.3.3   The role of transcription factors in progression of disease  
The mechanisms of transformation to blast crisis appear to be varied and are not well 
understood. A number of potential mechanisms have been identified including 
differentiation arrest, genomic instability, telomere shortening and loss of tumour 
suppressor functions (Melo and Barnes 2007, Smith, et al 2003). There is accumulating 
evidence that acquired alterations in transcription factor activity do underlie transition to 
blast crisis in some patients (Zhang 2008). In common with AMKL this event is likely to 
vary between individuals and a single genetic cause for progression is extremely unlikely. 
Deletion or inactivation of p53, p16, Rb and Evi-1 have been reported but are 
demonstrable in <30% of cases of blast crisis (Pabst, et al 2006). Several different 
mutations in Runx-1 including translocations and point mutations have been described as 
have translocations involving HoxA9 but again these only represent sporadic cases (Zhang 
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by mouse transplantation assays showing that these translocations can act synergistically 
with bcr-abl in promoting acute leukaemia development in mice (Cuenco and Ren 2001, 
Dash, et al 2002). Gene expression profiling comparing blast crisis with chronic phase has 
identified further candidates including Runx-1 and Ets2 (Melo and Barnes 2007). In 
addition deregulation of the Wnt pathway - important for HSC interaction with the 
haematopoietic niche - was identified, as was up-regulation of PRAME – also identified in 
the TAM-AMKL transition (McElwaine, et al 2004, Melo and Barnes 2007). 
In addition to direct effects of aberrant transcription factor expression, a number of other 
mechanisms may contribute to the development of blast crisis. In particular CML cells 
have been shown to accumulate mutations in the tumour suppressor genes p53 and Rb, 
they may also display suppression of apoptosis although this is controversial (Smith, et al 
2003). Finally bcr-abl appears to promote DNA repair deficiency and therefore genomic 
instability. At least part of this is due to down regulation of the DNA repair enzyme, DNA-
PK, via proteosome dependent degradation (Deutsch, et al 2001).  
Although treatment of CML has been revolutionised by the availability of drugs targeting 
the abnormal tyrosine kinase fusion protein (such as Imatinib) (Druker, et al 1996), we are 
still a long way from complete eradication of the disease. These varied mechanisms of 
transformation to blast crisis, along with observations of the failure of Imatinib like 
compounds to eradicate bcr-abl containing stem cells (Elrick, et al 2005), suggest that 
molecularly targeted therapies will need to attack multiple pathways. However, it is clear 
from the above discussion that many leukaemias (and probably solid malignancies) share 
common themes when analysing the cellular and molecular basis for disease development 
and progression. Study of relatively rare malignancies that highlight specific features of 
these pathways can provide valuable insights into general mechanisms. Both Down 
syndrome AMKL and CML provide excellent biological models from which much can be 
learnt about the aetiology of malignancy and rational approaches to treatment.  
1.4 Aims and Objectives 
GATA-1 is an extensively studied haematopoietic transcription factor. The GATA-1s 
isoform is expressed at the protein level in haematopoietic cells and is clearly associated 
with human disease. Despite this, little is known about the normal biological role of 
GATA-1s. This thesis aims to address the distinct roles of GATA-1 isoforms in 
haematopoietic development and malignancy. A number of hypotheses have been 
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1. That the balance between GATA-1FL and GATA-1s isoform expression plays an 
important role in determining cell fate during haematopoietic development. 
2. That GATA-1s exerts a distinct effect when expressed in cells carrying trisomy 21 
compared to its effect in disomic cells. 
3. That abnormalities of GATA-1 expression may play a role in chronic myeloid 
leukaemia, possibly by determining progression to accelerated phase or blast crisis. 
In order test these hypotheses a number of experimental approaches will be used: 
1. A comprehensive analysis of the normal patterns of GATA-1 isoform expression in 
primary cells and cell lines, both in mature tissues and during embryonic development, 
alongside analysis of any possible additional isoforms. 
2. Attempts to selectively knock-out isoform expression by generating targeted ES cells. 
3. Analysis of the impact of isoform overexpression on the haematopoietic differentiation 
capacity of murine embryonic stem cells. 
4. Analysis of the effects of over-and under-expression of GATA1 isoforms on cell fate, at 
the molecular and cellular level, in human haematopoietic cell lines with and without 
trisomy 21.  
5. A mutational analysis of GATA-1 in CML blast crisis samples. 
The results of these investigations are presented in the following chapters. 82 
2  Materials and Methods 
2.1 General solutions and consumables 
The composition of chemical solutions, used in experiments detailed in the following 
chapters, is given in table 2.1 below. All laboratory chemicals were supplied by Sigma-
Aldrich (Dorset, UK) unless otherwise stated.  
Solution Component  Concentration 
1 x PBS  NaCl 
KCl 
Na2HPO4 
KH2PO4 
137mM 
2.7mM 
10mM 
1.76mM 
50 x TAE  Tris (tris(hydroxymethyl)aminomethane)  base 
EDTA (Ethylene diamine tetra-acetate) disodium 
salt 
Glacial acetic acid 
2M 
50mM  
                              
5.7% (v/v) 
1 x TE  Tris (HCl) pH 8 
EDTA 
10mM 
1mM 
1x EB  Tris (HCl) pH 8.5  10mM 
20 x SSC  NaCl 
Sodium citrate 
3M 
300mM 
20 x MOPS  MOPS (4-morpholine propane sulphionic acid) 
Tris base 
SDS (sodium dodecyl sulphate) 
EDTA 
1M                        
1M 
69.3mM 
20.5mM 
Red cell lysis 
buffer 
NH4Cl 
KHCO3 
EDTA 
155mM 
10mM 
0.1mM 
ES cell lysis 
buffer 
Tris (HCl) pH 8.5 
EDTA 
SDS 
NaCl 
Proteinase K  (Promega) (added just prior to use) 
100mM 
5mM 
0.2% 
200mM 
100µg/ml Materials and Methods    83 
PBST (0.1%)  PBS 
Tween 20 (Polyoxyethylene sorbitan monolaurate) 
1x 
0.1% (v/v) 
5% Milk PBST  PBS 
Tween 20 
Marvel skimmed milk powder 
1x 
0.1% (v/v) 
5% (w/v) 
Southern blot 
alkaline transfer 
buffer 
NaOH 
NaCl 
0.4N 
1M 
Southern blot 
neutralisation II 
buffer 
Tris-Cl (pH 7.2) 
NaCl 
0.5M 
1M 
Southern blot 
high stringency 
wash buffer 
SDS 
SSC 
0.1% 
0.1x 
Southern blot 
low stringency 
wash buffer 
SDS 
SSC 
0.1% 
2x 
Nuclear extract 
buffer A 
HEPES  (4-(2-hydroxyethyl)-1-piperazineethane- 
sulfonic acid)  pH 7.9 
MgCl2 
KCl 
Just before using add: 
PMSF (phenylmethylsulphonyl fluoride) 
DTT (Dithiothreitol) 
10mM                   
 
1.5mM 
10mM 
 
0.2mM 
0.5mM 
Nuclear extract 
buffer C 
HEPES pH 7.9 
Glycerol 
NaCl 
MgCl2 
EDTA 
Just before using add: 
PMSF 
DTT 
20mM 
25% (v/v) 
420mM 
1.5mM 
0.2mM 
 
0.2mM 
0.5mM 
Western blot 
stripping buffer 
SDS 
Tris (pH 6.8) 
β-mercaptoethanol 
2% (w/v) 
50mM 
100mM Materials and Methods    84 
Propidium 
iodide mix 
Propidium iodide 
RNase (DNase free) 
PBS 
40µg/ml 
100µg/ml 
1x 
Haemin (4mM 
stock) 
Haemin (C34H32N4O4FeCl) 
Dissolve in: 
NaOH 0.5M 
Tris (pH 7.8) 0.1M 
ddH2O 
filter sterilise prior to use 
50mg 
 
3.3ml 
0.99ml 
14.9ml 
Plasmid lysis 
buffer 
EDTA 
Sucrose 
SDS 
NaOH 
KCl 
Bromophenol blue 
5mM 
10% (w/v) 
0.2% (w/v) 
100mM 
60mM 
0.005% (w/v) 
10 x DNA 
loading buffer 
Bromophenol blue 
Glycerol 
0.25% (w/v) 
30% (v/v) 
6 x sucrose gel 
loading buffer 
Bromophenol blue 
Xylene cyanol  
Sucrose 
ddH2O 
25mg 
25mg 
4g 
10ml 
Table 2.1: Solution composition 
 
General plastic lab-ware and other consumables were obtained from a variety of suppliers 
listed below. Manufacturers and suppliers of equipment, reagents and commercial kits are 
detailed in the main body of the text in parentheses after the equipment / reagent / kit 
name. 
ABgene (Vancouver, Canada) 
Thin walled 0.2ml and 0.5ml PCR tubes 
 
Applied Biosystems (Warrington, UK) 
MicroAmp 96-well optical reaction plates and adhesive covers 
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BDH laboratory supplies (Poole, UK) 
1mm thick twin-frosted microscope slides 
 
Becton-Dickinson Labware (Le Pont de Claix, France) 
BD Falcon ™ conical tunes 15ml and 50ml 
BD Plastipak™ syringes (1ml, 2ml, 5ml, 10ml, 20ml and 50ml) 
Polypropylene 2059 tubes 
Polystyrene 2054 5ml round-bottomed FACS tubes 
 
Bibby Sterlin Ltd. (Bargoed, UK) 
Petri dishes 100mm diameter 
Universal containers 
 
Corning Inc (Poole, UK) 
Tissue culture plates – 6-well, 12-well, 24-well and 96-well 
 
Dow Chemical Co (Midland USA) 
Saran-wrap 
 
Eppendorf (Hamburg, Germany) 
1.5ml microfuge tubes 
 
Greiner Bio-One (N.Carolina, USA) 
Tissue culture flasks with filter cap - 25cm
2, 75cm
2 and 175cm
2 
 
Nunc International (Thermo-Fisher Scientific, Roskilde, Denmark) 
1.5ml cryo-tubes 
Nalgene filter unit 500ml 
 
Swann-Morton Ltd (Sheffield, UK) 
Disposable Scalpels 
 
Whatmann International Ltd (Maidstone, UK) 
3MM filter paper 
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2.2 Media 
The following base media were used for tissue culture: 
Base media  Abbreviation  Supplier 
Dulbecco’s Modified Eagles medium  DMEM  Invitrogen, 
Paisley, UK 
Knockout Dulbecco’s Modified Eagles medium  KO-DMEM  Invitrogen 
Iscove’s Modified Dulbecco’s medium  IMDM  Invitrogen 
RPMI-1640 medium  RPMI  Invitrogen 
Leibovitz’s L-15 medium  L15  Invitrogen 
 
Table 2.2 below lists the cell lines used along with their basic characteristics and culture 
requirements: 
Cell line  Adherent or 
suspension 
Culture medium  Special 
considerations 
Seeding 
density 
K562 
Jurkat 
WEHI-3B 
P815 
U937 
Raji 
 
 
Suspension 
Complete RPMI 
RPMI 1x 
FCS 10% (v/v) 
L-glutamine 1x (2mM) 
Penicillin and Streptomycin  
1x (final concentration 
50μg/ml each) 
 Jurkat, 
P815, 
U937: 
3x10
5/ml 
WEHI-3B 
1x10
5/ml 
Raji 
4x10
5/ml 
Meg01 Suspension 
(semi-
adherent) 
Complete RPMI –as above  Dislodge 
adherent cells 
by pipetting 
 
2-4x10
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E14 
(murine ES 
cells) 
Adherent  Complete Knockout DMEM  
KO DMEM 1x 
ES cell FCS 15% (v/v) 
L-glutamine 1x 
PenStrep 1x 
Β-mercaptoethanol 0.1mM 
LIF 1000u/ml 
Non-essential amino acids 
0.1mM 
Gentamicin 50μg/ml 
See section 2.14  Split every 
2 days 1:3 
to 1:6 
 
HEK293,  
COS7, 
NIH3T3, 
RAW264 
 
 
Adherent 
Complete DMEM  
DMEM 1x 
FCS 10% (v/v) 
L-Glutamine 1x 
PenStrep 1x 
RAW264 semi-
adherent 
remove 
mechanically, 
do not allow to 
become 
confluent 
2-4x10
5/ml 
M07E Suspension  RPMI  1x 
FCS 20% (v/v) 
L-glutamine 1x 
PenStrep 1x 
GM-CSF 10ng/ml 
Split 1:2 to 1:3 
every 2 days 
4x10
5/ml 
 
32D 
B6SutA 
 
Suspension 
complete RPMI (see above) 
plus 10% (v/v) WEHI-3B 
conditioned media 
WeHI 3B 
conditioned 
media used as a 
source of IL-3 
32D: 
5x10
5/ml 
Split 1:10-
1:50 every 
2-3 days 
P388 Semi-
adherent 
complete L15  
L15 1x 
FCS 10% (v/v) 
PenStrep 1x 
Detach by 
tapping sharply 
3x10
5/ml 
FDCPmix  Suspension  Iscoves MDM 80% 
FCS 20% 
muIL-3 10ng/ml (or 10-20% 
WeHI-3B conditioned 
media) 
Low cell 
recovery – thaw 
into 24 well 
plates and add 
fresh IL-3 after 
8 hours, then 
daily until 
established 
1x10
6/ml 
split 1:2 
every 3-4 
days 
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2.3 Bacterial culture media 
Medium Component  Concentration 
Luria-Bertani (LB) Broth  Tryptone 
Yeast extract 
NaCl 
Sterilise by autoclaving 
1% (w/v) 
0.5% (w/v) 
1% (w/v) 
LB agar plates  Agar 
LB-broth 
On cooling add: 
Ampicillin 
OR 
Kanamycin 
1.5% (w/v) 
1 x 
 
50μg/ml 
 
50μg/ml 
Table 2.3: Bacterial culture media 
2.4 Primers, RNAi reagents and antibodies  
All primers were synthesised by VH Bio (Gateshead, UK) using reverse phase cartridge 
purification unless otherwise stated. All sequences are reproduced in 5’ to 3’ orientation. 
2.4.1 GATA-1 primers 
Primer name  Species  Forward sequence  Reverse sequence  Annealing 
temp °C 
GATA-1 (exon 
4/5) 
Mouse cgaatgattgtcagcaaacg  accagctaccaccatgaagc  55 
Alt spl 1  Mouse  atcctctgcatcaacaagcc  tccatactgttgagcagtgg  52 
Alt splice 
version 2 
Mouse actcgtcataccactaaggtg  aaggtgtccaagaaggtgttg  55 
Exon1/3 splice   Mouse  tcaacaagcccagtctttcag tcaaggctattctgtgtacc  55 
Exon1/3 splice 
site 4bpmm 
Mouse tcaacaagtatggtctttcag  tcaaggctattctgtgtacc  55 
Human alt spl  Human  ctccgcaaccaccagcccag tatggtgagccccctgggatc 58 
Exon 1 & 6  Human  ctccgcaaccaccagcccag tcatgagctgagcggagccac  55 
Exon 3 & 6  Human  ccgtggaagatctggatgg  tcatgagctgagcggagccac  55 
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2.4.2 Primers used for vector construction 
Name  Species  Forward primer sequence  Reverse primer sequence  Annealing 
temp °C 
BFT4 FL 
GATA 
mouse gttcccatggattttcctg  gctattctgtgtaccttcaagaac 52 
BFT4 GATA1s  mouse  caacagtatggagggaattcc gctattctgtgtaccttcaagaac  55 
GATA-1FL human  accatggagttccctggcctg  tcatgagctgagcggagccac  58 
IMAGE human  ctgggatcacactgagcttg tttttatcaggactttggtgg  52 
Table 2.5: Primers used for vector construction 
 
2.4.3 Primers for site-directed mutagenesis 
Name  Forward primer  Reverse primer 
GATA-1s 
SDM  
gccccactcagtctcttgaaggtacacag ctgtgtaccttcaagagactgagtggggc 
GATA-1FL 
SDM 
ccactgctcaacagtacagagggaattcctgg ccaggaattccctctgtactgttgagcagtgg 
GATA-1s 
targeting 
accccagtgttcccatcgattttcctggtc gaccaggaaaatcgatgggaacactggggt
GATA-1FL 
targeting 
tatccactgctcaacagtctagagggaattcctgggggc gcccccaggaattccctctagactgttgag 
cagtggata 
GATA-1FL 
His tag 
gccccactcagttctgaaggtacacag ctgtgtaccttcagaactgagtggggc 
Table 2.6: Primers for site directed mutagenesis 
 
2.4.4 Primers for RT-PCR transcriptional profiling 
Name  Species  Forward primer  Reverse primer  °C 
β-actin Mouse  / 
human 
tgaaccctaaggccaaccgtg gctcatagctcttctccaggg  58 
GAPDH human  caaggctgagaacgggaag  ggtggtgaagacgccagt  55 
Glycoprotein 1b  human  tgccttttgcttttctccac cccctttcctgggtatttg 52 
CD41 human  ggtgagagggagcagaacag  accttgagagggttgacagg  55 
Cyclin D2  human  ttacctggaccgtttcttgg ctgaggcttgatggagttgtc  55 
Platelet factor 4  human  ctgttcctggggttgctg gctatcagttgggcagtgg  55 Materials and Methods    90 
β-globin major  human  ggctcacctggacaacctc tggacttagggaacaaaggaac  55 
Glycophorin A  human  tagttctggaggctgggaag  tctgatgaaaggatgtgtttgg  52 
ε-globin human  gcaagatgaatgtggaagagg  caggatggcagagggagac  55 
Table 2.7: Primers for RT-PCR transcriptional profiling 
 
2.4.5 Primers for CML mutational analysis 
2.4.5.1   Direct sequencing: 
Names  Forward primer  Reverse primer 
HuGP1/4 (ex2)  tgaggtgatggagtgggaggaggg ggtcggcacatccatttgagaagc 
HuGP5/8 (ex3)  ccatgttgggggtgctgggaacca  gtggggtggagaggagaagaggga 
HuGP9/10B (ex4)  aaaaaggacagggaagttgaggtg  gcagtagcttcctgtaatcatgag 
HuGP11/12 (ex5)  cctcacttcttgggtcctcctga  agagaggtagaacaggaacagagt 
HuGP13/14 (ex6A)  gcacccaaaaattatcttaccctg tgaagccacctccccacaattccc 
HuGP15/16 (ex6B)  ctggaaaagggaaaaagaaacggg  aaggttcaagccagggggtgcctg 
Table 2.8: CML direct sequencing primers 
 
2.4.5.2   WAVE 
Primer 
name 
Forward Reverse Tm Buff
er 
Elution 
temps 
2C1F / 
2C4R 
aaaggagggaagaggagcag  aagcttccagccatttctga  60  A  60.2 / 61.2 
/ 62.2 
3.1F/ 
3.1R 
ggaacttggccaccatgttgg agccgctctgtcttcaaagtctc  58  A  61.9 / 62.9 
3.2F / 
3.2R 
ggatcccagggggctcaccata gtggggtggagaggagaagagg
ga 
58  B  60.4 / 61.1 
/ 62.1 
4F/4R gacagggaagttgaggtgggag  cttcctgtaatcatgagaacagcg  56  B  58.7 / 60.7 
/ 62.7 
5F/5R  ggcatcaccctgtaaacaaagcc  gggcagtgtggcatgaagac  58  B  62.3 / 64.3 
6.1F / 
6.1R 
gtgtccctggttgacacagag ggcccagtgtcaggcctgaagcc
a 
58  B  62.6 / 63.6 
6.2F / 
6.2R 
gaaggaccagctggtggctttatg  ggctacaagaggagaaggac  60  B  63.9 / 64.9 
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2.4.6 Primers and probes for ES cell targeting 
Name  Forward primer  Reverse primer  Tm 
Exon  2 xho1/kpn1 # 1  attctcgagatagacatggacggccaa
ag 
aatggtaccaagaggctgcaggt
caagtg 
53 
Exon 3-6 EcoRV  attgatatcacttgacctgcagcctcttg gagggaagcttgaactgcac  55 
Exon  2 xho1/kpn1 # 2  attctcgagcaaagaaggcagtgggac
ac 
aatggtaccacagcttcgtacaca
cattccag 
55 
PCR+ screening plasmid  gccgagctgtgtgtagtaagg  attgcatcgcattgtctgag  52 
PCR screen # 1  gccgagctgtgtgtagtaagg  ctaccggtggatgtggaatg  55 
Nested ext primers  ggaaagaggggaaaggtgag  cagaaagcgaaggagcaaag  55 
Nested int primers  gccgagctgtgtgtagtaagg  ctaccggtggatgtggaatg  55 
S.blot BamH1 probe  tatcccaaattctggccttg  ggtcagagttcctggagcag  52 
S. blot AflII probe  agtagagccatcagcccatc gtttctctaatatcttcccatctttc  55 
Table 2.10: ES cell gene targeting primers 
 
2.4.7 Probe/primer pairs for real-time PCR 
Target Sequence  Component 
GATA-1FL ccaggttaatccccagagg 
cccaggttaatccccagag 
ccagaggctccatggagttccct 
5’ primer 
3’ primer 
Probe (FAM/TAMRA) 
GATA-1s accaccagcccactct 
cagttgaggcagggtagagc 
ccatatgccggctgggccta 
5’ primer 
3’ primer 
Probe (FAM/TAMRA) 
Table 2.11: qPCR primer/probe sets 
2.4.8 RNAi duplexes 
Duplex   Sense sequence  Antisense sequence  Exon 
targeted 
HuGATA duplex 5  ggacaggccacuaccuauguu  cauagguaguggccuguccuu  4 
HuGATA duplex 6  acgcugaggccuacagacauu  ugucuguaggccucagcguuu  2 
HuGATA duplex 7  gcugguggcuuuauggugguu ccaccauaaagccaccagcuu  6 
HuGATA duplex 8  ccaagaagcgccugauuguuu  acaaucaggcgcuucuugguu  4 
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2.4.9 Antibodies 
2.4.9.1   For Western blotting 
Name Raised  in  / 
immunogen 
Secondary 
antibody 
Species 
reactivity 
of primary 
antibody 
Working 
dilution 
1°/ 2° 
Suppliers 
GATA-1 C-
terminus 
(M20) 
Goat anti-mouse 
polyclonal 
Protein G 
HRP 
(bacterial 
protein) 
human, 
mouse 
1:100 / 
1:5000 
 
SantaCruz 
Biotech /  
Bio-Rad 
GATA-1 N-
terminus (N6) 
Rat anti-mouse 
monoclonal 
Goat anti-
rat IgG 
HRP 
mouse 1:1000  / 
1:1000 
SantaCruz 
Biotech. 
Actin (JLA20)  Mouse anti-
chicken 
monoclonal 
Goat anti-
mouse IgM 
HRP 
human 1:10000/ 
1:2000 
Calbiochem 
GAPDH Rabbit  anti-
human 
polyclonal 
Goat anti-
rabbit HRP 
human, 
mouse 
1:5000/ 
1:2000 
 
Abcam 
His(C-
terminal) 
Mouse 
monoclonal 
Goat anti-
mouse IgG 
n/a 1:5000  / 
1:10000 
Invitrogen 
Table 2.13: Antibodies for Western blotting 
HRP = Horseradish peroxidase 
 
2.4.9.2   Antibodies for flow cytometry 
Name Species  Fluorochrome  Channel  Supplier 
Glycoprotein Ib 
(CD41a) 
Mouse anti-human  APC  FL4  BD Pharmingen 
Glycophorin A 
(CD235a) 
Mouse anti-human  PE-Cy5  FL3  BD Pharmingen 
FcR blocking 
reagent 
Anti-human -  -  Miltenyi  Biotec 
Table 2.14: Antibodies for flow cytometry 
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2.5 Cell Culture Methods 
Table 2.2 lists the various cell lines utilised in this thesis along with their routine culture 
conditions and any special notes. Methods for the thawing, maintenance and freezing down 
of cell lines are given below. Biological assays involving the use of cell lines are described 
in section 2.13, embryonic stem cell protocols are described in section 2.14. All procedures 
involving cell culture were carried out using sterile precautions i.e. all manipulations were 
performed in a laminar flow hood with HEPA filtration along with use of pre-sterilised 
pipettes, glassware and plasticware, 70% Ethanol spray on all surfaces and non-
autoclavable equipment and use of a “no-touch” technique. All tissue culture reagents were 
sterilised by autoclaving or passage through a 0.22μm filter. Unless otherwise mentioned, 
all centrifugation steps for cell culture were performed at 1200rpm for 5 minutes using a 
Centaur 2 bench-top centrifuge (MSE, London). All cultures were incubated at 37°C / 5% 
CO2/ 95% humidity. 
2.5.1 Thawing of cell lines from frozen stocks 
Cell lines were grown up from stocks stored in liquid nitrogen (-196°C). Recovery of cells 
from liquid nitrogen was performed by rapid thawing in a 37°C water bath. Thawed cells 
were washed in 5ml of the appropriate culture medium (warmed to 37°C), followed by 
centrifugation (1200rpm, 5 minutes). The supernatant was then discarded and the cell 
pellet resuspended in 5ml of fresh warmed culture medium before transfer to 25cm² tissue 
culture flasks.  
2.5.2 Cell counting 
Cells were counted using a modified Neubauer Haemocytometer. 10μl of cell suspension 
was loaded into the counting chamber and the number of cells in the 4 x 4 grid was 
counted. This number was then multiplied by 10
4 to give the number of cells per ml of 
suspension. In cases where accurate counting of live cells was required, dead cells were 
excluded using Trypan blue: 2μl of Trypan blue was added to 8μl of cell suspension, 
incubated at room temperature for 5-15 minutes and then the sample was loaded into the 
haemocytometer chamber as before. Dead cells were stained blue and were excluded from 
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2.5.3 Maintenance of cell lines in culture 
Cell lines were routinely passaged when they reached 70-80% confluency or according to 
cell line specific requirements as detailed in Table 2.2. Methods differed depending on 
whether cells grew as adherent or suspension cultures. In order to minimise acquisition of 
new mutations, low passage cells were used whenever possible. Cells were routinely 
cultured in the presence of antibiotics (Penicillin and Streptomycin) unless this was contra-
indicated (e.g. in the 48 hours prior to transfection with some transfection agents – see 
section 2.12.3 below). Cultures were visually inspected daily under an inverted microscope 
to assess confluency and rule out infection. In addition ES cell cultures were inspected for 
evidence of differentiation as described in section 2.14.1. 
2.5.3.1   Passage of adherent cell cultures 
Media were aspirated and adherent cells were washed with 5-10 ml of warmed phosphate 
buffered saline (PBS) to remove any remaining traces of fetal calf serum. The PBS was 
replaced with 0.05% Trypsin (w/v) (Invitrogen) (1ml for 25cm² flask, 3ml for 75cm² and 
5ml for 175cm²) warmed to 37°C. After incubation for 2-5 minutes at 37°C the cells were 
observed under an inverted microscope to ensure adequate detachment. Trypsinisation was 
stopped by addition of 3-7ml of warmed media and the cells were resuspended by vigorous 
pipetting. The resulting suspension was centrifuged at 1200rpm for 5 minutes. After 
removal of the supernatant cells were resuspended in an appropriate volume of fresh 
culture media and transferred to a new flask. In general cells were split between 1:3 and 
1:10. In the case of new cell lines or cell lines with particularly fastidious requirements the 
cell suspension was counted and then seeded at the published optimum density (listed in 
Table 2.2).  
2.5.3.2   Passage of suspension cell cultures 
Suspension cultures were centrifuged at 1200 rpm for 5 minutes, resuspended in 3-10ml of 
fresh culture medium and a proportion of this was transferred to a sterile tissue culture 
flask depending on the split required, as detailed for adherent cells above.  
2.5.4  Freezing down of cell lines 
Frozen stocks of early passage cells were established for all cell lines. Cells for freezing 
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1x10
7/ml in a mixture of 90% culture media, 10% v/v dimethylsulphoxide (DMSO) to 
prevent formation of ice crystals. 1ml aliquots were transferred to 1.5ml cryovials and 
placed in a freezing container (Nalgene, Hereford) containing room temperature 
isopropanol. The container was placed at -80°C overnight to allow gradual cooling (1°C 
per minute), then transferred to liquid nitrogen tanks (-196°C) the following day.  
2.6 Animal methods 
2.6.1 Isolation of mouse bone marrow 
C57/BL6 male mice were sacrificed humanely by CO2 asphyxiation. Femurs were 
dissected by cutting just below the knee joint and above the hip joint and placed 
immediately in ice-cold PBS. Bones were separated from surrounding soft-tissue, cut at 
both ends and repeatedly flushed through with 1ml of ice-cold PBS via a 26 gauge needle. 
6mls of red cell lysis buffer was added to the resultant cell suspension, the mixture 
incubated at room temperature for 5 minutes followed by centrifugation for 10 minutes at 
1500rpm. The cell pellet was resuspended in 10ml PBS and cells counted using a modified 
Neubauer haemocytometer (see 2.5.2 above). Cells were then pelleted once more and 
resuspended in an appropriate volume of Trizol reagent (see 2.8.1.1 below) for subsequent 
RNA extraction. 
2.6.2 Mouse embryonic dissections  
Following timed mating, C57/BL6 female mice were sacrificed humanely by cervical 
dislocation on days E8.5, E9, E10.5 and E12.5. The uterus was dissected out using forceps 
and placed in ice-cold PBS. All subsequent steps were performed using micro-dissection 
instruments under a dissecting microscope following published protocols (Nagy 2003). 
Initially individual embryos were dissected away from the muscular wall of the uterus, 
Reichert’s membrane and the visceral yolk-sac. Embryo gestation was confirmed by 
morphological features and somite counting. For day 8.5 and 9 embryos the embryo and 
yolk sac were separated and placed in individual wells of a 12-well tissue culture plate 
containing ice cold PBS. At day 10.5 the AGM region was dissected away from the rest of 
the fetal body and placed in PBS, fetal blood was collected by placing the dissected 
embryo into 1ml of ice cold PBS and allowing the blood to flow into the solution. At day 
12.5 the embryo was rapidly and humanely sacrificed by severance of the fetal head from 
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the rest of the fetal body. All samples were washed in ice-cold PBS, centrifuged at 
3000rpm for 4  minutes and the resuspended in 50μl PBS and 50μl 2x Laemmli sample 
buffer (Sigma-Aldrich) before being stored at -20°C. Prior to use in western blotting whole 
cell lysates were DNase treated to reduce sample viscosity as described in section 2.8.2. 
2.7 Molecular Biology Methods: DNA 
2.7.1 Preparation of genomic DNA  
The following protocol was used to extract genomic DNA from ES cell colonies growing 
in 24 well tissue culture plates: 
Add 100µg/ml Proteinase K (Promega) to ES cell lysis buffer prior to use 
Aspirate medium from cells, wash twice in 1ml cold PBS 
Add 250µl ES cell lysis buffer (with proteinase K) to each well 
Seal sides of plate with tape and place in humidified container, incubate 55°C overnight 
The following day transfer lysates to a fresh 1.5ml microcentrifuge tube 
Add 0.7 volumes (175µl) isopropanol and mix by inversion until a precipitate is visible 
Spin 5 minutes at 5000rpm 
Pour off supernatant and wash pellet in 0.5ml 70% Ethanol 
Spin 5 minute 500rpm, remove supernatant and briefly air-dry pellet 
Resuspend in 100µl TE, heat 65°C 5 minutes to evaporate residual ethanol and shake at 
4°C overnight prior to use 
 
This buffer and protocol could also be used for extraction of DNA from standard cell lines 
such as HEK293.  
2.7.2 Purification, concentration and quantification of DNA 
DNA was purified for use in downstream applications by use of phenol/chloroform 
extraction followed by ethanol precipitation or the use of commercial PCR/gel purification 
kits as described in section 2.7.5 below. DNA was concentrated by ethanol precipitation 
followed by resuspension in a reduced volume of TE or ddH2O.  
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Phenol chloroform extraction 
Add equal volume of phenol:chloroform:isoamyl alcohol (25:24:1 v/v/v) to DNA solution 
Mix by vortexing 
Centrifuge 14,000rpm for 5 minutes 
Transfer upper aqueous (DNA) phase to a fresh microcentrifuge tube and perform ethanol 
precipitation. 
 
Ethanol Precipitation 
Add 1/10
th volume 3M sodium acetate (0.3M final concentration) 
Mix well then add 2 volumes ice-cold 96-100% ethanol 
Incubate on ice 15-30minutes 
Centrifuge 14,000rpm for 10 minutes at 4°C 
Carefully remove supernatant then add 750μl 70% ethanol, centrifuge 14,000rpm for 2 
minutes at 4°C 
Remove supernatant, air dry pellet for 15 minutes (in sterile hood if needed) 
Redissolve in appropriate volume of Tris-EDTA (TE) buffer or ddH2O 
Heat 2-3minutes at 45°C to evaporate residual ethanol 
 
DNA was quantified by measurement of the amount of UV absorbance at 260nm. 3μl of 
the test sample was diluted with 297μl of TE buffer and the OD260 measured using a 
Biophotometer (Eppendorf). The OD260 was automatically multiplied by the dilution factor 
and the extinction co-efficient to give a concentration in μg/ml. Purity was assessed by 
measurement of the OD260:OD280 ratio aiming for levels between 1.7 and 1.9. Levels below 
1.7 indicate contamination by proteins or organic chemicals. Quantitation was also 
performed in some cases by gel electrophoresis with comparison against standard 
concentrations of DNA used in DNA marker ladders, this method also established 
contamination with other DNA (additional bands) and RNA as well as revealing plasmid 
degradation (lack of supercoiled fast migrating band).  
2.7.3 Restriction enzyme digests 
Restriction enzymes were obtained from a variety of commercial suppliers (New England 
Biolabs, Roche, Fermentas, Invitrogen). A standard diagnostic digest comprised: 
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Restriction enzyme digest   
DNA sample (eg plasmid miniprep)  5μl (approximately 0.5μg) 
Restriction enzyme (RE) buffer (10x)  1μl 
ddH2O 3.5μl 
Restriction enzyme (10 units/μl) 0.5μl (5 units) 
Mix gently, incubate at 37°C (or alternative temperature as specified in datasheet) for 1-2 
hours. 
 
Where possible double digests were performed using compatible buffers as determined by 
compatibility charts (www.neb.com). If not, then sequential digests were performed with 
removal of the first buffer by use of a Qiagen PCR purification kit (section 2.7.5) prior to 
the second round of digestion. 
For diagnostic digests, results were analysed by gel electrophoresis (see 2.7.4 below). The 
test sample was run alongside uncut vector DNA to allow distinction between bands due to 
supercoiled and nicked plasmid DNA and linear fragments. 
See section 2.7.7.1 for restriction enzyme digestion of high molecular weight genomic 
DNA for use in Southern blotting, and section 2.12.1.2 for restriction enzyme digests prior 
to DNA ligation. 
2.7.4 Gel electrophoresis of DNA 
DNA molecules were size separated on 0.8-2% agarose gels depending on the expected 
molecular weight of the products: 
Size of DNA fragments  %  agarose  w/v dissolved in Tris-acetate -
EDTA buffer (TAE) 
100bp-2kb 2%   
200bp-3kb 1.5% 
500bp-7kb 1.0% 
800bp-10kb 0.7% 
 
Electrophoretic grade agarose was added to TAE buffer and dissolved by microwaving. 
After partial cooling, ethidium bromide was added (0.5μg/ml) to allow DNA visualisation 
under UV light. The gel was cast in a tray with appropriate sample combs. Once set, the Materials and Methods    99 
gel was placed in a suitable horizontal electrophoresis tank, combs removed and TAE 
buffer was added to the tank until just covering the surface of the gel. Samples were mixed 
with 1/10
th volume of 10x loading buffer. 5μl of a marker either (i) 1kb ladder (Invitrogen) 
or (ii) Hyperladder I (Bioline) (for fragments 1-12Kb) or (iii) Hyperladder IV (Bioline) 
(for fragments 100bp-1kB), were loaded alongside to allow DNA sizing and/or 
quantitation. Electrophoresis was performed at 90-120V depending on the size of the 
electrophoresis tank (max 5V/cm) until the band of visible loading dye reached 
approximately 3cm from the end of the gel. The gel was then carefully removed and 
visualised under UV illumination at the 365nm wavelength (using suitable protective 
apparatus). Photographs were taken using an Alpha Imager (Alpha Innotech, San Leandro, 
USA) gel imager system. 
2.7.5 Gel extraction and PCR purification 
If DNA was to be used for downstream applications the gel was exposed to the minimum 
duration of UV light at reduced wavelength (302nm) to avoid DNA damage. Bands were 
excised using a clean scalpel blade and placed in a microcentrifuge tube. DNA extraction 
was performed by utilisation of spin-column technology exploiting the ability of DNA to 
adsorb to a silica membrane, allowing removal of impurities by wash buffers followed by 
elution of the DNA with Tris buffer or water. This was achieved by use of a QIAquick Gel 
extraction kit (Qiagen) according to manufacturer’s instructions. Similar technology was 
also used to directly purify PCR products using the QIAquick PCR purification kit 
(Qiagen), again procedures were carried out according to manufacturer’s instructions.  
2.7.6 Sequencing of DNA 
Sequencing was performed by a variety of sources (i) Technology services department – 
Beatson Institute, Glasgow, (ii) Agowa commercial DNA sequencing service 
(www.Agowa.de) (iii) Weatherall Institute of Molecular Medicine (WIMM) sequencing 
service, Oxford. All services employed Sanger sequencing methodology based on Dye 
terminator cycle sequencing technology. The initial labelling reaction was performed by 
the sequencing service in (i) and (ii) above.  Samples sequenced post WAVE analysis (iii) 
were labelled using a BigDye terminator sequencing kit v3.1 (Applied Biosystems) in the 
following  20μl reaction carried out in 96 well thin-walled PCR plates: 
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Purified PCR product  4μl 
Big Dye ready reaction pre-mix  4μl 
Big Dye Dilution buffer (5x)  4μl 
Primer (2μM) 1μl 
Ultrapure water  7μl 
Mix well, spin briefly then overlay with mineral oil and run on a thermal cycler overnight 
according to manufacturer’s instructions, the next morning ethanol precipitate products as 
described in section 2.7.2 
 
Cycle sequencing products were then analysed on an ABI 3100 capillary array sequencer 
(Perkin Elmer, Beaconsfield, UK). 
2.7.7 Southern blotting 
2.7.7.1   DNA digestion and gel electrophoresis 
To ensure complete digestion of high-molecular weight genomic DNA a 50μl reaction was 
performed with 2μg genomic DNA, 5μl 10x buffer, 0.5μl Bovine serum albumin (BSA) 
(100x), 3μl (30units) of restriction enzyme and xμl ddH2O to a final volume of 50μl. The 
reaction was stored at 4°C for several hours prior to the addition of enzyme and kept on ice 
for a couple of minutes after addition of enzyme. A second 3μl aliquot of enzyme was 
added after 12 hours followed by a further 24 hour incubation. If stored at 4°C prior to 
analysis then the digest was heated to 56°C for 3 minutes to disrupt any base pairing 
between cohesive termini. 7.5μl of 6x sucrose gel loading buffer were added and the 50μl 
of this digested DNA was loaded into wells of a 0.7% (w/v) agarose gel cast in 1xTAE 
buffer with 0.1μg/ml ethidium bromide. 10μl of Hyperladder I were loaded in the first and 
last lanes to allow size discrimination. Following application of a 110V current for 10 
minutes to allow the samples to run into the gel, electrophoresis was then performed at low 
voltage (25V) overnight. The gel was then photographed alongside a UV ruler to allow 
subsequent sizing of bands.  
2.7.7.2   Preparation of the gel and membrane for transfer 
The gel was trimmed, marked in the bottom left-hand corner and transferred to a glass 
dish. DNA denaturation was performed by soaking the gel at room temperature in several 
volumes of alkaline transfer buffer with constant gentle agitation on a rotary platform. Materials and Methods    101 
After 15 minutes the solution was exchanged for fresh alkaline transfer buffer and agitation 
continued for a further 20 minutes. A nylon Hybond-XL (Amersham International/GE 
Healthcare) membrane was used for nucleic acid transfer, this was cut to the same size as 
the gel along with 2 sheets of thick filter paper (Whatman 3MM). The membrane was 
floated in a dish of ddH2O until it wetted completely from below. It was then immersed in 
alkaline transfer buffer for a minimum of 5 minutes. A triangle was cut from the bottom 
left hand corner of the membrane to allow subsequent orientation.  
2.7.7.3   Assembly of transfer apparatus and transfer of DNA 
DNA was transferred to the membrane by capillary blotting using downward transfer. The 
assembly of the transfer apparatus is shown in Fig 2.1. Briefly a glass dish was filled with 
alkaline transfer buffer, a glass plate placed on top and then a stack assembled (all cut to 
same size as gel) comprising: a 5-7cm stack of absorbent paper towels, 8 pieces of dry 
filter paper, 2 pieces of wet filter paper (soaked briefly in transfer buffer), the Hybond-XL 
membrane, the denatured agarose gel, another 2 pieces of wet filter paper then a wick of 
filter paper the same width as the gel with both ends immersed in the buffer reservoir in the 
glass dish and finally a gel tray with 400g weight on top. The stack was assembled 
carefully to ensure no air bubbles between the layers and no bridging between the layers 
above and below the membrane/gel interface. The blot was then left overnight to allow 
DNA transfer between the gel and the membrane.  
Glass plate
Gel tray 400g
Paper towels
Gel
Hybond-XL membrane Wick
2x wet filter paper
8x dry filter paper
2x wet filter paper
Alkaline transfer buffer
 
Fig 2.1 Assembly of Southern blot downward transfer apparatus 
The following day the blot was disassembled and the position of the wells and bottom left 
hand corner marked on the membrane with pencil. The DNA was then fixed to the 
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2.7.7.4   Preparation of 
32P labelled DNA probe 
Complementary DNA probes of 300-450bp were synthesised by PCR and TOPO cloned 
into a pCR4TOPO vector (Invitrogen) as described in section 2.12.1.1. To release the 
probe from this vector, 5μg of vector DNA were digested with appropriate restriction 
enzymes, the products were run on a gel, the appropriate sized band excised and gel 
purified (Qiaquick gel extraction kit) with elution in 50μl elution buffer (EB). A 10μl 
aliquot was then used in a 
32P labelling reaction taking standard radioactive precautions: 
10μl gel purified unlabelled probe added to 35μl TE in a screw-top microcentrifuge tube 
Denature by boiling for 5 minutes then place on ice for 5 minutes   
Spin down and add to  Ready-to-go DNA labelling beads –dCTP (Amersham Biosciences) 
Add 5μl (50μCi) [α-
32P] dCTP (3000Ci/mmol) (Amersham Biosciences), mix by gently 
pipetting up and down 
Incubate 37°C for 30 minutes. 
Remove un-incorporated [α-
32P] dCTP using a ProbeQuant G50 microcolumn (Amersham 
Biosciences) according to manufacturer’s instructions 
Denature labelled probe by boiling for 5 minutes, place on ice 5 minutes 
Add 1μl of probe to 1 vial of scintillation fluid, and count on a scintillation counter 
(Beckman LS6500 Multipurpose Scintillation Counter). 
 
2.7.7.5   Probing of membrane for complementary DNA sequence 
The fixed Hybond-XL membrane was wetted with 2x SSC and then placed DNA side up 
on to nylon mesh and into a hybridisation bottle. 0.1ml/cm² of prewarmed (50°C) 
hybridisation buffer - ULTRAhyb (Ambion) was added and the bottle was placed in a 
hybridisation oven (Hybaid mini-10 oven, Thermo Hybaid, Ashford, UK) with rotation for 
between 40 minutes and 4 hours. At the end of this pre-hybridisation period the buffer was 
replaced with the same volume of fresh ULTRAhyb and labelled probe was added to 
achieve 1x10
6 counts/minute per ml of buffer. The membrane was hybridised at 50°C 
overnight in a Hybaid oven with rotation. 
The following morning, wash solutions were prewarmed to 55°C and then the radioactive 
hybridisation buffer was carefully discarded. The membrane was washed for 2x 5 minutes 
with low stringency wash buffer followed by 2x 15 minutes with high stringency wash 
buffer. The blot was then dried between two pieces of filter paper, wrapped in saran wrap 
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cassette was placed at -80°C overnight and after thawing the next day was developed using 
a KONICA medical film processor (SRX-101A). If images were indistinct then the blot 
was re-exposed to film for up to 7 days at -80°C.  
2.7.7.6   Stripping the Hybond-XL membrane 
In cases where repeat hybridisation with fresh probe was required the Hybond–XL 
membrane was stripped by immersion in a 0.1% SDS solution at boiling point. It was then 
shaken on a rotary platform for approximately 30 minutes until the solution had cooled. 
The membrane was then washed in 2xSSC prior to prehybridisation as described above.  
2.8 Molecular Biology Methods: RNA 
In all methods involving RNA careful attention was paid to minimising RNA degradation 
by environmental RNases. All plasticware and glassware was either supplied guaranteed 
RNAse free or was autoclaved using an RNase removal protocol. Diethyl pyrocarbonate 
(DEPC) treated water was used in all solutions and all surfaces, pipettes and non-
autoclavable equipment were sprayed with RNAzap (Ambion) RNase decontamination 
solution. Filter tips were used throughout. 
2.8.1 Isolation of Total RNA from cell lines 
2.8.1.1   Using Trizol reagent 
RNA was extracted from cell lines using a commercial mono-phasic solution of phenol and 
guanidine isothiocyanate (Trizol reagent, Invitrogen). Disruption of cells was achieved by 
direct lysis on tissue culture plates for adherent cells (1ml Trizol added per 10cm
2 plate 
surface area). Suspension cells were pelleted by centrifugation (300g x 5 minutes) and 1ml 
of trizol added per 5x10
6 cells. Following addition of Trizol reagent, cells were 
homogenised by repeated pipetting. The homogenised samples were incubated for 5 
minutes at room temperature to permit complete dissociation of nucleoprotein complexes. 
Phase separation was then performed by addition of 0.2ml of chloroform per 1ml Trizol 
reagent. Tubes were vigorously shaken then incubated for 2-3 minutes at room 
temperature. The samples were then centrifuged at 11000g x 15 minutes (at 4°C). 
Following this, the mixture separates into a lower red phenol-chloroform phase and an 
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fresh tube and RNA precipitated by the addition of 0.5ml isopropyl-alcohol per 1ml Trizol 
reagent. Following incubation for 10 minutes at room temperature the samples were 
centrifuged at 11000g x 10 minutes (at 4°C). After removal of the supernatant the RNA 
pellet was washed with 75% Ethanol (1ml per 1ml of Trizol), mixed by vortexing and 
centrifuged at 7500g for 5 minutes (at 4°C). The pellet was allowed to air-dry for 5-10 
minutes before dissolving in an appropriate volume of RNase free water or TE buffer 
(usually 50µl). To evaporate any residual ethanol this solution was incubated at 60°C for 
10 minutes.  
2.8.1.2   Using RNeasy kit 
A second method using a RNeasy mini kit (Qiagen) was utilised to prepare RNA for 
subsequent use in quantitative PCR. This commercial kit uses a high salt buffer system in 
combination with ethanol to bind RNA to a silica membrane and uses spin-column 
technology to allow rapid washing and subsequent elution of high purity RNA. This 
procedure only isolates RNA greater than 200bp and therefore relatively enriches for 
mRNA as many ribosomal RNAs are smaller than this. Cells were counted and then 
pelleted by centrifugation at 300g x 5 minutes. The supernantant was fully removed and 
lysis buffer added (350µl for < 5x10
6 cells or 600µl lysis buffer for 5x10
6-1x10
7 cells). The 
lysates were homogenised by passage 5-10 times through a blunt-ended 20 gauge needle. 
Samples could be stored at this stage at -80°C if required. If so then thawing was 
performed in a 37°C waterbath to ensure all salts were dissolved. Subsequent ethanol 
addition, binding to the membrane, and wash steps were performed according to the 
manufacturer’s instructions. Following the initial wash step an on-column DNase digestion 
was performed to eliminate any genomic DNA contamination using an RNase-free DNase 
set (Qiagen) again according to manufacturer’s instructions. After the final wash step an 
additional centrifugation step was performed to remove any residual traces of wash buffer 
before elution of the RNA in 30µl of RNase-free water.  
2.8.2 Removal of contaminating DNA from RNA 
On column DNase digestion was performed for all RNA samples isolated with the RNeasy 
kit as described above. For other samples DNase digestion was performed using a 
commercial DNase enzyme: DNA-free (Ambion) as described: 
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DNase treatment (perform in 0.5ml tube)   
Sample (up to 10µg RNA)  xμl 
DNase I buffer (10x)  5 μl 
Recombinant DNase I  2μl (1μl at outset, 1μl after 30minutes) 
Water  To final volume of 50µl 
Mix gently, incubate room temp 1 hour, add 5µl DNase inactivation reagent (resuspend 
thoroughly before use), mix well, incubate room temp for 2-3 minutes mixing several 
times, centrifuge at 10,000g for 1.5 minutes and transfer the RNA containing supernantant 
to a fresh tube 
 
2.8.3 Quantification of RNA 
RNA concentration was estimated by measurement of A260.  Purity was assessed by 
calculation of the A260:A280 ratio which should be ≥ 1.8 (when diluted in TE).   
2.8.4 Reverse transcription of RNA 
Two commercial methods were used for generation of a cDNA from an RNA template. In 
early experiments Superscript First-Strand Synthesis (Invitrogen) was performed using 
oligodT primers to enrich for cDNA copies of mRNA, according to manufacturer’s 
instructions. Later, and for all quantitative PCR, cDNA was made with random hexamer 
primers using AffintyScript multiple temperature reverse transcriptase (Stratagene) in the 
following reaction: 
Affinity Script Reverse Transcription: To a nuclease free centrifuge tube add (in order): 
2µg total RNA 
300ng (3µl) random primers 
xµl RNase-free water to a total volume of 14.2µl 
Mix and incubate at 65°C for 5 minutes, slowly cool (over 10 minutes) to room 
temperature (to allow primers to anneal to RNA). Then add: 
2 µl 10x Affinity Script RT buffer 
2µl 100mM DTT 
0.8µl 100mM dNTP mix 
1µl Affinity Script reverse transcriptase 
Pre-incubate 25°C for 10 minutes then incubate at 42°C for 1 hour. Inactivate by heating 
to 70°C for 15 minutes then place on ice for subsequent use as template in PCR 
 Materials and Methods    106 
Where required, a second reaction was performed with all the above components except 
the reverse transcriptase to provide a minus (-) RT control. This was used to rule out 
genomic DNA contamination during RT-PCR. 
2.9 Molecular Biology Methods: Protein 
2.9.1 Protein extraction from cell lines and tissues 
Between 1x10
5 and 1x10
7 (typically 1x10
6) cells were used for western blots. Suspension 
cells were pelleted by gentle centrifugation (300g x 5 minutes), washed in ice cold PBS, 
pelleted once more. Adherent cells were washed on the plate then harvested by mechanical 
scraping before pelleting as above. Murine tissues from section 2.6.2 were homogenised by 
passage through a 26 gauge needle prior to lysis. All cells then underwent lysis using either 
Laemmli 2x sample buffer diluted with and equal volume of PBS or using CelLyticM 
(Sigma) mammalian cell lysis/extraction reagent according to manufacturer’s instructions.  
2.9.2 Preparation of nuclear and cytoplasmic extracts 
All reagents and tubes were pre-cooled on ice. Cells were harvested as above, followed by 
washing with 1ml ice-cold PBS. The suspension was then centrifuged 14,000rpm for 10 
seconds and the pellet resuspended in 500μl of cold Buffer A. The mixture was placed on 
ice for 10 minutes, flicking the tube every few minutes to resuspend the cells. Then it was 
vortexed for 10 seconds and spun 14,000rpm for 10 seconds. The supernatant was 
aspirated, placed in a fresh tube and stored at -80°C until use – this is the cytoplasmic 
fraction. The pellet was then resuspended in 25-50μl of cold buffer C, depending on the 
desired final concentration. This reaction was placed on ice for 20 minutes, flicking the 
tube once or twice, followed by centrifugation 14,000rpm for 3 minutes at 4°C. This 
supernatant (the nuclear fraction) was transferred to a fresh tube and stored at -80°C until 
use. 
2.9.3 Separation of proteins on polyacrylamide gels 
21μl of the protein extracts from above (except those already in Laemmli buffer) were 
mixed with 7μl of 4x NuPAGE LDS sample buffer (Invitrogen). All samples were then 
heated to 70°C for 10 minutes. Samples were loaded onto a pre-cast 4-12% NuPAGE 
Novex Bis-Tris gradient gel (Invitrogen) in a vertical electrophoresis tank (Xcell Surelock, Materials and Methods    107 
Invitrogen) filled with NuPAGE MOPS SDS running buffer (Invitrogen) with addition of 
100μl 1M DTT to the 200ml of buffer in the central chamber.  For size determination 
either (i) Novex Sharp (ii) Magic mark or (iii) Multimark protein standards (all Invitrogen) 
were run in lanes 1 and 10. Electrophoresis was performed for 1-2 hours at 100-150V until 
the loading dye front reached the bottom of the gel.  
2.9.4 Western blotting 
Following electrophoresis proteins were transferred to NuPAGE nitrocellulose membranes 
(Invitrogen) using a tank transfer method (Xcell II blot module). Briefly, 6 blotting pads 
were soaked in 1x NuPAGE transfer buffer (Invitrogen), 2 pieces of filter paper and the 
nitrocellulose membrane were briefly wetted in the same buffer. The gel was rinsed under 
running water, the plastic casing cracked open with a spatula and the gel trimmed. A piece 
of filter paper was placed on top of the gel, this was then inverted and the membrane 
placed on the other side ensuring no air bubbles are trapped, The membrane was covered 
with a second piece of filter paper and then sandwiched between the 6 blotting pads (3 
either side) in the blot module with the gel closest to the cathode core. After insertion into 
the vertical tank the blot module was topped up with transfer buffer and the outside of the 
module cooled by filling the outside chamber with distilled water. A current of 150mA 
(low voltage) was applied for 1-2 hours.  
Following transfer the membrane was blocked in 5% milk/PBS Tween 0.1% (PBST) at 
4°C overnight (or 1-2 hours at room temp if required) with gentle agitation. Membranes 
were then incubated with primary antibody diluted in 5% milk PBST at optimal 
concentration (listed in table 2.13) for 1-2 hours. They were then rinsed and washed in 
large volumes of PBST with gentle agitation and frequent changes of wash buffer ie 2 x 5 
minutes then 1 x 15 minutes and 1 x 30 minutes. This was followed by a 45-60 minute 
incubation with an HRP conjugated secondary antibody diluted in 5% milk/PBST at 
optimal concentration (table 2.13). A second wash step was then performed as above. 
Binding of antibody was detected by an HRP mediated chemiluminescent reaction using  
Supersignal West Pico chemiluminescent substrate (Pierce) according to manufacturers 
instructions. The membrane was then placed between acetate sheets and exposed to X-ray 
film. Films were initially exposed for 2 minutes and then the exposure times were varied 
between 15 seconds and 2 hours according to the intensity of any bands resulting from the 
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2.9.5 Estimation of protein loading 
Where possible, equal starting amounts of cells were used for protein extraction. Equal 
protein loading was then confirmed either protein staining of the membrane with Ponseau 
S reagent (Sigma) or by stripping the membrane and reprobing with a housekeeping gene 
(actin or GAPDH). For Ponseau staining the membrane was covered with stain, rocked for 
5 minutes at room temperature and then washed with distilled water until all background 
staining was removed. For stripping, membranes were incubated in western stripping 
buffer at room temperature for 1 hour before washing in PBST and proceeding to re-
blocking followed by primary and secondary antibody incubations as described above. 
2.10 Molecular Biology Methods: Polymerase Chain 
Reaction 
2.10.1  Standard PCR 
PCR was performed using a variety of commercially available DNA polymerases 
depending on the downstream application. Oligonucleotide primers were designed either 
by eye or with the help of Primer3 express software (http://frodo.wi.mit.edu). All potential 
primer sequences were checked for secondary structure and predicted melting temperature 
using oligo.exe software. Primers were designed according to the following criteria: 
Length 19-24  basepairs 
GC content  Approximately 50% 
Terminal G or C bases  1 or 2 
Melting temp (Tm) (to match as closely as 
possible for forward and reverse primer) 
62-65°C 
Location  Near 3’ end of gene (for RT PCR) 
Span introns if possible (for RT PCR) 
Secondary  structure  No loop or loop with Tm well below 
annealing temperature of primer pair 
 
Primer sequences are listed in section 2.4. All primers were supplied lyophilised. Initially 
100μM stocks were made by addition of ddH2O. A 1 in 10 dilution produced a 10μM 
working solution for use in PCR. Standard PCR was preformed using commercially 
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DNA polymerase) – either ReddyMix (Abgene) or Red PCR Mastermix (Rovalab). These 
were supplied as 45µl pre-aliquoted PCR tubes to which 2.5µl of template cDNA/DNA 
and 1.25µl of each primer (forward and reverse 10µM solutions) was added. Certain 
downstream applications (WAVE, generation of targeting construct) required custom PCR 
reagents and set up and are discussed in the relevant sections (2.11.2 and 2.10.4 
respectively). PCR was performed on a PTC-200 thermal cycler (MJ Research) using the 
following cycling parameters: 
Segment  RT - PCR  PCR from genomic DNA 
Segment 1 – initial denaturation  95°C for 2 minutes  95°C for 5 minutes 
Segment 2 – thermal cycling  95°C for 30 seconds 
55°C* for 30 seconds 
68°C for 1 minute per kb 
Segment 3- final elongation  68°C for 10 minutes 
4°C  until use 
 
*Annealing temperature was varied between 52 and 58°C depending on the calculated Tm 
of the primer pair – initially a temperature was chosen that was 2-5°C below the predicted 
Tm. If this failed to produce a satisfactory single product then the temperature was titrated 
in 2°C increments (down for poor yield, up for non-specific bands) optimum annealing 
temperatures are listed alongside primer sequences in section 2.4.  
2.10.2   Semiquantitative PCR 
Semiquantitative PCR was performed by reducing the number of amplification cycles to 25 
to ensure product accumulation is still in the exponential phase. Genes of interest were 
amplified alongside actin or GAPDH housekeeping gene controls. 20µl of product was run 
on an agarose gel with ethidium bromide. Gels were then photographed using a UV gel 
imager system. The amount of amplified product was estimated using Alpha-imager 
software to perform densitometric analysis of photographed bands. Results were 
normalised to densitometric readings of the corresponding housekeeping gene control. 
2.10.3   Nested PCR 
PCR screening for gene targeting events was performed using nested PCR. 30 cycles of 
PCR amplification were performed with external primers before transferring 5μl of this 
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reaction mixture to a fresh PCR tube containing mastermix with internal primers. This 
second PCR reaction was run for a further 35 cycles and the products analysed on a 1.2% 
agarose gel with ethidium bromide alongside size markers and a positive control. 
2.10.4  Proof-reading PCR 
Platinum Pfx proof reading DNA polymerase (Invitrogen) was used for generation of the 
ES cell targeting construct. Reaction parameters were optimised as described in chapter 
4.4.2. Following optimisation, the following reaction conditions were used: 
10x Pfx Amplification buffer  10μl (final concentration  2x) 
10x PCRx enhancer solution  5μl 
10mM dNTP  1.5μl 
50mM MgCl2 1 μl 
Primer mix (10μM each)  1.5μl 
Template 1μl 
Platinum Pfx polymerase  1μl 
Nuclease free water  29μl 
Reaction components were  mixed, spun down and cycled using standard genomic DNA 
cycling conditions (section 2.10.1) 
 
2.10.5   Quantitative PCR using fluorescent probes 
Quantitation of relative transcript levels of the GATA-1 isoforms was performed using 
Taqman technology (Applied Biosystems). Primer and probe design were carried out by 
collaborators (Dr Oliver Tunstall-Pedoe, Imperial College, London) and sequences are 
listed in section 2.4.7. The assay was performed on an Applied Biosystems 7900HT Fast 
Real-Time system. All assays were performed in triplicate and normalised to ribosomal 
18S RNA transcript levels also assayed in triplicate.  A no template control was also run 
for each primer/probe pair. Assays were prepared as follows: 
For each reaction prepare diluted template and a master mix containing primers and 
probes, all reactions were performed in triplicate 
Mastermix: 1  reaction 
2x Universal PCR Master Mix (Applied Biosystems) 
Forward primer (20µM) 
10µl 
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Reverse primer (20µM) 
FAM/TAMRA probe (10µM) 
Total volume 
0.3µl 
0.4µl 
11µl 
Template mix  1 reaction 
cDNA (diluted 1 in 5 following RT reaction using 2µg RNA) 
Nuclease free water 
Total 
2µl 
7µl 
9µl 
To perform an assay in triplicate 3x template mix (27µl) and 3x master mix (33µl) were 
transferred to a fresh microcentrifuge tube, vortexed gently to mix, spun down and 20µl 
was transferred  to each of 3 wells on a 96 well thin-walled PCR plate. Once all the 
samples were loaded in this way, the plate was sealed, spun down briefly and run on 
7900HT thermal cycler using standard reaction conditions: initial denaturation 94°C x 10 
minutes, then 40 cycles of 15 seconds at 95°C followed by 60 seconds annealing/extension 
at 60°C, with fluorescence measured at the end of each extension step.  
 
Control 18SrRNA reagents were supplied as a 20x primer/VIC/TAMRA probe mix 
(Applied Biosystems). For a single reaction, 1µl was added to 10µl 2x universal PCR 
Master Mix and then mixed with 9µl template mix, as described above, to produce a final 
reaction volume of 20µl.   
Results were analysed using Sequence detection systems (SDS) software v2.1. 
2.10.6   Use of Taqman low-density array plates 
To simultaneously quantitatively assay 15 genes of interest alongside an 18SrRNA control 
a custom Taqman low density array (Applied Biosystems) was designed using ABI 
software (www.appliedbiosystems.com). This consists of a 384 well micro-fluidic card 
preloaded with validated primer and probe pairs (in triplicate) for each gene. cDNA was 
mixed with PCR master mix and a loading port used to add the reaction mixture evenly to 
all the wells for that particular sample. 8 biological samples were analysed per 384 well 
card (8 samples x 16 genes x 3 = 384). To reduce variability due to sample processing all 
RNA was extracted on the same day, quantification of RNA by spectrophotometry was 
performed in a single batch and 2μg of RNA were used in cDNA synthesis again in a 
single batch. The assay was set up as follows: 
Dilute cDNA (made using random primers) 1 in 10 (acceptable range 30-1000ng) 
Add 50μl diluted cDNA to 50μl Universal PCR Master Mix (Applied Biosystems) 
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Load 100μl into the fill port, spin 1200rpm x 1 minute (twice) to fill the wells 
Seal the plate and cut off the loading ports with scissors 
Run on 7900HT PCR system using low density array thermal cycling block using standard 
cycling conditions: Initial denaturation 94.5°C x 10 minutes then 40 cycles of 97°C x 30 
seconds followed by 59.7°C x 1 minute.  
Analyse results using SDS v2.1 software 
 
2.11 Molecular Biology Methods: Mutation detection 
using DHPLC (WAVE) 
2.11.1  PCR set-up for exon amplification 
WAVE primers and PCR conditions had been previously optimised by our collaborators 
(P.Vyas, C.Fisher WIMM, Oxford). Primer pairs were split in to two groups – those 
requiring buffer A and those requiring buffer B as detailed in section 2.4.5. These buffers 
were identical except for the addition of 7µl 5M Betaine to buffer B (to reduce secondary 
structure formation) as shown below: 
  Buffer A  Buffer B 
10x Applied Biosystems 
PCR buffer II 
5µl 5µl 
25mM MgCl2 3µl  3µl 
25mM dNTP mix  0.4µl  0.4µl 
Amplitaq Gold DNA 
polymerase (Applied 
Biosystems) 
0.2µl 0.2µl 
Pwo polymerase (Roche)  0.05µl  0.05µl 
Nuclease free water  38.35µl  31.35µl 
5M Betaine  n/a  7µl 
To buffer mix add 1µl of forward and 1µl reverse primers (10µM) plus 1µl template 
(100ng genomic DNA) 
Cycling conditions: (i) initial denaturation 95°C for 10 minutes (ii) 35 cycles of 95°C 1 
minute, annealing temp (see table 2.9) 1 minute, extension 72°C 1 minute (iii) final 
extension 72°C 5 minutes (iv) store at 4°C until ready to use. 
Check amplicon by electrophoresis on 2% agarose gel 100V for 1 hour 
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2.11.2  WAVE Heteroduplex conditions 
10µl test PCR reaction and 10µl of HEK293 control reaction were mixed in a WAVE 96-
well plate. Plates were sealed with an adhesive lid and centrifuged briefly, then run on an 
ABI thermal cycler, using the following conditions: 
Denature 95°C for 5 minutes 
Ramp down to 68°C at 0.1°C per second 
Maintain at 68°C for 5 minutes 
Ramp down to 64°C at 0.1°C per second 
Maintain at 64°C for 1 minute 
Ramp down to 60°C at 0.1°C per second 
Maintain at 60°C for 1 minute 
Ramp down to 55°C at 0.1°C per second 
Maintain at 55°C for 1 minute 
Ramp down to 20°C at 0.1°C per second 
Maintain at 20°C for 5 minutes 
Centrifuge briefly and place on WAVE platform, inject 5µl for separation of homo and 
heteroduplexes at two different temperatures (as predicted by melt profile software) 
 
2.12 Molecular Biology Methods: Vectors 
2.12.1  Insertion and manipulation of vector DNA 
2.12.1.1   TOPO cloning 
TOPO cloning exploits the fact that Taq DNA polymerases possess non-template 
dependent terminal transferase activity that adds single deoxyadenosine overhangs to the 
3’ end of PCR products. Therefore, if the foreign DNA segment has been produced using 
Taq polymerase it can be directly introduced into a linearised plasmid vector which 
contains complementary unpaired 3’ deoxythymidine at the two ends. The TOPO cloning 
reaction is performed as follows: 
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Fresh PCR product 4μl 
Salt solution 1μl 
TOPO vector 1μl 
Mix gently and incubate for 5-30 minutes at room temperature (30 minutes for PCR 
products >1kb) 
 
The reaction is then placed on ice and used to transform One-Shot cells as described in 
section 2.12.2 below 
Addition of 3’A overhangs to PCR products 
In cases where PCR had been performed with a non-Taq polymerase (e.g. Pfu polymerase) 
3’ deoxyadenosine can be added to the final product using the following method: 
Gel purify or PCR purify product (QiaQuick kit) and elute in 30μl EB. Take 7μl of this and 
add: 
1μl 10x Taq polymerase buffer  
1μl dATP 
1μl Taq DNA polymerase (New England Biolabs) 
Incubate 10-15 minutes at 72°C, use 4μl in TOPO cloning reaction as described above. 
 
2.12.1.2   DNA  Ligation 
Ligation reactions were used to join plasmid and insert DNA that were either both blunt-
ended or that had been digested with restriction enzymes to produce compatible sticky 
ends. 5μg of vector and insert DNAs were digested in a 35μl reaction volume with 20 units 
of enzyme, 3.5μl of 10x RE buffer and ddH2O to 35μl. The products were run on a gel and 
the desired band excised and then purified (QIAquick kit, section 2.7.5). Where the vector 
contained internally compatible sticky ends, the vector fragment was dephosphorylated to 
prevent vector religation in the following reaction: 
Plasmid DNA 30μl 
Shrimp Alkaline Phosphatase (SAP) 1μl (Roche) 
10 x SAP buffer 4μl (Roche) 
ddH2O 5μl 
Incubate at 37°C for 30 minutes, heat inactivate 70°C for 10 minutes and purify with 
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3 ligation reactions were set up for each pair: (i) vector plus insert (ii) vector alone (iii) 
insert alone. A commercial rapid DNA ligation kit (Roche) was used according to the 
following method: 
Reagent  Vector + Insert  Vector only control  Insert only control 
5x DNA dilution buffer  2μl 2μl 2μl 
Vector DNA  2μl 8μl 0μl 
Insert DNA  6μl 0μl 8μl 
Add 10μl 2x ligase reaction buffer and 1μl DNA ligase to each tube, mix gently and 
incubate at room temperature 10-15 minutes 
Use 2μl of ligation reaction to transform DH5α cells (section 2.12.2) 
 
In difficult reactions the proportions of vector to insert were varied between 1:1 and 1:10. 
Following growth overnight on selective plates, the numbers of colonies on test and control 
plates were compared. The ratio of test:vector-only colonies allowed an estimation of the 
rate of vector religation. If religation rates were high 24 colonies were picked, if low then 
approximately 10 colonies were picked and processed as described in section  2.12.2.3. 
Blunt ended ligation 
In cases where no compatible sticky ends could be identified, vector and insert were either 
cut with restriction enzymes that produce blunt ends, or protruding 5’ or 3’ termini were 
blunted by the use of T4 DNA polymerase. This enzyme removes 3’ overhangs via its 3’-
5’exonuclease activity and fills in 5’overhangs to form blunt ends. The following reaction 
was performed:  
5x T4 reaction buffer 4μl 
Digested DNA 1μg 
dNTP mix (2mM each) 1μl 
T4 DNA polymerase 0.2μl (1 unit) 
Nuclease free water to 20 μl 
Incubate for 5 minutes at room temperature, then stop the reaction by heating to 75°C for 
10 minutes 
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2.12.1.3   Site-directed mutagenesis 
To introduce targeted mutations into plasmids carrying a DNA sequence of interest 
commercial mutagenesis kits were used (QuikChange II and QuikChange XL site directed 
mutagenesis kits, Stratagene). Two oligonucleotide primers were designed containing the 
desired mutation according to the following criteria: (i) annealing to the same sequence on 
opposite strands (ii) 25-45 basepairs in length (iii) mutation should be in the middle of the 
primer with 10-15 basepairs of normal sequence either side (iv) minimum GC content of 
40% and end in ≥1 G or C bases (v) purified by HPLC. Primer sequences are listed in table 
2.6. Primers annealed to plasmid DNA and were extended during a thermal cycling 
reaction using a high fidelity DNA polymerase as detailed below. At the end of the 
procedure native (un-mutated) plasmid DNA was degraded by an endonuclease (Dpn1) 
which only recognises methylated DNA (almost all E.coli strains used to produce plasmid 
preparations Dam methylate DNA and therefore mark it for degradation by this enzyme). 
Following digestion of the parent DNA, the mutated vector DNA was transformed into 
XL1-Blue supercompetent cells, spread on selective plates and colonies picked the next 
day. Screening of colonies for those that have incorporated the mutation was performed by 
taking advantage of changes in restriction enzyme sites introduced by the mutation (as 
described in results chapter 4). Mutations were confirmed by plasmid DNA sequencing. 
For plasmids <8kB the QuikChange II kit was used, for greater than 8kB QuikChange XL 
was used. The two methods are similar apart form the addition of Quikchange solution and 
the use of a highly competent bacterial strain (XL1-Gold) to optimise transformation 
efficiency for larger plasmids. The mutagenesis reaction is detailed below: 
In a thin-walled 0.2ml PCR tube add the following: 
5μl 10x reaction buffer 
10ng (xμl) dsDNA template 
xμl (125ng) of primer 1, xμl (125ng) of primer 2 
1μl dNTP mix (proprietary) 
(for QuikChange XL add 3μl QuikSolution) 
ddH2O to a final volume of 50μl 
Then add 1μl PfuUltra HF DNA polymerase (2.5U/μl) 
Denature 95°C for 30 seconds then perform 12 cycles comprising: 95°C 30 seconds, 55°C 
1 minute and 68°C for 1 minute per Kb of plasmid 
Add 1μl of Dpn1 restriction enzyme directly to the amplification products, mix by 
pipetting up and down, spin and incubate at 37°C for 1 hour. 
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Use 1μl of this Dpn1 digested product to transform XLI-Blue (QuikChange II) or XL1-
Gold (QuikChange XL) competent cells (as described in section 2.12.2). 
2.12.2  Bacterial Transformation with vector DNA 
2.12.2.1   Transformation of bacterial strains 
Chemically competent cells were stored at -80°C and single-use aliquots (50μl) thawed on 
ice prior to use. Cells were then transferred to pre-chilled Falcon 2059 tubes and 2μl of 
vector DNA were added and gently mixed. The mixture was then incubated on ice for 5-30 
minutes before being heat-shocked in a 42°C water bath for 20-45 seconds (without 
shaking) depending on the bacterial strain as detailed below: 
Strain  Incubation time on ice  Heat shock   Additional notes 
One shot TOP 10 
(Invitrogen) 
5-30 minutes  30 seconds   
XL1-Blue 
(Stratagene) 
30 minutes  45 seconds  Add 1.7μl  β-mercaptoethanol 
to thawed aliquot and incubate 
on ice 10 minutes before 
adding DNA 
XL1-Gold 
Ultracompetent cells 
(Stratagene) 
30 minutes  30 seconds  Add 2μl  β-mercaptoethanol to 
thawed aliquot and incubate as 
above 
DH5α library 
efficiency 
(Invitrogen) 
30 minutes  45 seconds   
DH5α subcloning 
efficiency 
(Invitrogen) 
30 minutes  20 seconds   
 
After heat-shocking, cells were placed on ice for 2 minutes and then 250μl of prewarmed 
SOC media (without antibiotic) were added. Tubes were capped tightly and shaken 
horizontally (200rpm) at 37°C for 1 hour. 10-50μl were then spread onto an LB Agar plate 
pretreated with an appropriate selective antibiotic (usually Ampicillin or Kanamycin) 
and/or IPTG and X-gal if blue white colour screening is required. (see 2.12.2.2 below). 
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2.12.2.2   Selection strategies 
A number of different strategies were employed to select for bacteria that were 
transformed with the DNA sequence of interest. Firstly bacterial cells that had taken up 
plasmid DNA were selected by growth of bacteria in nutrient medium containing an 
antibiotic normally effective against that strain. The plasmid encodes an antibiotic 
resistance gene and therefore only bacterial cells that contain plasmid DNA are able to 
survive and proliferate. To further select for plasmids that had incorporated foreign DNA 
two methods were employed: 
Blue-white colour screening 
Some vectors (e.g. pCR2.1TOPO and pBluescript II) contain a β-galactosidase gene whose 
promoter and coding sequence are interrupted by the multiple cloning site. Vectors that 
contain insert will be unable to produce β-galactosidase (or only at very low efficiency) 
whereas those that have religated without an insert will produce active enzyme. Plates are 
prepared by spreading the β-galactosidase substrate X-gal (5-Bromo-4-chloro-3-indolyl β-
D-galactopyranoside) (40μl of 40mg/ml stock solution) and IPTG (Isopropyl-thio-β-D-
galactosidase) (40μl of 100mM stock) on to the plate prior to plating of bacteria. Colonies 
containing β-galactosidase activity are stained dark blue. For these vectors, only white or 
pale blue colonies were picked for further analysis. 
Use of lethal genes 
The pCR4TOPO vector has a lethal E.coli gene ccdB fused to the C-terminus of the Lac-Z 
sequence. This gene is disrupted by the presence of insert but is lethal in cases where the 
plasmid has religated without insert. In this way only colonies containing recombinants 
should survive plating on antibiotic selective agar.  
2.12.2.3   Isolation and purification of vectors from bacteria 
Following growth of transformed bacteria on selective plates, individual colonies were 
picked with sterile pipette tips and grown up in 3mls (minipreps) or 100mls (maxipreps) of 
nutrient medium containing selective antibiotic prior to isolation of plasmid DNA: 
Small-scale isolation of plasmid DNA (miniprep) 
Minipreps were generally performed using a commercially available kit (QIAprep 
Miniprep, Qiagen). This method is based on alkaline lysis of bacterial cells followed by 
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washing and subsequent elution of plasmid DNA. No phenol, chloroform or alcohol 
precipitation is involved. 
Minipreps were performed on bacterial cultures grown from single colonies picked from 
selective plates. Colonies were cultured in 3mls of LB medium containing the appropriate 
antibiotic, shaken horizontally at 200rpm 37°C overnight.  The cells were then harvested 
by centrifugation at 7500g for 3 minutes using a standard benchtop microcentrifuge. The 
cells were resuspended in 250µl of lysis buffer (buffer P1) and extraction of DNA 
performed according to manufacturer’s instructions. DNA was eluted in 30µl EB buffer. 
Isolation of DNA from large plasmids (>10kb) was also performed using commercial 
reagents (Qiagen Mimiprep kit) but spin columns were not used as these significantly 
reduced DNA yield. Instead cell pellets were resuspended in 150μl buffer P1 followed by 
addition of 150μl of buffer P2. Following mixing by inversion, 250μl of buffer P3 was 
added. The samples were spun at full-speed on a bench-top centrifuge for 10 minutes. The 
supernatant was then mixed with 1ml of 100% ethanol and spun for 15 minutes at full 
speed. The ethanol was decanted and the pellet resuspended in 30μl of EB buffer. 
In some cases, where screening of multiple colonies with large inserts was required, 
colonies were picked using sterile pipette tips and the tip ejected into a well of a 96-well 
tissue culture plate containing 100µl LB medium with selective antibiotic. The plate was 
sealed and shaken at 200rpm overnight. The following day 20µl of the overnight culture 
were transferred to a fresh 96-well plate (test plate) and mixed with 50µl of pre-warmed 
plasmid lysis buffer (with bromophenol blue). The original plate (master plate) was placed 
at 4°C to allow later expansion of any positive colonies. The test plate was incubated at 
37°C for 5 minutes then placed on ice for 5 minutes. It was then spun at 1200rpm for 5 
minutes and 20µl the loaded directly onto an agarose gel, run alongside the native vector 
and a size marker. Colonies containing the desired insert were identified by a size change. 
They were then grown up from the master plate, mini or maxi-prepped and their identity 
checked by restriction enzyme digestion or sequencing. 
Large scale isolation of plasmid DNA (maxiprep) 
To produce larger amounts of endotoxin-free plasmid suitable for transfection into 
mammalian cell lines, DNA was prepared using the Qiagen endo-free plasmid Maxi kit 
(Qiagen). This kit employs a different principle than the mini-prep kit with a modified 
alkaline lysis protocol followed by endotoxin removal and then binding of plasmid DNA to 
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salt conditions, and plasmid DNA eluted in a high salt buffer before iospropanol 
precipitation and ethanol washing of the DNA pellet.  
Single colonies were picked from selective agar plates, grown in 5ml LB at 37°C with 
shaking for 8 hours then transferred to 100ml of LB media – followed by overnight 
incubation at 37°C with horizontal shaking. Bacteria were then harvested by centrifugation 
at 6000g for 15 min at 4°C (using a Sorvall RC5B centrifuge with a GS3 rotor). The pellet 
was resuspended in 10ml of lysis buffer (Buffer P1) and DNA extraction performed 
according to manufacturers instructions (for plasmids <8kb). Following isopropanol 
precipitation and ethanol washing of the DNA pellet (as described in manufacturer’s 
protocol) the pellet was air-dried for 5-10 minutes and resuspended in  200µl of endotoxin-
free TE buffer. 
For plasmids >8kB the Qiagen kit was still used but samples were filtered through sterile 
gauze rather than using the Qiafilter cartridge, prior to passage through an equilibrated 
QIAGEN-tip 500 anion-exchange resin. In addition, elution buffer was warmed to 50°C 
prior to use.  All other steps were as directed in the manufacturer’s protocol.  
2.12.3  Transfection  of vectors into mammalian cell lines  
The majority of routine transfections in adherent cells were performed using the 
commercial lipid-based transfection reagent Fugene 6 (Roche). In some cases alternative 
reagents were used such as Effectene (Qiagen), Polyfect (Qiagen) and Lipofectamine 
(Invitrogen). Suspension cells were more commonly transfected by nucleoporation using 
an Amaxa system. All these methods are described below. SiRNA was transfected into 
suspension cultures using Lipofectamine 2000 (Invitrogen) as discussed in section 2.13.7.  
2.12.3.1   General considerations  
Cells were routinely passaged 24 hours prior to transfection and fed on the day of 
transfection to ensure they were in log-growth phase. Plasmid DNA was prepared using a 
commercial maxiprep kit (Qiagen see section 2.12.2.3) with an additional endotoxin 
removal step (maxiprep – endo-free). For stable transfections, plasmid DNA was linearised 
with a suitable restriction enzyme, gel-purified and ethanol precipitated (with resuspension 
in sterile TE or water in a tissue culture hood) prior to transfection.  Transient transfections 
were assayed 48-72 hours post transfection. Stable transfections were placed in selective 
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stable clones. Depending on the downstream application either individual clones were 
picked and expanded up, or pools of stable transfectants were used, as described in the 
relevant chapters.  
For stable transfections in previously untested cell lines antibiotic titration was performed 
to determine the minimum concentration of antibiotic required to kill all untransfected 
cells. Serial dilutions of antibiotic (within its published working range) were added to cell 
culture medium in 6-well plates and untransfected cells seeded at a density of 1x10
5 
cells/ml. Cultures were observed daily for cell death. The lowest concentration of antibiotic 
to cause 100% cell death after 1-2 weeks in culture was used in subsequent selection 
experiments. 
2.12.3.2  Transfection with Fugene 6 reagent 
Optimisation was performed for each individual cell line using Fugene 6:DNA ratios of 
3:1, 4:1, 3:2 and 6:1 in 6 well plates. The majority of assays were performed using 10cm 
tissue culture plates. All quantities are given for transfection of a single 10cm plate. The 
reaction was scaled up or down depending on the individual experiments. Scaling ratios are 
given in the manufacturer’s instructions for use. For a standard transfection using a 4:1 
ratio of Fugene 6:DNA: 
Add 20μl of Fugene 6 directly into 550μl of serum-free medium - do not allow the 
undiluted Fugene 6 to come into contact with plastic surfaces. Vortex for 1 second and 
incubate for 5 minutes at room temperature 
Add 5μg DNA to the above (max volume 50μl), vortex 1 second, incubate 15-30 minutes 
at room temperature 
Add the mixture drop by drop to the cells to be transfected, swirling the dish to ensure even 
distribution. 
Incubate under standard cell culture conditions, assay for gene expression at 48-72 hours 
(transient) or place in selective antibiotic at 24 hours for stable transfectants. 
 
2.12.3.3   Transfection with other reagents 
In certain cases alternative transfection reagents (as described in the relevant results 
sections) were used. The methods of transfection were similar to Fugene 6. These reagents 
were used according to the handbooks supplied with the kit with no deviations from 
protocol.  Materials and Methods    122 
2.12.3.4   Nucleoporation  
K562 and Meg-01 cells were transfected using a commercial nucleoporation system 
developed by Amaxa. Nucleofector kit C (Meg01) and kit V (K562) were used according 
to manufacturer’s instructions. All nucleoporation was performed on an Amaxa 
Nucleofector device. Briefly: 
Passage cells 2 days prior to transfection and aim for a density of 2x10
5 cell per ml  
Prepare 2µg of DNA in 1-5µl of sterile TE for each sample, add 1.5ml warmed culture 
media to each well of a 12-well plate 
Add 0.5ml supplement to 2.25ml Nucleofector solution prior to use, then pre-warm. 
Count cells and centrifuge 1x10
6 per nucleofection sample at 1200rpm for 5 minutes 
Discard the supernatant and resuspend in warmed Nucleofector solution at a density of 
1x10
6 cells/ml 
Perform each nucleofection separately: mix 100µl of cells with 2µg DNA, transfer to an 
Amaxa cuvette and close cap. Insert into machine and lock in position 
Select programme T-16 (K562) or X-05 (Meg01) and press X key to start 
Remove samples from the cuvette immediately by adding 500µl of pre-warmed media and 
transferring to the pre-prepared 12-well plate using a plastic pipette. Incubate at 37°C.  
 
2.12.3.5   Electroporation 
Transfection of large plasmid vectors into murine ES cells was achieved by electroporation 
as follows: 
Wash cells in PBS and resuspend in sterile PBS at a concentration of 5x10
6 cells per 700µl 
Add 5-10µg linearised plasmid DNA and mix gently, avoid air bubbles 
Transfer to a 4mm electroporation cuvette, and place on ice 
Dry cuvette and place in Genepulser II device (Bio-rad), electroporate at 250V/cm, 
capacitance 500µF. For transient transfections leave the cuvette in the electroporation 
chamber for 1-2 minutes before removing 
Transfer cells to ice then to a 10cm plate and add 10ml pre-warmed culture medium 
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2.12.4  Assessment of efficiency of transfection 
2.12.4.1   β-galactosidase assay 
A control vector carrying the bacterial lacZ gene (encoding β-galactosidase) under the 
control of the SV40 early promoter and enhancer (pSVβgal) was used to monitor 
transfection efficiency. For adherent cells, in situ β-galactosidase staining was performed 
to assess the proportion of cells that had taken up plasmid DNA. Transfection efficiencies 
in suspension cells and quantitative estimation of transfection efficiency were obtained by 
using a β-galactosidase assay kit measuring enzyme activity in whole cell lysates. 
β-Gal staining kit 
To detect the proportion of cells that had taken up plasmid DNA, cells were fixed and then 
stained in the presence of X-gal using a commercially available kit (β-gal staining kit 
(Invitrogen)). X-gal hydrolyis is catalysed by β-galactosidase and produces a visible blue 
colour change. All quantities described are for staining a single 60mm plate. Cells were 
initially washed in 2.5ml PBS, followed by fixation with 3ml 1x fixative solution for 10 
minutes at room temperature. Meanwhile the staining solution was prepared by adding 
25µl each of solutions A,B and C to 125µl of X-gal (20mg/ml in dimethylformamide) and 
2.3ml 1x PBS. After the 10 minute incubation the plate was rinsed twice with 2.5ml 1x 
PBS. 2.5ml of the staining solution was added to the plate and it was then incubated at 
37°C for 30 minutes to 2 hours. Transfection efficiency was assessed by counting the 
number of blue cells versus the total number of cells in 5-10 random fields using 200x total 
magnification.  
β-Gal assay kit 
A quantitative estimation of β-galactosidase expression was obtained by measuring the 
yellow colour change produced by β-galactosidase mediated hydrolysis of the substrate 
ONPG  (ortho-Nitrophenyl-β-galactoside). Cells were washed twice with PBS and then 
lysed with reporter lysis buffer (RLB) (Promega). For adherent cells RLB was added 
directly to the tissue culture plate (400µl for a 60mm plate and 900µl for a 100mm plate) 
and the plate rocked a couple of times to ensure even distribution of reagent. The plate was 
then incubated at room temperature for 15 minutes at the end of which cells were removed 
using a cell scraper and transferred to a microcentrifuge tube placed on ice. They were then 
vortexed for 10-15 seconds and centrifuged at top speed for 2 minutes at 4°C. The 
supernatant was transferred to a fresh tube and stored at -80°C until use. Materials and Methods    124 
β-galactosidase assays were performed in 96-well plates and a standard curve was run 
alongside the samples to ensure results were in the linear range, untransfected cells were 
run as a negative control to control for endogenous β-galactosidase activity and 
background absorbance. A commercial assay was used (β-galactosidase enzyme assay 
system #E2000, Promega), according to manufacturer’s instructions and is summarised 
below: 
Mix 30µl cell lysates with 20µl 1x RLB and transfer to a 96-well plate 
Add 50µl 2x assay buffer to each well and mix well by pipetting 
Cover and incubate at 37°c for 30 minutes – 3 hours until faint yellow colour appears 
Stop the reaction by adding 150µl 1M sodium carbonate, mix well  but avoid air bubbles 
Read absorbance of the samples at 420nm (410-430nm) in a plate reader 
For standard curve plot the absorbance at 420nm versus the concentration of β-
galactosidase and ensure sample values are on the linear portion of the curve, if not repeat 
assay with more concentrated or dilute samples as needed 
 
2.12.4.2   Estimation of transfection efficiency using GFP 
Cells transfected with an internal ribosomal entry site (IRES) green fluorescent protein 
(GFP), IRES-GFP vector were examined directly for GFP expression using a fluorescent 
microscope (Axiostar plus with HBO50/AC mercury lamp, Zeiss) with image analysis 
using Axiovision MR software. An estimation of transfection efficiency could be obtained 
by counting the number of cells per high powered field. To give a more accurate estimation 
GFP negative cells could also be enumerated by counterstaining nuclei with DAPI and 
viewing under a confocal microscope (as described in section 2.13.6). Alternatively GFP 
expression levels could be quantitated by flow cytometry using the FL1 channel as 
described in section 2.13.2. 
2.12.5  Cell sorting for GFP expression 
Cell sorting for high GFP expression was performed with the help of Dr Ashley Gilmour – 
Glasgow Biomedical Research Centre. 2x10
6 cells were washed in PBS, resuspended in 
FACS buffer with 1% fetal calf serum and passed through a cell strainer into a FACS tube 
before being placed on ice. Cells were sorted on a FACSAria (Becton Dickinson) 
instrument. Cells were initially gated on forward scatter (FSC) and side scatter (SSC) and 
then gated on high GFP expression. Cells in this sorting gate were diverted into the Materials and Methods    125 
collection stream and collected in FACS tubes containing 1.5ml of media. Where possible, 
100,000 cells were collected. Following sorting, cells were counted and replated in an 
appropriate sized tissue culture vessel (usually a 24-well plate) to produce an optimum 
seeding density of 2x10
5 cells per ml. 
2.13 Cell biology methods 
2.13.1  Luciferase assay 
The pGL3hGATA-1 lucifease vector was a kind gift from Dr Paresh Vyas, WIMM, 
Oxford and is described in chapter 5 (5.2.4.3). NIH3T3 cells were co-transfected with a 
test plasmid (or positive/negative control plasmids), pGL3hGATA-1 and the β-
galactosidase vector pSVβ-gal (# E1081, Promega). Cells were seeded at 4x10
5 cell per 
6cm tissue culture plate the day prior to transfection. Optimisation experiments (as 
described in chapter 5 section 5.2.4.3) led to the use of 1.5μg pGL3hGATA-1, 300ng 
pSVβ-gal and 1.5μg test plasmid, with a 4:1 ratio of Fugene 6 to DNA. Cells were lysed in 
situ with reporter lysis buffer (900µl per 10cm plate) and 30µl was used in a β-
galactosidase assay (see 2.12.4 above) and 20µl in a commercial luciferase assay system 
(#E4030, Promega) read on a Fluoroskan Ascent FL Luminometer (Thermo Lab Systems). 
The assay was performed according to manufacturer’s instructions, briefly: 
Prepare luciferase assay reagent by the addition of 10ml luciferase assay buffer to the vial 
containing the lyophilised luciferase assay reagent, mix gently 
Add 20µl cell lysates per well of a 96-well luminometer plate, place in the luminometer 
Prime the injector port and programme the luminometer to add 100µl of luciferase assay 
reagent per well just prior to reading 
Measure light produced for a period of 10 seconds  
Move on to next well for a repeat of the injection-read process 
 
Results were expressed as luminescence normalised to β-galactosidase activity in arbitrary 
units. A positive control (pGL3Luc control vector) and a negative control (untransfected 
cells) were run with each assay. 
2.13.2  Flow cytometry  
Cells were prepared for flow cytometry as follows: Materials and Methods    126 
Harvest 1x10
4-1x10
7 cells (usually 1x10
6), spin and wash in 5mls PBS 
Resuspend cell pellet at a concentration of 2x10
5/100µl in BDFACS flow buffer (Becton 
Dickinson) with 1% FCS 
If staining required: Take 100µl, place in FACS tube and add 5µl of human Fc receptor 
blocker, incubate 2-5 minutes at room temperature 
Then add 5µl of each antibody gently flick to mix and incubate room temperature for 10 
minutes 
Add 2-3mls of FACSflow buffer/1%FCS to each tube, spin 1200rpm for 5 minutes 
Pour off supernatant leaving about 200µl residual fluid 
Analyse on FACS instrument 
 
Flow cytometry was performed using FACSCalibur (Becton Dickinson), FACScan 
(Becton Dickinson) or MACSQuant (Milltenyl Biotec) instruments.  Data were acquired 
from 10-20,000 gated events per sample and analysed using Cell Quest Pro software or 
MACSQuant software. In cases where more than one fluorochrome was being analysed 
compensation was performed with the help of experienced personnel.  
2.13.2.1   Propidium iodide staining for DNA ploidy 
Ploidy analysis was performed using the following procedure: 
Wash 1x10
6 cells in cold PBS, spin and resuspend in 200µl cold PBS and vortex 
In a 15ml centrifuge tube vortex 4mls ice-cold ethanol and add the cell suspension 
dropwise.  
Incubate for a minimum of 45 minutes (overnight if possible) 
Spin down, 1200rpm 10 minutes, aspirate supernatant and resuspend in 2ml PI mastermix, 
incubate 37°C for 30 minutes 
Filter through a 40-70µm cell strainer 
Analyse on FACSCalibur or MACSQuant instruments 
 
A known 2N cell line (Raji) was used as a control and run alongside test samples 
2.13.3  In vitro differentiation with TPA 
1x10
6 cells were seeded into each well of a 6-well plate along with 3ml of tissue culture 
media. The phorbol ester TPA (12-O-Tetradecanoylphorbol-13-acetate) was added to a Materials and Methods    127 
final concentration of 100nM (100μM stock, diluted 1 in 1000 in culture media i.e. 1μl per 
ml culture media). 
2.13.4  In vitro differentiation with Haemin 
Cells were prepared as above. A 4mM Haemin stock was prepared as described in section 
2.1 and filter sterilised prior to use. Haemin was added to a final concentration of 10μM by 
addition of 2.5μl of 4mM stock per 1ml of culture media. 
2.13.5  Cytospin and staining of suspension cells 
10
5 cells were washed twice in cold 2% FCS-PBS and then resuspended in 200µl of the 
same and placed on ice. A labelled glass slide, cardboard filter and sample chamber were 
then assembled, clipped together and placed in the cytospin rotor (Cytospin 3, Shandon). 
The sample was quickly aliquoted into the chamber and spun at 200rpm for 3 minutes. The 
filters were then removed, taking care not to contact the cell smears, and the slides allowed 
to air dry. Cells were then stained with May-Grunwald-Giemsa stain as described below: 
Places slides in May-Grunwald stain for 5 minutes 
Place slides in phosphate buffer pH 7.2 (Sigma-Aldrich) for 1.5 minutes 
Place slides in dilute Giemsa solution (1:20 in deionised water) for 15-20 minutes 
Rinse slides briefly in deionised water 
Air dry, mount and evaluate 
 
2.13.6  Confocal microscopy 
Confocal microscopy was performed with the help of experienced users. Specialised 
mounting medium was used to stain nuclei with 4', 6-diamidino-2-phenylindole (DAPI) 
and protect fluorescent signals from photobleaching (Vectashield DAPI). Cells were 
prepared as follows: 
Draw a 1cm diameter circle on a Poly-lysine coated slide using a hydrophobic pen 
Drop 200µl of cell suspension into the centre of the circle, Incubate for 20 minutes at 37°C 
Wash by briefly dipping into PBS  
Add one drop of Vectashield DAPI soft mount (Vector Laboratories) to cells 
Cover with a coverslip, seal edges with clear nail polish and place slides on ice in the dark 
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Slides were then examined under a x40 objective using an Axiovert 200M/LSM 510 
confocal microscope (Zeiss). Images were viewed and analysed using LSM510 Meta 
software. Z-stack processing was used to view the distribution of fluorescence within the 
cell. 
2.13.7  RNA interference 
RNA interference was performed using a commercially designed pool of 4 sequence 
specific siRNAs directed against 4 different GATA-1 regions known as ON-TARGET plus 
SMART pool (Dharmacon). A number of experimental controls were also performed. 
Transfection efficiency was estimated by co-transfection of a non-targeting, non-functional 
siRNA with a Rhodamine fluorescent tag (siGLO RISC-free siRNA) which can be viewed 
using fluorescent microscopy or flow cytometry. This siGLO reagent also controlled for 
off target effects produced by introduction of any siRNA into the cell. A  third control was 
provided by use of a pool of non-targeting but functional siRNAs (siCONTROL) capable 
of activating RISC and the siRNA pathway but not producing gene specific effects. 
Experimental design and optimisation are discussed further in Chapter 5, section 5.5.6. 
Cells were grown for 48 hours in antibiotic free medium then seeded in 6-well plates at a 
density of 5x10
5 cells per ml (50% confluency). Following initial optimisation experiments 
transfection was performed using Lipofectamine 2000 reagent (Invitrogen) using the 
following method: 
Resuspend siRNA (siCONTROL, siGLO or SMART pool) in 1x siRNA buffer (supplied) 
to produce a stock concentration of 20µM.  
Mix gently and place on orbital shaker for 30 minutes at room temperature 
Verify the concentration of siRNA by measuring the A260 
Dilute 150pmol (7.5µl of 20µM stock) of test siRNA (SMART pool or siCONTROL) and 
50pmol (2.5µl) of siGLO in 250µl Opti-MEM I reduced serum medium (Invitrogen), mix 
gently 
Dilute 5µl of Lipofectamine 2000 reagent in 250µl Opti-MEM I. Incubate for 5 minutes at 
room temperature 
Combine the diluted lipofectamine and siRNA, mix gently and incubate for 20 minutes at 
room temperature then add to the well containing cells and medium and rock gently to mix.
Incubate at 37°C for 24-96 hours before assaying for gene knockdown using western 
blotting or qPCR 
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2.14  Embryonic stem cell methods 
2.14.1  Special considerations for embryonic stem cell 
cultures 
In order to maintain ES cells in an undifferentiated state a number of additional 
precautionary steps are needed during routine maintenance of ES cell culture. In particular 
cells must not be split too thinly, seeded as clumps or allowed to overgrow as all these 
factors will encourage differentiation. Cells were routinely passaged every 2-3 days, 
splitting when 70-80% confluent. A single cell suspension was achieved by trypsinisation 
and manual pipetting.  Cells were seeded at 2x10
5/ml on gelatine coated tissue culture 
flasks (0.1% w/v gelatine in ddH2O, autoclaved, 5ml added to plate, incubated for 5-15 
mins and then removed). All serum was batch tested by the manufacturer and confirmed as 
being suitable for ES cell maintenance (StemCell Technologies) and all cells were grown 
in the presence of recombinant Leukaemia Inhibitory Factor (LIF) 1000units/ml (ESGRO, 
Chemicon Intl). Cells were inspected daily for evidence of differentiation (colonies 
surrounded by flattened cells that differ morphologically from central undifferentiated 
cells- often darker and with long processes and prominent nucleus). Low passage cells 
were used whenever possible and fresh low passage stocks obtained from the Beatson 
Laboratories Gene Targeting facility and Dr Lesley Forrester (Scottish Centre for 
Regenerative Medicine, Edinburgh) for gene targeting experiments.  
2.14.2  In vitro differentiation of ES cells 
2.14.2.1  Transcriptional profiling 
ES cells were allowed to differentiate by formation of embryoid bodies followed by 
withdrawal of LIF and maintenance of embryoid bodies in suspension culture as previously 
described (Baird, et al 2001, Jackson, et al 2002). Cells were harvested daily for 7 days, 
placed in Trizol reagent, RNA extracted and gene expression assessed by PCR. The 
process is illustrated in fig 2.2 and described below: Materials and Methods    130 
Trypsinise plate of 
undifferentiated ES cells
Resuspend and culture as hanging 
drops for 2 days to allow formation of 
embryoid bodies
Wash and resuspend in 
differentiation medium, 
maintain embryoid bodies in 
suspension culture
 
Fig 2.2 in vitro differentiation of ES cells 
Trypsinise one plate of undifferentiated ES cells, wash and resuspend at a concentration of 
2x10
4cells/ml 
Using a multichannel pipettor dispense 100 drops (20μl (400 cells) per drop) concentrically 
onto the lid of a 10cm tissue culture dish 
Invert the lid and place over the bottom of the tissue culture dish filled with 2ml of sterile 
PBS, incubate at 37°C to allow formation of cellular aggregates (embryoid bodies) 
After 2 days use 5ml of ES cell differentiation medium (no antibiotics, no LIF) to wash the 
embryoid bodies off the top of the dishes and transfer to a universal container 
Spin for 3 minutes at 1200rpm and wash with 5-10ml of ES cell differentiation medium 
Resuspend in 10ml differentiation medium and transfer to a 10cm Petri dish (note not a 
tissue culture dish as this would allow attachment of the embyroid bodies to the plate) 
Incubate at 37°C and harvest one plate daily for 7 days 
 
2.14.2.2  Colony formation assays 
Colony formation assays were performed by plating ES cells in methylcellulose medium 
(ES-CULT M3120, StemCell Technologies) in the presence of haematopoietic cytokines. 
Proprietary 35mm culture dishes recommended for colony forming assays were used 
(StemCell Technologies). The differentiation medium comprises: 
ES cell 
methycellulose 
differentiation 
medium (for 
40ml) 
ES-CULT (2.3%) 
IMDM 
FCS 
Monothioglycerol (1%) 
rhuEPO 500U/ml 
15.6 ml (0.9%) 
19.1 ml 
4 ml (10%) 
150μl (340μM) 
80μl (1U/ml) 
StemCell technologies 
Invitrogen 
StemCell technologies 
Sigma-Aldrich 
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Insulin (10mg/ml) 
rmuIL-3 (100μg/ml) 
L-glutamine 100x 
Pen-Strep 100x 
 
40μl (10μg/ml) 
16μl 
400μl 
200μl 
Sigma-Aldrich 
R&D systems 
Invitrogen 
Invitrogen 
 
Method for performing in vitro differentiation assay: 
Thaw methylcellulose medium for 24 hours at 4°C prior to addition of cytokines as 
described above, aliquot 1.5ml of this methylcellulose mix per 35mm tissue culture plate 
using a 16G blunt ended needle and syringe, ensuring no air bubbles are formed 
Grow undifferentiated ES cells on gelatine with LIF, for at least one passage after thawing, 
change medium a few hours before trypsinising.  
Wash cells with PBS, trypsinise and resuspend at 1x10
5 cells per ml in IMDM/10%FCS 
Take up 12.5μl (1250 cells) of ES cell suspension in a pipette and eject into the aliquoted 
methycellulose medium with a swirling motion to ensure even distribution of the 
suspension in the semi-solid media 
Place 2 plates into a 100mm Petri dish with a third 35mm dish containing 3-4ml sterile 
water to provide humidity. Incubate at 37°C for up to 14 days observing plates daily from 
day 5 onwards for formation of haematopoietic colonies 
Qualitative and quantitative analysis of colonies on days 10-14 using a counting grid, 
BFU-E identified on the basis of morphology and pale pink/red haemoglobinisation, CFU-
GM on the basis of characteristic morphology. 
 
2.14.3  Picking and storing targeted ES cell clones for 
screening 
10-14 days following electroporation of the targeting vector and growth in selective 
medium ES cell colonies were picked for screening for the targeted allele. Duplicate plates 
were made for each clone – one master plate to be frozen down and a test plate for 
genomic DNA extraction. The following method was used: 
Add 20μl trypsin to each well of a 96-well plate. Add 500μl of ES cell media to each well 
of 8 x 24-well plates (96 wells in duplicate). Label 24-well plates A1-12, B1-12 etc in 
duplicate (master and test), incubate at 37°C until use. 
Wash ES cell colonies with warmed PBS (37°C), leave about 2-3ml PBS in the plate to 
prevent drying 
Using a p200 Gilson pipette set to aspirate 150μl, draw up a small amount of trypsin from 
well A1, use this tip to scrape/aspirate a colony then eject the tip back into the well A1. Materials and Methods    132 
Repeat for wells A2-A12.  
Reattach the tip from well A1 to the Gilson pipette, draw up 150μl of media from the 
corresponding well in the 24-well master plate, return to well A1, pipette up and down 3 
times and then draw up total volume (150μl) and split evenly between corresponding 
duplicate wells in the master and test 24-well plates. 
Repeat for wells A2-A12 
Repeat the process for the next 12 colonies B1-B12 etc until all the colonies are picked 
Incubate master and test plates at 37°C until the majority of wells are confluent. At this 
stage freeze down the master plate (see section 2.14.3.1 below) and extract genomic DNA 
from the test plate (section 2.7.1) 
 
2.14.3.1  Freezing and Thawing 24-well master plates 
To freeze a 24-well master plate:  
Aspirate the medium, wash in PBS x1 
Add 100μl trypsin 0.05% to each well, incubate 37°C x 5 minutes 
Add 200μl of 1.5x freezing medium (8.5ml ES cell media, 1.5ml DMSO) and pipette up 
and down to mix 
Seal edges of plate with tape, place on ice, wrap in cotton wool and place in polystyrene 
box at -80°C  
 
To thaw a 24 well master plate: 
Float plate in a 37°C waterbath 
Once thawed transfer contents of each well to a fresh 24-well plate containing 0.5ml fresh 
media, incubate at 37°C 
Once cells have adhered to the wells (approximately 8 hours later), remove DMSO 
containing media and replace with fresh warmed ES cell media. 
 
2.15 Statistical methods 
Statistical analysis was performed using Graph Pad Prism software. A two-tailed student’s 
t-test was used to compare normally distributed variables between two test groups. 
Analysis of variables in three test groups at more than one time point was performed using 
two-way ANOVA analysis. In all cases a p value of ≤ 0.05 was considered significant. 133 
3  An analysis of endogenous GATA-1 isoform 
expression in primary tissues and cell lines 
The GATA-1s isoform was first reported in 1995 (Calligaris, et al 1995). This paper 
described the presence of a 40kDa GATA-1 band in addition to the expected 47kDa full-
length band on western blotting of mouse and human haematopoietic cell lines. This was 
shown to be a shortened form of GATA-1 lacking the N terminus. Expression of the short 
form was documented in early embryonic development and was said to precede expression 
of the FL form. However the published western blot is difficult to interpret (reproduced in 
Fig 3.10b) and this finding has not been independently confirmed. Functional assays in 
heterologous cell lines revealed a reduced transactivation potential for GATA-1s compared 
to GATA-1FL (Calligaris, et al 1995). This role of the N-terminus in enhancing trans-
activation of genes carrying upstream GATA-1 binding sites, was confirmed by 
experiments looking at the functional domains of GATA-1 in primitive and definitive 
haematopoiesis (Shimizu, et al 2001). Little progress was made in elucidating the 
biological role of GATA-1 isoforms until the description of GATA-1 mutations in DS-
AMKL (Wechsler, et al 2002). This paper rekindled interest in the physiological and 
pathological roles of GATA-1s. 
In order to contribute to an investigation of the possible functions of GATA-1s in 
haematopoiesis, the expression pattern of the two isoforms during ontogeny and in various 
primary tissues and cell lines was investigated. As discussed in 1.2.8.1 the production of 
GATA-1s in mice is thought to arise by alternative translation of a single mRNA 
(Calligaris, et al 1995), whereas more recent evidence has emerged for alternative splicing 
in humans (Rainis, et al 2003). Whether mice also produce alternatively spliced transcripts 
is unknown. This chapter describes experiments to determine: 
1. The best methods to detect isoform expression in humans and mice and whether 
alternative splicing also plays a role in the murine production of GATA-1s. 
2. Patterns of GATA-1FL and GATA-1s expression during ontogeny, in different cell 
lineages and during in vitro haematopoietic differentiation. 
3. Whether additional GATA-1 isoforms exist. 
4. The relevance of an identified human leukaemic transcript variant BC009797. Results Chapter 3    134 
In this way it is hoped to determine whether GATA-1s has a distinct pattern of expression 
which could shed light on its biological role in vivo. In addition, in order to understand the 
complex roles of GATA-1 in haematopoiesis it is vital to identify any additional isoforms 
which could play novel roles in GATA-1 regulation of gene expression.  
3.1 GATA-1 isoforms are produced by different 
mechanisms in humans and mice 
3.1.1 PCR primers spanning potential splice sites show one 
product in mice and two products in humans. 
To investigate the existence of alternative splicing in mice, and confirm its occurrence in 
humans, a number of PCR primers were devised. These are illustrated in Fig 3.1a and 
listed in table 2.4. In the presence of alternative splicing, primers spanning the splice sites 
should produce two different sized products; one corresponding to the exon 1-2-3 splice 
variant and the other corresponding to the exon 1-3 splice variant which should be 238bp 
(human and mouse) smaller due to the skipping of exon 2. Initial results using these 
primers confirmed the presence of two bands in cDNA from the human cell line K562 (fig 
3.1b). These bands were excised, gel purified and cloned into the pCR2.1 TOPO cloning 
vector (section 2.12.1.1) before being sent for commercial sequencing (Agowa.de). 
Sequencing results confirmed that the larger band corresponded to the exon 1-2-3 splice 
variant and the shorter band lacked exon 2 and showed direct splicing from exon 1 to exon 
3 (data not shown). Only one band was seen in mouse bone marrow cDNA (fig 3.2a). 
Since GATA-1s is thought to be produced early in ontogeny (Calligaris, et al 1995), and 
may not be needed for adult haematopoiesis (Shimizu, et al 2001), it is possible that this 
result reflected lack of production of the GATA-1s isoform in adult tissues, rather than 
lack of alternative splicing. Therefore, murine samples from embryonic tissues (yolk sac 
day 9, embryo day 10.5) were also examined. Again only one band was seen (fig 3.2a). 
Finally a murine cell line - mouse erythroleukaemia (MEL) - that expresses both isoforms 
by western blot (fig 3.3b) was tested, again despite the existence of long and short isoforms 
at the protein level there was no evidence of alternative splicing at the mRNA level (fig 
3.2a). This result was confirmed using an independent set of primers (alt splice 2, fig 3.2a). Results Chapter 3    135 
805bp Not detected Mouse exon 1/3, 4bpmm 
splice site 5’, 3’
192bp 430bp Human alt splicing primers 
5’ 3’
805bp Not detected Mouse exon 1/3 splice 
site:5’, 3’
296bp 534bp Mouse alt splice version 2: 
5’, 3’
118bp 356bp Mouse alt splice 1: 5’, 3’
Exon 1/3 alt splice 
variant size
Exon 1/2/3 FL 
transcript size
Names Primers
805bp Not detected Mouse exon 1/3, 4bpmm 
splice site 5’, 3’
192bp 430bp Human alt splicing primers 
5’ 3’
805bp Not detected Mouse exon 1/3 splice 
site:5’, 3’
296bp 534bp Mouse alt splice version 2: 
5’, 3’
118bp 356bp Mouse alt splice 1: 5’, 3’
Exon 1/3 alt splice 
variant size
Exon 1/2/3 FL 
transcript size
Names Primers
? GATA-1short 
alternative 
splice variant
GATA-1FL
13 4 5 6
12 3 45 6
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Fig 3.1 Detection of alternative splicing by PCR 
(a) Details of primer design and expected product sizes, exon 1/3 primers should not anneal 
to the GATA-1FL transcript as shown by a red cross (b) clear evidence of alternative 
splicing in the human cell line K562, results were confirmed by cloning and sequencing.  
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Fig 3.2 PCR does not reveal alternative splicing in mice 
(a) 2 different primer sets only detect a single GATA-1 transcript. (b) Primers designed to 
anneal to the putative exon 1/3 splice site are still able to detect the full length transcript 
unless a 4bp mismatch is introduced. This mismatch prevents non-specific annealing but is 
unable to detect a short transcript. Primer binding sites and products are shown in Fig 3.1a. 
To increase the sensitivity of the technique, in an attempt to detect a low level of exon 1/3 
transcripts, PCR primers were designed that annealed to the theoretical exon 1/3 splice 
junction (fig 3.1a). Unfortunately due to a high degree of homology between the exon 1/3 
junctional region and the 1/2 junctional region these primers were able to pick up the full-
(b) 
(a) Results Chapter 3    137 
length transcript (fig 3.2b, top gel image), to overcome this a 4 base-pair mismatch was 
introduced into the primer which should leave sufficient homology to pick up the exon 1/3 
splice junction but should abolish binding to the already mismatched exon 1/2/3 junctional 
site. The latter was indeed confirmed (fig 3.2b, bottom gel image) but this primer was still 
unable to detect an alternatively spliced transcript. 
To strengthen these findings the mouse expressed sequence tag (EST) database (see 3.3.1.2 
for a discussion of this methodology) was examined for evidence of published mRNA 
transcripts corresponding to an exon 1/3 splice variant using the National Center for 
Biotechnology Information (NCBI) Basic Local Assignment Search Tool (BLAST) 
(http://blast.ncbi.nlm.nih.gov/Blast.cg). This in silico analysis also failed to confirm the 
presence of alternative splicing in mice (data not shown). A similar search of the human 
EST database showed evidence of an Exon 1/3 alternatively spliced transcript in a cDNA 
library constructed from human fetal skeletal muscle (NCBI accession number: 
AJ973498).  
In summary, these results confirm the existence of alternative splicing as a method of 
short isoform production in humans. They also strongly support the hypothesis that the 
short isoform is produced by alternative translation, rather than alternative splicing, in 
mice. These findings have implications for investigation of isoform expression patterns 
as PCR will only be informative in human samples, alternative methods of detection will 
be needed for mice. 
3.1.2 Western Blotting confirms presence of 2 isoforms in mice 
and humans 
In the absence of alternative splicing, detection of GATA-1 isoform production in mice 
relies upon Western blotting. There are two commercially available anti-mouse GATA-1 
antibodies. A polyclonal antibody raised against the conserved C-terminus GATA1-M20 
(Santa Cruz) and a monoclonal antibody raised against the N-terminus – GATA1-N6 
(Santa Cruz). Because GATA-1s lacks the N terminus it is predicted that it will not be 
detected by the N6 antibody but should be detectable as a smaller band of approximately 
40kDa when using the polyclonal M20 antibody. GATA-1FL should be detectable as a 
47kDa band with both antibodies. These antibodies are reported as suitable for detection of 
both human and murine proteins on the product datasheet.  Results Chapter 3    138 
3.1.2.1  Optimisation of western blotting techniques 
Initial attempts at western blotting followed standard protocols for whole cell lysates (see 
materials and methods section 2.9). These blots showed a large amount of non-specific 
binding. Differentiation between background and GATA-1 was impossible (Fig 3.3a). This 
problem persisted despite titration of primary and secondary antibody concentrations, 
varying incubation times, addition of bovine serum albumin, trying alternative lysis agents 
and increasing the stringency of washing.  
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Fig 3.3 Optimisation of western blotting technique 
(a) Whole cell extracts probed with M20 and N6 antibodies showing high level background 
and non-specific bands in negative control (b) The use of the same antibodies and blotting 
conditions but with nuclear extracts. The 47kDa GATA-1FL band is seen in with both M20 
and N6 antibodies whist the smaller 40kDa GATA-1s band is only seen with M20. Red 
arrow=50kDa and blue=40kDa size markers respectively. GATA-1 was not detectable in 
cytoplasmic extracts from the same cells (lane 3 M20). 
Since GATA-1 is a nuclear transcription factor a nuclear extraction protocol was attempted 
to concentrate the protein of interest and reduce non-specific background. This approach 
was much more successful as shown in Fig 3.3b. Using this approach the M20 antibody 
produced two bands corresponding to GATA-1FL (47kDa) and GATA-1s (40kDa) in both 
human (K562) and murine (MEL) cell line nuclear extracts (Fig 3.3b, top image). As Results Chapter 3    139 
predicted the N6 antibody only produced a 47kDa band corresponding to GATA-1FL (Fig 
3.3b, bottom image), this band is shown in NIH3T3 cells expressing two murine GATA-
FL plasmids (described in chapter 5.2.2) and in a murine erythroleukaemia cell line 
(MEL). Interestingly, the N6 antibody did not produce any bands with a human K562 
nuclear extract (lane 4 fig 3.3b bottom image) despite the clear detection of a GATA-1FL 
band using the M20 antibody (Fig 3.3b, top image). This finding is discussed in section 
3.1.2.2 below. The nuclear/cytoplasmic extraction protocol (described in section 2.9.2) was 
used in all subsequent blotting experiments. In order to ensure cytoplasmic expression was 
not being missed, cytoplasmic extracts were run on a number of occasions – these never 
showed bands corresponding to GATA-1FL or GATA-1s (fig 3.3b, top image lane 3). 
3.1.2.2  GATA-1 N6 antibody only detects murine GATA-1  
Although product information claims that the N6 monoclonal antibody picks up both 
murine and human GATA-1, results shown above suggest that only murine protein can be 
detected. To test this further a number of transfection experiments using GATA-1 
expression plasmids (described in chapter 5.2.2) were performed. Fig 3.4a shows a western 
blot of a mouse GATA-1FL plasmid transfected into a human cell line (K562) alongside a 
mouse GATA-1s plasmid transfected into the same cell line. The M20 antibody picks up 
both human and mouse isoforms (lane 1 and 2) but the N6 antibody is only able to detect 
the mouse GATA-FL transcript (lane 3) and not the human one (lane 4).  
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Fig 3.4 Characteristics of available antibodies 
(a) M20 antibody detects murine and human GATA-1 whilst N6 only detects murine protein 
(b) A double band was sometimes detected in cell lines expressing endogenous GATA-1. 
Red arrow – position of GATA-1FL, blue arrow- position of GATA-1s, gold arrow – additional 
band. Results Chapter 3    140 
This finding led to the use of the M20 antibody (able to detect both isoforms in both 
species) in the majority of experiments.  
3.1.2.3    An intermittent additional band suggests variable post-
translational modification 
As shown in Fig 3.4b an additional band could sometimes be detected just above the FL 
isoform (fig 3.4b). This double band was not consistently detected and was only ever seen 
when using cell lines. On review of the literature this pattern has been reported elsewhere 
with the larger band being identified as a phosphorylated form of GATA-1 (Crossley and 
Orkin 1994, Hernandez-Hernandez, et al 2006).  
In summary, these experiments confirm the existence of two isoforms of GATA-1 at the 
protein level in humans and mice. Methods of isoform detection by western blotting have 
been optimised, and important differences in antibody species reactivity identified.  
3.2 Patterns of GATA-1 isoform expression during 
haematopoietic development 
The studies described above establish that GATA-1 isoforms can be identified by PCR in 
humans and by western blotting in mice. Although the sites and timing of GATA-1 
expression have been extensively studied during haematopoietic ontogeny, very little is 
known about the relative utilisation of the different isoforms during this period. Apart from 
the intriguing report of GATA-1s expression preceding that of GATA-1FL in the early 
mouse embryo (Calligaris, et al 1995), there have been no other studies addressing 
differential isoform usage in different lineages or at different developmental stages either 
in humans or mice.  Therefore, a systematic analysis of the sites and timing of isoform 
expression in humans and mice was undertaken using the following material: 
1. Human primary haematopoietic cells  
2. Human haematopoietic cell lines 
3. Human embryonic tissues 
4. Human haematopoietic cell lines undergoing in vitro megakaryocytic and erythroid 
differentiation Results Chapter 3    141 
5. Murine embryonic tissues 
6. Murine cell lines 
7. Murine embryonic stem cells undergoing in vitro haematopoietic differentiation. 
3.2.1 GATA-1 isoform expression in human primary cells 
GATA-1 is known to be expressed in the erythroid, megakaryocyte, eosinophil, mast cell 
and dendritic cell lineages as well as the Sertoli cells of the testes (Crispino 2005), 
however isoform expression patterns in these cell types have not been reported. The 
existence of GATA-1s expression would provide circumstantial evidence for a functional 
role in these lineages. Expression patterns were analysed in various haematopoietic 
primary cells and in adult testis. Purified monocyte (2 preparations), eosinophil, T cell (2 
preparations), B cell and dendritic cell populations were obtained from Dr C McKimmie, 
Glasgow Biomedical Research Centre. Monocytes, eosinophils and lymphocytes were 
isolated by a standard MACS bead sorting approach (McKimmie, et al 2008) and dendritic 
cells isolated following Flt3 stimulation of in vitro cultures. RNA extraction using a 
commercial kit (RNeasy, Qiagen) and cDNA synthesis using AffinityScript (Stratagene) 
was performed as described in section 2.8.1.2 and 2.8.4. Testis cDNA was obtained 
commercially (Ambion). Expression was assessed by RT-PCR using exon 1 and 3 primers 
which should give a 430bp band with GATA-1FL and a 192bp band with GATA-1s. 
Results are shown in Fig 3.5. Both isoforms were expressed in eosinophils. Low level 
GATA-1FL and GATA-1s expression was seen in both monocyte preparations with one 
sample appearing to show a stronger GATA-1s band, one T cell sample was also positive 
but dendritic cells, B cells and the other T cell population were all negative. Although 
GATA-1 expression has been documented in dendritic cells previously (Gutierrez, et al 
2007) this was in mice not humans. In addition, the intensity of GATA-1 expression in 
murine DCs varies with their activation status with very low levels of expression in steady 
state DCs and significant up-regulation on activation and terminal differentiation 
(Gutierrez, et al 2007). It is possible that dendritic cells used in this experiment were not 
mature enough to express detectable GATA-1, alternatively the relatively small amounts of 
template (as shown by the weak GAPDH band) may have led to GATA-1 being below the 
level of detection in this PCR reaction. The expression in monocytes is interesting as these 
cells can act as precursors for dendritic cells under inflammatory conditions but their other 
cellular progeny - macrophages are not known to express GATA-1. Expression was not 
detected in testis consistent with use of an alternative first exon (Ito, et al 1993).  Results Chapter 3    142 
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Fig 3.5 GATA-1 isoform expression in human primary cells 
PCR was performed using exon 1 and 3 primers. Both isoforms are expressed in 
eosinophils, and T cells, monocytes also appear to express GATA-1 with one sample (lane6) 
expressing a stronger GATA-1s band.  
These experiments, using purified primary cells, always bear the caveat that low levels of 
contamination with other populations may be responsible for the detection of expression – 
especially when using sensitive techniques such as PCR. To explore these cell types 
further, without concern about contamination, the expression of GATA-1 isoforms in a 
number of cell lines was also studied. 
3.2.2 GATA-1 expression patterns in human cell lines  
Cell lines have the advantage that they can be grown in large quantities and represent pure 
populations without concerns about cross-contamination. However, they may not be 
entirely representative of the cell type from which they were derived and have acquired 
mutations to allow them to proliferate indefinitely in culture. In addition many are derived 
from malignant cells whose differentiation status and expression of lineage specific genes 
may be considerably disturbed. These factors should be borne in mind when interpreting 
experiments.  
A number of human haematopoietic cell lines were grown in culture as described in section 
2.2 and 2.5.3. These are listed in Table 3.1 along with their presumptive cell of origin.  Results Chapter 3    143 
Cell line  Putative cell of origin 
M07E Megakaryocyte  precursor 
Jurkat T  cell 
U937 Monocyte 
THP-1 Monocyte 
K562 Common  myeloid  precursor 
Meg-01 Meg-erythroid  precursor 
HMC-1 Mast  cell 
LAD-1 Mast  cell 
Table 3.1 Human haematopoietic cell lines and their normal counterparts 
Once sufficient cells had been obtained these cultures were harvested and RNA extraction 
and nuclear protein extraction were performed according to standard protocols (described 
in sections 2.8.1. and 2.9.2). cDNA was made from the RNA using AffinityScript with 
random primers (section 2.8.4) and used in RT-PCR with exon 1 and 3 primers (Fig 3.1). 
Results of PCR reactions are shown in Fig 3.6a. Expression of both isoforms was seen in 
the megakaryocytic cell lines Meg-01 and MO7-E along with K562 (a cell line known to 
be capable of meg-erythroid differentiation as shown in section 3.2.4 below). In addition 
the mast cell lines HMC-1 and LAD showed strong expression levels of both isoforms. 
Mast cells are known to require GATA-1 for terminal differentiation (Migliaccio, et al 
2003). These results also confirmed GATA-1FL and GATA-1s expression in one of two 
monocytic cell lines – THP-1. The T cell line Jurkat did not show any expression. To 
quantitate levels of expression of GATA-1s in megakaryocytic and monocytic cells qPCR 
was performed as described in section 2.10.5 –M07E and THP-1 cells showed equivalent, 
albeit low level, GATA-1s expression, the other monocytic cell line U937 showed 
negligible expression, whilst high level expression was confirmed in Meg-01 cells (fig 
3.6b). Western blotting (fig 3.6c) failed to show GATA-1 expression in both M07E and 
THP-1 presumably reflecting the low level expression in these cells. K562 and Meg-01 
cells expressed both isoforms at the protein level as expected.   
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Fig 3.6 GATA-1 expression in human cell lines 
(a) Expression of isoforms assessed by PCR confirms expression in meg-erythroid cell 
lines (M07E, Meg-01, K562), mast cells (HMC-1, LAD-1) and 1 monocytic cell line (THP-1) 
Arrows show position of the 430bp GATA-1FL band and the 192bp GATA-1s band (b) qPCR 
for GATA-1s using levels of expression in M07E cells as the calibrator (i.e. level of 
expression in M07E arbitrarily set at 1) shows equivalent levels of expression in THP-1 and 
increased expression in Meg-01 (n=3) (c) western blot analysis (M20 antibody) is unable to 
detect low level THP-1 and M07E GATA-1s expression but confirms 2 isoforms in Meg01 and 
K562, top arrow shows position of GATA-1FL and bottom arrow position of GATA-1s. 
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In summary, studies looking at GATA-1 isoform expression in human primary cells and 
haematopoietic cell lines have shown that both isoforms are expressed in 
megakaryocytic, erythroid, eosinophil and mast cell lineages. Monocytes show variable 
expression, confirmed by quantitative PCR. Unexpectedly, one primary T cell sample 
showed evidence of GATA-1 expression although this was not confirmed on 
examination of a T cell line, suggesting that the detectable expression may have been 
due to contamination of the preparation with other GATA-1 expressing cell populations. 
GATA-1s expression appears to accompany GATA-1FL in all the cell types studied, 
although one monocyte preparation showed preferential GATA-1s expression.  
3.2.3 GATA-1 isoform expression during human fetal development 
As discussed in chapter 1 the GATA-1s isoform may be particularly important for fetal 
haematopoiesis. Human fetal samples are obviously a scarce resource, making 
comprehensive analysis of isoform expression during human haematopoietic ontogeny 
difficult. However, in collaboration with Professor Irene Roberts and Dr Oliver Tunstall-
Pedoe (Imperial College, London), a second trimester human fetal liver sample derived 
from elective surgical termination of pregnancy and two neonatal cord blood samples, one 
of which had undergone in vitro culture to enrich for neonatal megakaryocytes were 
evaluated. Whole cell lysates were made from provided cell pellets (as described in 2.9.1) 
and the results of western blotting are shown in fig 3.7. Although not conclusive, these 
blots suggest that both GATA-1 isoforms be detected in both cord blood samples (lanes 1-
3) and in fetal liver (lane 4). The short isoform is most strongly expressed in cells derived 
from CD61 selected megakaryocytic cord blood cultures (lane 1), with reduced expression 
of this isoform in the CD61 negative fraction, consistent with a role for GATA-1s in fetal 
megakaryocytic development. These western blotting results are supported by qPCR for 
the GATA-1 isoforms (fig 3.7b– analysis performed by Dr O Tunstall-Pedoe). These qPCR 
results show detectable GATA-1s and GATA-1FL expression in CD34+ cells derived from 
DS and normal fetal liver samples with a median gestation of 15 weeks, Down syndrome 
fetal liver samples had upregulated GATA-1 expression consistent with their increased 
proportion of MEPs, no GATA-1 mutations were detectable at this time. 
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Fig 3.7 GATA-1 isoform expression in human embryonic tissues 
(a) Western blotting with M20 (top, blue arrow – position of GATA-1FL band, red arrow 
position of GATA-1s band) and actin loading control (bottom, blue arrow- position of 42kD 
actin band). Lane 1: CD61 bead selected cord blood (CB) cells following in vitro culture. 
Lane 2: CD61 negative CB cells from same culture. Lane 3: unmanipulated mononuclear 
cells from term CB sample. Lane 4: Down syndrome fetal liver sample 15 weeks gestation. 
(b) qPCR results for GATA-1 isoforms in Down syndrome (DS1, DS2, DS3) and normal fetal 
liver (FL) samples (normal) from average 15 weeks gestation showing upregulation of both 
isoforms in the presence of trisomy 21. GATA1S = short isoform, GATAL = full-length 
isoform - this qPCR data was reproduced from  (Tunstall-Pedoe, et al 2008) with permission.  
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3.2.4 GATA-1 isoform expression during induction of terminal 
erythroid and megakaryocytic differentiation 
Studies described above addressed the presence or absence of GATA-1 expression in static 
cell populations. GATA-1 levels are known to be dynamically regulated during erythroid 
and megakaryocytic differentiation but whether this regulation affects both isoforms 
equally is unknown. Certain haematopoietic cell lines can be induced to differentiate into 
erythroid or megakaryocytic cells vitro. The chemical compound Haemin 
(C34H32N4O4FeCl) induces erythroid differentiation as measured by upregulation of 
erythroid genes and characteristic cytology. The phorbol ester TPA (12-O-
tetradecanoylphorbol-13-acetate) induces megakaryocytic differentiation via a mechanism 
that is poorly understood but appears to involve activation of protein kinase C. Two cell 
lines were chosen for study- both originated from patients with CML - K562 and Meg-01. 
These lines are discussed in more detail in Chapter 5 and data validating this model system 
are also presented in Chapter 5. Importantly, Meg-01 cells are trisomic for chromosome 21 
whist K562 are disomic, allowing additional evaluation of the role of trisomy 21 in 
modulating the effects of GATA-1s expression.  By serial harvesting of RNA the 
expression levels of genes during lineage commitment and differentiation can be studied. 
In vitro differentiation was performed (as described in section 2.13.3. and 2.13.4) to test 
whether GATA-1 isoforms vary during commitment to, and differentiation within, the 
megakaryocytic and erythroid lineages.  
Fig 3.8 shows results for Haemin-induced erythroid differentiation, with assessment using 
semi-quantitative RT-PCR (see section 2.10.2 materials and methods), for both isoforms. 
These results suggest that GATA-1FL is dynamically regulated during erythroid 
differentiation. K562 cells show rapid and profound down-regulation of GATA-1FL from 
day 3 onwards compatible with the need for GATA-1 down-regulation to allow terminal 
differentiation –as discussed in chapter 1.  Meg-01 cells appear initially to upregulate 
GATA-1FL before levels fall again at day 4-5. This may represent the need to reverse their 
partially committed phenotype (they have strong megakaryocytic features in culture) prior 
to terminal erythroid differentiation. However, the nature of these data (n=1 and use of 
semi-quantatiative PCR) means that caution should be exercised in their interpretation. The 
molecular basis for erythroid and megakaryocytic differentiation in these cells is further 
explored by qPCR in chapter 5. For the purposes of this experiment the important 
observation is that, unlike GATA-1FL, GATA-1s does not show any appreciable change in 
expression levels with erythroid differentiation.  Results Chapter 3    148 
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Fig 3.8 Variation of GATA-1 isoforms during in vitro erythroid differentiation 
(a) Results of densitometry assessment of RT-PCR gels, 25 cycles of PCR were performed  
for GATA-1 and the actin control, to ensure the reactions were still in the exponential 
doubling phase. The area under the peak was normalised to the actin control for each 
isoform (n=1 for each isoform/cell line). (b) Representative 25 cycle gel image showing 
variation in the intensity of GATA-1 bands and the need to normalise to actin levels. FL = 
GATA-1FL stable transfectants, SH = GATA-1s stable transfectants.  
Fig 3.9 shows results for TPA induced megakaryocytic differentiation. In addition to semi-
quantitative PCR, expression of the GATA-1s isoform was also assessed by qPCR using 
Taqman primers as described in section 2.10.5. Reassuringly these qPCR results broadly 
mirror those seen with semi-quantitative PCR. In contrast to erythroid differentiation there 
is evidence of modulation of GATA-1s levels early in megakaryocytic differentiation with 
significant falls in GATA-1s expression in qPCR experiments at 6 hours after exposure to 
TPA in Meg-01 and K562, and at Day 2 in K562 cells (3 biological replicates per group 
with each sample assayed in triplicate, experiments repeated on 2 occasions). This could 
represent a need to down-regulate GATA-1s to allow induction of terminal 
megakaryocytic differentiation. However an alternative explanation is that application of 
TPA produces non-specific toxic effects on mRNA synthesis or stability in the cells, Results Chapter 3    149 
manifesting as a non-specific reduction in all transcript levels. This is not supported by 
concurrent analysis of a housekeeping gene 18SrRNA which shows extremely stable 
expression levels even after TPA treatment (results shown in chapter 5.21). GATA-1FL 
expression also falls steeply in K562 cells although a low level rise is seen in Meg-01 (fig 
3.9a). Again the different levels of progenitor cell commitment in these two cell lines may 
explain the different behaviours, although it is also possible that the presence of trisomy 21 
in Meg-01 cells in some way prevents GATA-1FL down-regulation. These possibilities are 
investigated further in chapter 5. 
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Fig 3.9 GATA-1 isoform expression during in vitro megakaryocytic 
differentiation of cell lines 
(a) Shows results of semiquantitative PCR using densitometry as described for fig 3.8 (n=1). 
(b) Taqman qPCR for the GATA-1s isoform shows statistically significant fall in GATA-1s 
expression at 6 hours and Day 2 for K562 cells and at 6 hours only for Meg-01 (n=3). 
*=p≤0.05, **=p<0.01 
 
In summary, there is evidence of dynamic regulation of GATA-1 isoforms during in 
vitro erythroid and megakaryocytic differentiation. GATA-1FL is down-regulated during Results Chapter 3    150 
erythroid differentiation of K562 cells, GATA-1s levels are low and do not appear to 
alter significantly. However, GATA-1s shows statistically significant down-regulation 
during megakaryocytic differentiation in both K562 and Meg-01 cell lines. These results 
support a role for GATA-1s in maintenance of megakaryocytic precursor populations 
with a need to down-regulate expression to allow terminal differentiation.  
3.2.5 GATA-1 isoform expression during murine embryogenesis 
In parallel with the above human studies the expression of GATA-1 isoforms was also 
assessed in mice. As established in section 3.1, this analysis relies on western blotting to 
detect the two protein products produced by alternative translation of a single mRNA. 
As discussed in 1.2.8, GATA-1s has been reported to be expressed early in murine 
development prior to GATA-1FL expression (Calligaris, et al 1995). This assertion is 
based on a single western blot which has a lot of background making interpretation 
difficult. This blot is reproduced in fig 3.10b, the day 8.5 embryo sample, reported as 
showing exclusive GATA-1s expression, is in lane 4. No subsequent studies have 
addressed patterns of isoform expression early in development. In order to investigate this 
further, mouse embryos were obtained at E8.5, E9, E10.5, and E12.5 (gestation was 
confirmed by somite counting). Microdissection techniques were used to separate out the 
AGM region, yolk-sac, placenta and rest of body and fetal blood was also collected (see 
section 2.6.2 for details). These samples were red cell lysed (section 2.6.1) and then lysed 
in mammalian tissue lysis buffer (section 2.9.1), whole tissue extracts were used for 
western blotting. Results are shown in fig 3.10a. These blots are difficult to interpret due to 
high background, unfortunately attempts to improve clarity by the use of nuclear extracts 
failed. Attempts at optimising the nuclear extract protocol using mouse bone marrow were 
unsuccessful (data not shown) - the nuclear extract protocol in use appears to be very 
sensitive to the presence of contaminating red cells and is only really suitable for cell lines. 
This was confirmed by others (Isla Hamlett, IMM, Oxford – personal communication). A 
K562 whole cell extract was run as a positive control (far right-hand lane). Tentative 
interpretation of the blots suggests that GATA-1FL expression is seen in the E9 yolk-sac, 
E10.5 yolk-sac and embryo, and in all tissues at E12.5 i.e. fetal blood, fetal liver and rest of 
body. A number of the lanes - E8.5 embryo and E9 embryo, E10.5 AGM and Fetal blood - 
do not contain adequate protein (using higher band marked with a red arrow as an internal 
loading control) making them un-interpretable. Looking at GATA-1s expression this 
appears to be present in E9 and E10.5 yolk sac, the E10.5 embryo shows absent or weak 
expression and then GATA-1s is detectable in all embryonic tissues at E12.5. These Results Chapter 3    151 
findings confirm early GATA-1FL and GATA-1s expression in the yolk-sac but do not 
support the contention that GATA-1s expression precedes that of GATA-1FL. Although 
the expression of GATA-1s in the yolk-sac and not embryo at E10.5 is intriguing it may 
merely represent differences in protein loading in these two samples, in addition the 
embryo at day 10.5 had already had the AGM region removed, making it a relatively poor 
source of haematopoietic cells.  
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Fig 3.10 GATA-1 isoform expression during mouse embryonic development  
(a) Blue arrows show position of GATA-1FL and short isoforms, red arrow represents non-
specific band used as loading control (b) western blot analysing GATA-1 isoform 
expression in early murine embryogenesis – reproduced from Calligaris et al 1995. 
 
Therefore, like humans, mice express both isoforms of GATA-1 early in development. 
These results do not confirm the published report of early exclusive GATA-1s expression 
but do confirm both GATA-1FL and GATA-1s isoform expression at the protein level in 
early embryonic tissues.  
(a) Results Chapter 3    152 
3.2.6  Isoform expression in murine cell lines 
Again in parallel with human studies, GATA-1 isoform expression in murine cell lines was 
also investigated. A number of haematopoietic cell lines were cultured in vitro with 
harvesting for RNA and protein (nuclear extracts). The cell lines and their putative cell of 
origin are shown in Table 3.2. Initially PCR was performed to look for GATA-1mRNA – 
Fig 3.11a. Bearing in mind that this PCR cannot distinguish the two GATA-1 isoforms in 
mice, GATA-1 expression was detected at the mRNA level in cells representing 
haematopoietic precursors (FDCP-mix, B6SutA and 32D), erythroid precursors (MEL) and 
in a mast cell line (P815) but not in myelomoncytic and macrophage cell lines (Raw264, 
P388 and WeHi3B). It was also not seen in the murine embryonic fibroblastic cell line 
NIH3T3.  
Cell line    Putative cell of origin 
Factor-dependent cell mix – Patterson 
(FDCP-mix A4) 
Multipotent progenitor 
32D Multipotent  progenitor 
B6SutA Multipotent  progenitor 
Raw264 Monocyte/Macrophage 
P388 Lymphoid  macrophage 
P815 Mast  cell 
WeHi3B Myelomonocytic 
NIH3T3 Embryonic  Fibroblasts 
MEL Erythroid  progenitors 
Table 3.2 Murine cell lines 
Interestingly, at the protein level GATA-1 expression was only detected in the erythroid 
cell line MEL which expressed both isoforms (Fig 3.11b). The bone marrow precursor 
lines B6SutA and FDCP mix did not show evidence of expression. This may reflect the 
fact that haematopoietic precursors express transcripts for transcription factors at the 
mRNA level but often do not produce functional protein until the cell has undergone 
lineage commitment – so called lineage priming  (Hu, et al 1997) (this paper used FDCP 
mix as one of its model systems). The mast cell line P815 also failed to show expression at 
the protein level. Since mast cells are known to require GATA-1 for terminal Results Chapter 3    153 
differentiation, rather than proliferation in culture, this again may represent post-
transcriptional control of mRNA expression.  
F
D
C
P
-
m
i
x
3
2
-
D
B
6
S
u
t
A
R
A
W
-
2
6
4
P
3
8
8
P
8
1
5
W
e
H
i
-
3
B
N
I
H
-
3
T
3
W
a
t
e
r
M
E
L
GATA-1
Actin
(a)
 
F
D
C
P
-
m
i
x
3
2
-
D
B
6
S
u
t
A
R
A
W
-
2
6
4
P
3
8
8
P
8
1
5
W
e
H
i
-
3
B
M
E
L
(b)
 
Fig 3.11 GATA-1 isoform expression in murine haemopoietic cell lines 
(a) PCR using exon 4 and 5 primers gives a GATA-1 band of 279bp (top gel image), an actin 
positive control confirms adequate cDNA in all samples (b) western blot using M20 
antibody, arrows show the position of GATA-1FL and GATA-1s protein bands.  
 
These studies confirm GATA-1mRNA expression in haematopoietic progenitors, 
erythroid progenitors and mast cell populations but not in monocytic or macrophage cell 
lines. Detectable protein expression is only seen in erythroid precursors. This may be 
because of post-transcriptional regulation of GATA-1 mRNA  in earlier precursor cells, 
or simply reflect levels of GATA-1 below the limits of detection with these antibodies. Results Chapter 3    154 
3.2.7    GATA-1 expression during embryonic stem cell in vitro 
haematopoietic differentiation 
To address dynamic regulation of GATA-1 expression in murine haematopoiesis, 
embryonic stem cells were induced to differentiate in vitro. The use of embryonic stem 
cells to model haematopoietic differentiation is discussed in chapter 4. Briefly, embryonic 
stem cells can be maintained in a totipotent state in culture by addition of cytokines and 
serum, the most important component of which is leukaemia inhibitory factor (LIF). 
Withdrawal of LIF leads to loss of their multipotency and commitment to a variety of 
lineages with a particular propensity to form haematopoietic cells. Differentiation is 
encouraged by allowing the cells to aggregate and therefore mimicking cellular 
interactions during early embryogenesis. This is achieved by initial culture of cells as 
“hanging drops” to allow their association to form embryoid bodies followed by culture in 
non-adherent petri dishes in the absence of LIF. Cells can then be harvested daily and 
expression of genes associated with commitment to haematopoietic or other cell fates can 
be assayed. It has been shown that the sequence of gene expression in this system mimics 
that seen in vivo during haematopoietic differentiation with sequential switching on of 
primitive and definitive haematopoiesis.  
Following formation of embryoid bodies and withdrawal of LIF (as described in materials 
and methods section 2.14.2.1) ES cells were harvested daily. Transcriptional profiling of 
GATA-1 expression was performed by RT-PCR. Fig 3.12a shows expression of GATA-1 
mRNA (expected product size 1030bp), weakly detectable at day 2, increasing in intensity 
at day 6 and still detectable at day 7. It should be noted that there appears to be some 
modest variation in product sizes between the individual lanes, this was investigated and 
found to be due to the temporary use of SYBR Green (Invitrogen) in place of Ethidium 
Bromide as a DNA staining agent in the electrophoresis gel. Binding of SYBR Green to 
DNA leads to an alteration in molecular weight which can affect gel migration patterns (in 
a non-linear fashion). For this reason SYBR Green is best used to post-stain 
electrophoresis gels after DNA migration. All subsequent gel electrophoresis was 
performed with ethidium bromide.  Western blotting was performed on ES cell embryoid 
bodies from day 6 when GATA-1mRNA expression was strongest (fig 3.12b). These failed 
to show expression of GATA-1 at the protein level and therefore did not allow dissection 
of the timing of onset of isoform expression during ES cell in vitro haematopoietic 
differentiation. This finding is not entirely unexpected. As mentioned above there is good 
evidence that during early stages of cellular commitment key transcription factors are Results Chapter 3    155 
expressed at the mRNA level but that protein expression can be absent or at a very low 
level.  
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Fig 3.12 GATA-1 expression during in vitro haematopoietic differentiation of 
murine embryonic stem cells 
(a) PCR using exon 1 (alt splice 1 forward) and exon 5 (GATA-1 reverse) primers (b) Western 
blot using M20 antibody. Middle lane shows magic mark size marker dark bottom band 
(lower arrow) = 40kDa. Blue arrows mark position of GATA-1FL and GATA-1s respectively. 
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3.3 Identification of additional GATA-1 transcripts 
The experiments described above document GATA-1FL and GATA-1s isoform expression 
patterns in human and murine haematopoiesis. In order to comprehensively address the 
roles of GATA-1 isoforms in haematopoiesis it is important to establish whether additional 
GATA-1 isoforms exist. A number of haematopoietic transcription factors such as Erg, 
Runx-1 and C/EBPα have multiple isoforms, with evidence for differential usage of 
isoforms during haematopoietic ontogeny (Bedi, et al 2008, Corsetti and Calabi 1997, 
Fujita, et al 2001). To look for additional isoforms three approaches were taken: 
1. in silico analysis of GATA-1 genomic sequence and EST database to look for possible 
additional exons and alternatively spliced transcripts. 
2. Intron spanning PCR of GATA-1 cDNA at various points during ontogeny and in 
different lineages to identify alternatively spliced transcripts.  
3. Western blotting to look for different sized proteins detected by polyclonal GATA-1 
antibodies. 
The results of these studies are described below. 
3.3.1 In silico analysis of GATA-1 
3.3.1.1   GATA-1 exon analysis 
A number of software programmes exist for prediction of the position of introns and exons 
in genomic sequences. One of the most accurate for human/vertebrate sequences is 
GENSCAN (http://genes.mit.edu/GENSCAN.html). This programme claims to identify 
exons with a sensitivity of 78% and a specificity of 81%, this compares to 44% and 45% 
for the commonly used GeneID programme (http://genome.imim.es/software/geneid). 
Using the human GATA-1 genomic sequence derived from an X-chromosome contig 
assembly (geneID 2623 NCBI Entrez gene: http://www.ncbi.nlm.nih.gov/sites/entrez 
?db=gene), Genescan accurately predicted all the known GATA-1 exons but did not 
identify any further exons either internally or up or downstream of the known coding 
sequence. The same was true for the mouse GATA-1 genomic sequence (GeneID 14460). 
This suggests that if additional isoforms do exist, then they will utilise different 
combinations of known GATA-1 exons, rather than novel exons.  Results Chapter 3    157 
3.3.1.2  GATA-1 EST analysis 
Expressed sequence tags (ESTs) are small pieces of DNA sequence generated by 
sequencing of cloned cDNA derived from cellular mRNA (fig 3.13). This technique allows 
the identification of coding portions of the genome, discovery of new genes and discovery 
of alternatively spliced transcripts of existing genes (Nagaraj, et al 2007). Of note EST 
sequences tend to be short ie 200-500bp long and these sequences are not checked for 
sequencing errors (the whole point of EST generation is to provide a rapid, inexpensive 
tagging system for expressed transcripts in various tissues rather than comprehensive 
assessment of individual genes) so results should be interpreted with caution.  
As mentioned above the GATA-1 EST database confirms the expression of an exon1/3 
spliced transcript (GATA-1s) in humans but not in mice, no further alternative splicing 
variants were detected by this method. 
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3.3.1.3    GATA-1 related sequences held on the NCBI gene 
database 
 A second approach was taken by analysing reference and related mRNA sequences for the 
entire GATA-1 open reading frame held in the NCBI database. Besides the verified human 
mRNA transcript - NM_002049, a second transcript was listed - BC009797, which is said 
to encode GATA-1 mRNA. This transcript was generated by the mammalian gene 
collection programme (MGC) – a multi-institutional effort to identify and sequence a 
complete open reading frame for all human and mouse genes (Strausberg, et al 2002). 
BC009797 was sequenced from a cDNA library derived from chronic myeloid leukaemia 
bone marrow cells. Comparing BC009797 against NM_002049 reveals that this transcript 
lacks the first 335bp of exon 6 and the new exon 5/6 splice site results in a frameshift 
producing a shortened protein with a completely different predicted C-terminal amino acid 
sequence. This is illustrated in fig 3.14. Following this in silico analysis the reference clone 
was obtained for further in vitro investigation as detailed in section 3.4. 
mefpglgslg tseplpqfvd palvsstpes gvffpsgpeg ldaaasstap stataaaaal ayyrdaeayr hspvfqvypl
mefpglgslg tseplpqfvd palvsstpes gvffpsgpeg ldaaasstap stataaaaal ayyrdaeayr hspvfqvypl
lncmegipgg spyagwaygk tglypastvc ptredsppqa vedldgkgst sfletlkter lspdlltlgp alpsslpvpn
lncmegipgg spyagwaygk tglypastvc ptredsppqa vedldgkgst sfletlkter lspdlltlgp alpsslpvpn
sayggpdfss tffsptgspl nsaaysspkl rgtlplppce arecvncgat atplwrrdrt ghylcnacgl yhkmngqnrp
sayggpdfss tffsptgspl nsaaysspkl rgtlplppce arecvncgat atplwrrdrt ghylcnacgl yhkmngqnrp
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3.3.2 RT-PCR analysis of mRNA 
Two PCR strategies were used to detect additional GATA-1 transcripts and these are 
shown in fig 3.15. Primers designed to anneal to exon 1 and 6 should produce bands 
corresponding to GATA-1FL and GATA-1s in humans. Any additional splicing variants, 
as long as they incorporated exon 1 and 6 would produce additional bands of different 
length. Fig 3.16a shows GATA-1FL and GATA-1s bands but no additional sized products 
in human K562 cells. Since GATA-1 is already known to utilise a different first exon in 
Sertoli cells it is possible that use of an exon 1 forward primer may miss some isoforms 
lacking this exon, therefore primers were also designed to anneal to exons 3 and 6 (fig 
3.15). Use of these primers in samples from patients with CML, normal controls and the 
cell line K562, confirmed the presence of the expected 1094bp exon3/4/5/6 product but 
also produced a large band of approximately 1500bp (fig 3.16b). To establish its identity, 
this larger band was excised from the gel, TOPO cloned into pCR2.1 (see materials and 
methods, section 2.12) and commercially sequenced (www.agowa.de). Sequencing 
revealed that it was composed of exons 3-5 plus intron 5 and exon 6 (fig 3.16c). It 
therefore is likely to represent a splicing intermediate rather than a functional alternative 
isoform. 
1094bp 1094bp Human exon 3 and 6
1151bp 1389bp Human exon 1 and 6
GATA-1s GATA-1FL Names Primers
1094bp 1094bp Human exon 3 and 6
1151bp 1389bp Human exon 1 and 6
GATA-1s GATA-1FL Names Primers
12 3 45 6 12 3 45 6
?
?
 
Fig 3.15 PCR strategies to detect novel GATA-1 transcripts 
Annealing sites of exon 1, 3 and 6 primers shown with expected product sizes of  GATA-1FL 
transcript (red bar) and GATA-1s transcript (green bar), question marks indicate possible 
additional products if alternative isoforms exist. Results Chapter 3    160 
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Fig 3.16 Detection and analysis of an additional 1500bp transcript in human 
samples 
 
3.3.3 Western blotting reveals only two bands 
Alternative isoforms can also be separated on the basis of molecular weight of their 
corresponding protein. As discussed in 3.1.2 use of the polyclonal M-20 GATA-1 antibody 
detects two isoforms by western blot corresponding to the full-length and short isoform, 
whist the N-terminus N-6 antibody identifies a single band (fig 3.3b). M-20 is raised 
against the C-terminus of GATA-1FL, since GATA-1 proteins have highly conserved zinc 
fingers in the C-terminus it is unlikely that any functional isoform would lack this domain 
and therefore escape detection by this antibody. Even postulating that an isoform might 
lack DNA binding activity, conservation of the N-terminus (and therefore detection by the 
N6 antibody) would have to occur for the protein to bear any resemblance to GATA-1. 
Therefore it would be predicted that any alternative isoforms should be detected by a two-
pronged approach targeting antibodies to the N- and C-termini. Western blotting of a Results Chapter 3    161 
variety of tissues in both mouse and humans as shown throughout this chapter (figs 3.3b, 
3.4, 3.6, 3.7, 3.10, 3.11, 3.12 and 3.19) failed to reveal additional bands attributable to 
additional isoforms.  
In summary, in silico, PCR and western blotting approaches were used to try and 
identify any additional GATA-1 isoforms. Two additional GATA-1 transcripts were 
identified. Firstly, a cDNA clone with an altered C-terminus – BC009797 isolated from 
CML bone marrow. Secondly, an elongated exon 3-6 PCR product corresponding to an 
exon3/4/5-intron5-exon6 splicing intermediate. The latter is unlikely to be functionally 
significant but the former warranted further investigation as discussed below. 
3.4 In vitro analysis of BC009797 
The MGC BC009797 clone could represent: (i) an additional physiological isoform of 
GATA-1 (ii) a mutant transcript (with either widespread or sporadic occurrence in CML) 
or (iii) an artefact. In order to distinguish these possibilities, further investigations were 
performed. All MGC clones are available for public distribution via the IMAGE 
consortium (Integrated  Molecular  Analysis of Genomes and their Expression) whose 
primary goal is to create arrayed cDNA libraries and associated bioinformatics tools, and 
make them publicly available to the research community. Therefore in order to assess the 
possible relevance of the BC009797 transcript the corresponding IMAGE clone was 
ordered (MGC:13628, IMAGE:4048082) (Geneservice, Cambridge UK) and analysed. 
3.4.1 Analysis of IMAGE clone reassigns cloning vector but 
confirms sequence 
The IMAGE clone was supplied as a streak on LB Agar with chloramphenicol. This clone 
was re-streaked onto an LB Agar plate containing 27μg/ml chloramphenicol and incubated 
at 30
oC for 24 hours to produce single colonies. 10 single colonies were picked, grown 
overnight in LB broth with chloramphenicol and DNA was extracted using a commercial 
miniprep technique (Qiagen – see materials and methods, section 2.12.2.3). IMAGE clones 
are supplied in a number of different cloning vectors depending on the laboratory that 
initially isolated them. The datasheet indicated that BC009797 was cloned into the pOTB7 
cloning vector. A predicted restriction enzyme site map was constructed using this data and 
the restriction enzymes NcoI and PvuII were chosen to analyse BC009797 orientation 
within this vector and confirm the identity of the supplied clone. As seen in fig 3.17 the Results Chapter 3    162 
restriction enzyme fragments produced from this diagnostic digest do not correspond to the 
predicted sizes in either orientation (fig 3.17a & b). A single DNA prep was sent for 
sequencing using the T7 sequencing primer whose sequence is present in the majority of 
cloning vectors. The results of this sequencing confirmed the presence of BC009797 
cDNA, ruling out the possibility that the wrong clone had been despatched. Analysis of the 
short stretch of associated vector sequence revealed similarity with another commonly 
used MGC cloning vector – pDNRLIB. Construction of a theoretical RE site map of 
BC009797 in this vector led to prediction of fragment sizes (fig 3.17a) that exactly 
matched those seen with the NcoI PvuII digest (fig 3.17b). Therefore the identity of the 
cloning vector was reassigned from pOTB7 to pDNALIB. Fortunately, both these vectors 
carry chloramphenicol resistance genes. 
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Fig 3.17 Restriction enzyme analysis of IMAGE clone suggests an alternative 
cloning vector.  
(a) predicted sizes of digest products (b) diagnostic digests were performed as described in 
section 2.7.3. Blue arrows  indicate size markers in 1kb ladder (Invitrogen). NcoI digest 
produces fragment sizes of approximately 3500bp and 1500bp, PvuII digest produces 
fragments of approximately 2000bp, 1700bp and 1200bp. These fragment sizes equate to 
predicted values for pDNRLib-BC009797 digest in correct orientation as shown in (a) Results Chapter 3    163 
Extended sequencing of 1700bp from the T7 priming site confirmed that the full 
BC009797 sequence exactly matched the NCBI database sequence and therefore that the 
skipping of the 5’ end of exon 6 and resultant frameshift were not due to sequencing 
artefacts 
In summary, these results confirm that the published BC009797 sequence is correct, 
ruling out the possibility that BC009797 C-terminal alterations were a sequencing 
artefact.  
3.4.2 Analysis of BC009797 expression at the mRNA level  
Having established that BC009797 appears to be a true transcript, further investigations set 
out to look at whether this transcript was widely expressed and whether it had functional 
consequences. 
Since BC009797 was originally cloned from the bone marrow of a patient with chronic 
myeloid leukaemia (CML) it was decided to use primary CML samples to look for 
expression of this transcript in other individuals. cDNA generated from bone marrow 
mononuclear cell mRNA samples from 9 patients with CML at diagnosis or relapse, and 
for comparison, 5 patients with chronic lymphocytic leukaemia (CLL) and one normal 
bone marrow sample, was obtained (kind gift Dr Paz Carreno and Dr Andrew Clarke, 
Glasgow University). PCR was performed with primers annealing in exon 3 and the 3’ end 
of exon 6. As shown in Fig 3.15, these primers would be predicted to give a 1094bp band 
with the GATA-1FL and GATA-1s isoforms but produce a shorter 765bp band in the 
presence of a BC009797 transcript. The IMAGE expression plasmid was used as a positive 
control and confirmed the ability of the primers to amplify a 765bp fragment. No other 
samples amplified this product but instead all produced the 1094bp fragment (fig 3.18). 
The larger 1500bp band seen on these gels corresponds to the intermediate splicing variant 
discussed in section 3.3.2 and also shown in Fig 3.16. The existence of detectable GATA-1 
transcripts, albeit at low level, in CLL samples is surprising and is presumed to reflect a 
low level of red cell or myeloid cell contamination in these samples.  
In addition, an in silico analysis of the human EST database using a query term that 
encompassed the novel exon 5/6 splice site junction was performed. Despite being only 
150bp from the 3’ end of the mRNA this analysis did not pick up any cloned sequences 
corresponding to this variant.  Results Chapter 3    164 
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Fig 3.18 PCR screening for BC009797-like transcript in other human primary 
cells  
 
Overall, these results suggest that the BC009797 variant is not widely expressed in CML. 
However, sample sizes were too small to establish whether this transcript occurs at low 
frequency in this condition, or whether it is likely to represent a unique patient specific 
mutation. 
3.4.3 A functional analysis of BC009797 
Analysis of the functional consequences of the C-terminal changes in BC009797 was 
performed to establish whether this transcript was likely to be of pathological or 
physiological significance. In order to analyse BC009797 at the protein level it was 
recloned into a vector known to produce good expression levels in haematopoietic cell 
lines – pEF6/V5HisTOPO (Invitrogen)- as discussed in chapter 5.2.5.1. This was achieved 
by design of forward and reverse primers corresponding to the 5’ and 3’ ends of the gene – 
ensuring all coding sequences including the stop codon were included – (sequences listed 
in section 2.4.2) and PCR using ReddyMix followed by gel purification and TOPO cloning 
(see materials and methods, section 2.10 and 2.12). After overnight growth on LBAgar 
with Ampicillin (50μg/ml), 6 colonies were picked and subsequent miniprep and restriction 
digest confirmed the presence of the BC009797 insert in the correct orientation in 5/6 
clones. One of these was maxi-prepped (section 2.12.2.3) and subsequent sequencing of 
this clone (pEF6IMAGE) confirmed that the PCR amplification had not introduced any 
errors.  Results Chapter 3    165 
3.4.3.1   Western blotting is unable to detect BC009797 
pEF6IMAGE, was transfected into HEK293 (6x10
5 cells seeded on a 6-well plate) using a 
commercial transfection reagent – Polyfect (Qiagen). Cells were harvested at 48 hours and 
a nuclear extract was made (section 2.9.2). Western blotting using M20 (polyclonal, C-
terminus) and N-6 (N-terminus) revealed no band in the extract from IMAGE transfected 
cells, despite bands on the positive control (K562 for M20, MEL for N6), fig 3.19a. This is 
consistent with the lack of N6 binding to human GATA-1 (as discussed in 3.1.2.2) and 
suggests that M20 may be unable to bind to the aberrant C-terminus predicted for 
BC009797. However the possibility that lack of detection was due to lack of expression 
from the vector cannot be ruled out by this experiment. To look for production of mRNA 
transcripts by the vector RT-PCR was performed using GATA-1 exon 1 and 6 primers 
(sequence listed in 2.4.1), these primers would be predicted to give a 1054bp product with 
the IMAGE transcript. Fig 3.19b confirms the presence of a 1054bp transcript. The 
absence of a band in the –RT control excludes the possibility that this band is due to 
contamination with vector DNA. These findings are supported by reporter gene analysis, 
discussed in section 3.4.3.2 below, which shows that at least partially functional GATA-1 
was being made by the vector (fig 3.20).  
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Fig 3.19 BC009797 mRNA and protein expression  
(a) Western blotting with M20 and N6 GATA-1 antibodies reveal positive control bands (K562 
and MEL respectively) but no band with the IMAGE expression vector transfected into 
HEK293 cells. Adequate protein loading is confirmed by the actin control (b) PCR using 
human GATA exon 1 and 6 primers should produce a band of 1054bp as shown. The minus 
(-) RT control confirms this was not due to contaminating vector DNA.  Results Chapter 3    166 
3.4.3.2    Reporter assays suggest BC009797 has enhanced 
transactivation potential 
The lack of BC009797 protein detection by commercially available antibodies could imply 
that the mRNA was not transcribed into protein or that the altered C-terminus abolished 
binding of the M20 antibody. An alternative approach, using a GATA-1 reporter assay to 
detect GATA-1 protein production, was taken. This approach has the advantage of not only 
detecting protein production by the vector but also assessing its functional ability. The 
reporter plasmid pGL3hGATA-1 (kind gift from Dr P Vyas, WIMM, Oxford) contains cis-
acting GATA-1 DNA binding elements. Binding of functional GATA-1 protein at these 
sites results in activation of transcription, leading to the expression of firefly luciferase. 
Sections 2.13.1 and 5.2.4.3 describe this reporter assay methodology in more detail. 
pEF6IMAGE was cotransfected into NIH3T3 cells alongside pGL3hGATA-1 and a β-
galactosidase producing vector to normalise for transfection efficiency. Optimisation of 
this technique is discussed in chapter 5.2.4.3. After 48-72 hours cells were harvested, lysed 
and the supernatant analysed for β-galactosidase activity (Promega) and luciferase activity 
(Promega). Fig 3.20 shows that pEF6IMAGE was able to produce a 5-6 fold induction of 
reporter activity over background. This was higher than the induction of expression from 
GATA-1FL and GATA-1s human plasmids which showed 2-3 fold induction over 
background.  
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Fig 3.20 Function of BC009797 in a luciferase reporter assay 
Graph shows fold induction of luminescence in NIH3T3 cells co-transfected with the test 
plasmid (Human GATA-1FL, Human GATA-1s or IMAGE), a luciferase reporter plasmid and a 
β-galactosidase producing plasmid. Results were normalised to β-galactosidase activity to 
control for transfection efficiency and expressed as fold induction compared to reporter 
plasmid alone (lane 1 PGL3 luc). Background levels of luminescence from untransfected 
NIH3T3 cells were negligible (lane 2 NIH3T3). Results from one representative experiment 
out of three shown. Results Chapter 3    167 
The fact that GATA-1FL and GATA-1s both only produce low level induction of reporter 
activity over background is surprising given that previous reports (albeit using different 
reporter constructs) suggest that GATA-1FL should produce considerable enhancement of 
reporter activity (up to 5 -10 fold) compared to GATA-1s (Wechsler, et al 2002). The 
design and testing of these human GATA-1 plasmids is discussed further in chapter 5. 
However, the ability of BC009797 to induce luciferase expression both confirms that it 
encodes a functional protein and raises the intriguing possibility that it might have 
enhanced DNA binding activity. BC009797 diverges from GATA-1FL and GATA-1s at 
position 959 and the GATA-1 C-terminal zinc finger sequence ends at position 970 so the 
majority of the C-Zinc finger remains intact. The function of the C-terminus beyond the 
zinc finger is largely unknown although Runx-1 has been shown to bind in this region 
(Elagib, et al 2003). It is possible that the distal C-terminus region interacts with 
transcriptional repressors, or is the site of post-translational regulation of protein activity, 
and that the altered BC009797 terminus escapes from these influences. Further 
investigation of this poorly defined region is warranted. 
Overall, these results suggest that the BC009797 transcript encodes a functional protein. 
This protein is undetectable by commercially available antibodies, but has demonstrable 
GATA-1 like activity on reporter assays. These assays also suggest it may actually have 
enhanced trans-activation ability. This implies that it may have had a functional 
consequence for the original patient from whom it was cloned. It also highlights the 
possibility that the distal C-terminus may be an important, previously underappreciated, 
functional domain of GATA-1. 
3.4.4 Summary of the relevance of BC009797 
A number of observations made above suggest that BC009797 is unlikely to be a 
physiological isoform of GATA-1 i.e. 
1. The expression of this transcript has not been detected in cell lines or patient samples 
(other than the founder patient) by PCR (fig 3.18), or by in silico analysis of EST 
databases.  
2. The existence of an alternative shorter exon 6 is not predicted by in silico Genescan 
analysis. 
3.  It is very unusual for alternatively spliced isoforms to produce frameshifts. Results Chapter 3    168 
Despite this two important findings emerged from these studies: 
1. The existence of this transcript in a patient with chronic myeloid leukaemia along with 
its possible increased activity suggests that BC009797 may represent a mutated aberrantly 
functioning form of GATA-1 rather than a normal isoform. As discussed above, this 
mutation may have had functional consequences for the patient. These observations led to 
further investigation of possible GATA-1 mutations in CML – the results of which are 
presented in Chapter 6.  
2. Investigation of this transcript has shown a possible enhanced transactivation potential 
associated with an altered distal C-terminus. The function of this region of GATA-1 
requires further investigation. 
3.5 Chapter 3 summary  
Overall this chapter describes experiments designed to assess (i) the mode of GATA-1 
isoform expression in humans and mice (ii) temporal and spatial expression patterns of 
GATA-1 isoforms during haematopoietic ontogeny (iii) expression patterns in different 
lineages (iv) whether additional GATA-1 isoforms are detectable. With the aim of 
uncovering patterns of expression that may shed light on the role of GATA-1s and/or novel 
isoforms in haematopoietic development.  The following conclusions can be drawn: 
1. There is good evidence for alternative splicing as a method of isoform production in 
humans but no evidence of this mechanism in mice. In contrast mice appear to produce 
GATA-1s by alternative translation of a single mRNA by a mechanism known as “leaky 
scanning”. 
2. GATA-1s expression seems to accompany GATA-1FL expression in the majority of 
tissues both during ontogeny and in different cell lines. On only one occasion was GATA-
1s production seen to be more prominent than GATA-1FL, this was in a human primary 
monocyte population, this result was not duplicated in an independent sample or in 
monocytic cell lines although GATA-1s expression could be detected in some of these 
alongside GATA-1FL. GATA-1s expression in monocytes, eosinophils and mast cells has 
never previously been reported.  Results Chapter 3    169 
3. GATA-1s expression does not appear to be dynamically regulated during erythroid 
differentiation but rapid down-regulation of expression occurs on induction of 
megakaryocytic differentiation.  
4. Two novel GATA-1 transcripts were identified in these studies. One represents a likely 
intermediate splicing form of doubtful significance. The other - BC009797- appears to be a 
mutated from of GATA-1 with an altered C-terminus. Intriguingly this transcript showed 
increased activity in reporter gene assays, suggesting that the distal C-terminus may be an 
important functional domain of GATA-1. Its occurrence in CML raises the possibility that 
this disease may be associated with aberrant GATA-1 expression – a hypothesis tested in 
chapter 6. 
Further investigation of the differences between GATA-1FL and GATA-1s at a functional 
level will be described in the following chapters. 
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4  GATA-1 gene targeting in murine embryonic 
stem cells 
4.1 Aims 
In order to assess any functional differences between the two GATA-1 isoforms it was 
decided to look at their ability to drive haematopoietic differentiation in vitro. This chapter 
describes attempts to engineer murine embryonic stem (ES) cells to exclusively express 
either GATA-1FL or GATA-1s isoforms. These cells could then be used to study the 
ability of the two isoforms to independently support primitive and definitive 
haematopoietic colony formation using in vitro haematopoietic differentiation in 
methylcellulose (Keller, et al 1993). In addition, transcriptional profiling could be used to 
look at isoform specific regulation of gene expression (Baird, et al 2001). Although these 
targeted ES cells could, in theory, be used to make transgenic mice (Bradley, et al 1984), 
this aim was beyond the time scale and funding parameters of this project. 
4.2 Introduction 
Assessment of gene function is greatly aided by transgenic technology, allowing 
introduction of cloned copies of a gene of interest into a cell and evaluation of the impact 
of expression of this transgene on cellular processes. These transgenes can be over-
expressed from an exogenous promoter or can target the endogenous gene either 
inactivating it, or replacing it with an altered version. Gene over-expression studies, 
described in chapter 5, are very useful tools to study gene function. These approaches 
provide information on the cellular pathways that the target gene interacts with and the 
molecular consequences of gene expression. However, use of an exogenous promoter 
produces unregulated expression. Because transcription factors show significant 
concentration dependent effects, and are tightly temporally and spatially controlled, these 
studies must be interpreted with caution. An artificial promoter/enhancer construct for 
GATA-1, termed GATA-1 HRE has been devised that encompasses all the regulatory 
elements required to express a downstream gene in the same temporal and spatial pattern 
as GATA-1, as shown by recapitulation of GATA-1 expression patterns using a LacZ 
reporter gene (McDevitt, et al 1997a). Although use of this construct overcomes some of 
the problems associated with over-expression vectors, the cell still possesses its own 
endogenous copy of GATA-1. This means that it is impossible to look exclusively at the Results Chapter 4    171 
function of a single isoform, as the cell still retains the capacity to express the other 
isoform from the endogenous locus. Furthermore, expression of the additional GATA-1 
gene from the transgenic construct will alter the stoichiometry of transcription factors in 
the cell. 
A more physiological way to study the biological effects of GATA-1 isoform expression 
would be to target the endogenous GATA-1 locus and replace the normal GATA-1 gene 
with a construct capable of exclusive GATA-1FL or GATA-1s expression – a process 
known as gene targeting (Capecchi 2001). This approach is sometimes termed ‘knock-in’ 
technology i.e. the endogenous gene is replaced by an alternative gene (as opposed to 
‘knock-out’ where gene expression is ablated from the endogenous locus). Although in this 
particular case it could equally be thought of as an isoform specific ‘knock-out’. 
Replacement of the endogenous gene is achieved by exploiting the biological process of 
homologous recombination (Alberts 2008). This involves genetic exchange between two 
similar or identical strands of DNA. Homologous recombination is the method by which 
cells repair double stranded breaks in DNA, and also the mechanism by which sister 
chromatids cross-over at meiosis allowing random assortment of genetic information. 
Introduction of exogenous DNA with large regions of homology with the endogenous 
locus can induce the cell to exchange the exogenous and endogenous DNA, albeit at low 
frequency. Although technically difficult, use of this approach has been aided by a number 
of advances in molecular biology, most importantly the ability to culture embryonic stem 
cells (ES cells) in vitro and maintain them in an undifferentiated totipotent state. Since 
over 10 million cells can be grown in a single 10cm culture dish even extremely low 
frequency events (such as homologous recombination) will occur within this cell 
population. The difficulty comes in being able to identify these events. This is aided by 
positive selection strategies to narrow down cells that have incorporated the targeting 
construct and negative selection strategies to enrich for cells that have undergone 
homologous recombination (Capecchi 2001). This must be followed by a sensitive 
screening strategy to identify the cells that have undergone the desired recombination 
event. Once targeted cells have been identified it is possible to excise the positive selection 
marker by utilising site specific recombinases (such as Cre-recombinase) that recognise a 
target sequence (LoxP sites) flanking the selectable marker. The principles behind this 
method of gene targeting are illustrated in Fig 4.1 and described in more detail below. Results Chapter 4    172 
Dipth Dipth Plasmid
Endogenous GATA1
Recombinant GATA1
After Cre mediated 
excision
Neo
Point mutation
LoxP LoxP
Dipth Dipth
Negative 
selection gene 
excised during 
recombination
(a) Homologous recombination
LoxP LoxP
 
 
Dipth Dipth Plasmid
Endogenous DNA
Random insertion of 
transgene
Neo
Point mutation
LoxP LoxP
Dipth Dipth
Negative selection 
gene retained and 
produces toxic product
(b) Random Insertion
XX
Cell death
Neo
 
Fig 4.1 Outline of gene targeting approach 
(a) Introduction of a point mutation by using a positive (neomycin resistance gene- neo) and 
negative (diphtheria toxin) selection strategy, followed by Cre recombinase mediated 
removal of the selectable marker. (b) If the targeting construct randomly integrates, 
expression of the negative selection marker will result in cell death. Results Chapter 4    173 
4.2.1 Targeting selection strategies 
4.2.1.1   Positive selection 
Introduction of an antibiotic resistance gene into the middle of the targeting construct, as 
long as it is flanked by significant lengths of homologous DNA, will not prevent 
homologous recombination occurring (Hasty, et al 1991). Cells that have integrated 
foreign DNA can then be selected for by virtue of their resistance to antibiotics.  
The commonest antibiotic resistance gene is neomycin phosphotransferase (neo) which 
confers resistance to the aminoglycoside antibiotic G418 by promoting G418 
phosphorylation. For reliable expression of this gene in ES cells, the mouse Pgk-1 gene 
promoter is usually used (Nagy 2003).  
4.2.1.2   Negative selection  
Although positive selection helps narrow down the cell population to those that have 
incorporated the targeting construct, the frequency of random insertion is many orders of 
magnitude higher than that of homologous recombination (Mansour, et al 1988, Thomas 
and Capecchi 1987). Both scenarios will confer antibiotic resistance. Initial experiments to 
establish methods for gene targeting chose target genes with a selectable phenotype. For 
example, the hypoxanthine phosphoribosyl transferase (Hprt) gene on the X-chromosome 
was used – which confers resistance to 6-thioguanine (6-TG) treatment when mutated 
(Hooper, et al 1987, Thomas and Capecchi 1987). Therefore cells which had undergone 
homologous recombination with a construct that inactivated the endogenous Hprt gene 
could be selected for by exposure to 6-TG. In order to extend gene targeting to non-
selectable genes it is necessary to have an alternative method to enrich for homologous 
recombination events. One possibility is to incorporate a second selectable marker at the 
distal end of the targeting construct. Cells that randomly integrate the construct will 
express this marker since the vast majority of random insertion events occur at the ends of 
a linearised molecule (Roth, et al 1985). In contrast, cells that undergo homologous 
recombination will excise it as it lies out with the area of homology (see fig 4.1). If this 
marker confers a negative selection pressure (i.e. kills cells it is expressed in) then its use 
alongside a positive selection marker will allow preferential survival of cells that have 
undergone homologous recombination rather than random insertion. This positive/negative 
selection strategy was first described by Mansour et al (Mansour, et al 1988). A number of 
negative selection markers have been used, the most common is Herpes simplex virus Results Chapter 4    174 
thymidine kinase which confers sensitivity to the antiviral agent Gancyclovir. Alternatively 
the diphtheria toxin gene, derived from Corynebacterium diphtheriae, can be used 
(Awatramani, et al 2001, Soriano 1999). This gene product inhibits chain elongation in 
protein synthesis via its inactivation of elongation factor-2 (EF-2). It is extremely toxic to 
cells and has the advantage of not requiring addition of further drugs to the culture 
medium. 
4.2.2 Optimal design of the targeting vector 
4.2.2.1   Homology arms 
The length and degree of homology between the exogenous and endogenous DNA are 
critical for efficient recombination. There should be at least 6-8kb of homologous sequence 
(Hasty, et al 1991) and although the two arms flanking the selectable marker can be of 
unequal length, the minimum size for an arm is 1kb. The two sequences should be as 
identical as possible. Homologous recombination using a targeting construct derived from 
isogenic DNA is 20-fold more efficient than if the DNA is derived from an alternative 
mouse strain (te Riele, et al 1992). To ensure this, the targeting DNA should be amplified 
from cells from the same mouse strain as the ES cell parental DNA – most commonly this 
is the 129 inbred strain. In addition, for knock-in strategies, the desired genetic variation 
should be as close as possible to the selectable maker to minimise the chances of 
homologous recombination occurring between the selectable marker and the mutation 
which would make the locus appear targeted when in fact the desired mutation has not 
been introduced.  
4.2.2.2   Removal of the selectable marker 
The above approaches are sufficient to produce a gene knock-out by replacing the 
endogenous locus with the neo antibiotic resistance gene. For knock-in approaches where 
the endogenous locus is to be replaced by an altered gene product more sophisticated 
methods are needed. Although in theory placing the selectable marker in an intron would 
still allow production of the knock-in gene product (i.e. the mRNA would splice out the 
neo gene during processing), in practise the presence of a foreign gene in an intron 
severely reduces mRNA production from that allele (Meyers, et al 1998, Nagy, et al 1998). 
In addition the neo sequence could introduce cryptic splice sites leading to truncation of 
the target gene. Therefore, if more subtle changes are to be introduced, it is important to be 
able to excise this antibiotic resistance gene once targeted clones have been identified. In Results Chapter 4    175 
order to achieve this, the neo gene must be placed within an intron and be flanked by target 
sequences for site specific recombinases whose mode of action are described below: 
Site specific recombinases direct recombination between two consensus DNA sequences 
resulting in excision of the intervening DNA. They can be utilised to allow post-insertional 
changes to the targeted DNA sequence. Cre recombinase is derived from bacteriophage P1 
and is the most widely used recombinase for murine gene targeting. It catalyses 
recombination between two 34bp long lox-P sites which comprise two 13bp palindromic 
sequences flanking an 8bp core sequence as shown in fig 4.2. The latter is asymmetric and 
therefore confers orientation on the loxP sites. Cre protein monomers bind the consensus 
sequence and mediate strand cleavage and exchange. This technique has revolutionised the 
ability to produce subtle changes in genes such as point mutations, which cannot be 
achieved by knock-out techniques.  
 
4.2.3 Methods to screen for recombination events 
Using the two-pronged approach of positive and negative selection it is possible to narrow 
down the number of cells that have integrated the targeting construct and enrich for those 
that may have undergone homologous insertion. However, this event still remains rare – 
looking at published targeting frequencies for GATA-1, correct targeting is estimated to 
occur in the region of 1 in 100 cells remaining after positive and negative selection (Pevny, 
et al 1991). Therefore, it is necessary to devise a screening strategy capable of identifying 
correctly targeted cells amongst all the other cells that have undergone random insertion. 
The two main methods are PCR based screening and southern blotting.  
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Fig 4.2 Cre Lox-P mediated recombination to excise the selectable marker 
 
4.2.3.1   PCR 
PCR screening is rapid and relatively simple but often technically difficult as the targeted 
gene is present at low frequency amongst a lot of relatively impure genomic DNA. It is 
important to devise a sufficiently sensitive technique with adequate positive controls. The 
method relies on designing primers to amplify a fragment unique to the targeted locus. Results Chapter 4    177 
This is usually achieved by having one primer binding to a sequence within the antibiotic 
resistance gene (not present in the wild-type endogenous locus) and the second primer 
binding to a sequence just upstream of the targeting construct shorter homology arm (and 
therefore not present in the targeting vector). Therefore a product will only be amplified 
when the upstream sequence and the antibiotic resistance gene are brought into proximity. 
If the product is the correct size this situation should only arise if the endogenous locus has 
been targeted. This is illustrated in Fig 4.3 
1
neo
neo D
3’ homology arm 5’ homology arm
Targeting vector 
randomly inserted 
in genome
2
33
Endogenous locus
Targeted locus
Final PCR product
(a)
(b)
(c)
 
Fig 4.3 Principles of PCR screening for targeted colonies 
(a) Illustrates the situation during random insertion. The 3’ PCR primer, pale green arrow 
labelled 1, will anneal to the antibiotic resistance gene, but the 5’ primer will not anneal in 
close proximity, resulting in no amplification. (b) At the endogenous locus the 5’ primer will 
anneal (labelled 2) but there is no antibiotic resistance gene and therefore the 3’ primer is 
not present. (c) In the presence of a targeted locus the 3’ and 5’ primers will be brought into 
close proximity (labelled 3) and result in an identifiable PCR product. 
 
Since targeting is a rare event it is important to have a positive control to establish that lack 
of a targeted band is due to lack of targeting rather than technical limitations of the 
procedure. This is achieved by constructing an artificial plasmid containing the upstream 
sequences, not included in the targeting vector, and the antibiotic resistance gene in the 
correct position and orientation. It is important to take special care that the positive control 
plasmid never contaminates the PCR reaction mixture leading to false positive reactions. 
This can be verified by ensuring that the control vector has slight sequence variation Results Chapter 4    178 
compared to the targeting vector and therefore any positive bands can be investigated to 
see if they originate from the targeted endogenous locus or the control vector. This is 
discussed further in section 4.8.3.1 below. 
4.2.3.2   Southern blotting 
A lot of screening strategies still employ Southern blotting as the most reliable method for 
identifying correct targeting events. Targeted DNA is recognised by using an external 
probe (i.e. annealing to the target gene but outside the region present in the targeting 
vector) to detect a variation in the size of restriction fragments produced by digestion of 
the targeted or the endogenous locus. Two possible strategies can be used, as illustrated in 
Fig 4.4. Firstly a restriction enzyme that cuts in the endogenous DNA either side of the 
targeting construct integration site will produce a larger band in the presence of a targeted 
allele due to the presence of the selectable marker (Fig 4.4a). This strategy has the 
advantage of being able to distinguish a correctly targeted locus from one that has 
undergone integration of the entire vector without correct homologous recombination or 
that has undergone integration of a concatamerised vector. However the resultant fragment 
is often too large to be accurately resolved by Southern blot (ideally the fragments should 
be 5-10kb in size), and the occurrence of suitable restriction enzymes that do not cut within 
the targeting vector (which has been constructed from several vectors containing artificial 
multiple cloning sites) is relatively rare. Alternatively, a second strategy is to identify an 
enzyme that cuts within the selection gene of the targeting vector (and therefore not in the 
corresponding endogenous locus) and also just outside one of the homology arms (Fig 
4.4b). This produces a shorter fragment with the targeted locus and a larger fragment with 
the endogenous locus. However, this method is unable to distinguish correct homologous 
recombination from other events such as integration of the entire targeting vector or 
formation of concatamers prior to integration. To overcome this it is necessary to do an 
additional Southern blot using a probe at the opposite end of the targeting construct.  
When selecting restriction enzymes it is important that they are not sensitive to CpG 
methylation as genomic DNA extracted from ES cells is usually methylated, this may 
restrict the choice of suitable enzymes for digestion.  
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Fig 4.4 Principles of Southern blot analysis for targeted colonies 
(a) Using a restriction enzyme that cuts either side of the region targeted by the construct, 
results in a longer restriction fragment with the targeted locus due to the additional 
presence of the antibiotic resistance gene. (b) If the targeting construct introduces a new 
restriction site then the presence of the targeting vector will produce a smaller fragment.  Results Chapter 4    180 
4.3 Creation of GATA-1 isoform targeting constructs 
Following the general discussion of the principles of gene targeting above, this section will 
go on to address the specific methods used to generate targeting vectors capable of 
producing exclusive GATA-1FL or GATA-1s expression from the endogenous locus. 
Targeting of GATA-1 is facilitated by its position on the X-chromosome. All experiments 
used E14 embryonic stem cells originally derived from strain 129 mouse blastocysts 
(Hooper, et al 1987). The use of these ES cells, derived from a male embryo, means that 
only one allele needs to be targeted to produce the desired genetic change. 
4.3.1 Generating homology arms 
Because, as discussed above, even small variations such as point mutations can drastically 
reduce targeting efficiency, a high fidelity DNA polymerase with proof reading activity – 
Pfu-turbo (Invitrogen) was used to amplify the targeting arms. The template DNA was 
isogenic with the ES cell strain to be targeted (both 129). Once amplified, the products 
were run on a gel, the correct sized band excised, ‘A’ overhangs added, and the product 
was then TOPO cloned into the appropriate cloning vector. Following colony picking and 
minipreps, restriction enzyme (RE) digests were performed to identify clones containing 
the correct insert in the correct orientation. Informative restriction enzyme digests were 
chosen with the help of commercial DNA cloning software (Clone Manager Version 8.0, 
Scientific & Educational Software). The entire sequence of a single clone for each construct 
was obtained using primer walking methodology to produce a DNA sequence of sufficient 
length (Agowa.de). A problem arose when analysing the sequence of the amplified cloned 
product as the major gene reference bank sequence (Entrez Gene, NCBI) is derived from 
the C57Bl6 strain rather than the 129 strain. Fortunately the GATA-1 gene appears highly 
conserved between these strains as discussed below.  
4.3.2 Introduction of point mutations into first or second start 
codons 
Targeting vectors capable of exclusive GATA-1FL or GATA-1s production were designed 
by performing site directed mutagenesis of either the first or second ATG start codons 
therefore preventing translation of the GATA-1FL or GATA-1s protein respectively. 
Experiments described in the next chapter (chapter 5 section 5.2) used reporter gene assays 
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equivalent activity to wild type GATA-1 in its ability to transactivate luciferase expression. 
Since the mutation required to produce GATA-1s occurs upstream of its coding sequence it 
would not be predicted to introduce any functional differences in to the final protein 
product.  
Once the homology arms described above had been amplified up and their sequence 
confirmed, they then underwent site directed mutagenesis of the first or second ATG to 
produce the two isoforms as illustrated in Fig 4.5. The exact base pair change to ablate the 
second ATG was carefully chosen to produce an amino-acid change with similar 
biochemical properties (hydrophobic, neutral) to minimise any possible effects on protein 
folding or function. In addition, base-pair changes were chosen since they also produced 
alterations in restriction enzyme sites. Therefore screening for colonies containing the 
desired mutation in the targeting construct was straightforward.  
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23 4 5 6
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X
GATA-1WT
GATA-1FL
Site-directed mutagenesis
Codon 1 Codon 84
23 4 5 6
ATC ATG
X
GATA-1s
XbaI
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Fig 4.5 Production of isoform specific targeting vectors 
For GATA-1FL a methionine to leucine (ATG to CTA) change, and for GATA-1s a methionine 
to isoleucine (ATG to ATC) change, were chosen. This introduced an XbaI site for GATA-
1FL, whilst for GATA-1s an NcoI site was abolished and a ClaI site created. 
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4.3.3 Addition of selectable markers 
Having cloned, sequenced and performed site directed mutagenesis on the two homology 
arms, selectable markers were added to the targeting vector. The positive marker was the   
Neo gene (driven by the mouse Pgk-1 promoter), flanked by Lox-P sites to allow 
subsequent excision by Cre-recombinase. The Diphtheria toxin gene also driven by the 
Pgk-1 promoter was used for negative selection (Awatramani, et al 2001, Soriano 1999).  
4.3.4 Devising and testing a screening strategy for targeted 
clones 
It is very important to devise a robust screening strategy for correctly targeted colonies 
before finalising the target construct design as screening can be challenging and require 
modifications to the targeting vector such as preferential use of certain restriction enzyme 
sites in the multiple cloning sequence to ensure informative digests can be produced. In 
addition it is important to test the screening strategy using positive controls before 
undertaking large scale screening of ES cell clones. Screening strategies are shown for the 
two targeting approaches in the relevant sections below and illustrated in Fig 4.7. Both 
PCR and Southern blot screens were devised. In order to test PCR primers and to provide a 
positive control a PCR control vector was constructed comprising the 5’ arm of the 
targeting construct along with the flanking endogenous 5’ sequence and the neo resistance 
gene. This vector was carefully constructed with a small variation in the neo/5’ junction 
compared to the real targeting construct. This allowed differentiation between false 
positive PCR reactions due to low level contamination with control vector and the product 
produced by endogenous targeting. Southern blot probes were also amplified, cloned and 
sequenced and untargeted E14 cells were used as a positive control for the wild type band. 
5’ and 3’ external probes were chosen. The initial screen was with a BamHI digest which 
cut either side of the targeting construct and within the selection marker (see Fig 4.7b). 
These restriction enzyme fragments were detected with a 3’ external probe. An additional 
check was provided by an AflII digest which cuts either side of the targeting vector and 
therefore produces a larger fragment with the targeted allele due to the presence of the 
neomycin selection cassette. These fragments were detected with a 5’ probe (Fig 4.7c). 
Therefore this comprehensive screening strategy was able to identify potentially targeted 
alleles, check that both 3’ and 5’ recombination had occurred successfully and ensure that 
results were not due to integration of the whole vector or concatamer formation. 
Optimisation of these screening techniques is discussed in the relevant sections below. Results Chapter 4    183 
4.4 Targeting construct version 1 
The strategy behind the first attempt at producing a targeting vector is shown in fig 4.6. 
Vectors containing the positive (pgk-neo) and negative (Rosa diphtheria toxin) selectable 
markers were a kind gift from Dr D Gilchrist, Division of Immunology, Infection and 
Inflammation, Glasgow. In brief, construction of the final targeting vector comprised 5 
steps: 
Step 1: Amplification of a long 4480bp 3’ homology arm comprising exons 3-6 with 
intervening introns. An EcoRV site was added to the 5’ primer. This product was TOPO 
cloned into the commercial pCR4 vector (Invitrogen) (Vector A –pCR4exon 3-6). Fig 4.6a. 
Site-directed mutagenesis was performed on this construct to delete the second ATG 
(GATA-1FL targeting construct) discussed in 4.4.1.1. 
Step 2: Amplification of the short 5’ arm comprising of 2344bp of exon 2 and its flanking 
introns with Xho1/Kpn1 restriction sites added to the 5’ and 3’ primers respectively. This 
product was also TOPO cloned into the pCR4 vector (Vector B – pCR4exon 2). Fig 4.6b. 
Site-directed mutagenesis was performed on this construct to delete the first ATG (GATA-
1s targeting construct), discussed in 4.5.1.1. 
Step 3: Pgk-1 neo was excised from a Pgkneo vector using kpn1/notI restriction enzymes 
and ligated into vector B using the same restriction sites to produce vector C (pCR4exon 
2/neo). Fig 4.6c. 
Step 4: The 3’ arm was subcloned from vector A to vector C using EcoRV/NotI restriction 
sites to produce vector D (pCR4exon 2-6/neo). Fig 4.6d. 
Step 5: The diphtheria toxin negative selectable marker was excised from a Rosa 
diphtheria toxin vector using XhoI/SalI and ligated into a XhoI Site in vector D to produce 
vector E (pCR4exon2-6/neo/dipth). Fig 4.6e. 
The vector could then be linearised with NotI (Fig 4.6e), prior to electroporation into E14 
ES cells. 
The screening strategy to identify targeted clones is shown in fig 4.7. Results Chapter 4    184 
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Fig 4.6 Targeting construct version 1 
(a)-(c) Steps 1-3 are shown on this page. (d)-(e) Steps 4 and 5 are shown on the following 
page. The thin black line represents vector backbone, large coloured arrows/boxes are 
cloned DNA components of the targeting vector as labelled. Brackets indicate inserts used 
in ligation reactions.  Relevant restriction enzyme sites are shown in bold. Dark blue arrows 
indicate sites of insertion  Results Chapter 4    185 
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Fig 4.7 Screening strategy for targeted colonies Results Chapter 4    187 
The following sections describe the individual stages involved in construction of this 
vector 
4.4.1 Vector A pCR4 exon3-6 
Using primers listed in table 2.10 Chapter 2, the 3’ homology arm was amplified from 129 
genomic DNA. An EcoRV restriction enzyme site sequence was added to the 5’ end of the 
5’ primer to facilitate subsequent cloning steps. Use of Platinum Pfx polymerase (section 
2.10.4) produced a single 4480bp product which was excised (without prior gel 
photography to reduce exposure to UV light), gel purified and TOPO cloned into the pCR4 
vector after addition of A overhangs (section 2.12.1.1). Following overnight growth on 
LB-Agar plates, 5 colonies were picked for further analysis. Minipreps were made (section 
2.12.2.3) and vector DNA was assessed by RE digests (section 2.7.3). The results of these 
digests are shown in Fig 4.8a and b. Initially an EcoRI digest was performed to assess the 
presence of the correct insert (fig 4.8a). The predicted pattern of fragments was seen in two 
of the clones (10 and 16). To assess the orientation of these inserts an NcoI digest was 
performed (fig 4.8b) which suggested that both clone 10 and 16 carried the correct insert in 
the correct orientation. 
Clone 10 was sent for commercial sequencing (Agowa.de). Primer walking was used to 
sequence the entire 4480bp of the insert (data not shown). This confirmed 100% sequence 
identity with the available GATA-1 sequence (derived from the C57/Bl6 strain, GeneID 
14460, locus tag MGI: 95661, Entrez Gene) with the exception of a run of ‘A’s in the 
middle of intron 4. The published sequence had 17 ‘A’s, and clone 10 had 16’A’s. This 
was likely to be a strain difference between 129 and C57/Bl6. If this assumption was 
correct then this difference would have no impact on targeting efficiency (and since it 
occurs in an intron, it would also have no impact on the final protein product). If it was an 
error introduced by the PCR amplification process (unlikely as this type of error is rarely 
produced by Pfu polymerases) then it was felt that this single base pair deletion was 
unlikely to drastically impact on targeting efficiency. Therefore, clone 10 was designated 
vector A and used in all subsequent cloning steps. 
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Fig 4.8 Restriction enzyme digestion of Vector A 
(a) Results of EcoRI digest which should produce fragments of sizes 3938bp, 3017bp, 
1193bp and 288bp (shown by light blue arrows) in the presence of an exon 3-6 insert. 
Clones 10 and 16 produce appropriate sized fragments.  (b) To assess orientation an NcoI 
digest was performed. This should produce fragments of 6608bp and 1828bp (blue arrows) 
in the correct orientation or 5506bp and 2930bp in the wrong orientation. Both clones 10 
and 16 produce the correct pattern on digest. Results Chapter 4    189 
4.4.1.1   Site-directed mutagenesis of Vector A 
In order to produce the GATA-1FL targeting construct (i.e. capable of exclusive GATA-
1FL production) it was necessary to produce a version of vector A with a mutation in the 
second ATG start codon thereby preventing production of GATA-1s. Primers were 
designed (table 2.6, chapter 2) to alter the ATG (methionine) to CTA (leucine), this 2 
basepair change creates an XbaI site (which cuts at the sequence TCTAGA). Therefore 
successful site-directed mutagenesis can be confirmed by digestion of the mutagenised 
colonies with XbaI. Site-directed mutagenesis was performed using the Stratagene 
QuikchangeXL commercial kit (section 2.12.1.3). 10 clones were picked for further 
analysis. An EcoRV & XbaI double digest of mini-prepped DNA from these clones 
showed successful site-directed mutagenesis in all 10 as shown in Fig 4.9.  EcoRV cuts 
once at the vector/insert junction (this site was introduced by inclusion of its target 
sequence in the 5’primer during initial PCR amplification, described in 4.4.1 above, to 
allow subsequent cloning steps) and therefore should produce a linear fragment of 8463bp 
(as shown by the positive control clone 10 wild-type lane 14). XbaI does not cut in the wild 
type molecule and therefore should produce a pattern identical to uncut plasmid DNA: 
lanes 13 and 16 respectively). In the presence of a mutated second ATG an XbaI site is 
created producing a linear 8463bp fragment when the DNA is digested with XbaI (lane11) 
and two fragments of 8200bp and 263bp when a double digest using EcoRV and XbaI is 
performed (lanes 1-10). One of these clones (clone 6, lane 6) was used subsequently to 
produce the GATA-FL version of the targeting vector. 
Clones 1-10 XbaI, EcoRV
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Fig 4.9 Site-directed mutagenesis of Vector A 
Blue arrow denotes size of linearised vector DNA, purple arrow 263bp XbaI fragment Results Chapter 4    190 
4.4.2 Vector B pCR4 exon2 
In parallel with the creation of vector A described above attempts were also made to 
amplify and clone the shorter 5’ homology arm (2344bp) to produce vector B. Primer 
sequences are shown in table 2.10, chapter 2. XhoI and KpnI restriction enzyme site 
sequences were added to the 5’ and 3’ primers respectively to allow subsequent cloning 
steps. Initial PCR amplification from 129 genomic DNA produced a variety of products of 
different sizes, one of which roughly equated to the expected 2344bp fragment. This band 
was excised, gel purified, ‘A’ overhangs were added and it was TOPO cloned into PCR4. 
Unfortunately diagnostic digests with a variety of restriction enzymes (EcoRI, XhoI/NotI) 
did not produce the expected pattern of fragments (data not shown). Two further attempts 
were made to amplify up the 2344bp fragment with these primers, altering the annealing 
temperature, extension times and buffer conditions; again a fragment of approximately 
2344bp was amplified on each occasion. These fragments were TOPO cloned, and 
produced plentiful numbers of colonies, but diagnostic digests (EcoRI, NcoI) continued to 
show incorrect fragment sizes (data not shown). In an attempt to narrow down colonies 
that had incorporated GATA-1 sequences, PCR screening was performed directly on 
colonies picked from the Agar plate. This involved picking colonies with a sterile pipette 
tip, dipping the tip into a PCR tube (containing master mix and BFT4 FL GATA 5’ primer 
and Exon2-XhoI 3’ primers (listed in table 2.5 and 2.10, Chapter 2, respectively)) and then 
ejecting the tip into 3ml of LB-broth with ampicillin in a correspondingly labelled 
universal container. Following PCR screening any promising colonies could then be grown 
up from their corresponding universal container culture and mini-prepped for further 
evaluation. 41 colonies were screened by this approach using BFT4 FL GATA forward and 
Exon2-XhoI reverse primers, both of which should anneal within the insert. 24 colonies 
produced PCR products of the correct size, but again these colonies did not produce correct 
fragment sizes on diagnostic restriction enzyme digests (EcoRI, NcoI, DraI, PstI) (data not 
shown). To investigate the origin of these abnormal inserts, sequencing was performed on 
a couple of the more equivocal inserts (whose fragments on RE digest roughly equated 
with predicted patterns). Results showed that one was derived from a mouse chromosome 
7 segment and the other a mouse chromosome 2 segment. An initial screen of the primer 
sequences using the NCBI BLAST programme (http://blast.ncbi.nlm.nih.gov/Blast.cgi) to 
look for non-specific binding to other regions of the genome had appeared satisfactory. 
However, on more detailed analysis, the addition of the XhoI linker sequence to the 5’ 
primer had produced a short section of homology with this chromosome 2 sequence, and 
this same primer was also able to anneal to the chromosome 2 reverse strand (in the Results Chapter 4    191 
opposite orientation) thereby allowing  amplification of this segment of DNA. 
Amplification of the chromosome 7 segment remained unexplained.  
To try to prevent this non-specific annealing of the forward and reverse primers, a second 
set of primers were designed (exon 2 version 2 (#2), table 2.10, Chapter 2). Since Intron 1-
Exon 2 appeared to be a problematical PCR target the amplification reaction was optimised 
using (i) different combinations of primers (e.g. #2 forward, #1 reverse, #2 forward #2 
reverse etc) (ii) two different annealing temperatures and (iii) different concentrations of 
Pfx amplification buffer and enhancer solutions (2.5x buffer, 2x buffer 1x enhancer, 2x 
buffer, 1x buffer). Results of (i) and (ii) are shown in Fig 4.10 and show that #1 forward #2 
reverse gives the most intense band and that an annealing temperature of 55°C gives the 
highest yield.  Results of (iii) i.e. optimisation of buffer conditions, cannot be shown, as 
bands were excised without photography, but 2x buffer with 1x enhancer gave clearly 
superior results to all other combinations.  Use of these conditions was adopted for all 
subsequent amplification reactions.  
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Fig 4.10 Optimisation of exon 2 amplification  
 
Using these new amplification conditions a single band of approximately 2300bp was 
excised, TOPO cloned and 16 colonies mini-prepped. To look for the presence of the insert 
in the correct orientation a PstI digest was performed. This should produce fragments of 
5221, 464,409 and 177bp in the correct orientation and 4374, 1311, 409 and 177bp in the 
reverse orientation. Clone 11 appeared to produce fragment sizes corresponding to the 
correct insert but in reverse orientation (the presence of a 1311bp band is clearly seen as Results Chapter 4    192 
indicated in Fig 4.11a), the identity of the insert was further confirmed by EcoRI and DraI 
digests (fig 4.11b) which both produced the expected size of fragments for exon 2 reverse 
orientation. 
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Fig 4.11 Restriction enzyme digestion of clone 11 vector B  
(a) PstI digest produces fragment sizes compatible with an exon 2 insert but in the incorrect 
orientation in clone 11. Expected fragment sizes for the right orientation are shown in 
purple, wrong orientation in blue. (b) EcoRI (purple arrows) and DraI (blue arrows) digests 
confirm the expected fragment sizes for exon 2 reverse orientation in clone 11.  Results Chapter 4    193 
Having eventually cloned the exon 2 PCR fragment it was decided to try and reverse its 
orientation by exploiting the EcoRI restriction enzyme sites in the 5’ and 3’ multiple 
cloning sites as shown in Fig 4.12a, rather than attempt further cloning of primary PCR 
products. 5μg of clone 11 plasmid DNA were digested with EcoRI. The vector (3938bp) 
and insert (2318bp) bands were excised and gel purified. The vector was dephosphorylated 
(as described in 2.12.1.2) to prevent religation of the compatible sticky ends without 
recombining with the insert. Ligation was then performed using standard conditions 
2.12.1.2). Control reactions consisting of vector only and insert only were run to ensure 
that colonies produced on the test plate were due to religation between vector and insert, 
rather than contamination of the ligation reaction with uncut clone 11 plasmid DNA.   
These plates showed very small numbers of colonies (<5) whereas the test plate had more 
than 200 colonies. Minipreps of 8 colonies showed all 8 had religated in the incorrect 
orientation (fig 4.12b). A further 24 colonies were picked and again PstI digest confirmed 
the reverse orientation for all inserts (data not shown). Religation in this orientation would 
be predicted to occur in only 50% of the colonies.  
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Fig 4.12 Attempt to reverse orientation of clone 11 Results Chapter 4    194 
At this point it was decided to attempt an alternative cloning strategy as the cloning of 
exon 2 in the correct orientation appeared technically very difficult. This may be due to 
secondary structure within this region of DNA or other unknown factors. Results of the 
alternative strategy are described below. 
4.5 Targeting construct version 2 
Following the inability to clone vector B (pCR4exon 2) in correct orientation, a second 
strategy was devised. This is illustrated in Fig 4.13, in summary: 
Step 1: Transfer exon 2 pCR4 (clone 11- incorrect orientation), into pBluescript II KS- 
cloning vector using XhoI/EcoRI digest of pCR4exon2 and XhoI/EcoRI digest of pBSII to 
produce vector 1 (pBSIIexon2) Fig 4.13a. 
Site-directed mutagenesis was then performed on this construct to delete the first ATG 
(GATA-1s targeting construct) 
Step 2: Ligate exon3-6 into pBSIIexon2 (vector 1) by NotI/SpeI digest of pCR4exon3-6 
(vector A) and NotI/XbaI digest of vector 1 (XbaI and SpeI produce compatible sticky 
ends), to produce vector 2 (pBSIIexon2-exon3-6). Fig 4.13b. 
Step 3: Ligate pgk-neo into vector 2 using BamHI/EcoRV digest of pgkneo and 
BamHI/SmaI digest of vector 2 (EcoRV and SmaI are both blunt-ended cutters), to 
produce vector 3 (pBSIIexon2-pgkneo-exon3-6). Fig 4.13c. 
Step 4: Ligate in diphtheria toxin via XhoI digest of vector 3 and XhoI/SalI digest of Rosa 
diphtheria toxin vector to produce vector 4 (pBSIIexon2-pgkneo-exon3-6-diphth). Fig 
4.13d. 
This final targeting construct could be linearised with NotI prior to electroporation  
The screening strategy to identify targeted clones is essentially the same as that shown in 
Fig 4.7 with the exception that the neomycin selection gene is in reverse orientation 
requiring the use of alternative 3’ primers for PCR screening as listed in table 2.10, chapter 
2. Because of this reverse orientation the position of the neomycin BamHI restriction site is 
also altered with respect to the 3’ probe, resulting in a 5095bp targeted fragment instead of 
a 6715bp fragment (compared to a 9921bp wild-type fragment). Results Chapter 4    195 
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Fig 4.13 Outline of targeting strategy 2 Results Chapter 4    197 
4.5.1 Step 1 cloning of vector 1 (pBSII exon 2) 
Clone 11 (section 4.4.2 above) i.e. exon2 PCR4 in the wrong orientation, was sequenced to 
confirm that it matched the published GATA-1 genomic sequence. Like the exon 3-6 
clone, a single stretch of repetitive intronic sequence (on this occasion a string of GACT 
repeats) showed variation between the amplified 129 genomic DNA and the published 
C57Bl6 sequence (6 repeats versus 12 repeats respectively) again this was ascribed to 
inter-strain variation, as this kind of error is not usually due to aberrant DNA polymerase 
activity.  
5μg of clone 11 and 5μg of the cloning vector pBluescriptIIKS- were digested with XhoI & 
EcoRI (using compatible buffer – REact2 (Invitrogen)). The insert (clone 11) 2303bp band, 
and the vector (pBSII) 2928bp band were excised, gel purified and used in a standard DNA 
ligation reaction (2.12.1.2) before transformation into DH5α “library efficiency” cells and 
growth overnight in LB broth with Ampicillin. Again control reactions (vector only, insert 
only) were set up to ensure there was no contamination with uncut clone 11 or pBSII 
vectors. Several thousand colonies were produced on the test plate and only occasional 
colonies seen on the control plates. 6 colonies were picked and mini-prepped. Initial digest 
with XhoI/EcoRI confirmed the presence of insert with the expected 2303bp and 2928bp 
fragments on digest (data not shown). One of these clones (clone 2) was picked for further 
analysis. To double check that these colonies did not represent contaminating clone 11 
plasmid DNA a second set of restriction enzymes – ScaI/XbaI- were chosen that only cut 
in the insert and pBSII. Again the predicted size of fragments was confirmed 2562bp, 
1557bp and 1112bp (versus 3246bp and 3010bp in clone 11) (data not shown).  
Clone 2 was used as vector 1 in all subsequent steps. 
4.5.1.1   Site-directed mutagenesis of vector 1  
To produce a targeting construct capable of exclusive GATA-1s production a mutation in 
the first ATG was engineered to prevent synthesis of GATA-1FL but still permit use of the 
second ATG in exon 3 codon 84. Primers were designed (table 2.6, chapter 2) to alter the 
ATG (methionine) to ATC (isoleucine), this single basepair change abolishes an NcoI site 
(which cuts at the sequence CCATGG), and creates a ClaI site (which cuts at the sequence 
ATCGAT) as shown in Fig 4.5. Site-directed mutagenesis was performed using the 
commercial Quikchange SDM XL kit (Stratagene) as described in 2.12.1.3. Nine colonies 
were picked and screened for successful mutagenesis using a ScaI/ClaI double digest Results Chapter 4    198 
(using the compatible buffer React 6) which should produce fragments of 2562bp, 1591bp 
and 1078bp in the presence of the introduced ClaI site, this expected pattern was seen in 
7/9 colonies (fig 4.14). Clone 9 was picked for use in creation of the GATA-1s targeting 
construct. 
Clones 1-9
2562bp
1591bp
1078bp
Hyperladder I
 
Fig 4.14 Site-directed mutagenesis of vector 1 
ScaI/ClaI digestion of vector 1. Purple arrows denote expected fragment sizes in the 
presence of an introduced ClaI site. Successful mutagenesis is seen in clones 3-9. 
 
4.5.2 Step 2 cloning of vector 2 (pBSIIexon2-exon3-6) 
Step 2 involved combining the 5’ and 3’ homology arms into a single targeting vector. At 
the end of this process two different targeting vectors were produced i.e. 
1. Combination of exon 2 wild-type (vector 1) with exon 3-6 GATA-1 FL (vector A, 
product of site directed mutagenesis described in section 4.4.1.1 above) produced the 
GATA-1FL targeting vector 
2. Combination of exon 2 GATA-1s (vector 1, product of site-directed mutagenesis 
described in 4.5.1.1 above) and wild-type exon 3-6 (vector A) produced the GATA-1s 
targeting vector. 
5μg of vector 1 (wild-type or GATA-1s) DNA were digested with NotI/XbaI using a 
sequential digest i.e. digestion with NotI for 1 hour using REact 3 buffer at 37°C followed 
by purification using a Qiagen PCR purification kit (as described in section 2.7.5) and 
subsequent use in a XbaI digest using REact 2 buffer. 5μg of insert vector A (GATA-1FL 
or wild-type) were digested with a sequential NotI/SpeI digest using the same approach Results Chapter 4    199 
except for use of React4 buffer in place of React2 for the second digest. It should be noted 
that XbaI and SpeI produce compatible sticky ends allowing subsequent ligation of these 
products. Following restriction enzyme digestion the products were gel purified and used 
in a standard ligation reaction (section 2.12.1.2). On this occasion only very sparse small 
colonies were produced which may reflect the increasing size of the vector (now 9794bp in 
size).  14 GATA-FL colonies and 3 GATA-1s colonies were picked. Miniprep DNA was 
used in a diagnostic double digest with BamHI/ScaI restriction enzymes (using NEBuffer 
3, New England Biolabs). Clones 7, 10 and 14 GATA-1FL produced the predicted set of 
fragments (data not shown). No correct GATA-1s clones were seen. A second set of RE 
digests using EcoRI and a double XbaI/NotI digest showed that only clone 14 contained 
the correct insert, the other 2 clones appear to have incorporated the vector backbone from 
vector A. This may be because the two vector A fragments (vector backbone and insert) 
were similar in size after NotI/SpeI digestion (3910bp and 4526bp respectively) and the 
4526bp band may have been contaminated with small amounts of the smaller 3910bp band 
when the band was excised from the gel. To guard against this in subsequent ligations, a 
triple digest was used with NotI/SpeI and PvuI which produced fragments of 4526bp, 
2175bp, 1572bp and 163bp. Not only did this ensure that the 4526bp band was more easily 
separated from the vector backbone but also the vector backbone (digested with PvuI) no 
longer had compatible SpeI/NotI sticky ends making its ligation into vector 1 impossible. 
This strategy was used in a second ligation reaction to obtain further GATA-1s colonies. A 
better yield of colonies was seen and 18 were picked for further investigation. Of these 9 
produced correct sized fragments on BamHI/ScaI double digest, indicating successful 
ligation. Again results were checked using further combinations of enzymes using 
EcoRI/ClaI and EcoRI/XbaI double digests which produced the expected fragment sizes 
(data not shown).  
Vector 2-FL (clone 14) and vector 2-Sh (clone 4) were used in subsequent cloning steps: 
4.5.3 Step 3 introduction of pgkneo 
The next step was to “clone-in” the neomycin phosphotransferase antibiotic resistance 
gene (neo) into the targeting vectors. A plasmid containing this gene driven by the mouse 
Pgk-1 promoter and flanked by Lox-P sites was already in use in the laboratory. The Lox-P 
pgk-neo cassette was transferred into vector 2-FL and vector 2-Sh using a combination of 
blunt ended and sticky ended ligation. The targeting vectors were cut with BamHI and the 
blunt cutting enzyme SmaI whilst the pgkneo cassette was excised from its vector 
backbone using BamHI and EcoRV (EcoRV is also a blunt cutter). Both reactions required Results Chapter 4    200 
sequential digests using BamHI buffer (proprietary NEB buffer) initially, followed by 
purification and a second digest with EcoRV (React2) or SmaI (React 4). SmaI digestion 
was performed at 25°C as this is its optimum working temperature. Ligation was 
performed using standard conditions and 12 colonies for each construct (FL and Sh) were 
picked for further evaluation. Due to the increasing size of the targeting vector (now 
11464bp) minipreps were performed without the use of commercial spin columns (as 
described in section 2.12.2.3). An EcoRI digest was performed to look for correct 
incorporation of the pgkneo cassette. Clones 1, 3, 9 and 10 produced the correct pattern for 
vector 3-Sh and clones 16, 18, 19, 20, 21, 22 and 23 for vector 3-FL. These results, and 
existence of the expected mutagenesis sites, were confirmed with a second set of digests 
ClaI/BglII (GATA-1s) and XbaI/BglII (GATA-1FL) respectively, the correct pattern of 
fragments was seen in all cases (data not shown). 
4.5.4 Step 4 introduction of diphtheria toxin 
In order to enrich for colonies that have undergone homologous recombination a diphtheria 
toxin cassette was cloned into the 3’ end of the targeting vector. The diphtheria toxin gene 
driven by the ubiquitously active murine Pgk-1 promoter (Zambrowicz, et al 1997), was 
available in a plasmid vector in the laboratory. The cassette could be excised using 
flanking XhoI/SalI restriction sites. XhoI and SalI produce compatible sticky ends and can 
therefore be ligated into a corresponding XhoI site in targeting vector 3. This will produce 
an insert in either orientation. Sine the cassette contains an integral promoter it will be 
functional in either orientation.  
5μg of vector (vector 3-FL and vector 3-sh) and insert (Rosa-diphth) plasmid DNA were 
digested using XhoI and XhoI/SalI respectively. The linearised vector was gel purified and 
then dephosphorylated to prevent vector religation. A standard ligation reaction was set up 
and 12 colonies picked for each targeting construct. A XhoI/BamHI digest was performed 
to confirm the successful introduction of the diphtheria expression cassette (data not 
shown). Clones 2, 5, 11 and 12 (GATA-1FL) and 13, 14, 15, 16, 18, 21 and 23 (GATA-1s) 
produced the expected size of fragments. These results were confirmed with additional 
EcoRI, NotI, and BstXI digests (data not shown) and KpnI and NcoI digests which are 
shown in Fig 4.15. Note that the latter NcoI digest also confirms successful abolition of the 
NcoI site in the GATA-1s targeting construct (i.e. a single 3990bp band (denoted by a pink 
arrow) in place of the wild-type 2399bp and 1591bp bands (purple arrows)).   Results Chapter 4    201 
To further check the correct construction of the targeting vectors (vector 4–FL and 
vector4-Sh) and orientation of the two homology arms a number of PCR reactions were 
performed. These used forward primers that annealed in the short homology arm and 
reverse primers annealing in the long homology arm so producing a product that crossed 
the neomycin resistance gene. These reactions produced the correct sized bands and 
identity was further confirmed by restriction enzyme digestion of the PCR products (data 
not shown). 
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Fig 4.15 Diagnostic digests to confirm construction of the targeting vector 
Blue arrows denote expected sizes of KpnI digest fragments (9117bp & 3904bp). Purple/pink 
arrows denote expected sizes of NcoI digest fragments (4668bp, 4363bp, 2399bp & 1591bp 
for GATA-1FL, 4668bp, 4363bp, 3990bp (pink arrow) for GATA-1s) 
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4.6 Introduction into ES cells 
Once the targeting constructs had been made (vector 4-GATA1FL and vector 4-GATA1s) 
they were maxi-prepped using an endotoxin-removal protocol and methods suitable for 
large vectors (described in 2.12.2.3). 2μg of vector DNA was linearised and a 5μl aliquot 
was run on a gel to ensure effective RE digestion and to confirm purity of the plasmid 
DNA. The remainder was ethanol-precipitated and resuspended in TE under sterile 
conditions. Low passage ES cell clones, known to be competent for germ-line 
transmission, were used for transfection. Cells were harvested and resuspended in sterile 
PBS and electroporated according to the protocol described in section 2.12.3.5, chapter 2. 
Cells were plated in ES cell media at a density of 1x10
5/ml (sufficient to produce 50-100 
colonies per plate after selection). At 24 hours after transfection, media was replaced with 
selective medium containing 175μg/ml G418 and this medium was changed daily. A 
control plate was set up containing mock-transfected cells to monitor the effectiveness of 
G418 killing. As predicted, all the control cells died after approximately 5 days. Resistant 
colonies were sufficiently dense for picking at about day 10.  
Colonies were picked as described in section 2.14.3. For the first targeting attempt, 96 
GATA-1FL colonies and 132 GATA-1s colonies were picked. For attempts two and three 
192 colonies were picked for each construct. All colonies were plated in duplicate with one 
plate used to extract genomic DNA (as described in section 2.7.1) for use in screening 
assays as described below and the other master plate frozen down for later recovery of any 
positive/equivocal colonies. Individual colonies were numbered 1-96 and 1-132 and given 
the prefix FL or SH to identify the targeting construct used.   
4.7 Screening colonies 
Following extraction of genomic DNA, screening for targeting was performed in two 
ways. Initially all samples underwent PCR screening. However, given the low pick-up rate 
with this technique all samples were also screened by Southern blotting, initially using a 
BamHI digest with a 3’ probe. A confirmatory AflII digest with a 5’ probe was performed 
in equivocal/positive cases. The screening protocol was performed as described in section 
4.2.3 and illustrated in Fig 4.7 Results Chapter 4    203 
4.7.1 PCR screening 
4.7.1.1   Optimisation of technique 
As discussed in section 4.2.3.1, in order to screen for homologous recombination events by 
PCR it is necessary to construct a positive control plasmid which mimics the endogenous 
targeted locus. The design of this vector is illustrated in fig 4.16 and described here. 
Initially an exon 2 fragment, comprising the short 5’ homology arm and 511bp of upstream 
DNA sequence, was amplified from 129 genomic DNA using a PCR screening forward 
primer and exon 2 #2 reverse primers (listed in table 2.10, chapter 2). The resultant 2807bp 
amplified product was gel purified, ‘A’ overhangs were added and then it was TOPO 
cloned into the pCR4 cloning vector. Like vector B, discussed in section 4.4.2, this 
fragment also seemed to favour cloning in reverse orientation lending support to the theory 
that intrinsic physical properties of this region of DNA constrained its cloning efficiency. 
However for the purposes of designing a screening vector this was not a problem as long as 
correct orientation with respect to the neomycin cassette was maintained. 
PCR+plasmid
8400 bps
neo
GATA ex2 PCR
Exon2pcr+in pcr4
6774 bps
NotI
PmeI
GATA exon 2 PCR
pgk-neo
5567 bps
EcoRV
NotI
LoxP
neo
LoxP
 
Fig 4.16 Construction of PCR+ve control plasmid Results Chapter 4    204 
 A PstI diagnostic digest confirmed the presence of insert in reverse orientation in 5/9 
clones (data not shown). The insert from one of these clones (clone G) was ligated into the 
pGKneo vector using a NotI/EcoRV (sticky/blunt ended) digest of Pgkneo and a 
NotI/PmeI (sticky/blunt) digest of clone G. The 2820bp insert (clone G) and the linearised 
vector (pgkneo) were run on a 0.8% agarose gel, bands excised and gel purified and used 
in a standard ligation reaction. 16 colonies were picked and one of these produced the 
correct pattern of fragments with an EcoRI digest, this was confirmed with a subsequent 
BstXI digest (data not shown). 
This PCR+ plasmid was used to optimise PCR screening conditions. Initially forward and 
reverse primers were tested with undiluted PCR+ plasmid DNA and a strong band of 
correct size (2.3kb) was produced. The ability of the primers to detect the targeted locus in 
genomic DNA isolated from targeted embryonic stem cells was then modelled. This 
involved calculation of the number of copies of the mouse genome (which is equivalent to 
the number of copies of GATA-1, since it is X-linked and therefore has one endogenous 
copy per genome) in 2μg of starting genomic DNA. Using Avogadro’s number, the 
molecular weight (MW) of each basepair of DNA (approximately 650 daltons) and the 
number of basepairs in the diploid mouse genome (6 x10
9) the number of copies of the 
mouse genome in 2μg of genomic DNA is calculated as follows: 
Number of basepairs x MW of each basepair = MW of single copy of mouse genome  
i.e.  (6 x10
9)
 x 650 = 3.9 x10
12 
Copies of the genome per μl of genomic DNA (estimated concentration 2μg/μl) =  
(Avogadro’s number) x (2 x10 
-6) / MW of mouse genome i.e. 
(6.02 x10
23) x (2 x10
-6) / (3.9 x10
12) = (12.04 x10
17) / (3.9 x10
12) = 3.08 x10
5 copies per μl                
The molecular weight of PCR+ plasmid DNA was 8400bp x 650 daltons i.e 5.4x10
5. 
Therefore the number of copies of plasmid DNA (which is equivalent to the number of 
copies of GATA-1) in 100fg (1x10
-13g) is:  
(6.02 x10
23) x (1x10
-13) / (5.4x10
5) = (6.02 x10
10) / (5.4x10
5) = 1.11x10
5 copies per 100fg 
Therefore 300fg of plasmid DNA should contain the same number of copies of GATA-1 as 
2μg of genomic DNA. To test the sensitivity of the PCR primers to detect copies of Results Chapter 4    205 
GATA-1 down at this level, serial dilutions of plasmid DNA down to 1fg/μl were made. 
However plasmid DNA is much purer and easier to amplify by PCR than crude genomic 
DNA isolated from ES cell lysis preparations. To add complexity 1μl plasmid DNA was 
mixed with 1.5μl of E14 genomic DNA before use in PCR. Results of initial titration 
experiments are shown in fig 4.17. These reveal detection of 10fg of template plasmid 
DNA. Further optimisation showed that maximum sensitivity was achieved with an 
annealing temperature of 55°C and 35 amplification cycles (data not shown). Therefore, 
using these reaction conditions, the PCR+ plasmid and primers appeared suitable for use in 
PCR screening of targeted clones. 
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Fig 4.17 Titration of template DNA to confirm utility of PCR screening 
Blue arrow denotes expected product size, bands can be seen down to 10fg starting 
plasmid template. No product is seen with water or the E14 negative control DNA. 
 
4.7.1.2   Results of attempt 1 
PCR screening was performed on genomic DNA extracted from all 96 GATA-1FL and 
132 GATA-1s colonies. 2.5μl of test DNA was used in each PCR reaction and positive 
(PCR+ plasmid- 100fg and 10fg) and negative (H2O) template controls were run with each 
batch. Precautions were taken to prevent cross-contamination: PCR reactions were set up 
in a laminar flow hood whenever possible, separate dedicated pipettes were used for 
samples and the PCR+ control plasmid reactions, separate bench spaces were used to set 
up test samples and the positive controls. The PCR+control was positive at the 100fg level 
in all batches but not always positive at the 10fg level despite identical PCR conditions to 
those used for initial titration (Fig 4.17). No band corresponding to the targeted allele was 
seen in any of the 228 samples tested – representative gels are shown in fig 4.18.  Results Chapter 4    206 
This could mean that there were no targeted alleles in any of these samples (i.e. the 
targeting construct had a targeting efficiency of less than 1 in 96) or that the PCR method 
of screening was insufficiently sensitive given the quality and quantity of the genomic 
DNA prepared from these relatively crude large scale extraction methods. In order to 
address these issues: 
1. Colonies were also screened by Southern blotting, a tried and tested technique for 
identifying targeted clones under similar conditions. 
2. The PCR screening strategy was made more sensitive. 
3. A new batch of ES cells was targeted and more colonies picked to ensure that sufficient 
numbers of colonies were screened to pick up rare targeting events. 
Clones FL 25-45 Targeting attempt 1
Clones SH 25-72 Targeting attempt 1
100fg 10fg
 
Fig 4.18 PCR screening of targeting attempt 1 Results Chapter 4    207 
4.7.2 Southern blotting 
Southern blotting was performed using a 3’ probe and a BamHI digest as shown in fig 4.7 
(although note this figure gives fragment sizes appropriate for the initial targeting vector). 
The neomycin cassette introduces a BamHI site into the endogenous locus and the 3’ probe 
sits outside the targeting construct and therefore cannot pick up randomly inserted 
targeting construct DNA. Wild type DNA produces a 9921bp fragment whilst the targeted 
locus would produce a 5095bp fragment due to cleavage within the neo gene. To confirm 
effective targeting, a second probe which anneals to the 5’ end of the endogenous locus 
was also used. This probe, in combination with an AflII digest produces a 6670bp fragment 
with wild-type DNA and an 8417bp fragment with targeting of the endogenous locus (as 
shown in Fig 4.7).  
4.7.2.1   Preparation of 3’ and 5’ probes 
The 3’ and 5’ probes were designed to be between 250 and 500bp long and to sit just 
outside the region of DNA present in the targeting constructs. PCR primer sequences are 
listed in table 2.10. Probes were amplified using standard PCR (2.10.1). The 5’ probe was 
316bp in size and the 3’ probe 404bp, these products were TOPO cloned into the pCR4 
cloning vector and maxi-prepped. Identity was confirmed by commercial sequencing 
(Agowa.de). The probes could be released from the vector using a NotI/PstI digest (NEB 
buffer 3) for the 5’ probe and an EcoRI digest (REact3) for the 3’probe. Using 5μg of 
starting plasmid DNA the digestion products were gel purified and eluted in 50μl elution 
buffer (EB) before labelling with 
32P as described in section 2.7.7.4.   
4.7.2.2   Results of Southern blotting 
Southern blotting was performed as described in section 2.7.7. All samples were initially 
screened following BamHI digestion and detection using the 3’ probe. This was followed 
by AflII digestion and detection using the 5’ probe use in promising samples. Adequate 
DNA loading and digestion were confirmed by inspection of the ethidium bromide stained 
electrophoresis gel under UV light. A representative electrophoresis gel is shown in 4.19a 
and X-ray film detection of hybridised probe is shown in Fig 4.19b. As seen from 4.19a 
not all samples had adequate DNA content to allow screening (lanes) but the vast majority 
of samples produced a clearly identifiable wild type band (fig 4.19b and c). Since GATA-1 
is X-linked and E14 ES cells are XY the presence of a wild-type band acts as a negative Results Chapter 4    208 
control excluding targeting at the endogenous locus. All 96 GATA-1FL and 132 GATA-1s 
samples were screened by this method, no targeted bands were seen. 
(a)
(b)
10kb
10kb
5kb
5kb
5 kb
(c)
10kb
 
Fig 4.19 Southern blotting of targeting attempt 1 
(a) Representative electrophoresis gel stained with ethidium bromide and photographed 
under UV illumination. Note variable DNA loading in some lanes although the majority of 
samples were able to produce good quality bands on hybridisation with labelled probe. (b) 
shows a representative radiograph (target attempt 2 FL 39-56) following 3’probe 
hybridisation (note (a) and (b) are not derived from the same experiment). (c) Another 
representative gel – target attempt 2 SH 75-94.  The blue arrow shows the position of the 
10kb size marker (wild-type band = 9921bp), the purple arrow the position of the 5kb size 
marker (targeted band = 5095bp).  
 
4.7.3  Increasing the sensitivity of PCR screening 
A number of approaches were taken to try and increase the sensitivity of PCR screening. 
Unfortunately, use of 40 cycles of PCR amplification produced less distinct product bands 
on gel electrophoresis (data not shown). A commercial high yield DNA polymerase Results Chapter 4    209 
(Phusion high fidelity DNA polymerase (New England Biolabs)) also failed to produce 
superior results (data not shown). Finally, new PCR primers were designed for nested PCR 
with external and internal primers as described in section 2.10.3. This strategy was much 
more effective with detectable product using 1fg of template DNA as shown in Fig 4.20.  
This technique was employed for all subsequent PCR screening. 
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Fig 4.20 Nested PCR screening strategy 
(a) Diagrammatic representation of nested PCR strategy. 5μl of PCR product from the initial 
PCR reaction (external primers, 30 cycles) was added to a fresh PCR tube containing 
internal primers and a second round of amplification performed (35 cycles).  (b) 
representative products after use of limited nesting protocol (addition of internal primers 
after 5 cycles to the same PCR tube), internal primers alone or a full nested protocol as 
described in (a) and section 2.10.3 
 
4.8 Second and third targeting attempts 
The results above suggest that the targeting efficiencies of the two constructs are low (less 
than 1 in 100). Therefore a larger number of colonies need to be screened to pick up rare 
targeting events. A further two attempts were made to successfully target the endogenous Results Chapter 4    210 
GATA-1 allele. In both these cases 192 colonies for each targeting construct were picked 
and screened by PCR and Southern blotting.  
4.8.1 Screening by nested PCR 
The use of the nested PCR protocol resulted in a number of positive bands being obtained. 
Fig 4.21a shows a representative positive band seen with the FL40 clone from the second 
targeting attempt. Following this positive result the original PCR screening strategy and 
the new nested strategy could be compared: Fig 4.21b shows that the FL40 sample band 
would not have been obtained with the original screening strategy.  
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Fig 4.21 Nested PCR results for targeting attempts 1 and 2  Results Chapter 4    211 
Therefore it remained possible that the low targeting efficiency seen in the first targeting 
attempt was due to inadequate sensitivity of the screening technique. To address this, all 
samples from targeting attempt one were re-screened with the new protocol, two of these 
samples - SH44 and SH81- were found to be positive with this new screen.  Overall, 20 
samples from the three combined targeting attempts produced positive bands by PCR as 
summarised in table 4.1. Some representative PCR gels are reproduced in Fig 4.22. Only 3 
of these showed positive bands on an independent repeat PCR using the original DNA. To 
ensure the band was not due to contamination of the original DNA sample with the 
positive control plasmid, the corresponding master plates were then thawed (as described 
in 2.14.3.1). Following recovery of the cells, master stocks were frozen down in 1.5ml 
cryovials (as described in section 2.5.4) and remaining cells underwent cell lysis and 
extraction of genomic DNA as previously described (section 2.7.1). This fresh DNA was 
used for repeat PCR screening and Southern blotting. Repeat PCR on this new DNA was 
still positive for the FL40 sample as shown in Fig 4.21c but was negative for a number of 
other samples including SH81 (target attempt 1), FL83 (target attempt 2) and SH101 
(target attempt 2) as shown in fig 4.21c.  
SH 21 T3 SH 21 T3
FL 42 T3
FL 83  T2 FL 83  T2
SH 2 T3 SH 2 T3 SH 17 T3 SH 17 T3
SH 101 T2 SH 101 T2
SH 14 T3  
Fig 4.22 Positive PCR screening results from T2 and T3 
Nested PCR was performed as described in text. Blue arrows show lanes with positive 
bands - clone numbers and targeting attempt (T2 or T3) are shown alongside. Purple arrows 
show +ve control plasmid lanes (100fg and 10fg template). Results Chapter 4    212 
4.8.2 Screening by Southern blot 
Southern blotting was performed for all samples using BamHI digestion and hybridisation 
with the 3’ probe. Unexpectedly the FL40 clone produced a wild-type band on Southern 
blot using both 3’ and 5’ screening strategies (the 3’ BamHI blot is shown in Fig 4.24). 
However, 8 samples from targeting attempts 2 and 3 did produce bands in the position of 
the targeted allele (5095bp) (listed in table 4.1 and representative samples shown in fig 
4.23). In all cases these targeted bands were accompanied by stronger wild-type bands as 
shown in fig 4.23a. This finding is unexpected as E14 ES cells are male and therefore only 
carry one copy of the X-chromosome. Therefore, this X-chromosome should either be 
targeted (producing a 5095bp targeted band) or wild-type (producing a 9921bp wild-type 
band) but not both! One possible explanation for this finding is that, despite careful plating 
and picking, the ES cell colonies picked represented mixed colonies rather than a single 
clonal population. It should be noted that only 3 of the colonies with targeted bands on 
Southern blot had positive PCR results (SH2, SH14 (target attempt 2) and SH93 (target 
attempt 3)). This supports the need to screen with both strategies but also suggests that 
some results might be artefactual. 
All PCR positive samples and all samples with mixed colonies on Southern blot underwent 
AflII digestion and hybridisation with the 5’probe. All these blots showed the presence of 
wild-type DNA although the quality of these blots varied making ruling out the 
coexistence of an additional targeted band difficult as shown in Fig 4.23b. 
4.8.3 Further investigation of positive clones 
Results summarised above threw up a number of unexpected findings i.e. (i) despite 
targeted bands on PCR, wild type bands were seen on Southern blot (ii) targeted bands on 
Southern blot were accompanied by wild type bands in all cases (iii) 3’probe targeted 
bands were not confirmed on repeat with a 5’probe screening strategy. 
Overall no clone satisfied all the criteria necessary to establish it as unequivocally targeted. 
There are a number of possible explanations for these findings: 
1. The positive bands obtained from the original PCR could be false positives in some or 
all samples. This is supported by the lack of reproducibility in many cases using either the 
original sample or the thawed master plate. It is also supported by the increasing number of 
positive bands with each targeting event (by targeting attempt 3 over 800 PCR reactions Results Chapter 4    213 
had been performed, making environmental contamination with control plasmid DNA 
highly likely). This is certainly possible for many of the samples but unlikely for FL40 
which consistently gave high level positive results. 
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Fig 4.23 Southern blotting of targeting attempts 2 and 3 
(a) Clones SH 2 & SH 14 (targeting attempt 2 (T2)) FL 59, FL 83 and SH 63 (targeting attempt 
3 (T3)), appear to show co-existence of wild-type (9921bp, top blue arrow) and targeted 
(5095bp, bottom purple arrow) bands on BamHI digest with detection using a 3’ probe.  (b) 
these results are not confirmed on AflII digest of the same DNA with detection using a 5’ 
probe, in these cases only wild-type bands are clearly seen. Results Chapter 4    214 
Target 
attempt 
Clone PCR  Repeat 
PCR 
PCR 
master 
plate 
S. blot 
(3’probe)
S. blot 
(5’probe)
Further action 
1 SH44 +  -  ND  WT  WT  
1 SH81 +  -  -  WT  WT  
2  FL40  +  +  +  WT  WT  PCR band TOPO cloned and 
confirmed to represent 
targeted sequence not 
screening primer. Plated at 
low density and picked 96 
subclones, all negative by 
PCR screening and Southern 
blot  
2 FL83 +  +  -  WT  WT  
2 SH101  +  +  -  WT  WT  
2 SH129  +  -  ND  WT  WT  
3  SH2  +  -  +   Mixed  WT  Screen 24 subclones by nested 
PCR. Subclone 22 positive by 
PCR, negative by S.blot 
3  SH14  +  -  -  Mixed  WT  Screen 24 subclones by nested 
PCR. All negative 
3  SH17  +  -  -  WT  WT  Screen 24 subclones by nested 
PCR. All negative 
3  SH21  +  -  -  WT  WT  Screen 24 subclones by nested 
PCR. All negative 
3 SH36 +  -  ND  WT  WT  
3 SH63 - ND ND  ?  Mixed WT  
3 SH93 +  -  ND  ?  Mixed WT  
3 SH117  +  -  ND  WT  WT  
3 FL4  +  -  ND  WT  WT  
3 FL15 +  -  ND  WT  WT  
3  FL29  +  -  -  WT  WT  Screen 24 subclones by nested 
PCR. All negative 
3  FL38  +  -  +  WT  WT  Screen 24 subclones by nested 
PCR. Subclones 11 &16 
positve by PCR, negative by 
S.blot 
3  FL42  +  -  -  WT  WT  Screen 24 subclones by nested 
PCR. All negative 
3 FL44 - ND  +  Mixed  WT BamHI Southern blot 
remained positive (mixed) on 
repeat 
Screen 24 subclones by nested 
PCR. Subclone 11 positive by 
PCR, negative by S.blot 
3  FL48  -  ND  +  ? Mixed  WT  Screen 24 subclones by nested 
PCR. Subclones 2,13, 19 & 22 
positive by PCR, negative by 
S.blot 
3 FL59 - ND ND  ?  Mixed WT  
3 FL83 - ND ND  ?  Mixed WT  
3 FL102  +  -  ND  WT  WT  
WT= wild type, ND = not done 
Table 4.1 Investigation of possible targeted clones Results Chapter 4    215 
2. The positive PCR bands could represent true targeted alleles at the borderline of 
sensitivity by PCR detection therefore not always positive on repeat. This is not supported 
by the Southern blot results which did not show corresponding targeted bands in many 
cases. 
3. If the original picked colonies were mixed rather than clonal then the variable results 
with original test DNA and master plate DNA could represent differences in the proportion 
of the targeted and non-targeted clone. It is possible that the targeted clone had some kind 
of growth or survival disadvantage (possibly due to silencing  or reduced expression of the 
neomycin selection gene) and therefore was out-competed when the cells were thawed a 
second time. This mixed colony theory also supports the co-existence of wild-type and 
targeted bands on Southern blot. 
4. The wild-type band seen in the BamHI digest could be a composite band of GATA-1 
and artefactual contaminating DNA (such as partially digested microsatellite DNA) picked 
up incidentally by the GATA-1 probe. Therefore the WT band seen in the presence of the 
targeted band could be artefactual. This is unlikely as it would be necessary to postulate 
that the non-specific and GATA-1 bands always ran in the same position and were 
therefore indistinguishable, and also that independent AflII digest also produced an 
artefactual band.   
5. The targeted band seen in the BamHI digest could be a false positive. BamHI is a 6 
basepair cutter meaning that it cuts on average every 4096 basepairs in the genome. If the 
GATA-1 3’probe exhibited any non-specific binding to any of these random fragments 
then an approximately 5kb sized band would be a relatively common occurrence. This 
theory would explain why targeted bands were never seen on the corresponding AflII 
digest as this random event would be highly unlikely to be duplicated using a different 
restriction enzyme and probe in the same clone. It also explains the apparent discrepancy 
between PCR and Southern blot results i.e. positive Southern blots were not always 
accompanied by positive PCR reactions (such as clones SH63, FL44, FL48, FL59 and 
FL83, table 4.1) and vice versa (such as clones SH44, SH81, FL40, FL83, SH101, SH129, 
etc table 4.1).  
6. The targeted band in the BamHI digest could have been due to incomplete homologous 
recombination events. In this case the vector and the endogenous allele begin strand 
exchange which results in the vector picking up some of the flanking sequences of the 
target. However, this homologous recombination intermediate does not proceed to full Results Chapter 4    216 
exchange and the vector dissociates from the target and may go on to randomly integrate 
elsewhere in the genome. This would explain the presence of both wild-type and targeted 
sequences in the same clone. It is interesting that mixed colonies were only ever seen with 
the BamHI digest which detects homologous recombination events involving the 3’ long 
homology arm of the vector. As described above (section 4.4.1) this arm was easy to clone 
and had almost 100% sequence identity with GATA-1. It is possible that the shorter arm, 
which may have significant secondary structure, may have been particularly resistant to 
homologous recombination. If this was the case then this type of targeting intermediate, 
involving 3’ but not 5’ exchange, may have been commoner than full recombination. 
Hypotheses 1, 3 and 4 above were tested as detailed below: 
4.8.3.1   Are the PCR bands false positives? 
To test whether the PCR bands represented contamination with screening plasmid DNA 
the FL40 band (robustly positive on multiple repeat PCRs) and the PCR+ screening 
plasmid bands were excised, TOPO cloned and sequenced. Construction of the screening 
plasmid was subtly different from the targeting construct at the exon2-neomycin junction, 
with an additional 6 basepairs of sequence in the targeting construct. Commercial 
sequencing (Agowa.de) of the two PCR products confirmed that they differed by these 6 
basepairs and therefore that the FL40 product could not be due to contamination with 
screening plasmid DNA.  
4.8.3.2   Is there any evidence for mixed colonies? 
The picking of mixed colonies was felt to be the most likely explanation for the co-
existence of wild-type and targeted bands on Southern blot. To address this, the FL40 
sample was thawed from the frozen cryovial (described in section 4.8.1) and following cell 
recovery the cells were plated at low density on 10cm tissue culture plates. This was 
achieved by trypsinising and counting the cells, resuspending at 1x10
5/ml (ensuring a 
single cell suspension by vigorous pipetting) and then making serial dilutions to achieve 
plating densities of 1000 cells, 500 cells, 250 cells and 100 cells per 10cm plate. Cells were 
allowed to grow for 1 week and then 96 well-spaced colonies were picked for further 
screening, as previously described (section 2.14.3). Unfortunately, none of the 96 
subclones were positive either by PCR screening or Southern blot (representative PCR gel 
and blot shown in Fig 4.24). It is worth noting that PCR screening was still positive in the 
genomic DNA extracted from the original thawing of the master plate (described in section Results Chapter 4    217 
4.8.1) but not in individual colonies from this second thawing. This could either be because 
the targeted clone represented less than 1% of the original mixed colony (and therefore 
may not have been detected on individual testing of 96 subclones) or that the targeted 
clone had some kind of growth or survival disadvantage making its recovery on repeated 
freeze/thawing impossible.  
FL40 subclones 1-12 FL40 subclones 13-24
Nested PCR screen
BamHI Southern blot
FL40 subclones 1-19 E14 DNA
PCR+ plasmid 
100fg/10fg
 
Fig 4.24 Screening of FL40 subclones by PCR and Southern blot 
 
A similar approach was taken for 9 other potentially mixed colonies, either positive by 
Southern blot or PCR, as shown in table 4.1. These samples had not undergone previous 
thawing of the master plate and therefore it might have been easier to recover targeted 
clones. Due to practical constraints in sample handling, 24 subclones were picked for each 
colony, this would be expected to pick up targeted clones if they represented more than 
about 5% of the original mixed colony. All these subclones were screened by nested PCR 
and positive samples screened by Southern blot. Although 8 positive subclones from 4 
different colonies were positive by PCR (listed in table 4.1) none of these proved positive 
by Southern blot (data not shown). It seems likely that a number of these PCR results were 
false positives, although this was not formally tested.   Results Chapter 4    218 
4.8.3.3    Do clones with a targeted band also possess wild-type 
GATA-1? 
As discussed above the wild-type GATA-1 band, seen in addition to the targeted band on 
southern blots could conceivably be an artefact. In the presence of a correctly targeted 
GATA-1 locus no wild-type GATA-1 should be detectable. To test this hypothesis, 
colonies with a mixed pattern of bands by Southern blot were screened for the presence of 
wild-type GATA-1 by PCR. PCR primers were chosen that spanned the neomycin 
resistance gene with the forward primer (BFT4 FLGATA table 2.5, chapter 2) annealing in 
exon 2 (the short homology arm) and the reverse (alt spl 1 table 2.5, chapter 2) in exon 3 
(the long homology arm). In the presence of wild type GATA-1 an 864bp product should 
be seen, whilst a targeted allele or randomly inserted targeting construct would produce a 
2611bp product (incorporating the intervening neomycin cassette). The targeting vector 
was used as a positive control for introduced GATA-1 whilst untargeted native E14 DNA 
was used as a positive control for wild-type GATA-1, water template acted as a negative 
control for both reactions. The results are shown in fig 4.25. A strong wild-type GATA-1 
band was seen in all colonies tested (FL44, SH2, FL48, SH93, FL83) all of which had 
produced a mixed pattern on southern blotting. The presence of the larger targeting 
construct band was also seen although much fainter, suggesting that these clones had 
randomly integrated the GATA-1 targeting construct. 
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Fig 4.25 PCR reveals wild-type GATA in all colonies tested 
The purple arrow shows the expected product size for vector derived GATA-1 and the blue 
arrow for wild-type GATA-1. A wild-type band is seen in all colonies tested. Results Chapter 4    219 
4.9 Summary of targeting experiments 
Despite screening of more than 1000 colonies and subclones, no confirmed homologous 
recombination events were detected. There are a number of possible explanations for the 
failure to detect homologous recombination in these targeting experiments i.e. 
1. Technical problems with construction of the targeting vector: many precautions were 
taken to ensure that the targeting vector was correctly constructed and contained no DNA 
mismatches that would compromise targeting efficiency. These are detailed in sections 4.4 
and 4.5 above and include the use of isogenic DNA, full sequencing of the entire 6798bp 
(4480bp long arm and 2318bp short arm) of the two homology arms, and multiple checks 
of orientation by RE digest and PCR. Although even small degrees of DNA mismatch can 
compromise targeting efficiency it seems unlikely that the single basepair mismatch 
(GATA-1s) or the two-basepair mismatch (GATA-1FL) introduced by site-directed 
mutagenesis would be sufficient to prevent targeting, especially as the homology arms 
were longer than reported minimums for targeting (Hasty, et al 1991). One other 
possibility is that the negative selection strategy with diphtheria toxin was ineffective. 
Production of toxic diphtheria protein from this cassette was not formally tested. The 
absence of an effective negative selection marker would significantly increase the number 
of clones needed to be screened to pick up a homologous recombination event.   
2. Technical problems with the screening strategy: although the initial PCR screening 
strategy was of borderline sensitivity for the detection of targeted clones the nested 
protocol showed reproducible bands using 1fg of plasmid DNA which was calculated to be 
more than two logs below the required level to pick up endogenous targeted GATA-1 (as 
described in section 4.7.1.1). Since the Southern blot protocol reliably picked up wild-type 
bands using a BamHI digest and 3’ probe, it seems unlikely that it would be insufficiently 
sensitive to pick up a targeted band. The existence of the neomycin BamHI site was 
confirmed by BamHI digest of the targeting vector (data not shown). In addition, the 
presence of a wild-type band effectively ruled out targeting and so acted as a positive 
control. Only a few samples lacked wild-type bands and these always equated with low 
levels of DNA as visualised on the ethidium bromide stained electrophoresis gel.  
3.  Intrinsic properties of the endogenous GATA-1 locus: The extreme difficulties, 
detailed in section 4.4.1, in amplifying and then directionally cloning the exon 2 5’ 
homology arm (despite it being a much shorter, and therefore a theoretically easier, 
segment than the corresponding 3’ homology arm) suggest that intrinsic properties of this Results Chapter 4    220 
region of DNA make it difficult to manipulate. Although on visual inspection it is not 
particularly GC rich, intron 1 contains large segments of repetitive sequence including 
multiple GATA binding sites. It may be that physical properties of this region of DNA 
make it particularly unsuitable for cloning and targeting. Unfortunately in order to produce 
a targeted mutation in exon 2 it is impossible to leave out this region (especially as placing 
a mutation near the end of a homology arm puts it at risk of not being incorporated during 
the homologous recombination process).  Original descriptions of GATA-1 targeting in 
murine ES cells used targeting vectors with very short 5’ homology arms (<1.1kb) (Pevny, 
et al 1991). Although the reason behind this was not reported it is possible that this 
reflected similar difficulties in cloning this region of DNA. 
4. Abnormalities in ES cells used for targeting: again precautions were taken to use low 
passage germ-line competent ES cells for targeting to maximise the possibility of 
introducing stable genetic change. Nevertheless it is possible that these particular cells had 
acquired genomic instability making successful targeting less likely. ES cells rapidly 
acquire aneuploidy on repeated passage, with one report showing that only 20% of cells 
have euploid metaphases after 25 cell passages (Longo, et al 1997).  One intriguing 
possibility is that these male ES cells could have acquired a second copy of the X-
chromosome (i.e. making them XXY), this would explain the co-existence of wild-type 
and targeted bands in the same clone, although it would not explain the lack of an AflII 5’ 
band. This possibility could be further investigated by karyotypic analysis of the targeted 
ES cell clones.  
Following these exhaustive attempts to achieve targeted ES cell clones it was decided, due 
to time and practical constraints, to abandon further attempts at targeting. Instead 
experiments looking at over-expression of GATA-1 isoforms in the human K562 and Meg-
01 cell lines, as well as ectopic expression in murine ES cells were pursued, as described in 
the following chapter. 221 
5  A functional analysis of GATA-1 isoforms 
5.1 Introduction 
GATA-1 gene targeting, described in the previous chapter, is a particularly attractive 
approach to the study of gene function, mainly because it allows properly regulated 
expression of the transgene using the endogenous promoter and removes the endogenous 
source of GATA-1. However, the use of transgenic expression vectors randomly 
integrating into the host genome is a very well established approach for studying the 
functional consequences of gene (over)expression and has provided insights into the roles 
of several transcription factors as discussed in section 1.1.3.2 with examples given in table 
1.2. This approach brings its own advantages, particularly the ability to use human cell 
lines (gene targeting and in vitro haematopoietic differentiation of human ES cells are not 
yet well validated techniques). It appears that the GATA-1s mutation may have different 
phenotypic consequences in human and murine systems, as evidenced by the murine 
GATA-1s transgenic mouse phenotype (Li, et al 2005) compared to the GATA-1s 
expressing human kindred (Hollanda, et al 2006). Therefore, the study of human cells may 
provide insights not gained in the murine system. In addition, the gene targeting approach 
provides limited opportunity to study the interaction with trisomy 21, so vital for the 
TAM/AMKL phenotype. Both murine and human systems will be examined in this 
chapter. 
In order to study GATA-1 isoform function and interaction with trisomy 21 further, the 
individual GATA-1 isoforms were over-expressed in 3 different cell lines – murine ES 
cells (discussed in chapter 4), a human meg-erythroid cell line (Meg-01), and another 
human haematopoietic cell line with meg-erythroid differentiation capacity- K562. Meg-01 
cells carry trisomy 21, and are capable of inducible in vitro differentiation along both 
megakaryocytic and erythroid lineages. Results using this system were compared to 
isoform over-expression in K562 cells, which are also capable of megakaryocytic and 
erythroid differentiation, but without trisomy 21. This system is discussed in more detail in 
section 5.5 below. This chapter starts with a description of the construction and validation 
of plasmid vectors capable of exclusive GATA-1FL or GATA-1s expression. It then goes 
on to describe utilisation of these vectors to examine the effects of GATA-1 isoform 
expression on: Results Chapter  5    222 
1. The ability of murine embryonic stem cells to form haematopoietic colonies in semi-
solid culture medium. 
2. The biological properties of two cell lines -K562 and Meg-01- with meg-erythroid 
potential, one of which (Meg-01) is trisomic for chromosome 21. 
3. Gene expression profiles, expression of cell surface markers and development of 
increased DNA ploidy during in vitro differentiation of K562 and Meg-01 along the 
erythroid and megakaryocytic lineages. 
5.2 Construction of GATA-1 isoform specific expression 
vectors 
5.2.1 Human GATA-1 expression vectors 
The construction of human isoform specific expression vectors was facilitated by the 
presence of alternative splicing of GATA-1mRNA in humans. Therefore, after RT-PCR of 
human cDNA from K562 cells using GATA-1 exon 1 and 6 primers (listed in table 2.5) 
bands corresponding to the GATA-1FL and GATA-1s isoforms could be directly excised, 
gel purified and TOPO cloned into a commercially available pEF6V5HisTOPO expression 
vector (Invitrogen) as described in section 2.12.1.1. This vector was chosen because it uses 
a human EF1α promoter to drive gene expression which has been shown to be a strong 
promoter in haematopoietic cell lines (Goldman, et al 1996, Mizushima and Nagata 1990). 
Colonies were mini-prepped and analysed by restriction enzyme digestion for the presence 
of insert and its orientation. One putative GATA-1FL and 1 GATA-1s colony were sent for 
sequencing. Sequencing confirmed the presence of insert with correct orientation and 
confirmed 100% sequence identity with the published Human GATA-1 mRNA sequence 
(NM_002049). This not only confirmed the correct sequence in the vectors but also 
revealed that the source of the template DNA - K562 cells (derived from a patient with 
chronic myeloid leukaemia) did not carry any mutations in the GATA-1 coding sequence.  
The Human GATA-1 plasmids expressed GATA-1 at the mRNA level following 
transfection into HEK293 cells, as shown in fig 5.1a. However GATA-1 protein expression 
was not detectable by western blotting, despite multiple attempts (fig 5.1b). In addition, a 
luciferase reporter assay (described in detail in section 5.2.4.3) showed appropriate 
transactivation with the GATA-1s construct (2-3 fold induction of luciferase expression), Results Chapter  5    223 
but failed to show enhanced transactivation with the full-length construct (fig 5.1c) despite 
adequate transactivation by murine GATA-1FL (described in 5.2.4.3). A number of 
attempts were made at recloning the GATA-1FL vector including subcloning it into an 
alternative expression vector pcDNA3.1V5HisTOPO (Invitrogen), adding a Kozak 
sequence (Kozak 1986b) to the FL GATA-1 upstream of the first ATG and using 
alternative template cDNA. However GATA-1 luciferase reporter assays continued to 
show only low level transactivation by the products from these plasmids (Fig 5.1c).  
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Fig 5.1 Assessment of Human GATA-1 expression plasmids 
(a) The human GATA-1 plasmids produce GATA-1 mRNA as shown by RT-PCR using exon 1 
and 6 primers which produce a 1107bp product with GATA-1FL and an 813bp product with 
GATA-1s (arrowed) (b) western blotting with the M20 antibody does not reveal a GATA-1 
protein band despite GATA-1FL(47kDa) and GATA-1s (40kDa) bands in the positive control 
(K562) (c) a luciferase assay shows only modest transactivation of the reporter plasmid with 
equivalent levels in the human GATA-1FL and GATA-1s pEF6 plasmids (lanes 4 and 5). The 
GATA-1FL construct was recloned into a pcDNA3.1 vector but with no improvement in 
transactivation efficiency (lane 3). Levels of transactivation were equivalent to that seen 
with murine GATA-1s (lane 2) but well below murine GATA-1WT (lane 1). Results Chapter  5    224 
It was decided not to pursue these vectors further. Instead murine GATA-1 isoform 
expressing plasmids were used for in vitro cellular differentiation studies in the human cell 
lines K562 and Meg-01. Although this species difference might theoretically interfere with 
interactions with GATA-1 cofactors and other transcriptional machinery in the cell, 
GATA-1 is known to be highly conserved between humans and mice. There is published 
work showing that expression of a murine GATA-1FL construct in a human 
haematopoietic cell line can produce terminal erythroid differentiation (Xu, et al 2003). 
The use of murine vectors does have potential advantages, particularly the ability to 
separately track exogenous vector derived GATA-1 (murine) from endogenous GATA-1 
(human), and potentially the ability to use siRNA technology to knock–down human 
GATA-1 expression whilst leaving GATA-1 isoform expression from the murine transgene 
intact (as discussed in section 5.5.6 below). 
5.2.2 Murine GATA-1 expression vectors 
Since both GATA-1s and GATA-1FL can be transcribed from a single mRNA in mice it 
was necessary to modify this transcript to produce exclusive GATA-1FL expression. Fig 
5.2 illustrates the design of these isoform specific transcripts. GATA-1s was produced by 
amplifying up murine GATA-1 cDNA starting just upstream of the exon 3 start codon 
(position 84), and therefore only allowing expression of the short transcript. In order to 
produce a vector capable of exclusive GATA-1FL expression an exon 2 forward primer 
was used, it was necessary to mutate the second start codon and therefore abolish initiation 
of translation at codon 84. The reverse primers annealed downstream of the exon 6 stop 
codon. All sequences are listed in tables 2.5 and 2.6. 
5.2.3 Construction of pcDNAGATA-1FL, pcDNAGATA-1s and 
pcDNAGATA-1WT 
An N-terminal FLAG tagged murine GATA-1 cDNA (BFT4GATA-1) (kind gift from Prof 
Tariq Enver, Weatherall Institute of Molecular Medicine, Oxford) was used as the template 
DNA. The FLAG tag, a short hydrophilic 8-amino acid peptide (Asp-Tyr-Lys-Asp-Asp-
Asp-Asp-Lys), used to efficiently detect protein expression by the use of high affinity anti-
FLAG antibodies, was excluded from the final product as its N-terminal location could 
potentially interfere with the functional capabilities of this region of the molecule. Primers 
to amplify up the FL and short constructs are listed in table 2.5, chapter 2, and illustrated in 
Fig 5.2. PCR products were run on a 1% agarose gel, bands were excised and gel purified Results Chapter  5    225 
and then TOPO cloned into the pCDNA3.1V5HisTOPO expression vector (Invitrogen) (fig 
5.3a). Following restriction enzyme digestion to check for the presence of insert in the 
correct orientation, 2 promising clones (1 GATA-1WT (wild-type i.e. containing both start 
codons), 1 GATA-1s) were sent for sequencing (Technology services, Beatson Institute, 
Glasgow). 100% sequence identity with the published GATA-1 mRNA sequence (NM-
008089) was confirmed for both clones. 
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Fig 5.2 Creation of GATA-1 isoform specific products 
Arrows represent the position of GATA-1WT/FL primers (red arrows) and GATA-1s primers 
(green arrows). The GATA-1WT transcript underwent site-directed mutagenesis of the 
second ATG codon (red cross, ATG to ACA) to produce an exclusive GATA-1FL transcript. 
 
The GATA-1WT clone was then used for site-directed mutagenesis of the second ATG 
start codon to produce the GATA-1FL vector. This involved a two base pair change in 
codon 84 from ATG (methionine) to ACA (threonine). This amino-acid change was 
suggested to be optimal by commercial site-directed mutagenesis software 
(www.labtools.stratagene.com). Forward and reverse primer sequences are listed in Table 
2.6. Site-directed mutagenesis was performed using a QuikChangeII commercial kit, as 
described in chapter 2 section 2.12.1.3. Successful introduction of the mutation was again 
confirmed by sequencing. Results Chapter  5    226 
These vectors express the aminoglycoside phosphotransferase gene (neomycin resistance 
gene) under the control of the viral SV40 promoter which enables selection of stable 
transfectants by treatment of cells with the aminoglycoside antibiotic G418 (Geneticin). 
5.2.4 Validation of pcDNAGATA-1 expression vectors 
5.2.4.1   Expression at the mRNA level 
These vectors were then tested for GATA-1mRNA expression by transient transfection 
into a cell line that does not normally express GATA-1 (HEK 293). Cells were seeded at a 
density of 4x10
5/ml in 10 cm plates the day prior to transfection. Transfection was carried 
out using 2μg of plasmid DNA and the commercial transfection reagent Effectene (Qiagen) 
as described in section 2.12.3.3, chapter 2. Cells were harvested after 48 hours and RNA 
extracted using Trizol reagent (as described in section 2.8.1.1, chapter 2). Following 
DNase treatment (section 2.8.2), cDNA was made from the isolated RNA using a 
commercial kit (Superscript II, Invitrogen) as described in section 2.8.4, control reactions, 
excluding the reverse transcriptase (minus RT) were run for all samples. 2.5μl of template 
DNA was used in a standard RT-PCR reaction using GATA-1 forward and reverse primers 
(table 2.4) which produce a product 279bp in size with amplification of cDNA (1937bp for 
genomic DNA). Results of this PCR are shown in fig 5.3b and confirm good levels of 
GATA-1 expression from all constructs with no evidence of expression in the minus RT 
controls (confirming results are not due to contaminating plasmid DNA).  
5.2.4.2   Expression at the protein level 
Having confirmed expression at the mRNA level, expression at the protein level was 
assessed.  Fig 5.3c shows a western blot, using M20 antibody, of nuclear extracts made 48 
hours after a second transient transfection experiment using HEK293 cells (this time 
transfected using a nucleoporation protocol described in section 2.12.3.4). This experiment 
confirmed exclusive GATA-1FL expression (47kDa upper band) from the pcDNAGATA-
1FL plasmid and exclusive GATA-1s expression (40kDa lower band) from the 
pcDNAGATA-1s plasmid.  
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Fig 5.3 Construction and expression from pcDNA vectors 
(a) Vector maps for pcDNAGATA-1WT, pcDNAGATA-1s and pcDNAGATA-1FL. Positions of 
start codons (ATG) are shown in boxes with codon positions (1 for FL and 84 for short) in 
brackets.  (b) RT-PCR confirms expression of GATA-1 at the mRNA level, the primers 
produce a 279bp GATA-1 product (purple arrow), and lack of amplification from the vector is 
shown by absence of bands in the minus RT control lanes. (c) Western blotting confirms 
isoform specific GATA-1 protein production from the GATA-1FL plasmid, lane 1 (47kDa 
GATA-1FL protein detected, purple arrow) and the GATA-1s plasmid, lane 2 (40kDa GATA-1s 
protein, blue arrow) after transient transfection in HEK293 cells. Results Chapter  5    228 
5.2.4.3   Production of functional protein 
Finally, it was necessary to demonstrate that the proteins produced by the vector were 
functional and that the single amino-acid change at position 84 in the GATA-1FL 
expression plasmid did not alter GATA-1FL activity. To address this, a GATA-1 reporter 
plasmid (pGL3hGATA-1) was used (kind gift from Dr Paresh Vyas, Weatherall Institute 
of Molecular Medicine, Oxford). This plasmid was constructed with a number of GATA-1 
binding sites upstream of a minimal promoter driving a Firefly luciferase reporter gene. 
Binding of GATA-1 to these upstream sequences should transactivate reporter gene 
expression. The Firefly luciferase gene takes part in a bioluminescent reaction catalysing 
the conversion of luciferin to oxyluciferin plus light. Light emission is proportional to the 
level of gene expression. Therefore, the level of luciferase gene expression can be assayed 
on a luminometer by measuring light production on addition of a commercial luciferin 
containing substrate as described in section 2.13.1, chapter 2.  
Before assessment of luciferase transactivation could be made a number of parameters 
needed optimisation. In particular it was necessary to have a method for normalising for 
transfection efficiency to ensure that differing levels of light production did not merely 
reflect different levels of reporter and test plasmids within the cells. This necessitated co-
transfection of a third plasmid encoding a β-galactosidase gene (pSVβ-gal). Luminescence 
results were then normalised to β-galactosidase activity. A number of optimisation 
experiments were performed: 
1. To assess the optimum quantity and ratio of the three co-transfected plasmids ensuring 
that both luciferase and β-galactosidase reading remained within the linear range of their 
respective assays. Firstly, NIH3T3 cells seeded on 10cm plates were transfected with 
varying amounts of β-galactosidase vector (pSVβ-gal) (from 100ng to 1μg) and 1μg of a 
pGL3 control luciferase vector (pGL3Luc) (with constitutive luciferase expression). 100ng 
of β-galactosidase vector produced inconsistent results but amounts between 200ng and 
1μg were able to consistently normalise light intensity measurements (data not shown). β-
galactosidase standard curves (produced by serial dilution of a commercially provided β-
galactosidase standard) were run with all assays to ensure measured levels of absorbance 
were within the linear range of the assay as described in section 2.12.4.1. A typical 
standard curve is illustrated in Fig 5.4a. Using a similar approach, co-transfection of 
differing amounts of reporter plasmid (pGL3hGATA-1) or test plasmids (pcDNAGATA-
1FL) showed that maximal induction of luminescence could be achieved by using 4μg of 
test plasmid and 2μg of reporter plasmid. Results Chapter  5    229 
2. To optimise transfection reagent conditions. Using a 4:2:1 ratio of test plasmid: reporter 
plasmid: β-galactosidase plasmid, established above, the optimal transfection protocol was 
then assessed. Fugene 6 was used in ratios from 1:1, 3:1, 3:2 and 4:1. A ratio of 4:1 
produced the best transfection efficiencies (data not shown). This was used for all 
subsequent experiments 
3. Finally, reporter assay performance was tested into two different cell lines– HEK293 
and NIH3T3. Transfection into NIH3T3 cells produced good levels of luminescence (data 
shown below) but HEK293 cells were completely unable to sustain reporter gene activity 
(data not shown) despite good levels of protein expression by western blot (as shown in fig 
5.3c above). This presumably reflects lack of essential co-factors for reporter gene 
transactivation in this cell type. Following this result all assays were carried out in NIH3T3 
cells. 
Following these optimisation experiments co-transfection into NIH3T3 cells of the three 
plasmids: pcDNAGATA-1FL, GATA-1s or wild-type (WT) (test plasmids), 
pGL3hGATA-1 (reporter plasmid) and pSVβ-gal (normalisation plasmid), was performed 
in triplicate. For each set of experiments untransfected cells were also assayed to control 
for background levels of luminescence and β-galactosidase activity, background expression 
from the pGL3hGATA-1 reporter plasmid was also assayed, and a positive control plasmid 
(pGL3Luc) was run to verify luminescence readings. Cells were harvested at 48-72 hours 
and cell lysates prepared using a commercial cell lysis buffer (reporter lysis buffer, 
Promega) as described in section 2.12.4.1. 30μl of cell lysate was used for the β-
galactosidase assay (section 2.12.4.1) and 30μl for the luciferase assay (section 2.13.1).  
Results were initially corrected for background fluorescence (which was negligible) and 
background  β-galactosidase activity, and then normalised to β-galactosidase activity as 
follows:  
(luminometer reading  – background luminescence reading in untransfected cells) 
(β-galactosidase absorbance reading – background absorbance in untransfected cells). 
 
 
Results were expressed as fold induction of luminescence (over levels obtained with the 
pGL3hGATA-1 reporter plasmid in the absence of test plasmid, arbitrarily set at 1.0) and 
are shown in Fig 5.4b. As can be seen in the figure both FL and wild-type GATA-1 vectors 
produce about a 20-fold induction of luminescence and the GATA-1s construct produces 
about a 5-fold induction over reporter alone. The difference between FL and wild-type 
levels is not statistically significant meaning that the mutation of the second ATG codon Results Chapter  5    230 
did not produce a significant alteration in GATA-1 function as measured by this reporter 
assay. The difference between GATA-1s and GATA-1FL induction of reporter activity is 
consistent with published reports, and led to the original concept that the N-terminus was 
an important transactivation domain (Calligaris, et al 1995, Martin and Orkin 1990, 
Wechsler, et al 2002).  
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Fig 5.4 Luciferase assay of GATA-1 transactivation potential 
(a) Representative β-galactosidase assay standard curve, brackets indicate range of values 
within the linear range of assay, any samples outwith this range were excluded  (b) the 
GATA-1FL and GATA-1WT vectors produce high, and equivalent, levels of transactivation 
from the reporter plasmid, GATA-1s produces lower level transactivation (n=3) 
 
These studies confirm that the murine GATA-1FL and GATA-1s expression vectors 
produce the expected functional protein products and that the introduction of a point 
mutation does not significantly alter GATA-1FL activity.  Results Chapter  5    231 
5.2.5 Design of additional expression vectors 
5.2.5.1   EFIα vectors 
The pcDNA3.1 expression vector uses a CMV promoter to drive expression of the cloned 
insert in mammalian cells. This promoter is well established as suitable for expression of 
transgenes in a wide variety of cell lines, hence its choice for initial validation experiments 
and use in ES cell transfection (described in section 5.3 below). However, there are a 
number of reports of very poor expression levels using this promoter to drive transgene 
expression in haematopoietic primary cells and cell lines (Rodriguez, et al 2002, Salmon, 
et al 2000). Much better levels of expression are generally seen when using the human 
Elongation Factor 1α (EFIα) promoter which shows strong activity in human and murine 
cell lines (Goldman, et al 1996, Mizushima and Nagata 1990, Woods 2001). Therefore, to 
facilitate assessment of GATA-1 isoform expression in human haematopoietic cell lines, 
the GATA-1FL and short isoform cDNA sequences were amplified by standard PCR 
(using original BFT4 forward and reverse primers listed in table 2.5) from the pcDNA3.1 
vectors and TOPO cloned into the alternative pEF6V5HisTOPO expression vector 
(Invitrogen) shown in fig 5.5a. Colonies were picked and the presence of insert and its 
orientation were assessed by restriction enzyme digestion (data not shown). Clones 
producing the correct restriction enzyme digest pattern were re-sequenced (Agowa.de) and 
these confirmed that no mutations had been introduced during the PCR process. 
Expression was confirmed by western blotting of nuclear extracts from transient 
transfection in HEK293 cells, using the M20 antibody (Fig 5.5b). 
As shown in fig 5.5a, the pEF6α vector expresses a resistance gene for the nucleoside 
antibiotic Blasticidin (Invitrogen) rather than G418. This necessitated determination of the 
minimal concentration of this antibiotic needed to kill the untransfected host cell line prior 
to its use in stable transfectants. This procedure is described in 2.12.3.1. For K562 cells a 
Blasticidin concentration of 10μg/ml was required, for Meg-01 8μg/ml and for E14 ES 
cells 5μg/ml.   Results Chapter  5    232 
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Fig 5.5 Cloning into the pEF6 expression vector and addition of IRES-GFP  
(a) vector map of pEF6GATA-1WT, note the EF1a promoter and Blasticidin resistance gene 
and the position of a NotI site downstream of the TOPO cloning site (b) Western blotting 
confirms isoform specific GATA-1 protein production from the GATA-1FL plasmid (47kDa 
GATA-1FL protein detected, purple arrow) and the GATA-1s plasmid (40kDa GATA-1s 
protein, blue arrow) (c) Ligation of an IRES-GFP construct into the pEF6 vectors using Not1 
sticky ended ligation to produce pEF6GATA-1FL IRES-GFP and pEF6GATA-1s IRES-GFP 
(not shown)  Results Chapter  5    233 
5.2.5.2   IRES-GFP vectors 
The expression of some proteins in transfected cells can easily be assessed using western 
blotting, in situ hybridisation or flow cytometry. Unfortunately GATA-1 protein 
expression proved difficult to detect, requiring a nuclear extraction protocol and relatively 
large scale cell extracts (as described in section 3.1.2.1, chapter 3). To enable easier 
tracking and sorting of cells that had taken up the expression vector it was decided to add a 
green fluorescent protein (GFP) tag. GFP fluoresces green when exposed to blue light and 
this can be detected using the FL1 (FITC)  laser channel in flow cytometers or a FITC 
filter set for fluorescent microscopy, allowing easy and rapid identification of transfected 
cells.  Since the functions of the N- and C-termini were being evaluated it was decided not 
to directly fuse the GFP tag to the GATA-1 mRNA but instead introduce an internal 
ribosome entry site (IRES) sequence into the mRNA allowing formation of a bicistronic 
transcript capable of expressing both the intact GATA-1 protein and GFP (Mizuguchi, et al 
2000, Mountford and Smith 1995). This sequence was subcloned from an IRES-GFP 
expression vector available in the laboratory (kind gift from Dr D Gilchrist, Division of 
Immunology, Infection and Inflammation, Glasgow University) whose IRES-GFP 
sequence was flanked by NotI sites. The pEF6α vector also has a NotI site 3’ to the TOPO 
cloning site allowing insertion of the IRES sequence at this point as shown in Fig 5.5c. 
NotI restriction enzyme digestion of both the EF1α vectors (pEF6GATA-1FL and 
pEF6GATA-1s) and the IRES-GFP insert was performed. Products were gel-purified, the 
vector backbone was dephosphorylated (as described in section 2.12.1.2) to prevent 
religation and then the products were used in a standard ligation reaction (2.12.1.2). After 
colony picking, overnight culture and minipreps the presence of the insert was assessed 
using a NotI digest of plasmid DNA. 10/12 colonies for each isoform contained an insert. 
A KpnI digest was then performed to assess orientation and 3/10 GATA1FL colonies and 
5/10 GATA-1s colonies had incorporated the insert in the correct orientation. One of each 
of these was ‘maxi-prepped’ using an endotoxin-free commercial kit for use in stable 
transfections; the vector could be linearised prior to stable transfection using a ScaI 
restriction enzyme site which cuts within the ampicillin resistance gene. 
An empty vector control containing the IRES-GFP sequence but no upstream GATA-1 
cDNA was also constructed as a negative control for transfection experiments. This was 
achieved by removal of the GATA-1s insert from pEF6GATA-1s using the BstXI 
restriction enzyme. This enzyme cuts at the sequence CCANNNNN/NTGG and therefore 
does not usually produce compatible sticky ends. To allow religation, the ends were Results Chapter  5    234 
blunted (as described in 2.12.1.2.1) prior to use in a standard DNA ligation reaction. 
Following picking of colonies and screening with NcoI and PvuII digests 2/24 clones were 
found to have successfully excised the GATA-1s insert and religated. One of these was 
then digested with NotI and ligated with the NotI IRES-GFP insert in the same way as 
described for the pEF6GATA-1 vectors above. Again successful introduction of the IRES-
GFP insert was confirmed with a KpnI digest which showed that 9/12 colonies had 
incorporated the insert in the correct orientation.  
Expression of detectable GFP from these constructs was assessed following stable 
transfection into the haematopoietic cell lines K562 and Meg-01 (described in section 5.4.1 
below). Flow cytometry was performed as described in section 2.13.2 - results are shown 
in fig 5.6a. Confocal microscopy images using nuclear counterstaining with DAPI 
(performed as described in section 2.13.6) are shown in 5.6b. Both these analyses produced 
similar findings i.e. the majority of cells expressed GFP but the level of expression varied 
considerably from cell to cell. This is discussed further in section 5.4.1. 
(b)
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Fig 5.6 Expression of GFP in transfected cell lines 
(a) Representative FACS plots showing heterogeneous levels of GFP expression (b) 
confocal microscopy confirms GFP expression (green signal) by transfected K562 cells, 
nuclei are counterstained with DAPI (blue signal). Results Chapter  5    235 
In summary, this section describes the construction and validation of GATA-1 isoform 
specific expression vectors. Although human GATA-1FL and GATA-1s transcripts were 
easily amplifiable using RT-PCR, and subsequent cloning into vectors appeared 
successful (as judged by GATA-1 isoform mRNA expression with no errors on 
sequencing), it was impossible to demonstrate production of appropriately functioning 
human GATA-1 protein. Therefore murine vectors were pursued instead. 3 sets of 
murine vectors were produced using the CMV promoter (pcDNA3.1 vectors) or the 
EF1α promoter with or without an IRES-GFP tag (pEF6 and pEF6-IRESGFP 
respectively). These vectors produced functional GATA-1 protein and the introduction of 
a point mutation at the second ATG did not significantly affect GATA-1FL function 
compared to wild-type GATA-1. The utility of the IRES-GFP tag in identifying 
transfected cells was demonstrated and a negative control plasmid, containing all the 
vector elements including the IRES-GFP cassette but without GATA-1 (empty vector 
control), was constructed. The use of these vectors to assess GATA-1 isoform function is 
described in the following sections, starting with murine ES cells followed by use in 
human haematopoietic cell lines. 
5.3 Expression of GATA-1 isoforms in murine ES cells 
Having constructed and validated the pcDNA3.1GATA-1FL and GATA-1s expression 
vectors, as described in section 5.2.3 above, these vectors were then linearised (using the 
ScaI restriction enzyme) and stably transfected into murine ES cells using Fugene 6 
transfection reagent (see section 2.12.3.2). Cells were placed in selective media (G418 
175μg/ml) at 24 hours post-transfection and media was changed daily. After 12 days 
colonies were sufficiently large to allow picking. 24 single colonies were picked per 
construct, as described in section 2.14.3. After growth in 24-well plates, 6 healthy looking, 
undifferentiated, colonies per construct were transferred to 6-well plates for expansion. 
These colonies were expanded up to 75cm
2 flasks and then harvested. Cell pellets were 
divided into three aliquots, 1/3 being used for RNA extraction (stored in Trizol reagent), 
1/3 for protein extraction and 1/3 were frozen down and stored in liquid nitrogen for later 
use.  
5.3.1 Detection of GATA-1 expression 
Following RNA extraction (as described in section 2.8.1.1) and reverse transcription into 
cDNA using Superscript II (section 2.8.4) expression of GATA-1 at the mRNA level was Results Chapter  5    236 
assessed by PCR. As shown in fig 5.7a GATA-1 expression was detectable in all clones 
but not the minus RT controls, confirming expression from the vector (note 
undifferentiated ES cells, such as these, do not show detectable endogenous GATA-1 
expression as shown in Chapter 3 fig 3.12a). As might be expected with picking of 
individual colonies rather than pooled clones, the level of GATA-1 expression appears 
quite variable by standard (non-quantitative) PCR.  
Expression at the protein level was not seen despite good positive control bands (K562) 
and loading controls (data not shown). As described in section 5.2.4.2 above, these same 
vectors were known to produce GATA-1 protein in other cell lines (fig 5.3c). Several 
possibilities exist to explain this lack of detectable expression in ES cells: (i) There could 
be low level protein production below the limits of detection of Western blotting with these 
GATA-1 antibodies (ii) there could have been technical problems with the vector or these 
particular transfected clones (iii) there could be post-transcriptional control of GATA-1 
mRNA in ES cells (possibly by microRNAs or other mechanisms), preventing translation 
into protein. Of note, haematopoietic precursor cells are known to express multiple lineage 
specific genes at the mRNA level but not necessarily translate these into protein until a 
decision has been made to terminally differentiate (Hu, et al 1997).  
To test these possibilities several approaches were taken: 
1. Nuclear extracts were made from a further batch of stable transfectants and the resulting 
antibody binding to western blot membranes was detected using an ultra sensitive 
chemoluminescent reaction (Supersignal West Femto). No expression was seen (data not 
shown). 
2. To see if sensitivity could be improved by surrogate detection of GATA-1 expression 
using anti-His antibodies (table 2.13), site directed mutagenesis of the GATA-1 stop codon 
in the pcDNA3.1GATA-1FL plasmid was performed (as described in section 2.12.1.3, 
using primers listed in table 2.6). Primers were designed to delete the initial base of the 
TGA stop codon. This not only prevents termination of translation at this point but also 
produces a frameshift to allow run through translation to an in-frame His tag. This is 
illustrated in fig 5.7b. Despite adequate detection of a control His tagged protein (D6-His, 
available in the lab), no GATA-1His band was seen when this pCDNA3.1GATA-1His 
plasmid was stably transfected into ES cells (fig 5.7c).  Results Chapter  5    237 
3. To test whether lack of protein expression in the stable transfectants was due to 
transcriptional silencing of the integrated plasmid DNA, transient transfections were 
carried out to see if higher levels of expression could be achieved, resulting in detectable 
protein expression. These transient transfections were performed using the pEF6GATA-
1FLIRES-GFP and pEF6GATA-1sIRES-GFP plasmids (section 5.2.5.2 above) to allow 
detection of GFP as well as GATA-1 expression in the transfected cells. Good levels of 
GFP expression from these vectors had previously been demonstrated in K562 and Meg-01 
cells as shown in fig 5.6a. No detectable GFP expression (by FACS) from these vectors 
could be seen in ES cells despite reasonable transfection efficiency as shown by a control 
transfection with a GFP expressing plasmid (pMaxGFP). Western blotting on nuclear 
extracts from these cells confirmed no GATA-1 expression at the protein level (data not 
shown). 
As already described in Chapter 3, section 3.2.7 there is evidence that endogenous GATA-
1 production in ES cells is controlled at the post-transcriptional level. Fig 3.12 (chapter 3) 
shows good expression at the mRNA level (by RT-PCR) from day 3 of haematopoietic 
differentiation onwards, but no detectable protein production at day 6 (when mRNA levels 
appear highest).  
Overall, these results suggest that exogenously introduced GATA-1 is transcribed into 
mRNA but protein production is either low-level and therefore undetectable by western 
blotting, or the mRNA is subject to post-transcriptional control in ES cells (or both). 
Despite this, there is strong evidence that these GATA-1 isoform expression vectors 
produce functional effects in ES cells as shown in the next section. 
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Fig 5.7 Detection of transgene expression in murine ES cells 
(a) detection of GATA-1mRNA expression in ES cells by RT-PCR using exon 4 and 5 
primers. The arrow shows the expected size of the 279bp GATA-1 product (b) site-directed 
mutagenesis of the pcDNAGATA-1FL plasmid to produce an in-frame His tag (c) western 
blotting reveals no detectable His protein from stably transfected ES cells despite good 
detection of another His tagged protein (D6-His) using the same antibody. Results Chapter  5    239 
5.3.2 Effects of GATA-1 isoform expression vectors on 
haematopoietic differentiation of ES cells 
Despite low or absent protein expression from the vectors in undifferentiated ES cells, it is 
possible that protein production is switched on during haematopoietic differentiation and 
therefore it was decided to proceed to in vitro haematopoietic differentiation assays (note 
these vectors have previously been validated and are capable of producing functional 
protein as described in section 5.2.4 above). In order to assess whether the two GATA-1 
isoforms produced differential effects on haematopoietic colony formation three stably 
transfected ES cell clones per isoform were used in methylcellulose assays. These assays 
involve plating cells in semi-solid media (methylcellulose) in the presence of growth 
factors and cytokines (Erythropoietin, Interleukin 3 and insulin), and in the absence of LIF. 
Under these conditions ES cells will produce haematopoietic colonies, primarily erythroid 
(BFU-E) and granulocyte/macrophage (CFU-GM). These colonies can be recognised by 
characteristic morphology as shown in fig 5.8a. The assay was performed, in triplicate, as 
described in section 2.14.2.2 and colonies were counted after 12 days. Fig 5.8b shows the 
number of colonies produced from the GATA-1FL and GATA-1s stable transfectants 
compared to untransfected E14 cells. As can be seen from this figure, clones transfected 
with the GATA-1FL construct produce a statistically significant increase in erythroid 
colony formation over both GATA-1s and untransfected ES cells. In addition there is a 
statistically significant decrease in both erythroid and non-erythroid (mainly CFU-GM) 
colony formation in GATA-1s transfected clones compared to both GATA-1FL and 
untransfected ES cells. These quantitative differences were also supported by qualitative 
differences: GATA-1FL BFU-E colonies were large and very deep pink or red due to 
haemoglobin production, whilst GATA-1s colonies were small, dispersed and pale pink 
(data not shown). 
In summary, experiments looking at GATA-1 isoform expression in murine ES cells 
show good levels of mRNA production from the GATA-1 introduced transgene but 
undetectable protein expression. Despite this, these transgenes produced functional 
effects when stably transfected into ES cells. Haematopoietic colony forming assays 
showed a significant induction of erythroid colony formation in GATA-1FL expressing 
clones, and a significant reduction in both erythroid and non-erythroid colony formation 
in GATA-1s expressing clones. This suggests GATA-1FL expression can accelerate 
erythroid development in this assay but that GATA-1s expression may produce a 
dominant negative effect preventing normal haematopoietic colony formation. Results Chapter  5    240 
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Fig 5.8 Effects of GATA-1 isoform expression on in vitro differentiation of 
murine ES cells 
(a) shows typical BFU-E and CFU-GM colonies produced by in vitro differentiation of ES 
cells in methylcellulose. BFU-E colonies tends to consist of small dense cells which are 
relatively scattered, without a dense core, they may appear pink/red due to haemoglobin 
production. GFU-GM are larger colonies with  a dense core, individual cells are larger than 
BFU-E cells (photos courtesy of StemCell Technologies) (b) results of BFU-E and CFU-GM 
colony counts 10-14 days after ES cell in vitro haematopoietic differentiation (n=3). Wild-
type refers to untransfected E14 cells, Full–length = GATA-1FL transgenic ES cells, Short = 
GATA-1s transgenic ES cells 
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5.4 Expression of GATA-1 isoforms in K562 and Meg-01 
cells – creation of transgenic lines and study of 
baseline characteristics 
The next step was to investigate the effects of GATA-1 isoform expression in human cell 
lines. Cell lines K562 and Meg-01 were both derived from patients with chronic myeloid 
leukaemia in blast crisis. Both cell lines are capable of differentiation along the 
megakaryocytic and erythroid lineages in vitro in response to inducing agents (Alitalo 
1990, Lozzio and Lozzio 1979, Morle, et al 1992, Ogura, et al 1988).  As previously 
mentioned, K562 is disomic for chromosome 21 whilst Meg-01 is trisomic. It should be 
noted that their derivation from CML blast crisis makes them potentially genetically 
unstable and that numerical differences in copies of chromosome 21 are not the only 
cytogenetic differences between the two cell lines. This makes attributing any differences 
in the biological behaviour of the two cell lines to differences in chromosome 21 number 
difficult. However, comparisons between these two cell lines provide the opportunity to 
uncover biological properties of the GATA-1s isoform only seen in the presence of trisomy 
21, as suggested by the absence of leukaemic or pre-leukaemic phenotypes in mice (Li, et 
al 2005) and humans (Hollanda, et al 2006) carrying GATA-1s producing mutations 
without additional trisomy 21 (discussed in section 1.2.8). In addition, possible 
contributions of specific chromosome 21 genes to any observed differences could be 
formally tested by gene knockdown in Meg-01 cells or over-expression in K562 cells to 
see if this restores normal cell behaviour or reproduces the aberrant phenotype. Overall, 
these features make use of these two cell lines an attractive model for studying the effects 
of GATA-1 isoform expression on haematopoiesis. 
5.4.1 Stable transfection  
K562 and Meg-01 cells were stably transfected with pEF6GATA-1FL IRES-GFP, 
pEF6GATA-1s IRES-GFP or pEF6empty IRES-GFP vectors (after linearization with ScaI) 
using nucleoporation (as described in section 2.12.3.4, Chapter 2). After 24 hours cells 
were placed in Blasticidin containing selection media and media was changed every 48 
hours. After 1 week all cells on the control (untransfected) plate had died. An initial 
assessment of levels of expression from the transgene was made by FACS analysis looking 
for GFP expression from the IRES-GFP cassette (performed as described in section 
2.13.2). Good levels of GFP expression were seen (as already shown in Fig 5.6a and 
reproduced here in Fig 5.9a), with a wide range of expression from low to high levels in  Results Chapter  5    242 
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Fig 5.9 Stable expression of GATA-1 isoforms in K562 and Meg-01 cells 
(a) FACS histogram of GFP expression soon after stable transfection showing a spectrum of 
GFP expression levels. Cells in the marked region were sorted (section 5.4.2) for later use 
(b) western blotting shows expression of FL and short isoforms in all cells with evidence of 
increased expression from the transgenic GATA-1 plasmid particularly evident for K562 
GATA-1FL (as shown by N6 blot which only picks up murine GATA-1FL) and Meg-01 GATA-
1s (M20 blot) (c) this western blot data is mirrored by spontaneous selection of cells for 
different levels of transgene expression on continuous culture. After 6 weeks in selection 
Meg-01 cells show high level GATA-1s expression whilst K562 show high level GATA-1FL. Results Chapter  5    243 
individual cells. Western blotting confirms expression at the protein level as shown in Fig 
5.9b – transgenic murine GATA-1FL expression can be confirmed since only the murine 
protein is detected by the N6 antibody. Expression of the GATA-1s transcript is inferred 
by the greater intensity of this band in the GATA-1s cell line compared to empty vector. 
GATA-1FL appears to be most strongly expressed in K562 (as seen on N6 lower blot) and 
GATA-1s appears to be most strongly expressed in Meg-01 cells (M20 upper blot). This is 
consistent with GFP expression data discussed below. 
5.4.2  Selection for high transgene expression 
To try and maximise biological effects of isoform over-expression it was decided to try and 
pick out high transgene expressers from amongst these pools of cells with variable levels 
of expression. High GFP expressers were cell sorted as described in section 2.12.5. 2x10
5 
K562 GATA-1FL, GATA-1s and empty vector containing cells with levels of GFP 
expression ≥10
2 in the FL1 (GFP) channel (population shown in fig 5.9a) were sorted and 
resuspended in 2ml culture medium in a 6 well plate. However with Meg-01 stable 
transfectants, despite initial sorting of 2x10
5 cells, with no apparent technical difficulties, 
these cells did not survive in culture. Microscopic examination of these cells revealed 
prominent apoptosis. The sorting procedure was repeated with fresh stocks of Meg-01 
transfectants with the same results. The empty vector control was affected by this process 
as much as the GATA-1s and GATA-1FL transfectants. This argues against cell death 
being due to high level expression of the GATA-1 transgene. It is most likely that Meg-01 
cells, by virtue of their large size and megakaryocytic properties, may be intolerant of the 
sorting process. Another possibility is that high level GFP expression (rather than GATA-
1) is toxic to Meg-01 cells; this has been reported in other cell lines (Liu, et al 1999, 
Misteli and Spector 1997). 
5.4.3    Spontaneous selection for isoform-specific transgene 
expression on continued cell culture 
Following these sorting experiments K562 high expressers and Meg-01 pools were 
maintained in selective media for several cell passages. Prior to their use in in vitro 
differentiation experiments (described in section 5.5 below), GFP expression was 
reassessed by FACS analysis. Interestingly, as shown in fig 5.9c, the cells had 
spontaneously segregated themselves according to the expressed transgene i.e. in Meg-01 
cells there was no longer a spectrum of GFP expression as shown in fig 5.9a, instead cells Results Chapter  5    244 
carrying the GATA-1FL transgene had spontaneously selected for low levels of transgene 
expression, whilst cells carrying the GATA-1s transgene had spontaneously selected for 
high level expression. The empty vector showed intermediate to low level expression. The 
K562 cells showed opposite effects i.e. despite, in this case, the sorting of these 
populations for high level GFP expression, GATA-1FL transfectants had maintained high 
level expression but GATA-1s transgenic cells has down-regulated expression with empty 
vector remaining at intermediate levels. The down-regulation of introduced transgenes 
with continued cell culture (despite maintenance in selective medium) is a well recognised 
phenomenon (Pikaart, et al 1998, Recillas-Targa 2006) and may explain the low-
intermediate levels of the empty vector transgene. However the maintenance/selection for 
high levels or particularly low levels of expression suggests that the GATA-1 isoforms are 
having selective effects on cell growth or survival, which differ in the two cell lines. This 
may be due to effects on cell proliferation or prevention or induction of terminal 
differentiation i.e. 
1. High GATA-1s expression appears to have a selective advantage in Meg-01 cells 
(trisomy 21) but not K562 (disomy 21). It may be that GATA-1s is able to promote 
survival/proliferation of immature megakaryocytic precursors in Meg-01 cells and prevent 
terminal differentiation. Since this same phenomenon is not seen in K562 cells, it is 
tempting to speculate that the presence of trisomy 21 unmasks this potential, but this is 
unproven. 
2. High GATA-1FL expression appears to be advantageous in K562 cells whereas GATA-
1s expression appears to cause a growth or survival disadvantage. K562 cells are less 
committed than Meg-01 cells and the expression of GATA-1FL in these cells may promote 
cell expansion and initial commitment to meg-erythroid lineages. By analogy with the ES 
cell methylcellulose assay (described in section 5.3.2) high levels of GATA-1FL could 
promote progenitor expansion whilst high levels of GATA-1s isoform expression could 
have a dominant negative effect. This would lead to selection for high level GATA-1FL 
and low level GATA-1s expressers when K562 cells were maintained in culture. 
5.4.4 Methods of evaluation of baseline characteristics 
In order to explore these phenomena further and establish baseline characteristics of the 
transgenic cell lines, prior to their use in in vitro differentiation experiments (described in 
section 5.5), a number of experiments were performed: Results Chapter  5    245 
1. Measurement of cell growth rates in the presence of the different GATA-1 isoforms 
2. Examination of maturation status of the transfected cells under steady state conditions 
using:  
(i) cytospins to assess cell morphology and multinuclearity.  
(ii) measurement of the DNA ploidy of cells in steady-state culture 
(iii) analysis of erythroid and megakaryocytic cell surface marker expression  
3. Analysis of gene expression profiles of key GATA-1 interacting genes under steady-
state culture conditions. 
The results of these analyses are presented below: 
5.4.5  Cell growth rates  
To assess whether the presence of the transgene had any affect on cell growth rates a 
simple cell growth assay was performed. Cells were harvested and seeded at 1x10
5 cells 
per ml in 6 well plates for K562 cells and 1x10
4 cells per ml for Meg-01, assigning one 
well per construct per day. Each day the corresponding wells were harvested and the 
number of live cells was estimated using a modified Neubauer counting chamber with 
Trypan blue exclusion of dead cells (as described in section 2.5.2). Particular care was 
taken to scrape the wells prior to harvesting to resuspend any loosely adherent cells. Wells 
for days 4 onwards were re-fed on day 3 to prevent exhaustion of nutrients in the culture 
medium, cell counts were adjusted to account for this larger media volume from day 4 
onwards. Results are shown in Fig 5.10a and b for K562 and Meg-01 respectively. In 
addition to the GATA-1FL, GATA-1s and empty vector constructs, untransfected K562 
and Meg-01 cells were included in this analysis. This was done to ensure that the 
expression of GFP (from the empty vector) did not interfere with cell growth 
characteristics. As can be seen in Fig 5.10 the growth curves for the untransfected cells and 
the vector only controls were very similar with no statistically significant difference 
between the two cell populations in K562 cells (using 2 way ANOVA analysis p=0.599). 
The other two constructs – GATA-1FL and GATA-1s- both provided a modest but 
significant growth advantage by day 6 compared to empty vector (using a two-tailed 
students t-test p= 0.033 for GATA-1FL vs. empty vector control and p= 0.018 for GATA-Results Chapter  5    246 
1s vs. empty vector) but did not produce a statistically significant difference when 
compared to one another (GATA-1s vs. GATA-1FL p=0.40). In contrast GATA-1FL 
transgene expression produced a clear increase in cell growth rates in Meg-01 cells 
compared to both GATA-1s and empty vector/untransfected cells. GATA-1s, contrary to 
predictions made from GFP expression levels (section 5.4.3) appeared not to produce a 
growth advantage in Meg-01 cells. There was no difference in the proportion of dead cells 
(as measured by Trypan blue staining) seen with any of the constructs. 
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Fig 5.10 K562 and Meg-01 growth curves 
Growth curves for(a) K562 (n=3) and (b) Meg-01 (n=1) cell lines either untransfected (wild-
type) or containing empty vector (V), GATA-1FL (FL) or GATA-1s (SH) transgenes.  Results Chapter  5    247 
Therefore it appears that expression of the GATA-1FL transgene gives Meg-01 cells a 
proliferative advantage in cell culture, whilst GATA-1s behaves in a similar way to 
empty vector controls. In the K562 cell line both the GATA-1FL and GATA-1s 
transgenes produce a moderate growth advantage over the empty vector cell line. These 
data support a role for GATA-1 in promoting cell survival and proliferation of meg-
erythroid precursors. They also suggest that GATA-1FL may be more dominant than 
GATA-1s in this regard in a cell line specific manner. They do not, however, shed light 
on the mechanism of selection for high GFP expression in Meg-01 GATA-1s expressing 
cells. 
5.4.6  Maturation status of cells 
Besides affecting cell proliferation the GATA-1 transgenes may have an affect on 
maturation of the Meg-01 and K562 cell lines.  To assess whether maturation status varied 
between steady state (i.e. without induced differentiation) cells a number of different 
assays were used as detailed in section 5.4.4. Results are presented below: 
5.4.6.1   Evaluation of cell morphology 
Cells were harvested, counted and washed in PBS before being attached to glass slides 
using a cytospin technique as described in section 2.13.5.  Slides were air-dried and then 
stained with May-Grunwald-Giemsa stain. All slides were viewed using a conventional 
light microscope equipped with a cell imaging system (Axiostar plus, Carl Zeiss). 
Representative cell morphology is shown in Fig 5.11a. Megakaryocytic maturation is 
associated with endomitosis leading to multinuclearity. To quantitate this, the numbers of 
mononucleate, binucleate and multinucleate cells were counted in 10 high powered fields 
(minimum 200 cells). Representative examples are labelled in Fig 5.11a. As expected 
Meg-01 cells had slightly higher numbers of multinuclear cells than K562, but there was 
no overall difference between the different transgenes in the proportion of mononuclear, 
binuclear or multinuclear cells as shown in Fig 5.11b. Since Meg-01 cells are loosely 
adherent, it might be hypothesised that more mature cells (which are large and produce 
long processes, with occasional visible platelet budding) reside in the adherent portion and 
may be missed by cytospins made from cell suspensions. To test this hypothesis, cytospins 
were performed on the adherent proportion (isolated by removal of the supernatant, 
washing twice in PBS, adding 1ml of sterile PBS and then mechanically scraping the 
adherent cells before collecting by centrifugation). Cell counts performed on adherent cells 
did show an increased number of multinuclear cells compared to suspension controls Results Chapter  5    248 
(average 8% of adherent cells were multinuclear versus 3% of suspension cells) as shown 
in Fig 5.11c. Both the GATA-1 transgenes (GATA-1FL and GATA-1s) seemed to be 
associated with lower numbers of multinuclear cells in the adherent fraction than the empty 
vector control, although the significance of this is unclear.  
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Fig 5.11 Influence of transgene expression on cell morphology 
(a) cytospins of K562 and Meg-01 stable transfectants, examples of  mononuclear, binuclear 
and multinuclear cells are indicated by arrows (b) percentage of each cell type counted in 10 
high power fields (minimum 200 cells), no significant differences between the transgenes 
were seen (n=3) (c) percentage of multinucleate cells in  adherent and suspension 
populations (n=1). The adherent fraction is associated with increased numbers of 
multinucleate cells. Results Chapter  5    249 
5.4.6.2   Measurement of DNA ploidy 
Another method of assessing the degree of endomitosis (and therefore megakaryocytic 
maturation status) is to measure the DNA content of individual cells. Endomitosis involves 
an increase in DNA content with successive cycles of nuclear replication. This leads to an 
exponential increase in ploidy from 2N to 4N to 8N to 16N etc. Ploidy can be measured by 
flow cytometric evaluation of the intensity of cell staining with the fluorescent DNA 
intercalating agent propidium iodide. Cells were prepared and stained as described in 
section 2.13.2.1, Chapter 2. A cell line with known 2N DNA content (the Burkitt’s 
lymphoma derived cell line – Raji, cultured as described in table 2.2) was included as a 
positive control. Results are shown in Fig 5.12 below: 
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Fig 5.12 Ploidy analysis of K562 and Meg-01 stable transfectants 
a) Representative FACS plot (scattergram and histogram) showing location of 2N, 4N and 
8N peaks b) baseline DNA ploidy for Meg-01 (n=3 replicates, no significant differences seen 
between constructs) and K562 (n=1) cells, expressing the 3 transgenes (empty vector, 
GATA-1FL and GATA-1s)  Results Chapter  5    250 
As can be seen from this figure the three transgenes do not appear to have substantial 
differential effects on baseline ploidy, with the possible exception of reduced numbers of 
4N cells in the K562 GATA-1FL cell line. This result differs from the cytospin findings 
(which actually showed increased binucleate cells in K562 GATA-1FL) and its 
significance is unclear. In Meg-01 cells there were no statistical differences in ploidy class 
between the 3 transgenes. 
5.4.6.3   Analysis of cell surface marker expression 
As megakaryocytic cells mature they should upregulate essential platelet proteins such as 
the glycoprotein complex GpIIb/IIIa. Similarly, erythroid maturation is associated with 
increased expression of cell surface proteins such as Glycophorin A. Therefore expression 
of these proteins can be used as surrogate markers for cell maturation. Fluorescently 
labelled monoclonal antibodies were used to assess GpIIb/IIIa (antiCD41a-APC) and 
Glycophorin A (anti-CD235a-PE-Cy5) expression as described in chapter 2 section 2.13.2. 
These fluorophores were chosen to minimise overlap with transgenic expression of GFP 
(from the IRES-GFP sequence in the expression vectors). Despite this it was necessary to 
perform compensation prior to analysis to minimise interference between the different 
channels, this was done with the help of experienced FACS users (Dr A Fraser and Dr C 
Hansell, Division of Immunology, Infection and Inflammation, Glasgow University). Cells 
were initially gated on FSC and SSC to encompass a viable bulk cell population; they were 
then gated on GFP expression to allow correlation between the level of transgene 
expression and the measured cell surface marker. The levels of Glycophorin A and CD41 
expression and number of positive cells were then assessed. Fig 5.13a shows representative 
FACS plots. Fig 5.13b presents these results in graphical form.  
As can be seen from these plots both cell lines expressed detectable levels of both 
erythroid (GpA) and megakaryocytic (CD41) cell surface markers. The expression data are 
interesting. In K562 cells all three transgenes show similar levels of expression in the GFP 
low cells (as would be predicted, as transgene expression is assumed to be low in this 
population and they should therefore resemble the empty vector controls). In the GFP high 
cells the FL isoform produces marked upregulation of CD41 and GpA. The GATA-1s 
transgene is associated with less upregulation of CD41 and down-regulation of GpA in the 
GFP high group. In Meg-01 cells it is the GATA-1s isoform that is associated with the 
highest levels of CD41 both in the low and high GFP gates but again increases in GFP 
expression are associated with down-regulation of GpA. This suggests that the GATA-1FL 
transgene promotes expression of megakaryocytic and erythroid markers in both cell lines Results Chapter  5    251 
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Fig 5.13 Expression of erythroid and megakaryocytic cell surface markers in 
Meg-01 and K562 transgenic cell lines 
(a) representative FACS plot for Meg-01 cells showing high and low GFP expressing 
populations and variation in GpA and CD41 expression (b) Baseline CD41 and GpA 
expression expressed as mean fluorescence intensity for the high GFP (high) and low GFP 
(low) gated populations (n=1) Results Chapter  5    252 
(although most prominently in K562), consistent with its ability to drive differentiation of 
cells down either lineage. The GATA-1s isoform appears to favour expression of 
megakaryocytic (CD41) over erythroid markers (GpA) and appears to suppress GpA 
expression when present at a high level. This effect on GpA is particularly marked in the 
Meg-01 cell line (which carries trisomy 21).  
In summary, these 3 methods to assess maturation status of cells revealed little or no 
differences in baseline numbers of multinucleate cells or DNA ploidy between any of the 
transgenes, in either cell line. Cell surface marker expression suggested that the GATA-
1FL isoform drove expression of both megakaryocytic and erythroid markers (CD41 and 
GpA respectively) in both cell lines. The GATA-1s isoform showed little CD41 
upregulation in K562 but marked upregulation in Meg-01 especially in high GFP 
expressors. GATA-1s CD41 upregulation was associated with GpA down-regulation in 
both cell lines. This suggests that high GATA-1s expression down-regulates markers of 
erythroid commitment and enhances CD41 expression consistent with megakaryocytic 
commitment. These data are consistent with the findings in murine ES cells of 
accelerated erythroid and CFU-GM commitment in GATA-1FL transgenics and 
suppression of erythroid colony formation in GATA-1s transgenics. The lack of 
comparable differences in the cytospin and ploidy analysis suggests that this high CD41 
expression with GATA-1s is not accompanied by other signs of megakaryocytic 
maturation. However it may also reflect the use of bulk cell populations, in contrast to 
the gating on high GFP in the cell surface marker studies. 
5.4.7  Gene expression profiles of transfected cell lines 
To explore the consequences of transgenic GATA-1 isoform expression further it was 
decided to examine their effect on gene expression profiles in the two cell lines. As 
extensively discussed GATA-1 is a key haematopoietic transcription factor whose 
expression leads to alteration in the transcription of a very large number of genes either 
directly or via a cascade of intermediate factors. The genes whose transcription may be 
affected by GATA-1 can be classified into 3 broad groups: 
1. Lineage restricted genes - the vast majority of megakaryocytic and erythroid specific 
genes possess GATA-1 binding sites within their regulatory regions and it is likely that 
binding of GATA-1 to these sites is necessary to institute lineage specific gene expression. Results Chapter  5    253 
2. Genes involved in alternative cell fate decisions - in addition GATA-1 influences the 
transcription of master regulators of other lineages. This is consistent with its role, not only 
in specifying megakaryocytic and erythroid cell fate, but also switching off alternative 
lineage choices such as lymphoid and granulocytic differentiation.  
3. Genes involved in proliferation and cell cycle control. The initial observations of 
GATA-1 knockout cells revealed its essential function in promoting cell survival and 
proliferation as well as allowing terminal differentiation.  
The clinical phenotype of GATA-1s knockout mice, the human GATA-1s kindred and 
Down syndrome children with TAM/AMKL, suggest abnormalities in maturation, lineage 
choice and cell proliferation and therefore it is likely that the GATA-1s isoform shows 
differential effects on gene expression from all three of these categories. Initial data from 
microarray studies in Down syndrome associated disease (Bourquin, et al 2006, Ge, et al 
2006) and the GATA-1 transgenic mice (Li, et al 2005) has suggested a number of 
candidate genes that may be differentially regulated by the GATA-1s isoform (listed in 
table 5.1 below). Because of this, it was decided not to perform a further microarray study, 
but rather to concentrate on a smaller number of potentially informative genes to examine 
their response to GATA-1 isoform expression in more depth using quantitative PCR. To 
facilitate this micro-fluidic plate technology was utilised in the form of Taqman low 
density array (TLDA) plates. These plates consist of 384 wells preloaded with standardised 
primers and probes. These wells are connected via micro-fluidic channels allowing 
centrifugal loading of template and PCR master mix into multiple wells via one sample 
port. This technology ensures high reproducibility between plates, since variability in inter-
well pipetting, primer and probe mixing, and sample loading is virtually eliminated.  The 
format chosen for this set of experiments was the assay of 15 genes plus one endogenous 
control gene (18SrRNA) with each assay being performed in triplicate. Therefore each 
plate is capable of analysing 8 biological samples (8 (samples) x 16 (genes) x 3 (replicates) 
= 384). The choice of genes was based on promising published data or key roles in lineage 
determination likely to show differential regulation by the two isoforms. These genes are 
listed in Table 5.1 along with the reasons for their inclusion. 
Gene expression in each biological sample was assayed in triplicate and 3 biological 
replicates for each cell line/time point were run on the plate allowing statistical comparison 
between different biological samples where appropriate. Samples were placed in RLT 
buffer (RNeasy kit, described in section 2.8.1.2) and frozen at -80°C until ready for full 
RNA extraction. In order to minimise inter-assay variation due to reagent/kit differences,  Results Chapter  5    254 
Gene Class  Existing 
microarray data 
Reason for inclusion 
 
Erg3 
 
Chromosome 
21 gene 
Meg 
differentiation
 
None 
 
Expressed in HSCs and meg 
precursors, prime candidate 
chromosome 21 gene for TAM 
phenotype – upregulated in DS-
AMKL cells and megakaryoblastic 
cell lines (Rainis, et al 2005)  
Bach-1 Chromosome 
21 gene 
Meg 
differentiation
Erythroid 
differentiation
Upregulated in 2 
independent DS-
AMKL 
microarrays 
1, 2. 
Rapidly 
upregulated on 
GATA-1 rescue of 
G1E cells
3 
Candidate chromosome 21 gene for 
TAM phenotype. High levels block 
terminal megakaryocytic 
differentiation, negative regulator of 
erythroid differentiation  (Toki, et al 
2005). 
NFE2 Meg 
differentiation
Erythroid 
differentiation
Rapidly 
upregulated on 
GATA-1 rescue of 
G1E cells
3 
Identified as erythroid transcription 
factor but knock-out mice have mild 
erythroid phenotype with complete 
absence of platelets (Shivdasani 
2001). Likely to be direct 
transcriptional target of GATA-1 and 
may be differentially regulated with 
GATA-1s 
Ski Meg 
differentiation
None Selective  expression in Meg-erythroid 
progenitors with down regulation 
required prior to terminal 
differentiation. Prevents GATA-1 
DNA binding via direct interaction 
with C-zinc finger (Ueki, et al 2004). 
Should act as a marker for MEPs and 
may be differentially regulated by 
GATA-1s 
Gp1b 
(platelet 
glycoprotein 
1b) 
Meg 
differentiation
Not properly 
upregulated in 
transgenic murine 
GATA-1s 
megakaryocytes
4  
Important for meg proliferation and 
maturation – both defective in GATA-
1s mutants. Down-regulation 
associated with cellular 
transformation (Li, et al 2008b). 
Identified by microarray as possible 
GATA-1s target 
D6 GATA-1 
target gene, 
Meg 
differentiation
None  Transcription known to be regulated 
by GATA-1(McKimmie, et al 2008), 
high expression in megakaryocytes. 
GATA-1 Meg 
differentiation
Erythroid 
differentiation
Upregulated in 
DS-AMKL vs 
non-DS-AMKL
1 
GATA-1 regulates its own expression. 
Assay measures human GATA-1 
(transgene murine) therefore allows 
assessment of effect of transgene on 
endogenous GATA-1 levels Results Chapter  5    255 
 
EKLF 
(erythroid 
krüppel like 
factor) 
 
Erythroid 
differentiation
 
Rapidly 
upregulated on 
GATA-1 rescue of 
G1E cells
3 
 
Known to restrict megakaryocytic 
differentiation and promote erythroid 
differentiation (Bouilloux, et al 2008). 
GATA-1 target gene. 
Zeta-globin Erythroid 
differentiation
  Marker of embryonic erythropoiesis, 
may reveal ontogeny related 
differences in GATA-1 isoform 
effects 
Β-globin 
major 
Erythroid 
differentiation
Rapidly 
upregulated on 
GATA-1 rescue of 
G1E cells
3 
Marker of adult erythropoiesis to 
compare with zeta-globin above 
PU.1 (spi-1)  Lineage 
Choice 
Not properly 
repressed in 
transgenic murine 
GATA-1s 
megakaryocytes
4 
PU-1 and GATA-1 directly interact 
and determine lineage choice 
(myeloid/granulocytic versus meg-
erythroid) (Rekhtman, et al 1999).  
Ikaros Lineage 
Choice 
Not properly 
repressed in 
transgenic murine 
GATA-1s 
megakaryocytes
4 
As above, known to interact with 
GATA-1 and determine lineage 
choice (lymphoid versus myeloid) but 
also important later for γ to β-globin 
switching (Bottardi, et al 2008).  
GATA-2 Lineage 
Choice 
Not properly 
repressed in 
transgenic murine 
GATA-1s 
megakaryocytes
4 
Important for HSC maintenance but 
also higher levels needed for 
megakaryocytic differentiation and 
lower levels for erythroid 
differentiation (Ikonomi, et al 2000).  
Cyclin D2 
(CCND2) 
Cell cycle 
Cell survival 
Not properly up-
regulated in 
transgenic murine 
GATA-1s 
megakaryocytes
4 
Cyclin family regulated by GATA-1 
and important for megakaryocyte 
growth and terminal differentiation 
via regulation of cell cycling 
(Matsumura, et al 2000).  
c-myb Cell  cycle 
Cell 
proliferation 
Not properly 
repressed in 
transgenic murine 
GATA-1s 
megakaryocytes
4 
Essential for definitive 
haematopoiesis. High levels inhibit 
terminal differentiation. Target genes 
are involved in cell cycle progression 
and survival pathways. (Sakamoto, et 
al 2006) 
 
Table 5.1 Genes included in qPCR expression assays 
Abbreviations:  Meg=megakaryocytic 
1(Bourquin, et al 2006), 
2(Ge, et al 2006), 
3(Welch, et al 
2004) 
4(Li, et al 2005). Colours refer to scheme used to display microarray gene results i.e. 
blue = megakaryocytic differentiation, pink = erythroid differentiation, green = lineage 
choice, yellow = cell cycle 
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all RNA extractions for a sample group (e.g. K562 GATA-1FL/GATA-1s/empty vector) 
were performed on the same day. Reverse transcription into cDNA was again performed in 
one batch per sample group using Affinity Script reverse transcriptase as described in 
section 2.8.4. 2μg starting RNA were used and cDNA samples were then diluted 1 in 10 
before use in the TLDA plate assay. 
A number of different analyses were performed using different calibrators i.e. 
1. An assessment of baseline gene expression differences between K562 and Meg-01 cells 
(using empty vector transfected cells) with K562 empty vector as the calibrator. 
2. A comparison between empty vector, full-length and short transgenes in K562 cells, 
using K562 empty vector as the calibrator. 
3. A comparison between empty vector, full-length and short transgenes in Meg-01 cells, 
using Meg-01 empty vector as the calibrator. 
5.4.7.1   K562 vs. Meg-01 gene expression 
Initially baseline gene expression differences were examined between the two cell lines 
K562 and Meg-01 by analysing the results of gene expression from 3 Meg-01 empty vector 
control samples versus 3 K562 empty vector control samples. It should be noted that this 
kind of comparison between different cell types (rather than within a single cell line) is 
only valid if these cells express similar amounts of the endogenous control gene per unit of 
cDNA. If not, then apparent differences in gene expression will reflect changes in the 
baseline of the control gene rather than changes in the test gene of interest. To test this, the 
CT at which the endogenous control (18SrRNA) crossed the threshold was compared for 
standardised amounts of K562 (3 transgenes with 3 samples per transgene) and Meg-01 (3 
transgenes with 3 samples per transgene) template (i.e. 2μg starting RNA, reverse 
transcribed in one batch and resultant cDNA diluted 1 in 10 before use), results are shown 
in Fig 5.14a. Differences in levels of expression of 18SrRNA between the two cell lines 
would be manifested as a consistent trend in 18SrRNA expression, either higher or lower 
with one cell line. Instead a small degree of random variability which was not statistically 
significant was seen. Therefore these two cell lines can be directly compared. The level of 
gene expression from the K562 samples were arbitrarily set at 1 (i.e. the K562 samples 
were used as the calibrator for fold change) and compared to levels of expression 
(expressed as fold-change in gene expression) in the Meg-01 cells. Results are shown in Results Chapter  5    257 
Fig 5.14b. Groups of genes are colour coded to emphasise their particular roles in 
megakaryocytic differentiation (blue), erythroid differentiation (pink), lineage choice 
(green) and cell cycle control (yellow) – many genes obviously fall into more than one 
category and have been assigned a group according to their most relevant role. Statistical 
analysis was performed by comparing two sample groups using an unpaired two-tailed 
Student’s t-test (assuming unequal variance); values of p≤0.05 were considered significant. 
Significant differences are shown on the graphs using standard nomenclature (* = p≤0.05, 
** = p<0.01, *** = p<0.001).  
From Fig 5.14b it can be seen that Meg-01 cells have higher baseline levels of expression 
of the megakaryocytic transcription factor NFE2 (p=0.02) and genes important for 
proliferation and survival of haematopoietic progenitors cyclin D2 (P=0.015), c-myb 
(p=0.022) and GATA-2 (P=0.002). Genes associated with alternative lineages- Ikaros and 
PU.1- are expressed at lower levels in Meg-01 than in K562, presumably reflecting the 
more committed state of the former. Bach-1 is not upregulated (p=0.10) despite the 
presence of Trisomy 21 in these cells. Erg3, another chromosome 21 gene, and 2 other 
genes – Gp1b and β-Globin major - are expressed in Meg-01, but expression is not 
detectable in K562 cells, this makes calculation of relative expression levels impossible 
since the lack of a comparator makes RQ quantitation invalid.    
In contrast K562 cells have higher baseline expression of erythroid genes – zetaglobin 
(p<0.0001), EKLF (p=0.003) and GATA-1 (p=0.001) and lineage determining genes– 
Ikaros (P=0.0001) and PU.1 (p=0.0003). They also show expression of a GATA-1 target 
gene D6 which (like Gp1b, Erg3 and β-globin major in K562 above), is undetectable in 
Meg-01 cells making estimation of relative expression levels impossible. 
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Fig 5.14 Comparison of gene expression between Meg-01 and K562 
(a) 18SrRNA CT values for standardised amounts of K562 and Meg-01 template are not 
significantly different and therefore the two cell lines can be directly compared (b) Fold 
change (RQ) in Meg-01 cells (empty vector controls) compared to K562 cells (n=3) showing 
higher megakaryocytic and lower erythroid gene expression. *=p≤0.05, **=p<0.01 and 
***=p<0.001  
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Overall these findings support the observations that the Meg-01 cell line has a number of 
features of megakaryocytic precursor cells, but still retains some features of more primitive 
haematopoietic cells (GATA-2, c-myb and cyclin D2). The lack of upregulation of Bach-1 
is surprising, given the existing microarray data suggesting Bach-1 is consistently 
upregulated in AMKL (Bourquin, et al 2006, Ge, et al 2006), but may reflect the different 
stages of differentiation of these cells (adult haematopoietic precursors in CML vs. fetal 
haematopoietic precursors in TAM/AMKL). Unsurprisingly, K562 cells express lower 
levels of genes involved in megakaryocytic differentiation and higher levels of erythroid 
genes (presumably actively down-regulated in Meg-01 cells) when compared to Meg-01, 
their expression of PU.1 and Ikaros at higher levels than Meg-01 presumably reflects their 
more multipotent state, although recently a role for Ikaros in globin gene switching during 
erythroid maturation has been reported (Bottardi, et al 2008), so it may be acting as an 
erythroid gene in these circumstances. The expression of zetaglobin in K562 cells (an 
embryonic  α-globin chain) but not β-globin is intriguing. The production of fetal and 
embryonic haemoglobin in these cells has been reported previously (Baron and Maniatis 
1986, Rutherford, et al 1979), despite their derivation from an adult patient with CML. It is 
tempting to speculate that the high levels of Ikaros may be relevant here in causing a 
reversion of these adult progenitors to fetal haemoglobin production. This hypothesis 
requires testing. 
5.4.7.2   The effects of GATA-1 transgene expression in K562 cells 
Having established baseline characteristics of gene expression in the two cell lines, the 
effects of ectopic expression of the GATA-1 isoforms on this gene expression signature 
were examined.  Data for K562 are presented in this section and Meg-01 in the section 
below. Three biological replicates from each cell line (K562 empty vector, K562 GATA-
1FL and K562 GATA-1s) were cultured in 6-well plates for several passages and then 
harvested. Following RNA extraction and cDNA synthesis samples were run on TLDA 
plates as described above. 
Fig 5.15 shows gene expression data displayed as fold-change in gene expression 
compared to levels in the K562 empty vector line (used as the calibrator with gene 
expression arbitrarily set at 1). Expression of Erg3, β-globin and Gp1b were again 
undetectable in all 3 transgenic cell lines precluding further analysis. All of the remaining 
12 genes showed significant differences in gene expression levels between the K562 empty 
vector and the K562 GATA-1FL cell line (using a Student’s two tailed t-test, p≤0.05). The 
data are presented using a log 2 Y axis to allow fold reductions in gene expression to be Results Chapter  5    260 
displayed with equivalent magnitude to fold increases in gene expression (i.e. from 1 to 0.5 
= 2 fold reduction which is equivalent to a 2 fold increase): 
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Fig 5.15 Alterations in gene expression profile with GATA-1 isoform over-
expression in K562 cells 
(a) genes showing significant up-regulation with the GATA-1FL isoform (and, in the case of 
EKLF, down-regulation with GATA-1s) (b) Genes showing down-regulation with GATA-1 
transgene expression *=p≤0.05, **=p<0.01 and ***=p<0.001  
Genes showing significant up-regulation with GATA-1FL were the two erythroid specific 
genes Zetaglobin (p=0.01) and, to a lesser extent, EKLF (p=0.03). Significant down-
regulation was seen for genes associated with primitive haematopoietic precursors, cell 
cycling or other lineage choices: c-myb (p=0.008), cyclin D2 (p=0.002), GATA-2 (albeit a 
small fold change) (p=0.008), Ikaros (p=0.0004) and PU.1 (p=0.003). In addition down-
regulation of megakaryocytic genes was also seen: Ski (p=0.0004), NFE2 (p=0.03), D6 Results Chapter  5    261 
(p=0.002) and Bach-1 (p=0.006). Finally, consistent with GATA-1 autoregulation GATA-
1 levels were also significantly reduced (p=0.002), note that the TLDA plates measure 
human GATA-1 and that the transgene is murine GATA-1 allowing effects of transgene 
expression on endogenous GATA-1 levels to be assessed. Overall, these findings are 
consistent with a dominant role of GATA-1FL in driving K562 cells along the erythroid 
lineage and away from a more multipotent state. 
In contrast, ectopic GATA-1s expression was unable to modulate gene expression to the 
same degree. Only 3 genes were significantly altered when compared to expression levels 
in K562 empty vector controls. All 3 genes were down regulated – PU.1 (p=0.004), 
GATA-1 (p=0.01) and EKLF (p=0.004). Despite significant down regulation of PU.1 and 
GATA-1 this was to a lesser extent than seen with GATA-1FL expression (with a 
statistically significant difference between K562 GATA-1FL and K562 GATA-1s levels of 
expression of PU.1 (p=0.008) and GATA-1 (p=0.0004) when their fold-change values 
were directly compared). Other haematopoietic precursor genes (GATA-2, Ikaros) down-
regulated in GATA-1FL cells were also down-regulated in GATA-1s, but to a lesser 
extent. Other genes (down-regulated by GATA-1FL) showed no evidence of repression by 
GATA-1s particularly the megakaryocytic genes – ski, NFE2, D6, Bach-1 and cell 
proliferation associated genes – c-myb and Cyclin D2. Finally the erythroid genes – 
zetaglobin and EKLF, upregulated with GATA-1FL expression, showed failure of 
upregulation (Zetaglobin) or active down-regulation (EKLF) with GATA-1s.  
These findings suggest that GATA-1s expression in K562 cells is still able to promote 
differentiation away from haematopoietic precursor cells towards a meg-erythroid fate (by 
down-regulating genes associated with haematopoietic precursors) but that it does not 
drive erythroid commitment to the degree that GATA-1FL does. In addition the lack of 
repression of cyclin D2 and c-myb along with persistent expression of megakaryocytic 
genes are consistent with the proposed role of GATA-1s in the maintenance of a 
population of proliferative meg-erythroid precursors. Overall, this pattern of expression 
suggests a preference for megakaryocytic differentiation (lack of repression of 
megakaryocytic genes, failure to upregulate erythroid genes, active repression of EKLF) 
rather than erythroid differentiation with transgenic GATA-1s expression – the opposite 
of GATA-1FL. 
An alternative interpretation of the above is that these relative differences in GATA-1FL 
and GATA-1s effects on gene expression merely reflect differences in the expression 
levels of GATA-1 in the two cell lines i.e. the GATA-1FL construct is expressed at a Results Chapter  5    262 
higher level than the GATA-1s construct. Although this cannot be discounted, the active 
down-regulation of EKLF expression with GATA-1s as opposed to up-regulation with 
GATA-1FL suggests that GATA-1s has a distinct functional role, at least with some target 
genes. In addition Meg-01 data discussed below - where the GATA-1s gene is expressed at 
higher levels than GATA-1FL - suggest these changes are not merely concentration 
dependent effects. 
5.4.7.3    The effects of GATA-1 transgene expression in Meg-01 
cells 
Following sample preparation as described for K562 cells above, the effects of the two 
isoforms were also studied in Meg-01 cells. Results are shown in fig 5.16 and summarised 
below: 
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Fig 5.16 Alterations in gene expression profile with GATA-1 isoform over-
expression in Meg-01 cells 
*=p≤0.05, **=p<0.01 and ***=p<0.001 Results Chapter  5    263 
In contrast to its effects in K562 cells, the GATA-1FL transgene expression produced a 
significant fall in the expression of erythroid associated genes – zetaglobin (p=0.0002), 
EKLF (p=0.002), β-globin (p<0.0001) and GATA-1 (p=0.03). Modest, but statistically 
significant, reductions in c-myb (p=0.03), NFE2 (p=0.03) and GATA-2 (p=0.008) were 
also seen. The megakaryocytic genes Gp1b, Bach-1, Erg3 and Ski, along with cyclin D2, 
showed no significant changes in expression. Ikaros and PU.1 showed small reductions in 
gene expression but these were not statistically significant. It should be noted that the 
expression of these two haematopoietic precursor genes is already significantly down-
regulated in Meg-01 cells compared to K562. In addition the megakaryocytic genes (with 
the exception of Bach-1) are already up-regulated in Meg-01 cells (as shown in Fig 5.14b). 
The degree to which additional GATA-1 isoform expression can alter these pre-existing 
patterns is unclear. Since GATA-1 plays important roles in both megakaryocytic and 
erythroid differentiation it is not surprising that GATA-1FL expression in a more 
committed progenitor might cause down–regulation of erythroid genes. As discussed in 
Chapter 1, GATA-1 forms complexes with multiple different partner proteins and it is the 
particular combination of proteins that determines repression versus activation of target 
genes (Rodriguez, et al 2005). It must be assumed that the protein partners of GATA-1FL 
differ in K562 and Meg-01 cells leading to a balance favouring erythroid gene activation in 
K562 and repression in Meg-01. In summary, it appears that the GATA-1FL isoform 
when ectopically expressed in megakaryocytic cells leads to down-regulation of erythroid 
genes but no further active upregulation of megakaryocytic genes.   
The GATA-1s isoform expressing cells produced a significant down-regulation of GATA-
2 (p=0.02), β-globin (p=0.01) and PU.1 (p=0.02). All other genes showed no significant 
change in gene expression. Again this is consistent with published results showing that 
GATA-1s expressing megakaryocytic precursors fail to adequately down-regulate c-myb, 
ikaros, cyclin D2, and GATA-1, although the significant down-regulation of PU.1 in 
GATA-1s and not GATA-1FL expressing cells is unexpected. Levels of gene expression 
may be relevant here: as seen in Fig 5.9 in K562 cells both GATA-1FL and GATA-1s 
show detectable expression on western blot with good levels of the murine GATA-1FL 
transgene (using murine specific N6 antibody), in contrast in Meg-01 cell lines increased 
expression of the GATA-1s protein is easily detectable by western blot whereas GATA-
1FL expression is not seen using the N6 antibody (fig 5.9b). Therefore the effects of high 
level GATA-1s expression may have been able to down-regulate PU.1 to a greater extent 
than low level GATA-1FL expression producing this anomalous result. However, if this is 
the case then this does not explain the more profound down-regulation of erythroid genes 
with GATA-1FL compared to GATA-1s.  It is interesting that, despite this higher level Results Chapter  5    264 
GATA-1s expression, a much smaller subset of genes were down-regulated than with low 
level GATA-1FL expression. The preferential down regulation of PU.1 and GATA-2 
support a role for GATA-1s in allowing initial lineage choice or maintaining the 
differentiated state without the ability to drive terminal differentiation. Again the down-
regulation of erythroid (β-globin), but not megakaryocytic, genes by GATA-1s suggests a 
preference for megakaryocytic over erythroid differentiation.  
Finally, these data can be compared with the cell surface marker data presented in section 
5.4.6.3. The increase in GpA expression seen with the GATA-1FL transgene in K562 cells 
is mirrored by the significant increases in erythroid gene expression at the mRNA level. 
Similarly the lack of upregulation of GpA in the GATA-1s K562 transgenics is consistent 
with the lack of induction of erythroid genes. In Meg-01 cells there was no evidence of 
erythroid up-regulation at the mRNA level despite higher levels of cell-surface GpA in the 
GATA-1FL and GATA-1s transgenics at baseline (although this level of GpA expression 
was not correlated with GFP expression –high expressers actually showed reduced GpA 
expression). Given that this relationship between GpA, GATA-1 transgene expression, and 
expression of other erythroid genes at the mRNA level in Meg-01 cells, is complex, this 
assay may not be a good marker of cellular commitment in this cell line. It is possible that 
other factors drive aberrant GpA expression in Meg-01 cells. The CD41 data is equally 
complex. As discussed in section 5.5.1.1 below, despite its widespread use as a marker of 
megakaryocytic commitment, CD41 is also expressed earlier in haematopoietic 
differentiation. The alterations in levels of expression at the cell surface are not reflected in 
mRNA expression patterns of other megakaryocytic genes in either K562 or Meg-01 cells. 
This suggests that it cannot be used as a surrogate marker for megakaryocytic lineage 
commitment in these cell lines. 
In summary, gene expression profiles show that K562 and Meg-01 cells differ at 
baseline, with Meg-01 expressing megakaryocytic genes at higher levels than K562. 
K562 express higher levels of Ikaros and PU.1 and erythroid genes. These findings are 
consistent with the proposed cell of origin of these two cell lines, with K562 arising from 
a more multipotent precursor, whilst Meg-01 appears to possess features of an early 
bipotent meg-erythroid precursor (with a tendency towards a megakaryocytic fate). The 
additional presence of GATA-1 transgene expression leads to alterations in gene 
expression patterns. Whilst GATA-1FL is able to drive erythroid gene expression in 
K562 cells it leads to down regulation of these genes in Meg-01 cells, presumably 
reflecting the different levels of lineage commitment in these two cell lines. GATA-1s 
expression in both cell lines shows much less potent effects on the expression of most Results Chapter  5    265 
genes (with the exception of PU.1 and GATA-2), even when expressed at higher levels 
than the GATA-1FL transgene (as seen in Meg-01 stable transfectants). This suggests 
that, in agreement with the data from sections 5.3 (murine ES cells) and 5.4.6 (cell 
maturation status), GATA-1s is unable to drive terminal erythroid differentiation. In 
addition, it appears to act, in some contexts, as a hypomorphic allele of GATA-1, with 
alterations in gene expression that mimic GATA-1FL but to a lesser extent. 
5.5 The use of K562 and Meg-01 cells to model 
megakaryocytic and erythroid differentiation 
The K562 cell line was established in 1970 from a pleural effusion of a patient with CML 
in blast crisis (Lozzio and Lozzio 1979). Although originally thought to arise from an 
undifferentiated granulocytic precursor cell (Lozzio and Lozzio 1979), later studies 
suggested that it actually had properties more akin to a meg-erythroid precursor 
(Andersson, et al 1979, Rutherford, et al 1979, Tabilio, et al 1983). Erythroid properties 
were suggested by the fact that resting K562 cells express the red cell antigen glycophorin, 
usually first detected in proerythroblasts (Andersson, et al 1979). Furthermore, treatment 
of K562 cells with the known erythroid inducing agent Haemin (which is a crystalline 
chloride of heme (C34H32N4O4FeCl)) results in the synthesis of embryonic globin chains 
and the cells become positive for haemoglobin (detected by benzidine staining) 
(Andersson, et al 1979, Rutherford, et al 1979). More recent reports suggest Haemin 
treatment induces gene expression changes suggestive of erythroid commitment including 
expression of the Band 3 gene - an essential component of the red cell membrane 
(Yamada, et al 1998). In addition to these erythroid properties of K562 it was also shown 
that these cells could be induced to differentiate along the megakaryocytic lineage by 
treatment with Phorbol diesters, more commonly known as tumour promoting agents 
(Siebert and Fukuda 1985). The mechanism of action of these compounds in promoting 
megakaryocytic differentiation is unknown although it is thought that at least part of their 
activity comes from activation of protein kinase C with consequent effects on cell 
signalling pathways (Nagata, et al 1996). The commonest, and most effective, phorbol 
diester is 12-O-tetradecanoylphorbol-13-acetate (TPA). Treatment of K562 cells with TPA 
results in a reduction in erythroid properties and acquisition of various megakaryoblastic 
features including expression of megakaryocytic cell surface markers, production of 
platelet peroxidase, an increase in cell volume and an increase in DNA ploidy (Alitalo 
1990, Tetteroo, et al 1984). Expression of platelet derived growth factor (PDGF), Results Chapter  5    266 
plasminogen activator (PA) and plasminogen activator inhibitor (PAI-1) have also been 
demonstrated following TPA treatment (Alitalo 1990, Ogura, et al 1988).  
Meg-01 cells were also derived from a patient with CML blast crisis (Ogura, et al 1985). In 
contrast to K562 these cells show clear megakaryoblastic characteristics in their resting 
state. During culture a sub-population of the cells become loosely adherent to the tissue 
culture dish and extend pseudopodia, these cells have even been reported to shed platelets 
into the culture media (Mroske, et al 2000). Again, treatment of these cells with TPA leads 
to further megakaryocytic differentiation with up-regulation of platelet factor 4 (PF4) and 
cyclo-oxygenase (Cox1), an increase in DNA ploidy and increased expression of platelet 
surface antigens (Mroske, et al 2000, Ogura, et al 1988) . There is little published evidence 
on Haemin treatment of Meg-01 cells although one report suggests that these cells express 
globin genes at the mRNA level and levels of mRNA can be increased by Haemin 
treatment (Morle, et al 1992). In addition this same paper showed that 1/3 of Meg-01 cells 
became benzidine positive (indicating the presence of haemoglobin) after 3 days of culture 
with haemin. It seems likely, therefore, that these cells possess some residual erythroid 
potential.  
The following sections describe experiments using Haemin and TPA to examine the effect 
of GATA-1 isoform over-expression on the ability of K562 and Meg-01 cells to 
differentiate within the erythroid and megakaryocytic lineages. Differentiation status was 
assessed using ploidy determination, surface marker expression and gene expression 
profiling, as described above. Since TPA and Haemin differentiation assays were not in 
routine use in our laboratory, it was necessary to optimise and validate the experimental 
methods before assessing the impact of transgene expression. This is described below: 
5.5.1 Validation of model systems 
5.5.1.1   TPA 
Cells were treated with 100nM TPA as described in Materials and Methods section 2.13.3 
and harvested after 6 hours or after 1, 2, 3, 4, 5 or 7 days, depending on the assay being 
used. Cells were noted to rapidly adhere to the culture dish a few hours after treatment and 
by 24 hours many cells with long pseudopodia were evident. This was particularly 
prominent with K562 cells; Meg-01 cells also adhered but remained rounder with few 
pseudopodia. These adherent cells, in both cell lines, then gradually detached over the 
following days. This phenomenon has been reported in the literature (Ogura, et al 1988). Results Chapter  5    267 
To look for expression of megakaryocytic genes at the mRNA level, standard RT-PCR was 
performed on cDNA samples from days 0, 1, 2, 5 and 7 looking for evidence of induction 
of Platelet Factor 4 (PF4), CD41 (GpIIb) and Gp1b expression, as shown in Fig 5.17a.  
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Fig 5.17 RT-PCR for megakaryocytic and erythroid genes following TPA 
treatment of Meg-01 and K562 cell lines 
(a) RT-PCR for megakaryocytic genes Gp1b, PF4, CD41 in K562 and Meg-01 cell lines on 
days 0,1,2,5,and 7 following TPA treatment (b) RT-PCR for erythroid genes ε-globin and β-
globin in K562 and Meg-01cell lines on days 0,1,2,5 and 7 following TPA treatment Results Chapter  5    268 
1. The effect of TPA on megakaryocytic gene expression in K562 cells: TPA treatment 
resulted in clear induction of Gp1b expression, which appeared maximal at day 5 (although 
it should be noted that this PCR is not optimised for quantitation). PF4 was induced at day 
7 with undetectable bands before this. CD41 was weakly expressed at day 0 with an initial 
reduction in expression on day 1 followed by increasingly intense bands to day 7.  
2. The effect of TPA on megakaryocytic gene expression in Meg-01 cells: Again 
induction of Gp1b was seen with undetectable expression at day 0 and low level expression 
from day 1 onwards increasing to day 7. Interestingly CD41 expression was high initially 
but progressively fell with subsequent days of differentiation. This latter result may reflect 
a role for this molecule earlier in the commitment to the megakaryocytic lineage, as 
discussed below. PF4 expression could not be detected in Meg-01.  
The expression of erythroid genes was also examined to see if these fell with 
differentiation, Meg-01 cells down regulated both adult (β-globin) and embryonic globins 
(ε-globin) on TPA induction as expected. However, unexpectedly K562 cells showed 
increased levels of ε-globin expression (Fig 5.17b), β-globin expression was undetectable, 
consistent with the published reports of lack of adult globin expression in this cell line 
(Rutherford, et al 1979), this finding is discussed below. 
As an independent measure of megakaryocytic differentiation, the effect of TPA treatment 
on DNA ploidy was assessed. Results are shown in Fig 5.18a. As can be seen from the 
figure, treatment of either cell line with TPA induced an increase in DNA ploidy from a 
modal 2N to modal 4N, with an increase in 8N peaks over time. Meg-01 acquired modal 
4N ploidy by day 2, K562 by day 3, after TPA treatment. These changes are consistent, in 
magnitude and time course, with published reports in the literature of the DNA ploidy 
response of both cell lines to TPA (Jung, et al 2007, Ogura, et al 1988).  
Finally, the levels of surface CD41a (GpIIb/IIIa) expression were assessed by FACS. Fig 
5.18b shows that the percentage of CD41a+ cells increased from around 75% to 95% and 
that the mean fluorescence intensity of these positive cells increased in K562 cells. In 
Meg-01 cells a similar rise in CD41a+ cells was seen (data not shown). For comparison, 
expression of the erythrocytic cell surface antigen GpA was also assessed. In K562 
expression fell with TPA treatment (fig 5.18b) whilst in Meg-01 it remained stable. Results Chapter  5    269 
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Fig 5.18 The effect of TPA treatment on DNA ploidy and cell surface marker 
expression 
(a) Treatment with TPA is associated with increases in DNA ploidy in both K562 and Meg-01 
cell lines (n=1) (b) TPA treatment is also associated with increased intensity of CD41 
expression and down-regulation of GpA expression by FACS analysis (n=3). 
CD41 was initially thought of as a specific megakaryocytic marker as it comprises the 
GpIIb component of the GpIIb/IIIa complex, which is essential in platelet adherence to 
sites of injury via its binding to fibrinogen. However, more recently two groups have 
reported that. CD41 expression can be detected early during murine ontogeny at the time 
of emergence of definitive erythropoiesis in the yolk-sac and in vitro in embryoid bodies 
(day 6) (Mikkola, et al 2003, Mitjavila-Garcia, et al 2002). It then appears to be down-
regulated in haematopoietic progenitors by the fetal liver stage. Further in vitro 
differentiation of embryoid body derived ES cells showed that CD41 could be switched on 
again later in development, presumably reflecting commitment to more mature lineages. 
Further support for a role in establishment of definitive haematopoiesis is supported by 
gene targeting experiments where expression of Cre-recombinase was linked to regulatory 
elements of the CD41 gene. This resulted in expression of a Cre-inducible reporter gene 
restricted to haematopoietic tissues but found in all myeloid and lymphoid cells suggesting 
CD41 expression is switched on in the earliest HSCs (Emambokus and Frampton 2003). 
CD41 expression has also been linked to the earliest stages of primitive erythropoiesis in Results Chapter  5    270 
the yolk-sac (Ferkowicz, et al 2003). These observations are intriguing, particularly in 
view of the fact that CD41 knockout mice do not show any overt abnormalities in 
haematopoiesis apart from a platelet function defect (Tronik-Le Roux, et al 2000). This is 
also supported by human data – the disease Glanzmann’s thrombaesthenia is a severe 
autosomal recessive platelet function disorder characterised by mutations in either the 
GpIIb or GpIIIa genes. Affected individuals present with a severe bleeding disorder due to 
dysfunctional GpIIb/IIIa interaction with fibrinogen but do not show abnormalities in any 
of the other haematopoietic lineages (Saxena and Kannan 2008). Therefore, despite 
widespread expression, the role of CD41 in early haematopoietic precursors remains to be 
fully elucidated. From this discussion it can be seen that CD41 expression could be due to 
either terminal megakaryocytic differentiation or a residual marker of haematopoietic 
commitment. It is plausible that the differences in expression in K562 and Meg-01 reflect 
these dual roles for CD41.  
When comparing K562 and Meg-01 cell lines it appears that Meg-01 more rapidly acquire 
megakaryocytic characteristics (i.e. more rapid increase in DNA ploidy, earlier expression 
of Gp1b, down regulation of globin gene expression) but the lack of PF4 expression and 
failure to repress GpA expression suggests that they retain some primitive meg-erythroid 
characteristics. In contrast K562 do express PF4 and repress GpA but show less repression 
of globin genes synthesis, again suggesting they retain some meg-erythroid characteristics. 
These findings mirror those reported in the literature which confirm the ability of both 
lines to differentiate into megakaryocytes but are often conflicting in their reporting of co-
existent down regulation of erythroid markers. This is not surprising on two counts. Firstly 
there appears to be a marked tendency of both these cell lines, in the absence of overt 
selective pressure, to form subclones with distinct characteristics, particularly in the degree 
to which they display megakaryocytic or erythroid properties (Vainchenker, et al 1981). In 
fact, this observation was used as preliminary evidence for the existence of a bipotential 
meg-erythroid precursor, before later experiments (discussed in Chapter 1 section 1.1.2.2) 
confirmed the existence of these cells. Some of these studies may have used cell lines that 
had inadvertently (or deliberately in some cases (Ogura, et al 1988)) become skewed 
towards favouring megakaryocytic or erythroid differentiation, making comparison 
between results from different laboratories difficult.  Secondly, these cells are derived from 
CML blast crisis and therefore are highly unlikely to display completely faithful lineage 
commitment, high levels of co-expression of supposedly lineage restricted markers have 
been seen, even after induction of differentiation in vitro (Tabilio, et al 1983). For the 
purposes of testing the hypothesis that GATA-1 isoforms may produce different effects on 
lineage commitment this lack of completely faithful differentiation is not a major obstacle, Results Chapter  5    271 
but this caveat should be borne in mind especially when these systems are used as 
surrogate models for processes during physiological megakaryopoiesis.  
In summary, as might be expected, Meg-01 and K562 do not behave identically when 
treated with TPA which probably reflects different stages of initial lineage commitment 
and cytogenetic differences between the two cell lines. However, these results confirm 
the ability of TPA to induce megakaryocytic differentiation in both Meg-01 and K562 
cell lines as measured by expression of megakaryocytic genes, development of increased 
DNA ploidy and increases in the percentage of CD41+ cells and levels of surface CD41 
expression. 
5.5.1.2   Haemin 
Cells were cultured and treated with 10μM Haemin as described in chapter 2 section 
2.13.4. Cells were harvested after 6 hours or 1, 2, 3, 4, 5, or 7 days differentiation 
according to the assay being performed. K562 cells were noted to form clusters in the first 
day after Haemin treatment and this persisted over the course of the differentiation By day 
2 of differentiation harvested K562 cells formed a pink cell pellet, reflecting haemoglobin 
synthesis and the colour of the pellet was noted to become progressively deeper pink/red 
over the course of the differentiation. This phenomenon was not seen in Meg-01 cells, 
initial clumping of cells was seen but cell pellets were not visibly pink. 
To assess erythroid differentiation, in response to Haemin, levels of glycophorin A 
expression were assessed and quantitative PCR was performed for erythroid genes. 
Meg-01 and K562 cells clearly up-regulated surface glycophorin A levels on haemin 
treatment as shown in Fig 5.19a. This was associated with significant upregulation of β-
globin (4-fold) and the embryonic α-globin chain - zeta-globin (64 fold) by day 3 of 
differentiation (fig 5.19b) in Meg-01 cells, as measured by qPCR. Interestingly K562 cells 
showed little evidence of an erythroid response in terms of gene expression (with down-
regulation of zeta-globin and EKLF expression). This is despite clear haemoglobinisation 
of the harvested cell pellets from day 2 of differentiation onwards. However zeta-globin 
and EKLF expression were already higher in K562 cells (32 fold and 2 fold respectively) 
than Meg-01 so it may well be that the K562 response to Haemin is exerted at a post-
transcriptional level or affects a different subset of genes responsible for terminal 
differentiation.  Results Chapter  5    272 
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Fig 5.19 Effects of haemin treatment 
(a) Expression of glycophorin A (n=1) and (b) effect on gene expression patterns in K562 
and Meg-01 cells (n=3) in response to haemin treatment 
These qPCR data illustrate some of the difficulties in interpreting fold-changes in gene 
expression rather than absolute quantitation of transcript levels, plus the limitations of 
studying gene expression purely at the mRNA level. However, for the purposes of 
examining whether the different GATA-1 isoforms show differential effects on induction 
of gene expression, fold-change is an adequate measure.  Results Chapter  5    273 
Overall, the induction of haemoglobin production in K562 (as measured by development 
of pink/red colouration of the cell pellet),  the induction of GpA cell surface expression 
in both cell lines, along with increased zeta-globin and EKLF expression in Meg-01 
were taken to indicate that erythroid differentiation was induced by haemin in these two 
cell lines. Therefore, the impact of isoform expression on these parameters can be 
assessed. However the differences in qPCR data from the two cell lines suggest direct 
comparison between K562 and Meg-01 responses to haemin at the transcriptional level 
may be difficult.  
5.5.2 The effects of isoform expression on response to TPA in 
K562 and Meg-01 cells 
Having validated the ability of TPA to induce megakaryocytic differentiation in both K562 
and Meg-01 cells the impact of GATA-1 isoform over-expression on this differentiation 
was assessed. Results are presented below: 
5.5.2.1   Effects on DNA ploidy 
Fig 5.20a shows effects on ploidy in K562 cells and Fig 5.20b in Meg-01 cells. 
Comparison between the two isoforms and the vector only control shows: 
1. In K562 cells GATA-1FL expression is associated with lower baseline ploidy (90% of 
cells 2N compared to 60% in vector only control) but more rapid induction of 4N and >4N 
populations on TPA treatment suggesting accelerated differentiation down the 
megakaryocytic lineage. GATA-1s expression shows broadly similar baseline ploidy to the 
vector only control, but again a larger proportion of cells develop increased ploidy with 
TPA. In contrast to GATA-1FL the GATA-1s isoform produces more 4N cells and less 
>4N cells which may suggest it is capable of committing to megakaryocytic differentiation 
but that these cells mature less rapidly than with GATA-1FL. 
2. In Meg-01 cells GATA-1FL expression does not show more rapid induction of 4N status 
but by day 3 of differentiation higher numbers of >4N cells are seen. GATA-1s expressing 
cells show lower numbers of both 4N and especially >4N cells compared to both GATA-
1FL and empty vector by day 3. Results Chapter  5    274 
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Fig 5.20 DNA ploidy changes in response to TPA 
(a) percentages of K562 transgenic cell lines with 2N, 4N and >4N DNA content as measured 
by propidium iodide incorporation on days 0, 1 and 3 following TPA treatment 
(representative data from 1 of 2 experiments shown), Vector =K562 empty vector, FL=GATA-
1FL and SH=GATA-1s expressing cells (b) same analysis performed for Meg-01 cells 
(representative data from 1 of 2 experiments shown). 
Two interesting observations emerge from these data. Firstly Meg-01 cells, despite clear 
baseline commitment to the megakaryocytic lineage, actually show lower degrees of ploidy 
on differentiation with TPA, regardless of the transgene expressed, when compared to 
K562 cells. Secondly, whilst GATA-1s is capable of driving megakaryocytic commitment Results Chapter  5    275 
in K562 cells it appears to inhibit commitment (when compared to empty vector) in Meg-
01. As discussed above, it is impossible to directly attribute these results to the presence of 
trisomy 21 in these cells. However, these data are certainly consistent with current theories 
suggesting that the combination of GATA-1s and trisomy 21 leads to outgrowth of 
immature megakaryocytic precursors blocked in differentiation, whilst cells carrying 
GATA-1s in the absence of trisomy 21 are capable of terminal megakaryocytic 
differentiation.   
5.5.2.2   Effects on gene expression profiles 
The effect of transgenic over-expression of the GATA-1 isoforms were compared to empty 
vector controls using TLDA plate qPCR analysis of cDNA extracted from day 0, 6 hour, 
day 2 and day 5 time-points. The 15 genes assayed were previously described in section 
5.4.7. Prior to this analysis it was necessary to show that the expression of the reference 
housekeeping gene (18SrRNA) was not up or down–regulated with TPA treatment of cells 
as this would invalidate comparison between test genes at different time-points (levels of 
expression of the reference gene must remain constant if it is to accurately normalise for 
template cDNA levels between samples). Conventional Taqman qPCR was performed 
using a 1 in 10 dilution of cDNA prepared using 2µg starting RNA as described in 
materials and methods section 2.8.4. Each sample was assayed in triplicate and 3 biological 
replicates were run for each time point. A commercially available 18SrRNA primer and 
probe set (Applied Biosystems) was used.  Results are shown in Fig 5.21a and statistical 
analysis (one way ANOVA) confirmed that levels of 18SrRNA expression are unaffected 
by TPA differentiation in both cell lines. Fig 5.21b presents the same analysis for haemin 
differentiation (discussed in section 5.5.3 below) and again confirms that levels of 
18SrRNA expression are unaffected by Haemin treatment. 
Having established that comparison between time-points was valid the effects of GATA-1 
isoforms on TPA induced differentiation were analysed. Results are shown in Fig 5.22 (for 
K562) and Fig 5.23 (for Meg-01) and discussed below. Results Chapter  5    276 
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Fig 5.21 Variation of 18SrRNA levels with TPA and Haemin treatment 
(a) with TPA treatment (b) with Haemin treatment. No significant differences were seen with 
CT values over time (one way ANOVA) 
 
5.5.2.3   Gene expression in K562 transgenics 
Fig 5.22 overleaf summarises the results of gene expression analysis in K562 transgenic 
cells when treated with TPA.  All assayed genes (except 18SrRNA) showed statistically 
significant differences in gene expression over time when empty vector control cells were 
treated with TPA (i.e. day 0 versus 6 hours versus D2 versus D5 (one-way ANOVA 
looking at variation in gene expression levels in the K562 empty vector group). To 
examine the impact of individual isoforms on these gene expression patterns, 2-way 
ANOVA analysis was performed with Bonferroni post-tests to compare replicate means 
for each time point. Untreated (day 0) empty vector control cells were used as the 
calibrator for fold change (i.e. their expression levels were arbitrarily set at 1.0). Results Chapter  5    277 
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Fig 5.22 Gene expression patterns in TPA treated K562 transgenic cells 
Genes showing statistically significant variations in gene expression with the different 
GATA-1 isoforms are shown. Stars refer to the level of statistical significance when the test 
gene is compared between empty vector and the GATA-1FL or GATA-1s isoform  *=p≤0.05, 
** p<0.01, *** p<0.001. # = statistically significant difference when GATA-1FL and GATA-1s 
expression levels are directly compared (p<0.05). Genes are colour coded according to their 
dominant function. Red=erythroid differentiation, Blue=megakaryocytic differentiation, 
Green=lineage choice, Yellow=cell cycle/proliferation. Results Chapter  5    278 
The GATA-1FL isoform produced statistically significant alterations in zetaglobin 
(delayed down-regulation at 6 hours, followed by more profound down-regulation at day 2 
and 5), GATA-1 (down-regulation at 6 hours and day 5), ski (down-regulation at 6 hours), 
NFE2 (down-regulation at day 2 and 5) and  Ikaros (down-regulation at day 2) expression 
levels when compared to the empty vector control. The GATA-1s isoform produced a 
significant change in ski gene expression (up-regulation at 6 hours) compared to empty 
vector and less repression of c-myb at 6 hours than empty vector or GATA-1FL. When 
comparing expression levels in GATA-1FL and GATA-1s transgenics, statistically 
significant differences in their effect on gene expression were seen for all the same genes 
and time points as seen with GATA-1FL vs. empty vector. One additional gene – PU.1 
displayed a significant difference when expression levels were compared between the two 
isoforms, with GATA-1FL showing less down-regulation than with GATA-1s (p=0.05). 
Overall this pattern of changes suggests that the GATA-1s isoform does not exert a 
dominant role on gene expression in the context of K562 TPA differentiation and instead 
largely mimics, with the notable exception of ski, the expression patterns seen in empty 
vector controls. In contrast GATA-1FL over-expression produces a number of dominant 
changes with higher levels of zetaglobin expression early on and lower levels of NFE2 
later on. The higher levels of zetaglobin are explicable by the increased erythroid 
commitment of K562 cells expressing the GATA-1FL transgene (as discussed above), with 
the need to reverse this commitment prior to megakaryocytic differentiation. NFE2 has a 
more complex bimodal pattern of expression, is a GATA-1 target gene, and is important in 
both megakaryocytic and erythroid lineages. The lower levels of NFE2 at day 5 may 
simply reflect the lower levels of GATA-1 expression at this time-point. As far as GATA-1 
expression is concerned the GATA-1FL expressing cells show greater levels of repression 
at all time points, this may reflect more effective autoregulation by the FL transgene than 
the GATA-1s transgene either by virtue of the presence of the N terminal domain or due to 
higher expression levels from the GATA-1FL construct. 
Finally the expression patterns of the c-myb and ski genes are interesting. c-myb is a key 
haematopoietic transcription factor involved in stem cell self-renewal and lineage decisions 
and needs to be down-regulated to allow terminal differentiation. The reduced repression 
of c-myb with TPA treatment is similar to that observed for in vitro megakaryocytic 
differentiation of GATA-1s transgenic ES cells (Li, et al 2005) and may partly explain the 
apparent block to terminal maturation. Ski is an oncoprotein found to act in several 
signalling pathways resulting in transcriptional repression (Shivdasani 2001). Although 
widely expressed in haematopoietic and non-haematopoietic tissues at low level it shows a 
particular peak of expression in some murine bipotent meg-erythroid precursors with   Results Chapter  5    279 
much lower/undetectable levels in earlier precursors or unipotent megakaryocytic or 
erythroid precursors (Pearson-White, et al 1995). Other studies have established that ski 
expression is upregulated upon megakaryocytic differentiation of K562 cells with TPA 
(Namciu, et al 1994). In addition it has been shown to block erythroid differentiation by a 
direct interaction with GATA-1 involving the C-terminal Zinc finger preventing DNA 
binding of the GATA-1-ski complex to known GATA-1 target genes (Ueki, et al 2004). 
Overall these data suggest ski expression is essential for meg-erythroid commitment but 
that effective down-regulation is required to allow terminal differentiation. The higher 
levels of ski upregulation with the GATA-1s isoform may suggest an increase in bipotent 
MEP formation in these cells. The lack of upregulation of ski in GATA-1FL isoform 
expressing cells has several possible explanations. Since these cells clearly commit to the 
megakaryocytic lineage (as shown by ploidy analysis) this is unlikely to reflect decreased 
megakaryocytic differentiation in these cells, instead it is possible that the peak of 
expression occurred earlier (rapid modulation of mRNA levels has been documented 30 
minutes to 3 hours following TPA treatment of K562 cells (Alitalo 1990)) and was over by 
6 hours. Alternatively these cells may have already passed this ski peak prior to TPA 
treatment by virtue of their high baseline GATA-1FL expression. Further investigation of 
the role of ski in commitment to the meg-erythroid lineage is clearly needed and it would 
be extremely interesting to study ski levels in patients with TAM/AMKL.  
5.5.2.4   Gene expression in Meg-01 transgenics  
Next, the influence of GATA-1 isoform expression on TPA induced differentiation in 
Meg-01 cells was assessed. Similar to K562 cells, all studied genes with the exception of 
PU.1 showed a statistically significant difference in gene expression over time (i.e. day 0 
versus 6 hours versus D2 versus D5 (one-way ANOVA looking at variation in gene 
expression levels in the Meg-01 empty vector group). However, in contrast to K562 cells 
only a few genes showed differential regulation by the two isoforms. These results are 
shown in Fig 5.23. Expression of the GATA-1FL isoform produced a small but statistically 
significant change in GATA-2 levels (lower than empty vector at 6 hours of 
differentiation) and zetaglobin (down-regulated at the 6 hours and day 2). The GATA-1s 
isoform produced a similar modest down-regulation of GATA-2 at 6 hours and day 2, 
down-regulation of zeta-globin at day 2, and a more rapid and sustained down-regulation 
of Gp1b levels (significant at 6 hours and day 2). Otherwise all other genes showed similar 
responses in terms of alteration in gene expression with all three constructs. Results Chapter  5    280 
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Fig 5.23 Gene expression patterns in TPA treated Meg-01 transgenic cells 
Genes showing significant alterations with GATA-1 isoform expression are shown. *=p≤0.05, 
**=p<0.01 and ***=p<0.001 
These results suggest that GATA-1 isoform over-expression has only a very modest or 
negligible effect on commitment to the megakaryocytic lineage in Meg-01 cells. The low 
level expression from the GATA-1FL transgene (as discussed above and shown in fig 5.9) 
makes interpretation of these results difficult although the modulation of zeta-globin 
expression levels suggests that even at this low level it is having some effect. The GATA-
1s isoform appears to be expressed at higher level (fig 5.9) and its effects on Gp1b 
expression are intriguing – it may be that the excess GATA-1s in the transgenic cells is 
binding to Gp1b regulatory elements but cannot provide the necessary co-factors to 
stimulate expression leading to a down-regulation in these cells compared to the GATA-
1FL and empty vector expressing cell lines i.e. it is acting in a dominant negative manner. 
It might be expected that Gp1b would show up-regulation during megakaryocytic 
differentiation but it may be that expression levels in the day 0 (i.e. comparator) cells are 
already high in this cell line and therefore no further up-regulation is required. An 
alternative explanation is that this assay is relatively inefficient and does not accurately 
reflect Gp1b levels – this is supported by a number of observations: Results Chapter  5    281 
1. The high CT at which Gp1b expression crosses the threshold (which leads to difficulty 
in accurate relative quantitation since the number of cycles between detection of the 
endogenous control gene and the test gene is high- this magnifies any small errors in 
calculated efficiency values) 
2. The high inter-plate variation in assay results (making many of the observed variations 
in Gp1b expression statistically insignificant). 
For these reasons results obtained with Gp1b should be interpreted with caution. 
In summary, TPA treatment results in an increase in DNA ploidy which is more 
prominent in K562 cells than Meg-01. Expression of the GATA-1FL isoform causes 
increased numbers of cells with >4N DNA content in both cell lines. The GATA-1s 
isoform appears to inhibit the development of increased ploidy in Meg-01 cells (in the 
context of trisomy 21) whereas it mimics empty vector in K562 cells. Gene expression 
profiles show greater down-regulation of erythroid genes by the GATA-1FL isoform. 
The ski gene, a marker of bipotent MEPs, shows upregulation in K562 GATA-1s cells 
and down-regulation in K562 GATA-1FL cells. c-myb is inadequately repressed with 
GATA-1s and finally, Meg-01 GATA-1s transgenics show sustained and marked 
reduction in Gp1b mRNA levels. These latter observations suggest that expression of 
GATA-1s may block terminal differentiation and merit further investigation to 
determine their significance. 
5.5.3 The effects of isoform expression on response to haemin in 
K562 and Meg-01 cells 
The blast cells in TAM/AMKL show a mixed phenotype with both megakaryocytic and 
erythroid cell surface antigen expression and expression of erythroid and megakaryocytic 
genes at the mRNA level (Ito, et al 1995, Zipursky 2003). Therefore it is reasonable to 
hypothesise that the GATA-1s isoform may show unique properties in erythroid as well as 
megakaryocytic differentiation. To test this, the impact of GATA-1 isoform expression on 
in vitro erythroid differentiation was studied. 
5.5.3.1   Haemoglobin production in K562 cells 
As already described, Haemin treatment of K562 cells induces detectable haemoglobin as 
manifested by a pink colouration of the cell pellet on harvesting. This pink colouration Results Chapter  5    282 
appeared earlier (day 1 compared to day 2), and was more intense, in K562 GATA-1FL 
transgenic cells. K562 empty vector and K562 GATA-1s cells both became pink on day 2 
and showed similar intensities over the time course of TPA treatment (data not shown).  
5.5.3.2   Gene expression in K562 transgenics 
Following Haemin treatment cells were harvested at day 0, 6 hours, day 3 and day 5. RNA 
extraction and cDNA synthesis were performed as described above (section 5.4.7). TLDA 
plate assays were run on 3 biological replicates for each transgene at each time point. 
Results are shown in Fig 5.24 overleaf.  Again all genes showed significant variations in 
expression with time during haemin differentiation. The majority of genes showed 
differential levels of expression with the 3 transgenes with only cyclin D2, Bach-1 and D6 
showing no statistical differences between all 3 constructs. 
1. Effect of the GATA-1FL isoform: GATA-1FL expression led to significant upregulation 
of zeta-globin expression (6 hours and day 3), EKLF expression (6 hours) and NFE2 
expression (6 hours) compared to empty vector. Significant down-regulation of various 
known GATA-1 target genes was also seen – GATA-1 itself (day 3 and 5), GATA-2 (6 
hours and day 5), Ikaros (6 hours and day 3), c-myb (day 3), NFE2 (day 3 and 5) and PU.1 
(day 3). Ski again showed the most interesting pattern of expression with significant down-
regulation in the GATA-1FL isoform at baseline and 6 hours and day 3 whilst the vector 
and short isoform initially upregulated ski at 6 hours and then down-regulated it by day 3. 
Since ski down-regulation is an essential event prior to terminal erythroid differentiation 
this rapid down-regulation with the GATA-1FL transgene may reflect the more rapid 
erythroid commitment seen in these cells. 
2. Effect of the GATA-1s isoform: GATA-1s expression patterns generally mimicked 
GATA-1FL. Significant up-regulation (compared to empty vector control) was seen with 
zeta-globin (6 hours), EKLF (6 hours) and (unlike GATA-1FL) c-myb (6 hours, day 3 and 
day 5). Significant down-regulation was seen with GATA-1 (6 hours and day 5), GATA-2 
(6 hours), Ikaros (6 hours and day 5), and ski (6 hours). However, when comparing 
GATA-1s levels to GATA-1FL levels of gene regulation, the FL isoform showed 
significantly larger effects (either more repression or more up-regulation) for zeta-globin, 
c-myb, GATA-1, Ikaros, NFE2 and Ski.  Results Chapter  5    283 
K562 Haemin Zetaglobin
Day 0 6 hours Day 3 Day 5
0.125
0.25
0.5
1
2
4
8
16 Empty vector
GATA-1FL
GATA-1s
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin EKLF
Day 0 6 hours Day 3 Day 5
0.125
0.25
0.5
1
2
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin GATA-1
Day 0 6 hours Day 3 Day 5
0.125
0.25
0.5
1
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin GATA-2
Day 0 6 hours Day 3 Day 5
0.5
1
2 Empty vector
GATA-1FL
GATA-1s
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin Ikaros
Day 0 6 hours Day 3 Day 5
0.125
0.25
0.5
1
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin PU.1
Day 0 6 hours Day 3 Day 5
0.25
0.5
1
2
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin NFE2
Day 0 6 hours Day 3 Day 5
0.0625
0.125
0.25
0.5
1
2
Empty vector
GATA-1FL
GATA-1s
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
 K562 Haemin c-myb
Day 0 6 hours Day 3 Day 5
0.125
0.25
0.5
1
2
Empty vector
GATA-1FL
GATA-1s
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
 K562 Haemin  Cyclin D2
Day 0 6 hours Day 3 Day 5
0.25
0.5
1
2
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin ski
Day 0 6 hours Day 3 Day 5
0.25
0.5
1
2
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
**
**
**
**
*
** *
*
** ** *
*
**
***
*
*
*
* ***
***
** * *
******
*
***
**
**
**
*
*
K562 Haemin Zetaglobin
Day 0 6 hours Day 3 Day 5
0.125
0.25
0.5
1
2
4
8
16 Empty vector
GATA-1FL
GATA-1s
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin EKLF
Day 0 6 hours Day 3 Day 5
0.125
0.25
0.5
1
2
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin GATA-1
Day 0 6 hours Day 3 Day 5
0.125
0.25
0.5
1
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin GATA-2
Day 0 6 hours Day 3 Day 5
0.5
1
2 Empty vector
GATA-1FL
GATA-1s
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin Ikaros
Day 0 6 hours Day 3 Day 5
0.125
0.25
0.5
1
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin PU.1
Day 0 6 hours Day 3 Day 5
0.25
0.5
1
2
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin NFE2
Day 0 6 hours Day 3 Day 5
0.0625
0.125
0.25
0.5
1
2
Empty vector
GATA-1FL
GATA-1s
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
 K562 Haemin c-myb
Day 0 6 hours Day 3 Day 5
0.125
0.25
0.5
1
2
Empty vector
GATA-1FL
GATA-1s
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
 K562 Haemin  Cyclin D2
Day 0 6 hours Day 3 Day 5
0.25
0.5
1
2
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
K562 Haemin ski
Day 0 6 hours Day 3 Day 5
0.25
0.5
1
2
F
o
l
d
 
c
h
a
n
g
e
 
(
R
Q
)
**
**
**
**
*
** *
*
** ** *
*
**
***
*
*
*
* ***
***
** * *
******
*
***
**
**
**
*
*
 
Fig 5.24 Gene expression changes in K562 transgenics treated with Haemin 
*=p≤0.05, **=p<0.01 and ***=p<0.001 
Overall these data suggest that GATA-1FL is driving terminal erythroid differentiation in 
K562 cells and that GATA-1s expression produces similar gene expression changes but to Results Chapter  5    284 
a lesser extent. This implies that GATA-1s is acting as a hypomorphic variant of GATA-
1FL in these cases. The c-myb result is particularly interesting, it is thought that c-myb 
needs to be down-regulated prior to terminal differentiation, one of the key findings from 
the GATA-1s transgenic mice was that fetal liver derived megakaryocytic precursors failed 
to down-regulate c-myb when differentiated in vitro (Li, et al 2005). These results confirm 
these findings in a completely different experimental system. The same paper also 
described similar lack of repression with GATA-1s for Ikaros, PU.1, GATA-1 and GATA-
2 – also seen above. Whether this reflects lower levels of GATA-1s expression from the 
transgene, or lack of the N-terminus, remains unclear. 
5.5.3.3   Gene expression in Meg-01 transgenics 
The same experiments were performed in Meg-01 cells. Cells were prepared as described 
for K562 above. The results of transgene expression are shown in Fig 5.25 overleaf. The 
majority of genes showed significant differences in expression levels with the 3 constructs 
although ikaros, β-globin, zeta-globin, ski, Erg3 and cyclin D2 showed similar patterns in 
all 3. Results for the differentially expressed genes are discussed below: 
1. Effect of the GATA-1FL isoform: Significant up-regulation (compared to empty vector) 
was seen for NFE2 (6 hours and day 5), PU.1 (6 hours), GATA-1 (6 hours), EKLF (6 
hours), c-myb (6 hours) and Gp1b (6 hours). Only GATA-2 (6 hours), EKLF (day 5) and 
c-myb (day 5) were significantly down regulated compared to empty vector. 
2. Effect of the GATA-1s isoform: Again the short isoform results mimicked the FL 
isoform results with upregulation of NFE2 (6 hours and day 5), GATA-1 (6 hours), c-myb 
(6 hours) and EKLF (6 hours and day 5). Down regulation was seen in GATA-2 (6 hours), 
Bach-1 (6 hours) and Gp1b (all time points). However on this occasion there was less 
evidence of GATA-1s acting in a hypomorphic manner with the majority of genes showing 
equivalent or increased fold change with GATA-1s.  
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Fig 5.25 Gene expression changes in Meg-01 transgenics treated with 
haemin 
*=p≤0.05, **=p<0.01 and ***=p<0.001 
Since GATA-1s is more highly expressed in Meg-01 cells compared to K562 (as 
evidenced by spontaneous in vitro selection for high GFP expressers and western blot data) 
this lends support to the theory that at least some of the hypomorphic effects observed in Results Chapter  5    286 
the K562 assays may be overcome by over-expression of GATA-1s. As discussed in 
chapter 1 section 1.2.3.3, this has previously been reported with GATA-1s rescue of 
GATA-1 deficient transgenic mice, where only high levels of transgene expression were 
able to prevent embryonic lethality (Shimizu, et al 2001) . This observation makes the 
Gp1b results particularly interesting. In this case it would be predicted that the more highly 
expressed GATA-1s transgene would cause a greater rise in Gp1b than the FL isoform 
when in fact it produced a significant and sustained down-regulation both with Haemin and 
TPA treatment. Unfortunately Gp1b is not expressed in K562 cells making it impossible to 
compare these two cell lines. 
In summary, the two isoforms show different behaviour with Haemin differentiation in 
K562 cells. GATA-1FL appears to drive terminal erythroid differentiation with more 
rapid visible haemoglobinisation of harvested cell pellets. At a gene expression level 
erythroid genes are transiently upregulated by GATA-1FL and genes involved in 
alternative lineage choices are down regulated along with c-myb and cyclin D2. The 
GATA-1s isoform appears to act as a hypomorphic allele with reduced levels of gene 
activation and repression. This is consistent with previous reports. In Meg-01 cells there 
is a less marked difference in the expression patterns of the two isoforms, which may 
reflect higher expression levels of the GATA-1s transgene. 
5.5.4 The impact of GATA-1 isoform expression on Erg3 and 
Bach-1 
As previously discussed in Chapter 1 section 1.3.2.4 a number of chromosome 21 genes 
have been proposed as candidates for the exclusive link between trisomy 21, GATA-1s and 
TAM/AMKL. These include AML-1, Erg3 and Ets2 as possible drivers of a meg-erythroid 
response and Bach-1 as an inhibitor of terminal differentiation. The Erg3 and Bach-1 genes 
were included in this gene expression analysis. Results from these analyses did not always 
produce statistically significant differences between GATA-1FL and GATA-1s transgenics 
and therefore they are not included in many of the results reported above. However they 
merit separate consideration because comparison between their expression patterns in 
K562 (disomic for chromosome 21) and Meg-01 (with trisomy 21) may shed light on their 
potential roles in DS-AMKL/TAM.  
Erg3 is upregulated in a number of AMKL cell lines (Rainis, et al 2005). Erg3 is not 
detectable in K562 cells whilst it is easily detectable in Meg-01 cells compatible with 
increased expression in the presence of trisomy 21. In addition Erg3 expression levels are Results Chapter  5    287 
increased on TPA induced differentiation in Meg-01 and Erg3 transcripts become 
detectable in K562. In order to look at relative expression patterns in K562 and Meg-01 
during differentiation transcript levels, from 6 hours onwards, were compared to baseline 
Meg-01 empty vector cells – the results are shown in Fig 5.26a. As can be seen, baseline 
expression is higher in Meg-01 and although K562 cells upregulate Erg3 on differentiation 
they remain several fold lower than levels seen in Meg-01. Interestingly despite its 
postulated role in megakaryocytic differentiation Erg3 was also upregulated by day 3 of 
haemin treatment of both cell lines although levels then fell back to baseline. The 
expression of the various GATA-1 isoforms had no impact on Erg3 expression levels (data 
not shown) which is unsurprising given that it is not known to be a GATA-1 target gene.   
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Fig 5.26 Erg3 and Bach-1 expression levels in K562 and Meg-01 cells 
(a) Response of Erg3 to TPA and Haemin differentiation in Meg-01 and K562 cells, data is 
shown for the empty vector transgenic cells but there were no significant differences 
between any of the 3 transgenes (b) Response of Bach-1 to TPA and Haemin differentiation, 
again empty vector data is shown, the only significant difference between isoforms was 
seen with GATA-1s during haemin differentiation illustrated in the previous figure (fig 5.25). Results Chapter  5    288 
Bach-1 has been reported to be upregulated in 2 independent microarray studies of DS-
AMKL/TAM (Bourquin, et al 2006, Ge, et al 2006) and was also shown to be rapidly 
upregulated on GATA-1 rescue of a GATA-1 deficient cell line (Welch, et al 2004). 
Despite this the TLDA plate data showed no evidence of Bach-1 upregulation at baseline 
in Meg-01 cells compared to K562. During TPA and Haemin differentiation Bach-1 was 
upregulated in both cell lines at 6 hours and then down-regulated. In general expression 
levels were lower in Meg-01 than K562 suggesting that trisomy 21 in these cells did not 
increase levels during differentiation (as shown in Fig 5.26b). In addition the only 
difference between the transgenes was increased repression of Bach-1 by GATA-1s during 
haemin differentiation in Meg-01 (illustrated in Fig 5.25 bottom graph). This suggests that, 
even in the context of GATA-1s expression, Bach-1 is not over-expressed. Therefore these 
data do not lend support to the theory that Bach-1 is over-expressed in the context of 
trisomy 21, although it is possible that this varies with different cellular contexts.  
In conclusion, gene expression data support a potential role for Erg3 over-expression as 
a driving force for meg-erythroid expansion in trisomy 21. They do not, however, 
provide any evidence that Bach-1 is upregulated at baseline in trisomy 21 or that the 
GATA-1s isoform leads to upregulation of Bach-1 expression.  
5.5.5 Alternative approaches to studying the effects of isoform 
expression 
Although the studies above yielded a number of interesting results, one major problem 
with interpreting the results of isoform over-expression in K562 and Meg-01 cells is the 
fact that these cells express their own endogenous GATA-1FL and GATA-1s at relatively 
high levels. This is likely to obscure the effects of the expressed transgenes. This does not 
necessarily invalidate the results (and in fact may make any observed differences even 
more likely to be significant) but it considerably complicates the analysis and further 
investigation of these results. Since GATA-1 is such a fundamental transcription factor for 
megakaryocytic and erythroid differentiation, it is highly unlikely that any haematopoietic 
cell line capable of differentiation along these lineages would not show similarly high 
levels. The use of cells from other lineages is also impossible as GATA-1 requires cell 
specific co-factors in order to exert its transcriptional effects and therefore any alterations 
in GATA-1 activity in these cell lines could not be directly attributed to the transgene. This 
need for cofactors was confirmed by the failure of reporter gene assays in the HEK cell 
line described in section 5.2.4.3 above.  Results Chapter  5    289 
The approach of gene targeting in murine ES cells is obviously an excellent solution to this 
problem but, as described in chapter 4, is technically challenging. One other way of 
addressing this problem would be to knock-down endogenous GATA-1 expression in 
K562 and Meg-01 cells (using siRNA technology) and then look at the effect of transgenic 
expression of GATA-1 isoforms in these cells. This is facilitated by the fact that the 
transgene is murine GATA-1 and the cell lines are of human origin and therefore siRNA 
duplexes carrying sequence identity to human GATA-1 will knock down endogenous 
GATA-1 whilst leaving the transgene unaffected. In order to further explore some of the 
interesting results from the studies above, this approach was attempted as described below: 
5.5.6 siRNA mediated knockdown of human GATA-1 
siRNA mediated gene knockdown is a relatively new molecular biology tool. It involves 
the introduction of small (20-25bp) RNA duplexes with complementary sequences to the 
desired target sequence. Target recognition is followed by mRNA cleavage and therefore 
reduction of gene expression. Extremely high rates of gene knock-down have been 
reported in the literature for some genes although it should be noted that not all genes show 
these dramatic effects and that commercial siRNAs vary considerably in their efficacy (as 
discussed below). Many of these commercially available siRNAs are designed using 
computer algorithms which analyse the target mRNAs and identify theoretically optimal 
sequences likely to produce good levels of knockdown, the chances of these actually 
producing in vitro knockdown can be enhanced by targeting more than one section of the 
mRNA and pooling the individual duplexes before introduction into cells. From this 
discussion it can be seen that the vast majority of commercially derived siRNAs are not 
functionally tested prior to despatch.  
When devising siRNA experiments it is vital to include appropriate controls. Four controls 
are generally needed: 
1. A control for non-specific inhibition of gene expression or protein synthesis in the 
cell: introduction of RNA duplexes into mammalian cells can activate an interferon 
response which results in a general inhibition of protein synthesis and eventual cell death. 
In addition transfection of siRNA does not always produce entirely sequence specific 
effects. Besides the interferon response, other undesired changes can occur in the cell’s 
gene expression profile, these are usually referred to as off-target effects. In order to 
control for the interferon response and off–target effects it is necessary to include a 
negative siRNA control i.e. an siRNA that is non-functional and non-targeting. If this Results Chapter  5    290 
negative control leads to a reduction in expression of the target gene then induction of off-
target effects or the interferon response can be inferred. A commercial fluorescently tagged 
non-functional siRNA was chosen (siGLO RISC-free siRNA). 
2. A control for non-specific effects of activation of the siRNA processing pathway: a 
second control involves the introduction of non-targeting but functional siRNA capable of 
interaction with RISC and processing within the siRNA pathway (described in chapter 1 
section 1.1.3.3.2). A commercial validated control agent (siCONTROL) was used.   
3. A control for transfection efficiency: differences in the amount of gene knockdown 
between cells may reflect differences in transfection rates rather than differences in 
efficacy of the introduced siRNA – this is particularly important during the optimisation 
phase where different concentrations of siRNA are being tested. This was achieved by use 
of the siGLO RISC-free siRNA which acts as a dual control for off-target effects 
(discussed above) and, by virtue of a fluorescent tag (Rhodamine), for  transfection 
efficiency. 
4. Multiplicity controls to confirm gene specific knockdown: finally it is useful to be 
able to perform multiplicity controls. This involves using a pool of siRNAs directed 
against various regions of the gene. If a specific phenotype is detected on gene knockdown 
it is then possible to prove that this is a result of specific gene knockdown rather than off-
target effects by showing that each individual siRNA (components of the pool) is capable 
of reproducing the observed phenotype.  
Bearing all these factors in mind human GATA-1 gene silencing in K562 cells (wild-type) 
was attempted, with a view to proceeding to gene silencing in transgenic K562 cells and 
Meg-01 (leaving transgenic murine GATA-1 isoform expression intact) following proof of 
principle in K562. Unfortunately, at the time of devising these experiments there was no 
published data on human GATA-1 siRNA mediated knockdown and therefore no validated 
siRNA to chose. On the basis of a good reputation in the field and the availability of pools 
of siRNA duplexes it was decided to use a human GATA-1 siRNA pool (SMARTpool) 
designed by Dharmacon Inc. The sequences of the 4 pooled duplexes are listed in table 
2.12, chapter 2. It is notable that one of these duplexes (duplex 6) binds to a target 
sequence in exon 2 of the GATA-1 mRNA. In theory this duplex would selectively knock-
down the GATA-1FL isoform, as the alternatively spliced GATA-1s transcript lacks exon 
2 and therefore would escape cleavage.  Results Chapter  5    291 
5.5.6.1   Optimisation of transfection efficiency 
siRNA can be introduced to cells using lipid-mediated transfection or electroporation. 
Exposure to transfection reagents can affect gene transcription so a mock-transfected 
control was run for all experiments. A well established siRNA transfection agent was 
tested – Lipofectamine 2000 (Invitrogen). To examine transfection efficiency the non-
targeting fluorescently tagged –siGLO RISC-free siRNA was used. Cells were cultured 
and transfected as described in Materials and Methods section 2.13.7. 4 different 
concentrations of siGLO RISC-free siRNA (25-125nM) and 3 different quantities of 
lipofectamine 2000 (2.5μl-6μl) were tested. As shown in Fig 5.27a all combinations gave 
excellent transfection efficiencies. To ensure t h a t  t h e s e  F A C S  r e s u l t s  w e r e  n o t  d u e  t o  
adherence of transfection complexes to the surface of transfected cells rather than entry 
into the cells, confocal microscopy (as described in materials and methods, section 2.13.6) 
was also performed with nuclei counterstaining with DAPI. 3D visualisation was achieved 
using Z-stack software and confirmed distribution throughout the cytoplasm. Fig 5.27b 
shows a representative confocal image. Following this optimisation experiment 5μl of 
lipofectamine and 50nM of siRNA was used for subsequent experiments. 
(b) (a) Untransfected K562
25nM
50nM
75nM
125nM
 
Fig 5.27 Estimation of siRNA transfection efficiency using Rhodamine 
labelled RISC free siRNA 
(a) FACS analysis of transfected cells looking at Rhodamine fluorescence (FL2 channel), 
various concentrations of siRNA from 25nM to 125nM were tested, all gave acceptable 
transfection efficiencies with evidence of a dose response. 5μl of lipofectamine was used 
for all transfections except one (50nM pale blue line) which used 2.5μl, this did not 
dramatically affect transfection efficiency (b) representative confocal image, nuclei are 
counterstained with DAPI (blue) and Rhodamine fluoresces red. The intra-cytoplasmic 
location of the red signal was confirmed by Z-stack software (images not shown). 
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5.5.6.2   Effects of siRNA mediated GATA-1 targeting 
The next step was to attempt GATA-1 specific gene knockdown. 25nM of siGLO RISC-
free siRNA and 25nM of either siCONTROL or SMART pool GATA-1 siRNA were 
introduced into K562 cells. Mock transfected and untransfected cells were also used. After 
48 hours cells were harvested and counted. Cells (4x10
5) were used in a standard nuclear 
extract protocol (section 2.9.2 chapter 2), the remainder of the cell pellet was resuspended 
in FACS buffer and analysed for transfection efficiency. Excellent transfection efficiencies 
were again seen with a log shift in FL2 channel fluorescence in both SMART pool and 
siCONTROL transfected cells (data not shown). Western blotting was performed (as 
described in section 2.9.4) and equivalent protein loading was confirmed by Ponseau S 
staining of the membrane (section 2.9.5). Results are shown in fig 5.28a. It can be seen that 
both the SMART pool and siCONTROL reagents produced slightly lower levels of 
GATA-1 protein than untransfected K562 cells but that there was no evidence of specific 
GATA-1 silencing by the SMART pool.  
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Fig 5.28 siRNA knockdown of GATA-1 at the protein level 
(a) western blotting revels no evidence of protein knockdown 48 hours post transfection 
with siRNA (b) further attempts at knockdown with nuclear extracts at 72 hours post 
transfection using a variety of concentrations of siRNA (shown in boxes beneath figure) still 
failed to show significant knockdown at the protein level when control non-targeting siRNA 
(siCONTROL) was compared to GATA-1 specific siRNA (GATA-1 SMART pool) Results Chapter  5    293 
In case this effect was due to inadequate levels of siRNA in the cells the experiment was 
repeated using a variety of concentrations of SMART pool or siCONTROL siRNA from 
12.5nM to 100nM. Cells were left 72 hours prior to harvesting. Again, despite excellent 
transfection efficiencies (data not shown), and good cell viability (>90% with all 
transfectants, as measured by Trypan blue exclusion), there was no evidence of GATA-1 
specific silencing as shown in fig 5.28b. In fact, the lanes with the apparently lower 
GATA-1 protein levels all represented siCONTROL transfected cells and these differences 
were accounted for by small variations in the protein loading per lane (as seen by Ponseau 
S staining).  
As a final attempt to show specific knockdown of GATA-1 by the SMART pool it was 
decided to look for alterations in mRNA levels. Since mRNA represents the primary target 
of the siRNA, knockdown of mRNA may be more rapid and complete than knockdown at 
the protein level. 25nM of siGLO RISC-free siRNA and 75nM of SMART pool, duplex 6 
(no targeting of GATA-1s) or siCONTROL siRNA were transfected into K562 cells, a 
mock transfection control was also set up. Cells were harvested at 48 hours and following 
RNA extraction (RNeasy kit, section 2.8.1.2) and cDNA synthesis from 2μg starting RNA 
(Affinity Script II, section 2.8.4) the cDNA template was diluted 1 in 10 and qPCR 
performed. Custom GATA-1s primer and probes (table 2.11, chapter 2) were used to detect 
GATA-1s transcripts and levels were compared to the 18SrRNA housekeeping gene, K562 
untransfected cells were used as the calibrator. Results are shown in fig 5.29. In contrast to 
the western blotting results, a two-fold reduction in GATA-1s mRNA levels was seen with 
the SMART pool compared to either untransfected controls or siCONTROL transfected 
controls. The use of duplex 6 provided an additional negative control as this duplex, 
although showing sequence specificity for the GATA-1 target mRNA, should not alter 
GATA-1s mRNA levels (an exon 1-3 spliced transcript) as it binds to exon 2. This was 
confirmed with no change in gene expression levels compared to untransfected controls. 
Therefore, it appears that the GATA-1 SMART pool does achieve some gene specific 
knock-down at the mRNA level but that this is not translated into reduced protein levels at 
48 or 72 hours.  Results Chapter  5    294 
siRNA changes in GATA-1s gene expression levels
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Fig 5.29 Results of qPCR analysis of siRNA mediated GATA-1 knockdown 
 
5.5.6.3   Discussion of siRNA results 
Despite demonstration of specific GATA-1 knockdown at the mRNA level at 48 hours, 
GATA-1 protein knockdown could not be detected at 48 or 72 hours. To be of practical use 
in assessment of the impact of isoform expression on GATA-1 function, endogenous 
GATA-1 knockdown would have to occur at the protein level and be sustained and fairly 
complete. Therefore this technique was not pursued further. Various possibilities for lack 
of GATA-1 knockdown at the protein level include: 
1. A long half life of the GATA-1 protein: although the GATA-1 half-life has not been 
formally documented in the literature, the demonstration by other investigators of 
undetectable GATA-1 protein at 48 hours following successful siRNA knockdown (Li, et 
al 2008a) (discussed further below) suggests the 48 hour time point should have been 
sufficient to detect reductions in protein content. Results Chapter  5    295 
2. Incomplete mRNA knockdown: qPCR results show an approximately 2 fold reduction 
in mRNA levels. This may be insufficient to cause a drop in protein levels particularly if 
GATA-1 is subject to additional post-transcriptional or post-translational control  
3. Autoregulation: Since GATA-1 is known to autoregulate its expression, a transient fall 
in GATA-1 protein may be rapidly compensated for by increased gene transcription.  
4. A Growth/survival disadvantage in knockdown cells: since GATA-1 is known to 
promote survival and prevent apoptosis of erythroid precursors it is possible that cells with 
reduced levels of GATA-1 expression have a growth or survival disadvantage in culture. 
Therefore on more prolonged culture there would be a selective pressure for cells that had 
not undergone efficient gene knockdown.  
Subsequent to these studies three attempts at GATA-1 gene targeting by siRNA have been 
reported. Using a murine Dharmacon siRNA (D-045656-04) one group reported 
knockdown of murine GATA-1 although there was still easily detectable GATA-1 protein 
by Western blot and GATA-1 induced luciferase activity was about 70-80% of that seen 
with a control siRNA. Therefore this knockdown was modest at best (Masuda, et al 2007). 
In a human cell line (HT93) GATA-1 induction by ATRA treatment could be reduced at 
the protein level by transfection of a commercially available human GATA-1 siRNA (#sc-
29330, Santa-Cruz Biotechnology) at 10nM although again protein was still easily 
detectable by western blotting (Yoshida, et al 2007). Interestingly the group tried a variety 
of siRNA concentrations from 10-100nM and showed maximal specific inhibition at the 
lowest concentration. Finally one group have recently reported successful use of a 
commercial SiRNA (GenePharma Biotechnology) at a concentration of 1μM in K562 cells 
which showed moderate GATA-1 knockdown at 24 hours and complete absence of 
detectable expression at 48 hours by western blotting, although the control siRNA also 
showed moderate reduction in GATA-1 levels at this time point as measured by western 
blot. They also reported functional reduction in GATA-1 in that a GATA-1 reporter 
luciferase assay showed a reduction in transactivation from 100% to 50% with GATA-1 
siRNA knockdown (Li, et al 2008a). These published results suggest GATA-1 gene 
knockdown is possible but, unsurprisingly, the level of knockdown varies depending on the 
siRNA construct used.  In addition none of the studies was able to show complete 
knockdown of GATA-1, particularly at a functional level. This does not necessarily matter 
when the aim of the experiment is to assess the effects of reducing expression levels and 
then restoring expression levels on a defined output such as expression of a GATA-1 target 
gene. However, it would still complicate analysis of GATA-1 isoforms as differences Results Chapter  5    296 
between the constructs would be difficult to disentangle from subtle differences in the level 
or duration of (incomplete) endogenous GATA-1 knockdown. Successful use of siRNA for 
these purposes probably requires advances in siRNA technology allowing more prolonged 
and effective siRNA delivery with reduced non-specific toxic effects on cell protein 
synthesis. Given the rate of advance in this field these advances are likely to occur in the 
near future.  
5.6 Summary of the results of functional assessment of 
GATA-1 isoforms in murine and human cell lines 
This chapter has described experiments to investigate whether the two GATA-1 isoforms 
behave differently during in vitro assays of hematopoietic function. Using a variety of 
different techniques consistent differences between the two isoforms emerge i.e. 
1. The GATA-1FL isoform appears to drive terminal erythroid or megakaryocytic 
differentiation depending upon the context in which it is expressed. This is seen in murine 
and human cell lines. In murine ES cells there is an increase in erythroid and CFU-GM 
colony output compared to wild-type cells. In Meg-01 and K562 cells expression of the 
GATA-1FL transgene is associated with increased growth rates (particularly in Meg-01) 
and significant modulation of erythroid and alternative lineage genes at the mRNA level 
compared to empty vector and GATA-1s expressing cells. On induced differentiation with 
TPA, GATA-1FL expressing cells show increased DNA ploidy and rapid down regulation 
of genes required to allow terminal differentiation (c-myb, ski). On induced differentiation 
with haemin GATA-1FL rapidly become visibly haemoglobinised (< 24hours) and 
upregulate erythroid genes. 
2. The GATA-1s isoform is much less effective at supporting cellular differentiation. In 
murine cells expression of GATA-1s leads to almost complete ablation of erythroid and 
CFU-GM colony output. In human cell lines GATA-1s appears to act in most cases as a 
hypomorphic allele of GATA-1FL with similar changes in gene expression but to a much 
lesser extent. In general GATA-1s expression was associated with partial but incomplete 
differentiation with a reduced ploidy response to TPA treatment and inadequate repression 
of genes such as ski and c-myb which require down-regulation prior to terminal 
differentiation. In addition, expression of the GATA-1s isoform appeared to favour 
megakaryocytic over erythroid patterns of gene expression and features such as the 
upregulation of ski suggest it may promote maintenance of a bi-potential meg-erythroid Results Chapter  5    297 
precursor. The inability to up-regulate Gp1b expression, even when GATA-1s is expressed 
at high levels, suggests that the GATA-1s does not drive terminal megakaryocytic 
differentiation. 
Two human cell lines, K562 and Meg-01, were studied to test the hypothesis that the 
GATA-1s isoform may only manifest some biological properties in the presence of trisomy 
21. The comparison between these two cell lines is complicated because of differences in 
their stage of hematopoietic commitment, baseline gene expression profiles and the fact 
that they spontaneously segregated themselves into opposite high and low expressing 
transgene populations in culture (i.e. high expression of GATA-1FL and low expression of 
GATA-1s in K562 and vice versa in Meg-01). This observation is intriguing and cannot 
easily be explained by observed differences in growth rates or gene expression. However, 
it is extremely interesting that the cell line carrying trisomy 21 (Meg-01) spontaneously 
selected GATA-1s whilst the non-trisomy 21 cell line selected GATA-1FL. This mirrors 
the clinical observation that GATA-1s associated malignancy/myeloproliferation is only 
ever seen in the context of trisomy 21 leading to the hypothesis that the combination of 
GATA-1s and trisomy 21 confers a unique selective advantage not seen in disomic cells. In 
addition gene expression data suggest that Erg3 may be over-expressed in the presence of 
trisomy 21 but that Bach-1, another chromosome 21 candidate gene, does not show 
evidence of over-expression in this model system. Possible explanations for these 
phenomena are put forward in the discussion, chapter 7.  
Finally, these studies using CML cell lines suggest that modulations in GATA-1 levels of 
expression and isoform production can affect the ability of CML cells to proliferate and 
terminally differentiate. Taken alongside the discovery of a potentially hyper-functioning 
GATA-1 mRNA variant in a patient with CML – BC009797 discussed in chapter 3- it was 
decided to investigate the association between CML and GATA-1 further and in particular 
to test the hypothesis that GATA-1 mutations may be responsible for progression to blast 
crisis in CML. These studies are described in the next chapter. 298 
6  Analysis of GATA-1 Mutational Status in Chronic 
Myeloid Leukaemia 
6.1 Background 
The molecular basis for progression of chronic myeloid leukaemia from chronic phase to 
accelerated phase and blast crisis is not well understood. According to the type I and type 
II mutation hypothesis (Gilliland 2001) the bcr-abl oncoprotein, with aberrant tyrosine 
kinase activity, would provide a type 1 mutation and therefore a type II mutation in a gene 
involved in cellular differentiation would be predicted to be responsible for disease 
progression. This has been confirmed in a small number of cases (Zhang 2008), but in the 
majority of cases progression remains unexplained at a molecular level (Melo and Barnes 
2007).  
As discussed in Chapters 1 and 3, two pieces of circumstantial evidence suggest a possible 
role for aberrant GATA-1 expression in chronic myeloid leukaemia (CML) i.e. 
1. The cloning of an aberrant mRNA transcript – BC009797 from the bone marrow of a 
patient with chronic myeloid leukaemia. 
2. The strong morphological resemblance between transient abnormal myelopoiesis and 
the chronic phase of CML in particular the marked eosinophilia, thrombocytosis and 
basophilia in both conditions. 
Importantly, the study reporting the tight association between GATA-1 mutations and DS-
AMKL (Wechsler, et al 2002) did not investigate GATA-1 mutational status in CML. 
Given the plausible association between perturbations in GATA-1 function and 
progression of CML, it was hypothesised that mutations in GATA-1 could be involved in 
the transition from chronic phase to blast crisis in CML. To test this hypothesis, in silico 
analysis was performed followed by GATA-1 mutational analysis in CML patient samples. 
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6.2 In silico analysis  
To assess whether aberrant GATA-1 mRNA transcripts are a common feature of CML an 
in silico analysis was performed looking for all published ESTs aligning to the known 
GATA-1 mRNA sequence NM_002049. This search produced 14 ESTs longer than 500bp 
and a further 14 shorter sequences all derived from fetal tissues (and none from CML). 
Four of the fourteen longer sequences were derived from patients with CML the others 
came from normal adults (n=6) or fetal samples (n=4). Comparing the number of 
mismatches per 100 basepairs in the longer sequence set (so avoiding bias towards 
sequencing anomalies at the beginning of short transcripts) a statistically significant 
difference between CML samples and normal individuals was seen (p=0.007, fig 6.1). This 
finding needs to be interpreted with caution as ESTs commonly contain sequencing errors 
but it adds weight to the hypothesis that CML may be associated with GATA-1 mutations. 
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Fig 6.1 EST sequence error rate in CML and normal individuals 
Comparison of mismatches per 100bp in EST sequences derived from patients with CML 
(n=4) and normal individuals (n=10), p=0.007 using two-tailed t-test.   
 
6.3 Mutational analysis using patient samples 
6.3.1 Samples 
Genomic DNA from 24 patients with CML in accelerated phase (n=1), myeloid blast crisis 
(n=15) or lymphoid blast crisis (n=8) was kindly provided by Dr Gordon Strathdee 
**Results Chapter 6    300 
(Beatson Laboratories, Glasgow). This DNA was extracted from either peripheral blood or 
bone marrow samples. Leukocytes were isolated following ammonium chloride red cell 
lysis and CD34 selection was performed in some cases. DNA concentration varied from 
120ng/μl to 370ng/μl. A human embryonic kidney cell line – HEK293 was used to provide 
control DNA, extracted using cell lysis buffer and ethanol precipitation as described in 
materials and methods (section 2.7.1). Methods to optimise mutation detection and results 
of this analysis are described below. 
6.3.2 Optimisation of methods to detect GATA-1 mutations 
The in silico analysis above showed mismatches in CML samples scattered throughout all 
5 coding exons. Therefore it was decided to assess the entire coding sequence of GATA-1 
for mutations. A number of possible methods exist for analysis of mutations in DNA 
(Cotton 1997). These include single-strand conformation polymorphism (SSCP), 
Denaturing gradient gel electrophoresis (DGGE), mismatch cleavage methods, 
heteroduplex analysis including the use of denaturing high-performance liquid 
chromatography (DHPLC) and finally direct DNA sequencing (Cotton 1997). All except 
the latter rely on identification of a mismatch between wild-type and mutant sequences, the 
location and chemical nature of this mismatch still needs to be identified by sequencing. 
Therefore these methods are useful for screening multiple samples followed by targeted 
sequencing of only the abnormal products. Having assessed the various methods and 
considering the relatively small number of samples involved in this study, it was decided to 
test the sensitivity and specificity of direct sequencing. Experiments were initially 
performed on genomic DNA from HEK293 to establish methods before moving on to 
analysis of patient samples.  
6.3.3 Approach 1: PCR of coding exons followed by direct 
sequencing of products 
Amplification of DNA fragments for direct sequencing was performed by designing PCR 
primers to anneal to introns approximately 50-100 basepairs upstream and downstream of 
coding exons 2-6 to produce products of 200-570bp in length. Exon 6 is 518bp long and so 
was divided into two smaller fragments 6.1 and 6.2. The position of PCR primers, 
predicted products and representative electrophoresis gels are shown in fig 6.2, primer 
sequences are listed in materials and methods 2.4.5. These initial experiments confirmed 
that the primers produced a single band on gel electrophoresis. The PCR products were Results Chapter 6    301 
purified (QIAquick PCR purification kit, materials and methods section 2.7.5) and sent for 
standard Sanger sequencing (Agowa.de). Results confirmed that the PCR products 
matched the expected GATA-1 exons (data not shown). 
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Fig 6.2 PCR of coding exons with direct sequencing of products 
The position of primers is indicated with filled arrows. The striped arrows in exon 3 
represent additional splitting of this exon used approach 2, otherwise primer positions are 
approximately the same with both approaches. PCR amplification produces a single band of 
the correct size on gel electrophoresis (2% agarose gel). The identity of this band was 
confirmed on sequencing. 
 Since the amount of template DNA was limited it was important to test whether accurate 
sequencing could be achieved with low amounts of starting template. Therefore, a titration 
analysis was performed. The primer sets amplified DNA with variable efficiency so 
template titration was performed using a low efficiency primer set (exon 5) and a high 
efficiency combination (exon 6B). The results are shown in Fig 6.3 which shows that 50ng 
of template is sufficient for a strong product band using exon 6B primers but that 200ng is 
probably required to achieve adequate amplification with the less efficient exon 5 primers. 
In order to test whether direct sequencing could still produce good quality data from these 
small amounts of template 150ng of HEK 293 genomic DNA was used in the PCR 
reaction.  Following amplification using a Taq polymerase (ReddyMix, materials and 
methods section 2.10.1) fragments were purified using a QIAquick PCR purification kit. 
DNA concentration was estimated by gel electrophoresis and estimation of absorbance at 
260nm. Approximately 100-200ng of DNA was sent for commercial sequencing 
(Agowa.de). Good data were obtained from analysis of exon 3, 5 and 6A amplification 
products but other samples 2, 4 and 6B showed high background or were unable to deliver Results Chapter 6    302 
data. Although it would certainly have been possible to optimise this method further by the 
design of alternative primers, alteration of PCR reaction conditions, or use of alternative 
DNA polymerases with higher amplification efficiency, it was decided to explore other 
options in parallel as discussed below. 
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Fig 6.3 Titration of genomic DNA template for high and low efficiency PCR 
reactions 
HEK293 genomic DNA was diluted to produce stock solutions of 50ng/μl, 100ng/μl, 300ng/μl 
and 500ng/μl. 1-2μl of stock solution was added to a standard PCR reaction (ReddyMix plus 
1.25μl of forward and reverse primers) along with water to make a final template volume of 
2.5μl. 35 cycles of PCR were performed using optimised conditions for each primer pair.  
6.3.4 Approach 2: PCR of coding exons followed by analysis of 
products by DHPLC  
6.3.4.1   Principles of WAVE technique 
A second approach was to screen for mutations using detection of heteroduplexes by 
DHPLC followed by sequencing of any samples showing abnormal chromatograms (Xiao 
and Oefner 2001). A protocol was obtained from collaborators (Dr P Vyas and Dr C 
Fisher) who routinely perform GATA-1 mutational analysis as part of a neonatal screening 
programme for children with trisomy 21 (Vyas and Roberts 2006). Heteroduplex analysis 
can be performed in a variety of ways including by exploitation of different mobilities on 
non-denaturing gels but use of DHPLC allows automation and standardisation, which is 
particularly important for clinical applications (Cotton 1997). In this analysis a commercial Results Chapter 6    303 
DHPLC system optimised for heteroduplex analysis was used (WAVE – Transgenomics, 
Omaha, USA). An outline of the principles behind this technique is shown in Fig 6.4.   
Amplify fragments by PCR Mix test and control 
samples
Heat and cool
Analyse by DHPLC
Add hydrophobic negatively 
charged ions to allow retention 
of DNA on cartridge
Elute with 
acetonitrile
UV 
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Fig 6.4 Principles of WAVE mutation screening using DHPLC 
Essentially this involves amplification of test and control (ie non-mutated) DNA fragments 
by PCR. These reaction products are mixed and then heated to separate the DNA strands 
followed by cooling to allow reannealing. On cooling up to 4 possible duplexes are 
produced – control-control, test-test, control-test and test-control (Fig 6.4). These products 
are then mixed with the buffer triethylammonium acetate (TEAA). In solution this 
compound produces positively charged triethylammonium (TEA) ions with hydrophobic 
and hydrophilic ends. The positive charge on these ions associates with the negatively 
charged phosphate backbone of the DNA duplexes creating a hydrophobic “coating” on the 
DNA. This solution than passes through a cartridge (DNASep –Transgenomics) containing 
hydrophobic beads which retain the hydrophobic DNA-TEA complex. The cartridge is 
then heated to cause partial denaturation of the DNA duplexes and an increasing gradient 
of the organic solvent acetonitrile (ACN) flows through the cartridge. ACN provides a 
small hydrophilic counter-ion to cause disruption of the TEA-DNA bridge. This leads to 
elution of DNA complexes from the hydrophobic beads with mismatched complexes 
eluting first and then homoduplexes. The DNA is detected by passage through a UV Results Chapter 6    304 
detector measuring A260 and this measurement is plotted against time. If no mutation exists 
then the DNA will elute as a single homoduplex peak (sometimes with a prominent notch). 
If a mutation is present then between 1 and 2 additional peaks are produced (Fig 6.4). Each 
test DNA fragment will have an optimum elution temperature which is predictable by melt 
profile software.  
6.3.4.2   WAVE analysis of CML patient samples 
The design of PCR primers and optimisation of elution temperature conditions had already 
been performed for all 5 coding exons of human GATA-1 by our collaborators. The primer 
locations (but not sequences) essentially mirrored those used for direct sequence analysis 
above (as shown in Fig 6.2) with the exception of exon 3 which is 377bp long and was 
split into two fragments for amplification and analysis. All primer sequences are listed in 
section 2.4.5 materials and methods, along with the optimised elution temperature for each 
fragment. Primers were tested on HEK 293 genomic DNA and a CML blast crisis sample 
(M1277BC) and bands of the correct size were produced in all cases shown in Fig 6.5. 
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Fig 6.5 Amplification of coding exons of GATA-1 for analysis by DHPLC 
PCR was performed as described in section 2.11, 5μl was run on a 2% agarose gel to 
confirm amplification as shown. The residual sample was then used for DHPLC analysis 
(WAVE)  +/- direct sequencing.  
DNA fragments were amplified using AmpliTaq Gold DNA polymerase (Applied 
Biosystems) mixed with a proof reading DNA polymerase (Pwo, Roche). A hot-start 
protocol was used to increase specificity and yield (as detailed in section 2.11). 
Amplification was confirmed by running 5μl of product on a 2% agarose gel (fig 6.5). 10μl 
of sample was then mixed with 10μl of control DNA fragments amplified using the same 
primers from HEK293. Heteroduplexing was performed as described in section 2.11.2. The 
samples were then run on the WAVE platform. Each DNA fragment was analysed Results Chapter 6    305 
separately with two different elution temperatures (determined by melt profile software). A 
known mutant sample with a single basepair mismatch in exon 2 (OxMT) was run as a 
positive control. Representative chromatograms are shown in Fig 6.6. Overall 2 samples 
showed abnormal chromatograms: M949BC (myeloid BC) and M84BC (myeloid BC), 
both in the exon 5 fragment (Fig 6.6e and Fig 6.7), in addition to the exon 2 mutation in the 
positive control (Fig 6.6a). Another sample FMBC (myeloid BC) showed an aberrant 
chromatogram (Fig 6.6e), although the trace did not correspond to normal patterns of 
heteroduplex elution.  
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Fig 6.6 Chromatogram traces from WAVE mutational analysis 
Representative traces (a) to (g) are shown for all coding exons. The second set of elution 
temperatures produced similar results identifying the positive control (OxMT) and the three 
abnormal samples (M949BC, M84BC & FMBC), marked by arrows, with no additional 
abnormal chromatograms. The legend lists the samples tested and their corresponding 
trace colour. 
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6.3.4.3   Sequence analysis of samples with abnormal products 
To ascertain the cause of the abnormal chromatograms, samples M949BC, M84BC and 
FMBC along with 3 other randomly chosen control sequences with normal chromatograms 
(M997BC, M563BC, DTBC) and HEK293 genomic DNA underwent sequencing of all 
amplified fragments. Initially residual PCR products (35μl) were cleaned up using a 
Qiagen QIAquick PCR purification kit.  After suspension in 30μl of elution buffer, 4μl of 
product was used in a BigDye terminator sequencing reaction v3.1 (Applied Biosciences) 
using bi-directional primers (as described in section 2.7.6). The sequencing reaction was 
run overnight, the products were then  ethanol precipitated and then run on an ABI 3100 
capillary array sequencer (Perkin Elmer, Beaconsfield UK). Sequences were compared to 
the published GATA-1 sequence with annotation for known single nucleotide 
polymorphisms found in the Ensembl Human-Gene SNPView database 
(www.ensembl.org/Homosapiens/genesnpview). 
 
Fig 6.7 WAVE and sequencing chromatograms for the exon 5 fragment of 
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This analysis confirmed a mutation in M949BC and M84BC but in none of the other 
samples. M949BC had a single nucleotide substitution (C>T) in the intronic sequence 43 
basepairs upstream of exon 5. M84BC had a single nucleotide substitution (C>T) 40 
basepairs upstream of exon 5. The WAVE and sequencing chromatograms are shown in 
Fig 6.7(a) and Fig 6.7(b) respectively. These sequence variations do not correspond to 
known SNPs. 
6.3.5 Verification of results using TOPO cloning of PCR products 
To confirm these results and ensure they were not due to mutations introduced by PCR 
amplification these two samples were independently re-analysed. PCR of exon 5 was 
performed using AmpliTaq gold and Pwo polymerase under standard conditions (section 
2.10.1) followed by gel electrophoresis. Only one band was produced and this was excised, 
gel purified (Qiagen gel extraction kit) and eluted in TE buffer. Since use of a proof 
reading DNA polymerase with 3’-5’exonuclease activity results in blunt-ended PCR 
products it is necessary to add “A” overhangs before TOPO cloning. This was achieved by 
addition of dATP and Taq polymerase to the reaction mixture as detailed in section 
2.12.1.1. The resultant product was cloned into a pCR4 sequencing vector (Invitrogen) as 
described in section 2.12.1.1. After transformation into DH5α cells and growth overnight 
in LB medium in the presence of Ampicillin, cultures were lysed and DNA extracted using 
a Qiagen miniprep kit (section 2.12.2.3). Miniprep DNA (concentration 200ng/μl) was sent 
for commercial Sanger sequencing (Agowa.de). This sequencing confirmed the above 
mutations and did not reveal any additional changes.  
6.4 Summary 
The results presented above show that GATA-1 sequences in public databases, obtained 
from patients with CML commonly show a higher rate of sequence variation than 
sequences obtained from other sources. In addition the analysis of the BC009797 clone 
described in chapter 3 revealed a mutation producing a change in the coding portion of 
exon 6 and altered functional activity as measured by an in vitro luciferase reporter assay.  
To assess whether GATA-1 mutations are a common feature in chronic myeloid 
leukaemia, mutational analysis of 24 patients with CML was performed. This analysis 
revealed a mutation rate of 2/24 but these mutations were confined to non-coding regions. 
The possible impact of non-coding sequence variations on gene expression are discussed in 
chapter 7. Overall, it seems unlikely that GATA-1 mutations play a major role in the Results Chapter 6    308 
pathogenesis of CML blast crisis although this does not rule out an occasional role. In 
addition these experiments have not ruled out a role for aberrant regulation of GATA-1 
expression in this disease, this has yet to be formally tested.  309 
7  Conclusions and future directions 
7.1 Summary of findings 
This thesis set out to investigate the roles of GATA-1 isoforms in normal and malignant 
haematopoiesis and in particular to focus on the GATA-1s isoform and any unique 
properties it might display. The major findings from the previous chapters are summarised 
below: 
1. The GATA-1s isoform is widely expressed in the same haematopoietic tissues as the 
GATA-1FL isoform and at the same stages of development. Unlike previously published 
reports no evidence was obtained for GATA-1s expression preceding GATA-1FL 
expression in the early developing embryo. There was a suggestion that GATA-1s may be 
preferentially expressed in one monocytic primary cell population but other monocytic cell 
lines and primary samples showed both GATA-1s and GATA-1FL expression. This 
observation needs further investigation. 
2. Comprehensive examination of published databases and GATA-1 PCR products from 
various tissues revealed evidence of an intermediate splicing variant but no other 
physiological isoforms of GATA-1. However these investigations did reveal the existence 
of a mRNA with an altered C terminus, cloned from a patient with CML. Further 
investigation of this clone showed that it exhibited increased transactivation potential 
compared to human GATA-1FL in a luciferase reporter assay.  
3. Attempts to produce GATA-1 isoform specific gene knockouts in embryonic stem cells 
met with technical difficulties, despite apparently successful targeting on PCR screening of 
colonies.  
4. Ectopic over-expression of the GATA-1 isoforms in murine ES cells revealed that 
GATA-1FL promotes BFU-E and CFU-GM colony formation whilst GATA-1s over-
expression significantly reduces haematopoietic colony output. 
5.  Ectopic expression in human meg-erythroid cell lines reveals differential roles for the 
two isoforms in driving erythroid and megakaryocytic commitment. GATA-1FL drives 
increased erythroid gene expression in K562 cells. On induction of megakaryocytic 
differentiation (with TPA) GATA-1FL produces increased DNA ploidy and suppression of Conclusions   310 
erythroid genes. GATA-1s acts as a hypomorphic allele in most situations, unable to 
activate or repress genes to the same extent as GATA-1FL. However GATA-1s does show 
upregulation of ski – a gene associated with bipotent meg-erythroid precursors which 
requires down-regulation prior to terminal erythroid differentiation. Although generally 
producing more repression of erythroid genes than megakaryocytic genes the inability of 
GATA-1s to support terminal megakaryocytic differentiation is suggested by failure to up-
regulate Gp1b levels during TPA induced differentiation. 
6. Comparison between trisomy 21 containing cells and disomic cells did not reveal any 
clear mechanistic reasons for the tight association between GATA-1s producing mutations 
and trisomy 21. However the presumed selective advantage of this association was 
strengthened by the observation that a trisomy 21 containing cell line (Meg-01) 
spontaneously selected for high level GATA-1s expression in culture, whilst a disomic cell 
line (K562) selected for high level GATA-1FL expression. 
7. Further investigation of the possible association between GATA-1 mutations and 
malignancy did not reveal coding mutations in GATA-1 in blast cell genomic DNA 
isolated from a cohort of 21 patients with CML blast crisis. Two single base pair 
alterations in intronic sequences were discovered.  
The potential significance of these findings and how they fit into the current body of 
knowledge on GATA-1 along with possible future lines of investigation are discussed in 
the following sections: 
7.2 How do these findings extend current knowledge of 
GATA-1 function? 
These investigations aimed to shed light on two main areas: firstly the physiological role of 
the GATA-1s isoform and secondly the role it plays in TAM/AMKL. 
7.2.1 The physiological role of GATA-1s 
To date very little is known about the physiological function of GATA-1s. By inference 
from the phenotype of GATA-1s knock-in mice and DS-TAM/AMKL it appears that any 
physiological role is likely to occur in megakaryocytic or erythroid cells and may be 
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show defects in fetal haematopoiesis (Li, et al 2005, Vyas and Roberts 2006). However, 
this phenotype may be due to lack of the GATA-1FL isoform rather than the presence of 
GATA-1s in these cells. A number of hypotheses can be put forward as to the 
physiological function of GATA-1s; evidence from this thesis, in support of or against 
these hypotheses will be discussed: 
1. GATA-1s may play a unique role in the determination of a certain cell lineage: Up 
until now it was unclear as to whether GATA-1s expression was restricted to certain 
lineages or developmental stages. If so, this pattern of expression might shed light on its 
physiological role. The findings presented in this thesis suggest that GATA-1s almost 
always accompanies GATA-1FL expression (with the possible exception of one monocytic 
cell preparation). This argues against a dominant role for GATA-1s in driving a particular 
developmental pathway. In addition, confirmation that mice do not produce this isoform by 
alternative splicing, but instead appear to ensure low level production by “leaky scanning”, 
make it highly unlikely that the GATA-1s isoform would play a unique role in the absence 
of GATA-1FL since it is difficult to envisage a mechanism whereby leaky scanning could 
be controlled sufficiently to prevent GATA-1FL production but allow GATA-1s 
production. Although the possibility of differential post-translational control in different 
cell types exists, western blot data suggest that again GATA-1s and GATA-1FL expression 
usually accompany one another at the protein level. Therefore, the body of evidence 
presented in this thesis argues against GATA-1FL and GATA-1s acting in a classical 
“alternative isoform” manner i.e. the switching between isoform usage in different cells or 
different developmental stages to produce different transcriptional outputs (as is seen with 
other transcription factors such as CEBPα  (Ford, et al 1996)). 
2. GATA-1s may compete with GATA-1FL for DNA or co-factor binding and promote 
cellular proliferation rather than differentiation: Existing microarray data from GATA-
1s mice (Li, et al 2005) suggest that GATA-1s can activate the same set of genes as 
GATA-1FL but that a subset of these genes are inadequately repressed or up-regulated in 
the presence of GATA-1s. This is particularly true of genes associated with cell 
proliferation (such as c-myb, c-myc, cyclin D2) or alternative lineage choice (PU.1, Ikaros, 
GATA-2). This suggests that GATA-1s is capable of mimicking some of the functions of 
GATA-1FL but lacks the ability to promote lineage switching or terminal differentiation at 
physiological levels. Its particularly important role in promoting cellular proliferation at 
the expense of differentiation is supported by GATA-1 rescue experiments discussed in 
section 1.2.5.3 where GATA-1 N-terminal mutants could rescue the differentiation block 
but not the abnormal proliferation of GATA-1 knockout cells (Kuhl, et al 2005, Muntean Conclusions   312 
and Crispino 2005). These results tie in with cell line studies showing that GATA-1 effects 
on proliferation and differentiation appear to occur independently. For example, restoration 
of GATA-1 expression in the GATA-1 null cell line G1E  allows terminal differentiation 
(Weiss, et al 1997). This has been shown to be associated with G1 cell cycle arrest 
associated with down-regulation of Cyclin D2 levels and due, at least in part, to binding to 
and repression of the c-myc promoter by GATA-1 (Rylski, et al 2003). Over expression of 
c-myc in these cells prevented the cell cycle arrest but had minimal effects on restoring 
maturation. Other studies, using a tetracycline inducible conditional GATA-1 expression 
plasmid in knockout ES cells, showed that only short windows of GATA-1 expression 
early during in vitro differentiation were needed for rescue of proliferation defects whilst 
more sustained and later expression was needed for effective differentiation (Zheng, et al 
2006). 
Therefore it could be postulated that GATA-1s is expressed at a basal level and prevents 
repression of genes responsible for cell cycling. The fact that it also fails to repress 
alternative lineage specific genes suggests that it may act in fairly primitive HSCs and 
promote maintenance of these multi-potential cells in a primed but proliferative state ready 
for terminal maturation decisions (illustrated in fig 7.1a). GATA-1FL (and other master 
regulators such as PU.1) would then be free to interact with all the necessary co-factors and 
transcriptional partners in the cell, the balance of which would determine eventual cell fate. 
It would be envisaged that these transcription factor complexes would then compete with, 
and replace, GATA-1s binding at the various loci to produce terminal differentiation (as 
illustrated in Fig 7.1b). A similar model, whereby haematopoietic precursors exist in a 
primed state expressing genes from multiple lineages before commitment to a single fate, 
has been proposed (Hu, et al 1997) and is supported by demonstration of mRNA level 
expression of multiple, supposedly lineage specific, genes within a single haematopoietic 
progenitor cell.  
It is interesting that another key haematopoietic transcription factor AML-1 (Runx-1) also 
possesses a number of isoforms one of which (AML-1a) is very similar structurally to 
GATA-1s in that it contains the AML-1 DNA binding domain but lacks the transcriptional 
regulatory domain and has a reduced transactivation potential. Recent studies over-
expressing this isoform (AML-1a) in haematopoietic stem cells have shown that it 
promotes proliferation of progenitors, greatly increasing engraftment in an LTR-HSC 
assay and increasing primitive and committed progenitor activity. In contrast the full-
length isoform (AML-1b) promoted terminal differentiation (Tsuzuki, et al 2007). It seems 
entirely plausible that GATA-1, another “master regulator” of haematopoietic cell fate Conclusions   313 
might employ similar mechanisms, and this raises the interesting possibility that this could 
be a generic method for coupling the ability to maintain a suitable primed progenitor 
compartment with the ability to induce terminal differentiation – of note other master 
regulators such as PU.1 have multiple isoforms, the individual roles of which are unclear. 
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Fig 7.1 A potential role for GATA-1s in haematopoietic progenitor cells Conclusions   314 
This hypothesis must be able to explain the normal terminal maturation seen if the GATA-
1s isoform is over expressed (Muntean and Crispino 2005, Shimizu, et al 2001). Since a 
large number of GATA-1 co-factors and transcription factors bind to the Zinc fingers 
(FOG-1, AML-1, ski etc) and not the N-terminal domain, GATA-1s expressed at supra-
physiological levels might be able to compensate for absence of GATA-1FL and would tip 
the balance in favour of GATA-1 terminal differentiation (as opposed to alternative lineage 
outputs). There may however, still be low level detection of alternative lineage genes and 
failure to repress pro-proliferative genes resulting in expansion of precursors. This is 
illustrated in Fig 7.2. 
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Fig 7.2 High levels of GATA-1s may be able to compensate for loss of GATA-
1FL 
A number of pieces of evidence from this thesis support aspects of this hypothesis i.e. the 
gene expression studies show that GATA-1s generally acts as a hypomorphic allele 
compared to GATA-1FL during terminal differentiation. The higher levels of expression of 
cell cycle and alternative lineage genes with transgenic GATA-1s expression, compared to 
GATA-1FL expression, are confirmed. In general GATA-1s expression is associated with 
reduced terminal maturation (e.g. lower DNA ploidy). However, when GATA-1s is 
expressed at higher levels (as in the Meg-01 GATA-1s transfectants) it is associated with Conclusions   315 
increased ability to activate or repress target genes almost mimicking the GATA-1FL 
phenotype. Further testing of this hypothesis is required as discussed in section 7.3 below. 
3. GATA-1s may play a particular role in primitive haematopoiesis 
Early on in haematopoietic ontogeny rapid expansion of primitive haematopoietic 
precursors with a skew towards erythroid and megakaryocytic development occurs. In this 
context expression of the GATA-1s isoform has been shown to fully compensate for lack 
of GATA-1FL even when expressed at physiological levels (Shimizu, et al 2001). Since 
this subset of cells has much more limited developmental potential (i.e. primitive HSCs are 
unable to reconstitute the lymphoid compartment and have restricted myeloid potential) the 
need to interact with multiple co-factors may be reduced and DNA binding by GATA-1FL 
or GATA-1s may be sufficient to induce erythroid and megakaryocytic differentiation.  
The fact that GATA-1s promotes proliferation may be advantageous in this context by 
allowing rapid expansion of the progenitor pool. This role in primitive haematopoiesis is 
not mutually exclusive with the role in priming progenitors discussed above. It explains the 
particular propensity for GATA-1s mutations to affect fetal liver haematopoiesis but still 
permit terminal differentiation (in the absence of trisomy 21) (Li, et al 2005).  
This role in primitive haematopoiesis is supported by results presented in section 3.2.5 
showing GATA-1s expression at the protein level in murine embryonic tissues including 
the E9 yolk-sac. Studies presented here do not confirm an isolated report in the literature of 
GATA-1s production preceding GATA-1FL early in murine development (Calligaris, et al 
1995). As already discussed above, the isolated production of GATA-1s in mice would 
have to entail a complicated mechanism of “leaky scanning” favouring translation of the 
second ATG, or (probably more likely) differential post-translational regulation for the two 
isoforms (i.e. by modifications targeting the N-terminus). In addition, the balance of gene 
expression studies presented here, suggest that GATA-1s tends to favour megakaryocytic 
gene expression over erythroid. This taken together with the megakaryocytic phenotype in 
TAM/AMKL and GATA-1s knock-in mice suggests that GATA-1s may be important in 
the recently described primitive megakaryopoiesis detected in early murine embryos 
(Tober, et al 2007). This is also supported by the relatively “primitive” nature of the 
platelets (i.e. discoid, large and reticulated) seen in the human kindred with a GATA-1s 
producing mutation (Hollanda, et al 2006). Again this hypothesis remains to be tested. Conclusions   316 
7.2.2 The role of GATA-1 in TAM/AMKL 
Obviously understanding the physiological role of GATA-1s is of fundamental biological 
importance and may help shed light on its “non-physiological” role in malignancy. In 
addition, understanding the role of GATA-1s in haematological malignancy is important 
for a number of reasons: 
1. GATA-1s associated malignancies develop in a step-wise manner from an abnormal 
meg-erythroid compartment in trisomy 21; to emergence of TAM with GATA-1s 
mutations; followed by either resolution or acquisition of additional mutations to produce 
AMKL. Dissection of each stage of this process provides a rare opportunity to unravel the 
multiple processes involved in acquiring a haematological malignancy using an in vivo 
biological model with distinct pre-malignant stages. 
2. The fact that TAM often spontaneously resolves offers hope that understanding the 
mechanisms of GATA-1s cellular transformation may allow insight into how to reverse a 
malignant phenotype by promoting clonal extinction. Although this may be predominantly 
of use in paediatric malignancies, affecting lineages that occur during certain 
developmental windows, the observation (confirmed in this thesis) of reversion to fetal 
type haematopoiesis in cell lines derived from some adult malignancies (such as K562), 
suggests that it may have wider relevance. 
3. Knowledge of the effects of GATA-1s expression, its interacting partners in the cell and 
the mechanism by which it promotes a malignant phenotype may be of direct benefit to 
children with DS-TAM/AMKL, either by suggesting novel therapeutic strategies or 
allowing better prediction of which patients can safely be observed and which need early 
therapeutic intervention.  
As discussed in chapter 1 it is thought that GATA-1s contributes to the TAM/AMKL 
phenotype by promoting expansion/immortalisation of meg-erythroid progenitor cells in 
the fetal liver (a compartment already expanded in the presence of trisomy 21). How it 
does this is unclear, although its inability to suppress c-myb, c-myc, cyclins and cyclin 
dependent kinases has been suggested to be of importance (Li, et al 2005). The addition of 
trisomy 21 appears to be essential for the phenotype (GATA-1s associated malignancy is 
only seen in the presence of trisomy 21). Erg3, Ets2 and Runx-1 are all chromosome 21 
genes which are candidates for driving expansion of the meg-erythroid compartment and 
another chromosome 21 gene- Bach-1 (over-expressed in DS-AMKL and TAM in a Conclusions   317 
number of independent studies) may be important for blocking terminal differentiation 
(Rainis, et al 2005). 
Results presented in chapter 5 confirm higher levels of c-myb and cyclin D2 in K562 
GATA-1s transgenics and higher levels of c-myb in Meg-01 GATA1s transgenics, 
compared to GATA-1FL transgenics. This confirms a likely role for these genes but their 
mechanism of action is unclear. Unlike observations in the GATA-1s transgenic mice (Li, 
et al 2005), these human GATA-1s transgenic cell lines did not exhibit increased 
proliferation compared to GATA-1FL. c-myb in particular has a very complex role in 
haematopoiesis promoting both stem cell self-renewal and lineage decisions (Sakamoto, et 
al 2006). Therefore expression is likely to produce very different consequences depending 
on its exact cellular context. Since Meg-01 and K562 are both malignant human cell lines, 
it is not surprising that their phenotype might differ from murine megakaryocytic 
progenitors. Another interesting gene to emerge from this data is ski. As discussed in 
chapter 5 expression of ski appears to mark a bipotent meg-erythroid progenitor. Data 
presented here suggest that at baseline and during TPA and Haemin induced differentiation 
ski gene expression is significantly lower in the GATA-1FL transgenics compared to the 
GATA-1s and empty vector transgenics in K562 cells with a similar (but non-significant) 
trend in Meg-01 cells. Little is known about the mechanisms of action of ski in normal 
haematopoiesis and the literature suggests both that its presence is important for 
megakaryocytic differentiation (Namciu, et al 1994), and that its down regulation is needed 
for terminal differentiation (Pearson-White, et al 1995). Clearly further work is needed and 
these very preliminary data suggest that examination of ski expression levels during in 
vitro haematopoietic differentiation in other systems, and in TAM/AMKL cells, would be 
interesting.   
The data from Meg-01 stable transfectants also supports the hypothesis that GATA-1s may 
display a unique selective advantage in the presence of trisomy 21. The consistent selection 
for high level GATA-1s expression in this cell line (and low level expression in K562) is 
intriguing and does not appear to reflect a simple proliferative advantage. Unfortunately 
the multiple differences between the K562 and Meg-01 cell lines in terms of additional 
genetic abnormalities, stage of haematopoietic commitment etc make it difficult to tease 
out the reasons behind this selective pressure using this experimental system. Alternative 
approaches are discussed in section 7.3 below. 
Finally, the expression of two candidate chromosome 21 genes – Erg3 and Bach-1- was 
assessed in this thesis. Erg3 was detectable in Meg-01 cells but not K562 consistent with Conclusions   318 
its over-expression in trisomy 21 although the different levels of haematopoietic 
commitment may also be responsible. Erg3 was significantly up-regulated on TPA and 
Haemin treatment of both cell lines (although it remained persistently higher in Meg-01 
cells) but showed no differential expression patterns between the 3 transgenes. This is not 
surprising as Erg3 is not postulated to be a GATA-1 target gene and presumably acts 
upstream of GATA-1 to cause a pre-existing expansion of the meg-erythroid compartment. 
Therefore, from this data Erg3 remains a plausible candidate whose over-expression in 
trisomy 21 is a possible driver of the expansion of the meg-erythroid pool. Relevant to this 
a recent paper described the effects of ectopic over-expression of Erg3 (and Ets2) in 
GATA-1s transgenic ES cells, wild-type ES cells or the megakaryocyte restricted GATA-1 
knockdown ES cells (ΔneoΔHS – discussed in chapter 1 section 1.2.5.1) (Stankiewicz and 
Crispino 2009). Erg3 was able to promote immortalisation of GATA-1s transgenic ES cells 
but did not produce a fully malignant phenotype, as assessed by ability to produce disease 
when transplanted into mice. Therefore, unsurprisingly, it is unlikely that Erg3 is the sole 
partner for GATA-1s in producing the TAM phenotype. 
Gene expression data from Meg-01 and K562 cells, discussed in chapter 5, do not support 
a role for over-expression of Bach-1 in the context of trisomy 21. Meg-01 cells and K562 
cells showed almost identical baseline expression of Bach-1 and dynamic modulation 
during TPA and Haemin treatment showed increased up-regulation of Bach-1 gene 
expression in K562, with appropriate down-regulation in Meg-01. In addition, the only 
statistically significant difference between the transgenes showed increased repression of 
Bach-1 by GATA-1s during Haemin differentiation in Meg-01. This suggests that, even in 
the context of GATA-1s expression, Bach-1 is not over-expressed. Of course, there are a 
number of explanations for these data. The use of comparative fold-change rather than 
absolute quantitation of cDNA levels means it is equally possible that K562 cells show up-
regulation of Bach-1 (by mechanisms other than trisomy 21), rather than Meg-01 showing 
normal levels of expression, comparison with an equivalent normal cell population would 
be useful here. Alternatively, Bach-1 over-expression may be restricted to a particular 
stage during haematopoietic ontogeny, due to the need for co-factors or permissive 
epigenetic factors, and may be normal in haematopoietic cells derived from adults even in 
the presence of trisomy 21 (this hypothesis would provide an explanation for the 
developmentally restricted phenotype of GATA-1s knockout mice, but remains to be 
tested). 
Overall, results from this thesis support a role for GATA-1s in promoting cellular 
proliferation and survival, inadequately repressing genes associated with alternative Conclusions   319 
lineage choice and generally favouring megakaryocytic gene expression over erythroid. 
In addition GATA-1s expression seems to produce a selective advantage in cells carrying 
trisomy 21. All of these features are consistent with outgrowth of a primitive meg-
erythroid precursor in fetal liver cells carrying a GATA-1s producing mutation, with 
exacerbation of this phenotype in the presence of trisomy 21. In addition they confirm 
that GATA-1s can support terminal differentiation if over-expressed at high enough 
levels. Finally a role for Erg3 in promoting meg-erythroid differentiation in trisomy 21 
cells is supported but the role of Bach-1 in suppressing terminal differentiation could 
not be confirmed.  
7.2.3 The role of GATA-1 in other malignancies 
Although GATA-1 mutations were thought to be uniquely associated with DS-TAM and 
AMKL (Wechsler, et al 2002), the association between GATA-1 mutations and CML has 
never previously been investigated. As discussed in chapter 1 and Chapter 6, a number of 
observations suggested that perturbations in GATA-1 function may be important in the 
pathogenesis of CML. This thesis provides data showing that at least one CML patient 
expressed an abnormal GATA-1mRNA transcript characterised by shortening and 
frameshift in the final exon involving the C-terminal tail. Interestingly this mutant cDNA 
showed increased transactivation in a luciferase reporter assay compared to human GATA-
1FL and GATA-1s. The distal C-terminal tail of GATA-1 has not been extensively 
characterised but interestingly appears to bind AML-1 (Elagib, et al 2003, Waltzer, et al 
2003) and the conserved QTRNRK motif, found just distal to the C-terminal zinc finger, 
has been demonstrated to be important for determining sequence specificity of GATA-1 
binding (Ghirlando and Trainor 2003). In addition a recent structural analysis of a GATA-1 
homologue, MED-1, found in Caenorhabditis elegans, has shown that this GATA-type zinc 
finger domain possesses unique binding specificity by virtue of basic residues in the tail 
region of the molecule distal to the C-terminal zinc-finger (Lowry, et al 2008). These 
residues allow the tail to take up an α-helical structure and interact with the DNA major 
binding groove producing an altered and extended DNA consensus sequence. It is also 
known that the distal C-terminal tail contains residues that can be post-translationally 
modified by acetylation or phosphorylation (Boyes, et al 1998, Hung, et al 1999). 
Experiments using site-directed mutagenesis of terminal lysine residues in chicken GATA-
1 showed that alteration in acetylation patterns can alter DNA binding and transactivation 
potential (Boyes, et al 1998). The C-terminal mutant described in this thesis displays 
altered transactivation potential despite an intact N-terminus and N- and C-terminal zinc Conclusions   320 
fingers suggesting that the distal tail is responsible for this phenomenon. Interestingly the 
mutant frameshift occurs proximal to the important QTRNRK motif (Ghirlando and 
Trainor 2003). One exciting possibility is that the modifications to the C-terminal tail of 
GATA-1 (be it mutations, binding of co-factors or physiological acetylation or 
phosphorylation) could alter its conformation and thereby alter DNA-binding specificity. 
This could provide an additional mechanism whereby GATA-1 could switch between 
active and repressive states or produce a different pattern of gene expression in different 
lineages. This hypothesis needs testing. 
Further investigations of GATA-1 mutations in CML did not reveal any additional 
mutations in coding regions, two single base-pair mutations were seen approximately 40bp 
upstream of the 5
th exon. Although these may represent non-functional mutations or 
previously unrecognised SNPs it is also possible that these mutations are of functional 
significance. The role of intronic sequences in the regulation of gene expression is 
increasingly being appreciated both as potential microRNA precursors and in control of 
splicing. One possibility is that these mutations affect the branch-point consensus sequence 
required for lariat formation during intronic splicing. The human branch-point sequence is 
quite variable and generally located around 35 basepairs upstream of the 3’ end of the 
intron, (Gao, et al 2008), this corresponds to  the mutated region in these studies. Further 
analysis of the presence of aberrantly spliced transcripts in these patients would be 
interesting, but unfortunately is hampered by unavailability of RNA in these cases.  
Finally, the lack of coding mutations in GATA-1 in this cohort of CML patients does not 
rule out a functional role for GATA-1 in this condition. Since correct modulation of 
GATA-1 expression levels is critical for terminal differentiation it is possible that aberrant 
GATA-1 expression is just as important as mutation of the protein. There is some evidence 
of an interplay between bcr-abl and GATA-1 for example an investigation of the 
mechanism of upregulation of inducible heat shock protein 70 (Hsp70) in CML showed 
that the major p210 bcr-abl responsive element upstream of the Hsp70 promoter mapped to 
a GATA-1 binding motif (Ray, et al 2004). 
In conclusion, these findings suggest that GATA-1 mutations are not frequent 
occurrences in the evolution of blast crisis in CML. However, this does not rule out an 
important role for deregulated GATA-1 activity in the molecular pathogenesis of CML. 
In addition, investigation of a CML derived abnormal mRNA transcript suggests that the 
GATA-1 C-terminal tail may be an important, previously under-appreciated functional 
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7.3 Future investigations 
The results presented here throw up a number of potential avenues for further 
investigation. In particular: 
1. Is the GATA-1s expression in monocytes physiologically relevant or an artefact? 
The monocytic primary human cell sample described in section 3.2.1 remains the only 
tissue in which GATA-1s expression was seen in the absence of GATA-1FL. However, 
testing of another primary sample and a number of monocytic cell lines failed to confirm 
these findings. Despite this some pieces of circumstantial evidence suggest a possible role 
for GATA-1s in monocytic differentiation. In particular levels of D6 have been shown to 
be upregulated during monocytic differentiation into dendritic cells in a GATA-1 
dependent manner (McKimmie, et al 2008). Interestingly, D6 was significantly 
upregulated by the GATA-1s isoform compared to GATA-1FL in the K562 transgenic 
experiments reported in chapter 5 (Fig 5.15b). Overall these observations suggest that 
additional study of isoform expression in monocytes and dendritic cells might be 
informative. 
2. Testing the hypothesis that GATA-1s is associated with priming haematopoietic 
precursors. This interesting possibility could be further tested by transfecting primitive 
haematopoietic cells with GATA-1s and GATA-1FL expression plasmids and testing their 
behaviour in long-term reconstitution assays and colony assays. The real test of whether 
GATA-1s has a unique role in haematopoietic development (i.e. rather than just acting as a 
dispensable hypomorphic allele of GATA-1FL) would be provided by the generation and 
testing of a GATA-1s knock-out (as opposed to the GATA-1 “knock-in” already described 
in the literature (Li, et al 2005)). This was attempted in this thesis, without success, 
although the feasibility of mutating the second start codon without detriment to GATA-
1FL function was proven. It would still be worthwhile to pursue this aim. Huge advances 
in gene targeting technology have been achieved in the last 5 years (since the inception of 
this PhD thesis) in particular the availability of recombineering technology allows rapid 
cloning of targeting constructs from bacterial artificial chromosomes (BACs) using 
bacterial recombinases (Wu, et al 2008). This reduces the time taken to make a targeting 
construct from a number of months to a couple of weeks and therefore facilitates multiple 
attempts at producing an effective construct. It is well known that some genes are much 
more difficult to target than others, due to factors such as sections of repetitive DNA, 
significant secondary and tertiary structure or other unknown factors. Successful targeting Conclusions   322 
can often be achieved in these cases by altering the locations of the homology arms (Wu, et 
al 2008). This is often impractical using conventional cloning due to the time involved, but 
recombineering makes multiple attempts at targeting vector construction (or parallel 
attempts with a number of different vectors) feasible. In addition one of the major factors 
reducing targeting efficiency is lack of complete sequence homology. The use of BACs 
overcomes potential errors introduced by PCR amplification of homology arms and 
prevents exhaustive sequencing of PCR products and attempts to decipher whether 
sequence variations represent SNPs, genuine sequence variation or errors introduced by the 
DNA polymerase. 
Other approaches to assessing whether the GATA-1s isoform has a unique role in 
haematopoiesis include assessing whether it binds to a different subset of genes than 
GATA-1FL, at defined stages of ontogeny, or within defined cell lines, at both the level of 
DNA binding at gene regulatory elements and binding to different protein co-factors. 
Assessment of DNA binding at promoters, enhancers etc could be achieved using 
chromatin immunoprecipitation (ChIP) studies. Whereas binding to co-factors could be 
assessed by co-immunoprecipitation studies followed by mass spectrometry to identify co-
purifying protein partners. These investigations are made more difficult by the fact that 
GATA-1s doesn’t contain any unique domains and therefore antibodies to GATA-1s will 
also bind to GATA-1FL. This could be overcome in one of two ways. Firstly, a kind of 
“subtractive” ChIP or co-immunoprecipitation could be performed exploiting the fact that 
the N6 antibody will only bind to GATA-1FL whilst the M20 antibody will bind to both 
isoforms, therefore results using these two antibodies could be compared and differences 
ascribed to the GATA-1s isoform. Secondly, a better approach might be to tag the GATA-
1s isoform, allowing precipitation using antibodies to the tag rather than GATA-1s. This 
could be achieved either using a single tag such as FLAG or biotin or using a tandem 
affinity purification (TAP) approach which improves specificity and purity of protein 
complexes by two successive selection procedures (Knuesel, et al 2003).  
3. Testing the role of GATA-1s in primitive megakaryopoiesis. The existence of 
primitive megakaryopoiesis has only recently been described (Tober, et al 2007). This 
study used immuno-histochemical staining of embryonic tissues and culture of yolk-sac 
and embryo derived haematopoietic progenitor cells. In order to test the role of GATA-1s 
it would be very interesting to repeat these early progenitor assays in GATA-1s knock-in 
mice. Again, the real test of the role of GATA-1s would be to look at primitive 
megakaryopoiesis in a GATA-1s isoform specific knockout as discussed above. Therefore 
further attempts to generate these cells would also be worthwhile in this context. Although Conclusions   323 
these experiments would require generation of transgenic mice to look at yolk-sac derived 
progenitors, there are also in vitro assays of megakaryopoiesis using murine ES cells 
grown on OP9 stromal cell layers (Eto, et al 2002). These assays are reported to show two 
waves of megakaryopoiesis with small immature megakaryocytes appearing on day 8 of 
differentiation and larger cells exhibiting hyperdiploidy appearing on day 12 (Fujimoto, et 
al 2003). This is highly suggestive of  waves of primitive and definitive megakaryopoiesis, 
but this is yet to be proven. The use of GATA-1s and GATA-1FL knock-out ES cells in 
these assays would have enormous potential to address the hypothesis that GATA-1s plays 
a crucial role in primitive megakaryopoiesis.  
4. Further investigation of the role of GATA-1s in TAM/AMKL. This thesis has 
suggested that it would be interesting to look at the expression of ski in TAM/AMKL 
samples and that studies to address the role of ski in megakaryocytic development are 
needed. In addition, an improved model for assessing the role of trisomy 21 is needed, 
Meg-01 cells are interesting, but interpretation is limited by their additional genetic 
changes and derivation from adult CML. The recent development of a transgenic mouse 
carrying an additional copy of human chromosome 21 (O'Doherty, et al 2005) holds much 
promise for dissecting out the role of chromosome 21 genes in the pathogenesis of this 
condition. The use of ES cells from these mice for in vitro haematopoietic differentiation 
assays would be extremely interesting, with or without additional manipulation of GATA-
1s expression. Ultimately, it might be possible to cross breed these mice with GATA-1s 
transgenics to provide a better animal model of TAM/AMKL, although this might be 
hampered by lack of stability of the trisomic genotype.  
5. Further investigation of the C-terminal tail of GATA-1. Finally, one of the most 
biologically interesting findings from this thesis is the identification of the distal C-
terminal tail as a potentially important GATA-1 regulatory region. This could be further 
investigated in a number of ways. The importance of the tail could be assessed by creating 
C-terminal deletion mutants and assessing their function in various reporter assays or 
binding assays. The existing mutant could also be further investigated – the increased 
transactivation potential needs confirming using a different system. In addition, it would be 
interesting to look at the DNA binding profile of this mutant (by ChIP) and whether it is 
capable of interacting with AML-1 (by co-immunoprecipitation). It would also be 
extremely interesting to assess which other proteins bind in this region of the molecule. In 
terms of modulation of GATA-1 activity by post-translational modifications, it is already 
known that prevention of lysine acetylation in the C-terminal tail, as well as other regions, 
leads to reduction in GATA-1 activity in vitro (Boyes, et al 1998)) although the Conclusions   324 
physiological relevance of this remains unclear. Similar mutagenesis studies to prevent 
serine phosphorylation (Crossley and Orkin 1994) were unable to show an impact on in 
vitro erythroid differentiation in MEL cells. This does not rule out an important role for 
this type of modification in certain lineages or during ontogeny. This needs further 
investigation. If C-terminal modifications were identified that may influence DNA binding 
then analysis of the impact of these modifications on the structure of GATA-1 could be 
assessed either using predictive software programmes, nuclear magnetic resonance 
spectroscopy or by attempts to crystallise the protein and assess by X-ray crystallography. 
In conclusion, this thesis has produced a number of testable hypotheses concerning a 
wide range of potentially novel functions for the different domains of GATA-1 including 
a possible role for GATA-1s in haematopoietic progenitors and a role for the C-terminal 
tail in modulation of GATA-1 function. Rapid advances in molecular biological 
techniques should allow creation of improved systems in which to test these hypotheses 
and uncover novel roles for this key haematopoietic transcription factor, so vital in both 
physiological and malignant haematopoiesis.     325 
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